Genetics of cutaneous malignant melanoma by Lang, Julie M.S
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Genetics of Cutaneous Malignant Melanoma
Julie M S Lang BSc (Hons) MSc (Dist)
For the Degree of
Doctor of Philosophy (PhD)
Thesis submitted to
University of Glasgow
Faculty of Medicine
D ivision o f  D evelopm ental M edicine
N ovem ber 2004
© J Lang 2004
U NIVERSITY
GLASGOW
ProQuest Number: 10753970
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10753970
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
fpLASGOW 1 
UNIVERSITY 
LIBRARY:
Acknowledgments
It is a pleasure to thank the many people who have made this thesis possible.
I would especially like to thank my PhD supervisor Professor Rona MacKie for 
all her inspiration and enthusiasm. Throughout my research she has provided 
both encouragement and support, for which I am extremely grateful.
I would like to thank Dr Maureen Boxer for stimulating and technical 
discussions and for her helpful guidance when it was most required. My advisor 
Professor Fiona Lyall deserves special acknowledgement for her support and 
sound advice. I am thankful to Professor Michael Connor for giving me the 
opportunity to carry out this research within his department. I am especially 
grateful to Dr Vincent Macaulay for helping me to understand correlations and 
statistical significance. I am also grateful to Professor William Hunter for help 
with molecular modelling and relevant discussions.
Many thanks to Professor David Hogg from Canada, Dr Nick 
Hayward from Australia and Dr Hensin Tsao from the U.S.A, for kindly sending 
me DNA samples from their M53I mutation carrying families.
All the staff in the DNA lab are thanked for help with experimental setup, 
technical problems and general advice. In particular, I would like to 
acknowledge the help of Ann Weber with DNA extractions. I would like to 
thank Dr Gordon Graham for his kind assistance with computing. My 
appreciation goes to the university staff members in the Department of Medical 
Genetics for their encouragement and support.
I would like to thank the Shaw Melanoma Trust, which has supported me during 
my three years of research and for the award of travel grants.
Lastly, I wish to thank my family, whose constant encouragement, love and 
emotional support, I have relied on throughout my time at university.
It is to my gran that I dedicate this thesis:' . :;.'t
2
List of Contents
Page Number
Title Page 1
Acknowledgements 2
List of Contents 3
List of Figures 12
List of Tables 15
List of Publications 22
List of Abbreviations 23
Declaration 25
Summary 26
Chapter 1 28
Introduction
1.1 Introduction 29
1.2 Anatomy of the Skin 30
1.3 Melanin Pigment 31
1.4 Melanoma Growth Pattern 32
1.5 Types of Melanoma 33
1.5.1 Superficial Spreading Melanoma 3 3
1.5.2 Nodular Melanoma 34
1.5.3 Lentigo Maligna Melanoma 34
1.5.4 Acral Lentiginous Melanoma 35
1.6 Body Site 36
1.7 Ultraviolet Radiation 36
1.8 Changes in Incidence 37
1.9 Genetics o f Familial Melanoma 39
1.10 The CDKN2A Gene 40
1.10.1 Selection o f CDKN2A Allelic Variants 43
1.10.2 CDKN2A polymorphisms 44
1.10.3 CDKN2A mutations in Patients with Multiple Primary Melanomas 45
1.10.4 CDKN2A and UV Radiation 45
1.10.5 CDKN2A and Other Cancers 45
1.11 Other Melanoma Susceptibility Genes 46
1.11.1 ARF 46
3
1.11.2 MC1R 46
1.12 BRAF 49
1.13 Aims of the Thesis 51
Chapter 2 52
Details of Melanoma Patients Studied and Control Subjects 
Including Phenotypic Characteristics
2.1 Subjects 53
2.1.1 Melanoma Families 53
2.1.2 Sporadic Melanoma Cases 54
2.1.3 Control subjects 55
2.2 Samples used in this study 55
2.2.1 Venous Blood Samples 55
2.2.2 Paraffin Embedded Tissue Samples 55
2.2.3 Fresh Tissue Samples 55
2.3 Numbering of Families 56
2.4 Phenotyping of Patient and Control Cohort 58
2.4.1 Phenotype Grouping of Patients and Control Subjects for MC1R Study 58
2.5 Correlation between Phenotype and Melanoma 65
2.5.1 Statistical Analysis 65
2.5.2 Correlation between Skin Type and Melanoma 65
2.5.3 Correlation between Eye Colour and Melanoma 67
2.5.4 Correlation between Hair Colour and Melanoma 69
Chapter 3 71
Laboratory Methods
3.1 Extraction of Genomic DNA 72
3.1.1 DNA Extraction from Venous Blood 72
3.1.2 DNA Extraction from Paraffin Embedded Tissue 72
3.1.3 DNA Extraction from Frozen Tissue 73
3.1.4 DNA extraction from Bacterial Colonies 73
3.2 Storage of DNA 73
3.3 Determination of Concentration of DNA 73
3.4 The Polymerase Chain Reaction 74
3.4.1 Primer Design 74
3.4.2 Primer Synthesis 74
3.4.3 Resuspension o f Primers 75
4
3.4.4 PCRMastermix 75
3.4.5 Amplification 75
3.5 Gel Electrophoresis 76
3.5.1 Agarose 76
3.5.2 Spreadex 77
3.5.3 DNA Visualisation 77
3.5.4 Polyacrylamide Gel Electrophoresis 78
3.6 Denaturing High Performance Liquid Chromatography (dHPLC) 79 
Analysis
3.7 Purification of PCR Products 80
3.8 Sequencing Reaction 80
3.9 Purification of Sequencing Products by Ethanol/EDTA Precipitation 81
3.10 Sequence Analysis 81
3.11 Electropherogram Analysis 82
3.12 Haplotype Analysis 82
3.13 Sizing of Fragments 83
3.14 Digestion of Genomic DNA with Restriction Endonucleases 84
3.15 Cloning of PCR Products 84
3.16 Molecular Modelling 85
3.17 Statistical analysis 86
3.17.1 Calculating P-values 86
3.17.2 Bonferroni Correction 87
3.17.3 Calculating Odds Ratios and Confidence Intervals 88
Chapter 4 89
Mutation Screening of the CDKN2A Gene
4.1 Families in Study 90
4.2 CDKN2A Mutation Detection 90
4.2.1 Mutation Detection Strategy Employed 90
4.3 dHPLC Analysis Conditions 94
4.3.1 dHPLC Analysis o f Proband Samples 98
4.4 Direct Sequencing of Abnormal Amplicons 101
4.5 Determining the Nature of the Nucleic Acid Change 101
4.6 Polymorphisms 102
4.7 Confirmation of Mutation M53I by Restriction Digestion 102
5
4.8 Summary of Findings 103
4.8.1 Results o f Family Studies 103
4.9 The H83N Mutation 104
4.9.1 Mutation Analysis in Family 33 104
4.9.2 Identification o f a Chromatogram WAVE Shift 104
4.9.3 Identification o f Mutation H83N 104
4.10 The 32-33ins9-32 24bp Duplication 106
4.10.1 Mutation Analysis in Family 28 106
4.10.2 Identification o f a Chromatogram WAVE Shift 106
4.10.3 Identification o f Mutation 32-33ins9-32 24bp Duplication 107
4.10.4 Development o f a Gel Based Assay 108
4.10.5 Heteroduplex Analysis 111
4.11 The R24P Mutation 112
4.11.1 Mutation Analysis in Family 2 112
4.11.2 Identification o f a Chromatogram WAVE Shift 113
4.11.3 Identification o f Mutation R24P 113
4.12 The Y44stop Mutation 115
4.12.1 Mutation Analysis in Family 3 115
4.12.2 Identification o f a Chromatogram WAVE Shift 116
4.12.3 Identification of Mutation Y44stop 116
4.13 The M53I Mutation 118
4.13.1 Mutation Analysis in Families 1 ,4 , 5, 6 ,29  and 30 118
4.13.2 Identification o f a Chromatogram WAVE Shift 120
4.13.3 Identification o f Mutation M531 120
4.13.4 Cloning Analysis o f F29.2 122
4.13.5 Development o f a Restriction Test 124
4.14 The G67R Mutation 127
4.14.1 Mutation Analysis in Family 19 127
4.14.2 Identification o f a Chromatogram WAVE Shift 127
4.14.3 Identification o f Mutation G67R 127
4.15 The R112G Mutation 129
4.15.1 Mutation Analysis in Families 17 and 22 129
4.15.2 Identification o f a Chromatogram WAVE Shift 129
4.15.3 Identification o f Mutation R112G 130
4.16 The A148T Suspected Polymorphism 132
4.16.1 Mutation Analysis in Families 7 and 13 132
4.16.2 Identification o f a Chromatogram WAVE Shift 132
4.16.3 Identification o f the Suspected Polymorphism A148T 132
6
4.17 Multiple Primary Melanomas 134
4.18 The use of Molecular Modelling to Identify Mutation Sites 136
and their Possible Effects on Pathological Function
4.19 Statistical Analysis of the Correlation between Phenotype and 141 
Familial Melanoma Patients with and without a CDKN2A Mutation
Chapter 5 142
Studies to Establish a Common Founder of the M531 Mutation
5.1 Haplotyping of M53I Scottish Melanoma Families 143
5.2 Families 144
5.3 Determination of Allele Length Employed 146
5.4 Accuracy of Allele Sizing 149
5.5 Genotyping 150
5.6 Stutter Products 152
5.7 Haplotype Analysis 153
Chapter 6 159
MC1R Variants in Familial Melanoma, Unaffected Family Members, 
Sporadic Melanoma and Control Subjects
6.1 MC1R Sequence Variation Detection 160
6.2 Mutation Strategy Employed 160
6.3 Direct Sequencing of All Amplicons 162
6.4 Sequence Analysis 162
6.5 Results of Phenotyping & Genotyping o f Patient and Control Cohort 169 
for M CIR  Study
6.6 MC1R Variants and Statistical Analyses 176
6.6.1 MC1R Variants in Familial Melanoma Patients with CDKN2A Mutations 179 
Compared with those with no Detectable CDKN2A Mutation
6.6.2 MC1R Variants in Non-Familial Melanoma Cases 181
6.6 Comparison to the Number of MC1R variants in Melanoma Patients 181 
and Control Subjects
6.8 Comparison to the Number of MC1R variants in CDKN2A 184
Positive Melanoma Patients and Control Subjects
7
6.9 Comparison to the Number of MC1R variants in CDKN2A 184 
Negative Melanoma Patients and Control Subjects
6.10 Correlation Between MC1R Variants and Phenotype 186
6.10.1 Skin Type 186
6.10.2 Eye Colour 188
6.10.3 Hair Colour 188
6.11 Correlation between the MC1R Variants, Red Hair and Melanoma 189
6.11.1 Correlation Between Having Melanoma and Carrying a Postulated Red 190 
Hair Variant
6.11.2 Correlation Between Having Red Hair and Carrying a Postulated Red 190
Hair Variant
6.12 Summary of Statistically Significant Findings 194
Chapter 7 195
Mutation Screening of Exon 15 of the BRAF Gene
7.1 Exon 15 BRAF  Mutation Detection 196
7.2 Exon 15 BRAF  Studies on Germline DNA from Patients with 196
Familial Melanoma
7.2.1 Source o f DNA 196
7.2.2 Mutation Strategy Employed 196
7.2.3 Direct Sequencing o f all Amplicons 198
7.2.4 Sequence Analysis o f Amplicons 198
7.3 Detection of BRAF  Mutations in Frozen Melanoma Tissue from 199
Secondary Tumours from Patients with Sporadic Melanoma
7.3.1 Source o f Material 199
7.3.2 Mutation Strategy Employed 201
7.3.3 Sequence Analysis o f Amplicons 201
7.4 Confirmation of Mutation V599E in Tumour Tissue by Restriction 205 
Digestion
7.4.1 Development o f a Restriction Test 205
7.5 Detection of BRAF  Mutations in Formalin Fixed and Paraffin 208
Processed Tissue from Primary Melanomas from Patients
with Sporadic Melanoma
7.5.1 Source o f Material 208
7.5.2 Mutation Strategy Employed 210
7.5.3 Paraffin Embedded Primary Melanoma Tissue -  52 Samples 210
7.5.4 Sequence Analysis o f Amplicons 212
7.5.5 Allele Specific PCR for the Detection of Mutation V599E in Paraffin 
Embedded Primary Melanoma Tissue
214
7.5.6 dHPLC Analysis o f Paraffin Embedded Primary Melanoma Tissue 
Samples
217
7.5.7 Identification o f a Chromatogram WAVE Shift 218
7.5.8 Contamination 221
7.5.9 Summary o f Paraffin Embedded Primary Melanoma Tissue Studies 221
7.5.10 Summary o f all Exon 15 BRAF Frozen and Paraffin Embedded 
Melanoma Tissue Studies
226
C hapter 8
Discussion of M utation Screening of the CDKN2A Gene
228
8.1 CDKN2A Discussion 229
8.2 Detection of CDKN2A mutations by dHPLC 229
8.3 Determining the Nature of the Nucleic Acid Change 231
8.3.1 The H83N Mutation 231
8.3.2 The 32-33ins9-32 24bp Duplication 231
8.3.3 The R24P Mutation 232
8.3.4 The Y44X Mutation 233
8.3.5 The G67R Mutation 233
8.3.6 The R112G Mutation 234
8.3.7 The A148T Suspected Polymorphism 234
8.3.8 SNP 500 and SNP 540 235
8.4 CDKN2A Mutations and Age at Melanoma Diagnosis 237
8.5 CDKN2A and Other Cancers 237
8.5.1 Pancreatic Cancer 237
8.5.2 Breast Cancer 239
8.5.3 Ovarian Cancer 240
8.5.4 Lymphoma 240
8.6 Multiple Primary Melanomas 240
8.7 Future Studies 241
8.7.1 IVS2, A -G ,-105 242
8.8 International Collaboration 243
8.9 CDKN2A Screening 243
9
Chapter 9 245
Discussion of the M53I Founder Mutation
9.1 Founder Mutation Discussion 246
9.1.1 19bp Deletion ‘pi6-Leiden’ 246
9.1.2 3bp Duplication, 113insR 247
9.1.3 -34G-T 247
9.1.4 G101W 248
9.1.5 V126D 248
9.1.6 V59G 249
9.2 The M53I Mutation 250
9.3 Functional Studies of M53I 252
Chapter 10 254
Dicsussion of MC1R Variants in Phenotyped Familial Melanoma 
Patients, Unaffected Family Members, Sporadic Melanoma and 
Control Subjects
10.1 Correlation between Phenotype and Melanoma 255
10.1.1 Correlation between Skin Type and Melanoma 255
10.1.2 Correlation between Eye Colour and Melanoma 256
10.1.3 Correlation between Hair Colour and Melanoma 256
10.2 MC1R Discussion 257
10.2.1 MC1R Variants in Familial and Sporadic Melanoma Patients Combined 258
10.2.2 MC1R Variants in Familial Melanoma Patients 259
10.2.3 MC1R Variants in CDKN2A Positive Familial Melanoma Patients 260
10.2.4 MC1R Variants in Sporadic Melanoma Patients 261
10.3 Correlation between the Number o f MC1R variants and Melanoma 263 
Status
10.4 Correlation Between MC1R Variants and Phenotype 264
10.4.1 Correlation Between MC1R Variants and Skin Type 264
10.4.2 Correlation Between MC1R Variants and Eye Colour 265
10.4.3 Correlation Between MC1R Variants and Hair Colour 265
10.5 Correlation between the MC1R Variants, Red Hair and Melanoma 265
10.5.1 Correlation between the MC1R Variants and Red Hair 265
10.5.2 Correlation between the MC1R Variants and Melanoma 267
10
Chapter 11 268
Discussion of Mutation Screening of Exon 15 of the BRAF Gene
11.1 Exon 15 BRAF Mutation Discussion 269
11.2 V600E 269
11.3 Exon 15 BRAF Studies on Germline DNA from Patients with 270
Familial Melanoma
11.4 Exon 15 BRAF  Studies on Formalin Fixed and Paraffin 271 
Processed Tissue from Primary Melanomas from Patients
with Sporadic Melanoma
11.5 Exon 15 BRAF Studies on Frozen Melanoma Tissue from 272 
Secondary Tumours from Patients with Sporadic Melanoma
11.6 Melanoma Subtypes 274
11.7 BRAF  and UV Radiation 275
11.8 The Presence of BRAF  Mutations in Benign Melanocytic Nevi 276
11.9 Possible Function of the V599E Mutation 277
11.10 Loss of Heterozygosity in Tumour Cells 278
Chapter 12 279
Synthesis and Conclusions
References 283
Appendix 1 299
Primer Sequences
Appendix 2 305
Thermocycling Conditions
Appendix 3 309
Restriction Enzyme Digests
Appendix 4 311
Haplotype Analysis of M53I Mutation Non-Carriers
Appendix 5 313
Statistical Analysis
11
List of Figures Page Number
Figure 1.1 Cross Section of the Skin 30
Figure 1.2 Melanocytes in the Skin 31
Figure 1.3 Superficial Spreading Melanoma 33
Figure 1.4 Nodular Melanoma 34
Figure 1.5 Lentigo Maligna Melanoma 34
Figure 1.6 Acral Lentiginous Melanoma 35
Figure 1.7 Clark Levels 35
Figure 1.8 Incidence of Invasive Cutaneous Malignant Melanoma 37
Figure 1.9 CDKN2A Locus 41
Figure 1.10 The MC1R Gene 47
Figure 1.11 BRAF  Structure 49
Figure 1.12 Melanocyte Signal Transduction 50
Figure 4.1 Amplification of Exon 1 a  of CDKN2A 9 1
Figure 4.2 Amplification of Exon 2 of CDKN2A 92
Figure 4.3 Amplification of Exon 3 o f CDKN2A 93
Figure 4.4 Heteroduplex Formation 94
Figure 4.5 Heteroduplex and Homoduplex Elution Profiles 95
Figure 4.6 Exon l a  Optimum dHPLC Temperatures 96
Figure 4.7 Exon 2 Optimum dHPLC Temperatures 97
Figure 4.8 Detection of CDKN2A mutations by dHPLC 99
Figure 4.9 Scottish Melanoma Family 33 104
Figure 4.10 Family 33 -  Identification of Mutation H83N (247C>A) 105
Figure 4.11 Scottish Melanoma Family 28 106
Figure 4.12 Family 28 -  Identification of Mutation 32-33ins9-32 106
24bp Duplication
Figure 4.13 Development of a Gel Based Assay to Detect Mutation 108
32-33ins 9-32 24bp Duplication 
Figure 4.14 Development of a Gel Based Assay to Detect Mutation 109
32-33ins 9-32 24bp Duplication 
Figure 4.15 Scottish Melanoma Family 2 112
Figure 4.16 Family 2 -  Identification o f Mutation R24P (71 G>C) 114
Figure 4.17 Scottish Melanoma Family 3 115
12
Figure 4.18 Family 3 -  Identification of Mutation Y44stop (132C>A) 117
Figure 4.19 Scottish Melanoma Families 1, 4, 5, 6, 29 and 30 119
Figure 4.20 Families 1, 4, 5, 6, 29 and 30 -  Identification of 121
Mutation M53I(159G>C)
Figure 4.21 Development of a Bel I Restriction Site Created by 124
Mutation M53I
Figure 4.22 Scottish Melanoma Family 19 127
Figure 4.23 Family 19 -  Identification of Mutation G67R (199G>C) 128
Figure 4.24 Scottish Melanoma Family 17 129
Scottish Melanoma Family 22 130
Figure 4.25 Families 17 and 22 -  Identification of Mutation 131
R112G (334C>G)
Figure 4.26 Families 7 and 13 -  Identification of Mutation 133
A148T (442G>A)
Figure 4.27 Ribbon Representation of pl6INK4A and CDK6 137
Figure 4.28 The Site o f M53 139
Figure 5.1 Physical Map of the Eight Markers used in Haplotype 146
Analysis
Figure 5.2 Amplification of Markers Surrounding the CDKN2A Locus 148 
Figure 5.3 GeneScan Results of Male and Female AMXY Controls 149
Figure 5.4 GeneScan Results of the Eight Markers used in 151
Haplotype Analysis 
Figure 5.5 GeneScan Electropherogram of a Dinucleotide 152
Repeat Marker from a Heterozygous Individual with 
Stutter Peaks
Figure 6.1 Amplification of MC1R 161
Figure 6.2 Identification of MC1R Variants 164
Figure 7.1 Amplification of Exon 15 of BRAF  197
Figure 7.2 Secondary Melanoma Cells in a Lymph Node 201
Figure 7.3 Identification of Mutation V599E (1796T>A) in 202
Melanoma Tumour Tissue 
Figure 7.4 Development of a TspR I Restriction Site Created 206
by Mutation V599E for Secondary Melanoma 
Tumour Samples
13
Figure 7.5
Figure 7.6
Figure 7.7 
Figure 7.8 
Figure 8.1 
Figure 11.1
TspR I Restriction Assay for Paraffin Embedded 211
Primary Melanoma Tissues
Development of an Allele Specific PCR for the Detection 215
of Mutation V599E in Paraffin Embedded 
Primary Melanoma Tissue
Optimum dHPLC Temperatures 218
Identification of Mutation V599E (1796T>A) by dHPLC 219
Applications of dHPLC analysis 230
Possible LOH in Melanoma Tumour Tissue 278
14
List of Tables
Table 2.1
Table 2.2
Table 2.3 
Table 2.4 
Table 2.5
Table 2.6
Page Number
Details of Scottish Families with Two or More Members 57 
with Invasive Melanoma
Phenotypes of Familial Melanoma Patients & 59
their Unaffected Relatives
Phenotypes of Sporadic Melanoma Patients 62
Phenotypes of Control Subjects 63
Skin Types in Familial and Sporadic Melanoma 66
Patients Compared with Control Subjects 
Correlation between Skin Type 1 or 2 and Skin Type 3 66
or 4 and Melanoma Patients (Familial and Sporadic) 
and Control Subjects 
Table 2.7 Correlation between Eye Colour and Melanoma 67
Patients (Familial and Sporadic) and Control Subjects 
Table 2.8 Eye Colour in Melanoma Patients (Familial and 68
Sporadic) Compared with Control Subjects 
Table 2.9 Hair Colour in Melanoma Patients (Familial and 69
Sporadic) Compared with Control Subjects 
Table 2.10 Correlation between Hair Colour and Melanoma 70
Patients (Familial and Sporadic) and Control Subjects 
Table 3.1 ABI ROX 500 Size Standard Fragment Lengths 83
Table 4.1 CDKN2A Mutations Identified in Scottish 103
Melanoma Families 
Table 4.2 Multiple Primary Melanomas -  Patients with 134
Familial Melanoma
Table 4.3 Multiple Primary Melanomas -  Patients with 134
Sporadic Melanoma 
Table 4.4 Correlation between Skin Type and Familial 141
Melanoma Patients with and without a CDKN2A Mutation 
Table 4.5 Correlation between Eye Colour and Familial 141
Melanoma Patients with and without a CDKN2A Mutation 
Table 4.6 Correlation between Hair Colour and Familial 141
Melanoma Patients with and without a CDKN2A Mutation
15
Table 5.1
Table 5.2 
Table 5.3
Table 5.4
Table 5.5
Table 5.6
Table 6.1 
Table 6.2
Table 6.3 
Table 6.4 
Table 6.5 
Table 6.6 
Table 6.7 
Table 6.8 
Table 6.9
Table 6.10
Currently Reported Melanoma Families Worldwide 143
with M53I Mutations
Details of Melanoma Families with M53I Mutations 144
Allele Frequencies in Scottish Control Chromosomes at 150 
each Marker
Haplotype Analysis of Scottish M53I Mutation Carriers 153
for 9p Markers
Haplotype Analysis of Scottish M53I Mutation Carriers 155
with Sporadic Melanoma with Multiple Primary Melanomas 
Haplotype Analysis o f M53I Mutation Carriers from 156
Families from Toronto, Brisbane & Boston for 9p Markers 
MC1R Variants Identified in this Scottish Study 163
MC1R Variants, Skin Type, Eye and Hair Colour 170
and CDKN2A Mutations in Familial Melanoma Patients 
& their Unaffected Relatives
MC1R Variants, Skin Type, Eye and Hair Colour 173
and CDKN2A Mutations in Sporadic Melanoma Patients 
MC1R Variants, Skin Type, Eye and Hair Colour in 174
Control Subjects
MC1R Variants Found in Familial and Sporadic 176
Melanoma Patients Compared with Control Subjects
Correlation between MC1R Variants in Familial 178
Melanoma Patients and Control Subjects
Correlation between MC1R Variants in Familial 180
Melanoma Patients with and without a CDKN2A Mutation
Correlation between MC1R Variants in Sporadic 181
Melanoma Patients and Control Subjects
Correlation between the Number of MC1R Variants 182
and Melanoma (Familial and Sporadic Patients) and
Control Subjects
Correlation between the Number of MC1R Variants 182
in Familial Melanoma (Affected and Unaffected) and 
Control Subjects
16
Table 6.11
Table 6.12
Table 6.13
Table 6.14
Table 6.15
Table 6.16
Table 6.17
Table 6.18 
Table 6.19
Table 6.20 
Table 6.21 
Table 6.22 
Table 7.1 
Table 7.2
Correlation between the Number of MC1R Variants 
in Familial Melanoma Patients and Control Subjects 
Correlation between the Number of MC1R Variants 
in Familial Melanoma Patients with a CDKN2A Mutation 
and Control Subjects
Correlation between the Number of MC1R Variants 
in Familial Melanoma Patients without a CDKN2A 
Mutation and Control Subjects 
Number o f MC1R Variants in Familial Melanoma 
Patients Compared with their Unaffected Relatives 
Correlation between the Number o f MC1R Variants 
in Sporadic Melanoma Patients and Control Subjects 
Correlation between the Number of MC1R Variants 
in Familial and Sporadic Melanoma Patients 
Correlation between Skin Type and MC1R variants 
in Control Subjects
Correlation between MC1R Variants and Skin Type 1 
Correlation between MC1R Variants and Red Hair in 
all DNA Samples Available 
Correlation between the Presence of MC1R R142H, 
R151C, R160W or D294H Variant in Melanoma 
(Familial and Sporadic Patients) and Control Subjects 
Correlation between MC1R R142H, R151C, R160W 
or D294H Variant and Sporadic Melanoma Patients 
and Control Subjects
Correlation between MC1R R142H, R151C, R160W 
or D294H Variant and Familial Melanoma Patients 
with a CDKN2A Mutation and Control Subjects 
Details of Secondary Melanoma Samples Obtained 
from Sporadic Melanoma Patients Assessed for 
Exon 15 BRAF  mutations 
Summary of Sequence Analysis of Frozen 
Secondary Melanoma Tumours
183
184
184
185
185
186
187
187
189
191
192 
192 
200 
204
17
Table 7.3
Table 7.4
Table 7.5
Table 7.6
Table 7.7
Table 7.8a
Table 7.8b
Table 8.1
Table 9.1 
Table 9.2
Table 11.1
Table 11.2
Table 11.3
Appendix 4 
Table 1
Appendix 5 
Table 1
Table 2
Primary Tumours from Sporadic Melanoma 208
Patients Assessed for Exon 15 BRAF  Mutations
Summary of Sequence Analysis of Paraffin 212
Embedded Primary Melanoma Tumours
Summary of V599E Allele Specific PCR on 216
Paraffin Embedded Primary Melanoma Tumours
Summary of dHPLC Results of Paraffin Embedded 219
Primary Melanoma Tumours
Summary of Paraffin Embedded Primary Melanoma 223
Tissue Studies
Summary of Mutation Positive Paraffin Embedded 227
Primary Melanoma Tissue Studies
Summary of Mutation Positive Frozen Secondary 227
Melanoma Tumour Studies
Mutations Detected in the CDKN2A Gene in 48 236
Scottish Melanoma Families
Currently Reported Melanoma Founder Mutations 246
Currently Reported Melanoma Families Worldwide 250
with M53I Mutations
Mutation Positive Primary Tumours from 271
Sporadic Melanoma Patients
Mutation Positive Secondary Melanoma Tumours 272
from Sporadic Melanoma Patients
Primary Melanomas Analysed for BRAF Mutations 273
Haplotype Analysis of M53I Mutation Non-Carriers from 312 
a Family from Toronto and a Family from Australia for 
9p Markers
MC1R Variants Found in Familial and Sporadic Melanoma 314 
Patients Compared with Control Subjects 
Correlation between MC1R Variants in Familial 315
Melanoma Patients and Control Subjects
18
Table 3 
Table 4 
Table 5 
Table 6 
Table 7 
Table 8 
Table 9 
Table 10 
Table 11
Table 12
Table 13 
Table 14 
Table 15 
Table 16
Table 17
Correlation between MC1R Variants in Familial 
Melanoma Patients with and without a CDKN2A Mutation 
Correlation between MC1R Variants in Sporadic 
Melanoma Patients and Control Subjects 
Correlation between Hair Colour and MC1R Variants 
in Control Subjects
Correlation between Eye Colour and MC1R Variants 
in Control Subjects
Correlation between Skin Type and MC1R variants 
in Control Subjects
Correlation between Hair Colour and Melanoma 
Patients (Familial and Sporadic) and Control Subjects 
Eye Colour in Melanoma Patients (Familial and 
Sporadic) Compared with Control Subjects 
Correlation between Skin Type and Melanoma 
Patients (Familial and Sporadic) and Control Subjects 
Correlation between Lighter and Darker Hair Colour 
and Melanoma Patients (Familial and Sporadic) and 
Control Subjects
Correlation between Lighter and Darker Eye Colour 
and Melanoma Patients (Familial and Sporadic) and 
Control Subjects
Correlation between Hair Colour and Familial 
Melanoma Patients with and without a CDKN2A Mutation 
Correlation between Eye Colour and Familial 
Melanoma Patients with and without a CDKN2A Mutation 
Correlation between Skin Type and Familial 
Melanoma Patients with and without a CDKN2A Mutation 
Correlation between Lighter and Darker Hair Colour 
and Familial Melanoma Patients with and without 
a CDKN2A Mutation
Correlation between Lighter and Darker Eye Colour 
and Familial Melanoma Patients with and without 
a CDKN2A Mutation
317
318
319
319
320
321
321
322 
322
322
323
323
324 
324
324
19
Table 18
Table 19 
Table 20
Table 21
Table 22
Table 23 
Table 24 
Table 25 
Table 26 
Table 27 
Table 28
Correlation between Skin Type 1 or 2 and Skin Type 3 or 324 
4 and Familial Melanoma Patients with and without 
a CDKN2A Mutation
Correlation between the Number of MC1R Variants 325
in Unaffected Familial Melanoma and Control Subjects 
Correlation between the Number of MC1R Variants 325
in Familial Melanoma Patients with and without a 
CDKN2A Mutation
Correlation between Postulated Red Hair MC1R Variants 325 
in Melanoma Patients (Familial and Sporadic) and 
Control Subjects
Correlation between Postulated Red Hair MC1R Variants 325 
in All Red Haired Individuals (Affected and Unaffected 
Familial and Sporadic Melanoma and Control Subjects) and 
All Individuals without Red Hair (Affected and Unaffected 
Familial and Sporadic Melanoma and Control Subjects) 
Correlation between Postulated Red Hair MC1R Variants 326 
in Control Subjects with Red Hair and Control 
Subjects without Red Hair
Correlation between MC1R R142H, R151C, R160W 326
or D294H Variant in Familial Melanoma Patients 
and Control Subjects
Correlation between MC1R R142H, R151C, R160W 326
or D294H Variant in Familial Melanoma Patients without 
a CDKN2A Mutation and Control Subjects 
Correlation between MC1R R142H, R151C, R160W 326
or D294H Variant in Familial and Sporadic 
Melanoma Patients
Correlation between MC1R R142H, R151C, R160W 327
or D294H Variant in Affected and Unaffected 
Familial Melanoma
Correlation between MC1R R142H, R151C, R160W 327
or D294H Variant in Familial Melanoma Patients with 
and without a CDKN2A Mutation
20
Table 29
Table 30
Table 31 
Table 32 
Table 33
Correlation between MC1R R142H, R151C, R160W 327
or D294H Variant in Unaffected Familial Melanoma 
and Control Subjects
Correlation between MC1R R142H, R151C, R160W 327
or D294H Variant in Affected and Unaffected 
Familial Melanoma and Control Subjects 
Correlation between MC1R Variants and Skin Type 1 328
Correlation between MC1R Variants and Blue Eyes 329
Correlation between MC1R Variants and Red Hair in 330
all DNA Samples Available
21
List of Publications
Excerpts and preliminary results of this thesis have been published as detailed 
below:
Lang, J., Boxer, M., & MacKie, R. 2003, “Absence of exon 15 BRAF germline 
mutations in familial melanoma”, Hum.Mutat., vol. 21, no. 3, pp. 327-30.
Lang, J., Boxer, M., Hunter, W., & MacKie, R. 2004, “Analysis of CDKN2A 
mutations in 42 Scottish families with cutaneous melanoma: evidence that the 
M53I mutation originated in Scotland”, Clinical Molecular Genetics Society, pp. 
27.
Lang, J., Boxer, M., & MacKie, R. 2003, “Studies on B-RAF in familial and 
sporadic melanoma”, International Melanoma Consortium Annual Scientific 
Meeting.
Lang, J., Boxer, M., & MacKie, R. 2003, “Familial Melanoma: Absence of exon 
15 BRAF germline mutations”, EurJ.Hum.Genet., vol. 11, suppl. 1, pp. 72.
Lang, J., Boxer, M., & MacKie, R. 2002, “Variations in the CDKN2A Gene in 
Familial Melanoma in Scotland”, J.Med.Genet., vol. 39, suppl. 1, pp. S69.
22
List of Abbreviations
+ve positive
-ve negative
a  alpha
p beta
Acral Acral Lentiginous Melanoma
ASO allele-specific oligonucleotides
BRAF  v-raf murine sarcoma viral oncogene homolog B 1
CDK4 cyclin-dependent kinase 4
CDKN2A cyclin-dependent kinase inhibitor 2°
Cl confidence intervals
°C degrees centigrade
dHPLC denaturing high performance liquid chromatography
DNA deoxyribonucleic acid
EDTA ethylenediaminetetra-acetic acid
EtBr ethidium bromide
F female
FAM 6-Carboxy-fluorescein
FISH fluorescence in situ hybridisation
g grams
g gravitational force
LMM Lentigo Maligna Melanoma
log logarithm
M male
MC1R melanocortin 1 receptor
MPM multiple primary melamomas
mins minutes
Mucosal Mucosal Melanoma
Nodular Nodular Melanoma
NRAS neuroblastoma ras viral oncogene homolog
NS not significant
nt nucleotides
23
OD optical density
O/N overnight
OR odds ratio
p significance value
PCR polymerase chain reaction
rpm revolutions per minute
RT room temperature
UV ultraviolet
SE standard error
secs seconds
SNP single nucleotide polymorphism
SSM Superficial Spreading Melanoma
TAE tris acetate EDTA
TEMED N,N,N ’ ,N ’ -T etramethylethylenediamine
WT wild type
1 litre
ml millilitre
pi microlitre
b base
bp base pairs
kb kilobase pairs
kDa kilodalton
g gram
mg milligram
pg microgram
ng nanogram
M molar
mM millimolar
pM micromolar
mm millimetre
Declaration
Excerpts from the results of this thesis have been published as detailed on page 
22. I certify that this thesis does not contain any other material published or 
written by another person except where due reference is made in the text. The 
results presented in this thesis have not been submitted for any other degree or 
diploma.
Julie M S Lang
25
Summary
Cutaneous malignant melanoma has doubled in incidence in many 
countries over the past 20 years. The majority of melanomas are sporadic, but up 
to 5% of melanoma patients have one or more first-degree relatives also affected, 
and genetic analysis of these families shows germline mutations of CDKN2A in 
20-30% of patients.
This thesis has investigated 48 Scottish families with cutaneous 
malignant melanoma and also 28 patients with sporadic melanoma for mutations 
in the CDKN2A, MC1R and BRAF  genes using molecular genetic techniques.
The work presented in this thesis adds 32 new melanoma families to the 
16 already reported from Scotland (MacKie et al. 1998). In total, 13/48 (27%) 
Scottish families have detectable CDKN2A mutations. One of the mutations 
detected (H83N) has not previously been reported in melanoma, and molecular 
modelling suggests the likely functional result of this mutation.
In the course of studying the CDKN2A gene the M53I mutation was 
identified in six Scottish families making it the most common CDKN2A mutation 
identified in this thesis from the Scottish melanoma families studied. Haplotype 
analysis surrounding CDKN2A was therefore performed on the six Scottish 
families and also examined in 12 M53I carrying families from around the world.
This study provides further evidence that the M53I mutation appears to 
have originated from a common founder and provides further evidence 
demonstrating common founders for most o f the recurrent mutations in the 
CDKN2A gene.
The aim of the analysis of the MC1R gene was to investigate any 
underlying genetic relationship between MC1R variants and CDKN2A mutations. 
In total, 13 MC1R variants leading to an amino acid substitution were detected, 
three o f which have not been described elsewhere (L44I, M128K, A171G) and 
appear to be very rare. Collectively, both familial and sporadic melanoma 
patients are more likely to carry a MC1R variant than normal control subjects (P 
= 0.006; OR = 4.485; Cl 1.492-12.883) and melanoma patients carry 
significantly more MC1R variants than control subjects (P = 0.003; OR = 2.696; 
Cl 1.384-5.253).
Familial melanoma patients are more likely to carry the R151C variant 
than normal control subjects (P = 0.043; OR = 2.406; Cl 1.062-5.452). CDKN2A
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positive familial melanoma patients are more likely to carry the V60L and 
R151C variants than CDKN2A negative familial melanoma patients (P = 0.017; 
OR = 3.818; Cl 1.315-11.084 and P = 0.029; OR = 3.515; Cl 1.160-10.650, 
respectively). Conversely, CDKN2A negative familial melanoma patients are 
more likely to carry the V92M variant than CDKN2A positive familial melanoma 
patients (P = 0.021; OR = 9.308; Cl 1.112-77.888).
The variant R160W is significantly correlated with skin type 1 (P < 
0.001) and variants R142H (P = 0.019) and R160W (P = 0.018) are significantly 
correlated with red hair, although this significance is lost after the Bonferroni 
correction.
During the time of this study Davies et al. (2002) reported that the most 
frequently targeted gene in melanoma is BRAF. All mutations were within the 
kinase domain, with a single substitution in exon 15 (V599E) accounting for 
80% of mutations. BRAF mutations in germline DNA from familial melanoma 
patients had not been investigated, and the number of melanoma tissue samples 
investigated for BRAF  mutations was low. One of the aims of this thesis 
therefore was to screen exon 15 of BRAF to determine if the V599E mutation 
would contribute to melanoma predisposition in familial melanoma as a germline 
mutation. The study of this thesis also investigated primary and secondary 
melanomas for exon 15 BRAF  mutations.
DNA from the peripheral blood of 42 familial melanoma cases contained 
no exon 15 BRAF  mutations. DNA from two samples of secondary melanoma 
from two individuals with a family history of melanoma also failed to show exon 
15 BRAF  mutations. These results therefore suggest that exon 15 BRAF  
mutations are not causative germline mutations in melanoma.
The V599E substitution was however detected in formalin fixed paraffin 
embedded primary tumour DNA from 13/52 sporadic cases (25%). The V599E 
substitution was also detected in secondary tumour DNA from 6/22 sporadic 
cases (27%) of frozen secondary melanoma.
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CHAPTER 1
INTRODUCTION
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1.1 Introduction
In 1820 William Norris first reported an inherited predisposition to 
develop melanoma. In describing a case of malignant melanoma, Norris wrote: 
’It is remarkable that this gentleman's father, about thirty years ago, died of a 
similar disease. A surgeon of this town attended him, and he informed me that a 
number of small tumours appeared between the shoulders...This tumour, I have 
remarked, originated in a mole, and it is worth mentioning, that not only my 
patient and his children had many moles on various parts of their bodies, but also 
his own father and brothers had many of them. The youngest son had one of 
these marks exactly in the same place where the disease in his father first 
manifested itself. These facts, together with a case that has come under my 
notice, rather similar, would incline me to believe that this disease is hereditary.' 
Quoted in Hecht (1989).
Cutaneous Malignant Melanoma is the most lethal form of skin cancer, 
MIM# 155601 (MIM - Mendelian Inheritance in Man is a catalog of genetic 
disorders named after Gregor Mendel, who determined the basic principles of 
inheritance in the latter half of the 19th century. Each MIM entry is given a 
unique six-digit number whose first digit indicates the mode of inheritance o f the 
gene involved). The risk of developing melanoma increases with age, but 
nonetheless the disease may affect young, otherwise healthy people.
Melanoma is a malignant tumour of melanocytes or nevus cells, arising 
either de novo or from a pre-existing benign nevus. Melanocytes produce a 
brown-black pigment called melanin, which helps to protect against the 
damaging rays of the sun and to determine skin colouring. Melanocytes are 
found in the basal layer of the epidermis, comprising 5-10% of cells in the basal 
layer with approximately 1000-2000 melanocytes per square millimetre of skin. 
Melanin production is stimulated by ultraviolet (UV) radiation. Melanocytic 
nevi are most prevalent in the second and third decades o f life. Malignant 
transformation of the melanocyte to melanoma is a rare event. Most melanomas 
originate in epidermal melanocytes, but they can arise from ocular melanocytes 
and rarely in the membranes of the nasal passages, oral, pharyngeal mucosa, anal 
and vaginal mucosa.
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1.2 Anatomy of the Skin (Figure 1.1)
The skin is the largest organ o f the body, forming a protective barrier 
against infection and helping to maintain a constant body temperature. Skin is 
only about 2mm thick and is made up o f two layers that cover a third fatty layer. 
The outermost layer is called the epidermis, which is up to 20 cells deep or 0.1 to
1.5 millimetres thick. It is made up o f five layers: the basal cell layer, the 
squamous cell layer, the stratum granulosum, the stratum lucidum, and the stra­
tum corneum. These layers maintain the skin’s strength, protect against UV 
radiation and are constantly self-renewing. The basal cell layer, which is con­
stantly producing new basal cells, also contains the melanocytes. When skin is 
exposed to the sun, the melanocytes increase melanin production to protect the 
skin from damaging UV radiation.
Below the epidermis lies the dermis, ranging in thickness from one to 
four millimetres. The dermis contains nerve endings, eccrine sweat glands, 
sebaceous glands, hair follicles and blood and lymph vessels, which increase in 
number deeper in the skin. The main components o f the dermis however are 
collagen and elastin, which support the epidermis and keep the skin flexible.
Under the epidermis and dennis layers is a fatty subcutaneous tissue layer 
acting as an insulator and protecting the internal organs from damage. The blood 
and lymph vessels also cross this layer.
FIGURE 1.1
Cross Section of the Skin
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This image was taken from the Departm ent o f Biochemistry and M olecular Biology, The 
Pennsylvania State University website.
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1.3 Melanin Pigment
Melanin is a pigment that gives colour to hair, skin and the iris o f the eye. 
It is a water-insoluble polymer derived from the amino acid tyrosine. It is found 
in melanosomes produced by melanocytes, which are found in the basal layer of 
the epidermis (Figure 1.2).
FIGURE 1.2
Melanocytes in the Skin
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This image was taken from the Departm ent o f Biochemistry and M olecular Biology, The
Pennsylvania State University website.
Skin colour is determined by the various degrees of pigmentation found 
in the skin, which is directly related to the number, size and distribution o f 
melanosomes within the melanocytes. There are two types o f melanin, the 
red/yellow phaeomelanin and the brown/black eumelanin. Variation in both skin 
and hair pigmentation is due to varied amounts of eumelanin and phaeomelanin. 
Eumelanin is thought to give protection against UV radiation. Individuals with 
red hair have a predominance o f phaeomelanin in their hair and skin and have an 
impaired ability to produce eumelanin in response to UV light.
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The relative proportions of eumelanin and phaeomelanin are controlled 
by the melanocyte-stimulating hormone (MSH) by binding to its receptor, 
melanocortin 1 receptor (MC1R) on the surface of melanocytes (Thody et al. 
1991, Burchill et al. 1993, Hunt et al. 1995). MC1R controls the level of 
tyrosinase production therefore stimulating melanocytes to synthesise eumelanin. 
Only when the MSH binds to the MC1R does the receptor stimulate the 
melanocyte to increase the level of tyrosinase, causing the cell to produce 
eumelanin. In the absence of signalling, melanocytes make phaeomelanin 
(Burchill et al. 1993).
Variants in MC1R affect the pigmentation phenotype between 
phaeomelanin and eumelanin. Valverde et al. (1995) reported 21/30 (70%) of 
the individuals with red or fair hair and a poor tanning response analysed from 
their British and Irish population, had at least one variant of the MSH-receptor. 
In this paper, MC1R variants were even more abundant in those individuals with 
skin types 1 and 2 (see section 2.4.1 for skin type groups according to Fitzpatrick 
1988).
1.4 Melanoma Growth Pattern
Initially invasive melanoma cells expand laterally across the superficial 
or papillary dermis. This step is called the radial growth phase and at this early 
stage, of unknown duration, surgical excision of the melanoma gives an excellent 
chance of a complete cure. However, if not excised, the melanoma progresses to 
the vertical growth phase, invading downward into the deeper dermis as clusters 
of tumour cells which can invade the lymph and blood vessels, greatly increasing 
the likelihood of metastases. Primary melanomas that have become raised 
indicate that downward growth or the vertical growth phase has occurred. In 
some cases, this growth pattern is very rapid. Removal of the primary melanoma 
before it penetrates to the deeper layers of the skin is therefore crucial for 
achieving a cure.
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1.5 Types of Melanoma
Although there is some controversy, most pathologists classify melanoma 
into four major clinicopathologic types (lentigo maligna melanoma, superficial 
spreading melanoma, nodular melanoma, and acral lentiginous melanoma) 
(Clark et al. 1969).
1.5.1 Superficial Spreading Melanoma (SSM) (Figure 1.3) is the most common 
type o f melanoma. It is usually flat, asymmetrical, unevenly coloured with 
varying shades o f black and brown and grows laterally across the surface o f the 
skin. SSM can have a relatively long radial growth phase occurring over months 
to years. It may occur at any age or site and is most common in Caucasians. The 
greatest increase for histogenetic type in Scotland over the past 20 years is in 
superficial spreading melanoma, which is the most common type o f melanoma 
(MacKie et al. 2002).
FIGURE 1.3
Superficial Spreading Melanoma
Large Superficial Spreading Melanoma with central raised nodule. Note the 
irregular edge and colour.
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1.5.2 Nodular Melanoma (NM) (Figure 1.4) appears as a fast-growing brown or 
black raised nodule, although some lack melanin pigment. It is the second most 
common subtype o f melanoma. NM can occur at any body site although the 
trunk appears to be more frequently involved than with other types o f melanoma.
FIGURE 1.4 
Nodular Melanoma
Note the black raised nodule.
1.5.3 Lentigo Maligna Melanoma (LMM) (Figure 1.5), sometimes called 
Hutchinson's freckle, usually occurs in the elderly. The lesions are large and flat 
with intermixed mottled areas o f brown and black with irregular borders. These 
lesions most often appear on the face. The radial growth phase may last for 
years before invasion occurs.
FIGURE 1.5
Lentigo Maligna Melanoma
Extensive lentigo maligna on the nose.
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1.5.4 Acral Lentiginous Melanoma (ALM) (Figure 1.6) is the least common 
form o f melanoma in Caucasians, although it is the most common melanoma 
among African and Asian populations. It usually occurs as a dark patch on the 
palms, soles, or under the nails.
FIGURE 1.6
Acral Lentiginous Melanoma
The prognosis for a melanoma patient is mainly determined by the 
Breslow tumour thickness measured in millimetres (Breslow 1970) or by levels 
o f invasion related to skin structures (Clark et al, 1969). All patients presented in 
this thesis have invasive melanoma o f Clark level 2 or deeper. Clark level 2 is 
defined as melanoma cells that have extended into the papillary dermis (Figure 
1.7).
FIGURE 1.7 
C lark Levels
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1.6 Body Site
Common sites for melanoma in men are the head, neck, and trunk, and in 
women, the arms or legs. The most common body site for melanoma in Scotland 
is the female leg. In Scottish male patients, the melanoma is most commonly 
located on the back (MacKie 2002). Any area of the skin may be affected 
however, in either gender.
1.7 Ultraviolet Radiation
Epidemiologic studies suggest that exposure to UV radiation is the major 
environmental risk factor for melanoma, but the association is complex. 
Melanoma occurs more frequently in areas of the body receiving intermittent sun 
exposure (Elwood and Jopson 1997).
The relationship between UV radiation and melanoma risk was 
investigated in Denmark using a population-based case-control study of 474 
patients with melanoma and 926 population controls (Osterlind 1988). A 
significantly increased risk was associated with severe sunburn before the age of 
15 years, indicating that exposure to intermittent intense sunlight is an important 
risk factor for melanoma.
The association of melanoma risk with various measures of intermittent 
and chronic exposures to UV radiation was evaluated by analysing 583 
melanoma cases and 608 controls from Ontario, Canada (Walter 1999). 
Significant increased risk was identified from several measures of intermittent 
exposure, including beach holidays during adolescence and in the past 5 years 
and previous sunburn. Chronic exposure, measured by days of outdoor activity 
during adolescence and by outdoor activity during occupation in adult life, was 
associated with a significantly reduced risk. This work supports the hypothesis 
o f increased risk associated with intermittent UV exposure. This suggests that 
UV radiation may mutate melanocytes at an early stage.
Gilchrest et al. 1999 provided a potential explanation for the 
epidemiology of melanoma. Melanocytes transfer melanin to surrounding 
keratinocytes through their dendrites. When UV radiation penetrates the basal 
layer of skin it interacts with the DNA. When the damage to the DNA is 
extensive, keratinocytes undergo apoptosis and are eliminated. When the 
damage to the DNA is minimal the keratinocytes either repair the damage or give
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rise in the next round of DNA replication to a mutation induced by UV radiation. 
The skin responds to UV radiation with increased melanin production (tanning) 
and increases the capacity to repair DNA in the surviving cells. In the case of 
melanocytes, the amount of initial damage to DNA is also directly proportional 
to the dose of UV radiation, but the greater resistance to UV radiation-induced 
apoptosis leads to the survival o f virtually all melanocytes. Melanocytes that are 
damaged extensively are therefore at high risk for incorporating mutations into 
their DNA, and clonal expansion of these melanocytes with UV induced 
mutations may follow during melanocyte division. In contrast to its effect on 
keratinocytes, intense high-dose UV radiation results in many more mutated 
melanocytes than does low-dose UV radiation. Furthermore Gilchrest suggests 
that while the skin is tanned it has an increased capacity to repair DNA. The 
increased capacity to repair DNA results in nearly complete repair, although cell 
division stimulated by UV radiation may result in clonal expansion of the cells 
that are already mutated.
1.8 Changes in Incidence
Although a relatively uncommon cancer, melanoma has become an 
important public health issue because of the steady rise in incidence in Caucasian 
populations in all parts of the world including Australia, the U.S. and the U.K. 
over the past 70 years (Jemal et al. 2001; Marrett et al., 2001; Mackie et al.,
2002). The increase in melanoma incidence in the U.S. is the greatest for any 
cancer. It is estimated that over the last 50 years, the incidence has risen by 
approximately 6% every year, leading to a 10-fold increase in incidence since the 
late 1950s (Weinstock 1998).
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This increase in incidence is mainly attributed to greater intermittent 
periods of sun exposure over the last 30 years. The Scottish Melanoma Group 
recorded changes in melanoma incidence and survival in relation to prognostic 
factors. They investigated the incidence of melanoma in both sexes throughout 
Scotland during 1979-98 showing that there has been a steady and continuing 
rise in the incidence of melanoma in both sexes (Figure 1.8). They showed an 
incidence per 100,000 of population in 1998 of 10.6 in men and 13.1 in women 
(MacKie et al. 2002).
FIGURE 1.8
Incidence of Invasive Cutaneous Malignant Melanoma
Incidence of invasive cutaneous malignant melanoma in Scotland from 1979 to 1998. Every 
point is an average of 2 consecutive years.
Incidence rates and increases in incidence rates differ in different 
populations. There is an obvious difference in melanoma incidence between 
Australia (melanoma incidence in Queensland is 50/100,000) and Europe 
(melanoma incidence in UK is 10/100,000). Melanoma is the fourth most 
common cancer in Australia compared with the U.K. where it is the 11th most 
common cancer (World Health Organisation 2002, http://www- 
depdb.iarc.fr/globocan/GLOBOframe.htm). Even within Europe, there are 
differences between incidence rates. These differences in melanoma incidence 
rates may be relative to UV radiation exposure by geographic latitude.
1 4-,
Women
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1.9 Genetics of Familial Melanoma
A familial inheritance in malignant melanoma has been reported by many 
authors (Cawley 1952; Smith et al. 1966; Andrews 1968). Anderson et al. 
(1967) described 15 individuals with malignant melanoma in three generations of 
a pedigree. They showed an early age of onset and many had multiple primary 
melanomas. Patients have been reported from 36 pedigrees in which 106 
members had cutaneous melanoma (Anderson 1971). Clark et al. (1978) first 
described kindreds with melanoma in one or more first-degree relatives who had 
a large number of melanocytic nevi some of which were atypical and variable in 
size. They termed these features the 'B-K mole syndrome' after the family names 
of two patients. At the same time, Lynch et al. (1978) reported similar families. 
Lynch et al. (1980) referred to the 'B-K mole syndrome' as FAMMM (familial 
atypical mole—malignant melanoma syndrome). They studied three pedigrees 
with FAMMM. Father-to-son transmission was observed and one patient had 
nine separate primary melanomas in 18 years.
In 1983 Trent et al. identified a deletion and translocation in the 6ql5-q23 
chromosome region in four of five cases of melanoma. Becher et al. (1983) also 
found chromosome aberrations of 6q (ql l-q31 region) in a small number of 
families.
In 1989 attention moved to a locus on chromosome lp36a, thought to be 
involved in melanoma. Bale and colleagues performed linkage analyses using 26 
markers on the short arm of chromosome 1 on 99 relatives and 26 spouses from 
six families with a predisposition to melanoma. From the linkage analysis they 
found evidence that a familial melanoma gene maps to lp36 (Bale et al. 1989). 
Dracopoli et al. (1989) found loss o f heterozygosity at loci on lp  in 43% of 
melanomas and 52% of melanoma cell lines and they showed this loss of 
heterozygosity to be a late event in tumour progression. Kefford et al. (1991) 
assessed 119 family members, 30 of whom had cutaneous malignant melanoma, 
from eight Australian families and analysed the cosegregation o f the cutaneous 
malignant melanoma with eight markers on the short arm of chromosome 1. No 
evidence for linkage was found. Goldstein et al. (1993) extended this linkage 
analysis work with the addition of seven new families. Their results showed 
significant evidence for a melanoma locus linked to marker D1S47.
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Recently, Gillanders et al. (2003) have identified a novel familial 
melanoma susceptibility locus on chromosome lp22. They performed a 
genome-wide scan for linkage in 49 Australian pedigrees containing three or 
more cases o f melanoma, in which no cyclin-dependent kinase inhibitor-2A 
(CDKN2A) or cyclin-dependent kinase-4 (CDK4) mutations had been found. 
The highest LOD score was obtained at D1S2726, which maps to the short arm 
o f chromosome 1 (lp22). Furthermore they analysed 33 additional melanoma 
families from around the world to provide further evidence for linkage to the 
lp22 region. The highest LOD score of 6.43 was obtained at D1S2779. These 
data provide significant evidence of a novel susceptibility gene for melanoma 
located within chromosome band lp22.
To map the locus more finely, Walker et al. (2004) looked for loss of 
heterozygosity (LOH) across the region in a panel of melanomas from lp22- 
linked families, sporadic melanomas, and melanoma cell lines. Eighty percent of 
familial melanomas exhibited LOH making it likely that the susceptibility locus 
is a tumour suppressor. They screened the candidate genes in this region, but no 
coding mutations were detected. The Melanoma Genetics Consortium continues 
to search for the susceptibility gene for melanoma located within chromosome 
band lp22.
1.10 The CDKN2A Gene
In 1986 Bergman et al. studied families from a village in the Leiden 
region, The Netherlands. In six pedigrees, 33 patients were reported with 
melanoma. In 1994 Bergman et al. extended their studies on their Dutch 
melanoma families and found by linkage analysis that a melanoma gene 
(CDKN2A) was linked to markers on chromosome 9p21. This familial 
melanoma gene is one of the three investigated in this thesis.
The CDKN2A locus was mapped to chromosome 9p21 (Hussussian et al. 
1994; Kamb et al. 1994; Nobori et al. 1994) and its sequence as determined by 
Kamb et al. (1994) was identical to that o f the sequence as cloned by Serrano et 
al. (1993).
The CDKN2A locus is unique in the genome, because it encodes two 
overlapping tumour suppressor genes, CDKN2A also known as INK4A and the 
alternative reading frame ARF  (Stone et al. 1995) (Figure 1.9). These genes
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encode two distinct cell cycle regulatory proteins, pl6IN K 4A  and pM ARF (Ruas 
and Peters 1998). The 16kDa protein pl6IN K 4A  is encoded by exons la ,  2 and 
3, comprising 156 amino acids. An alternative first exon (1(3) is located 
approximately 22kbp upstream of the CDKN2A coding sequence. Transcripts 
initiating from exon 1(3 are spliced onto the common exon 2 and 3, giving rise to 
an alternative mRNA that encodes pl4A RF in a different reading frame.
FIGURE 1.9 
CDKN2A Locus
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The CDKN2A  locus encodes two gene products involved in cell growth regulation. Transcription 
from exons 2 and 3 is shared by p l6IN K 4A  and p l4A R F , in different reading frames. 
p l6IN K 4A  initiates within unique exon l a  and p!4A R F within exon 1(3, which is located 
approxim ately 20 kbp upstream o f  exon la .
Both o f these proteins have a crucial role in cell death and apoptosis via 
the retinoblastoma pathway for pl6IN K 4A  and p53 pathway for pM ARF (Zhang 
et al. 1998). The pl61NK4A protein acts as a tumour suppressor and a cell-cycle 
regulator that induces G1 cell-cycle arrest by binding to and inhibiting the kinase 
activities o f the CDK4 (MIM# 123829)/cyclin D and CDK6 (MIM# 
603368)/cyclin D complexes (Serrano et al. 1993). When CDK4 and cyclin D 
are in this complex they initiate the phosphorylation o f the retinoblastoma 
protein, which permits cells to enter the DNA replication stage in the S phase of 
the cell cycle.
Mutations in the CDK4 gene on chromosome 12, which encodes the 
cyclin-dependent kinase 4 protein that is normally inhibited by pl6IN K 4A , have 
only been reported worldwide in three melanoma-prone kindreds (Zuo et al. 
1996; Soufir et al. 1998). All the mutations occur in codon 24, with two families 
carrying an R24C mutation (Zuo et al. 1996) and another family with an R24FI 
substitution (Soufir et al. 1998). This must mean that this residue interacts with
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pl6INK4A. pl6INK4A binds to CDK4 at the arginine and so mutations at this 
residue will disrupt binding to CDK4 resulting in an activated CDK4. The 
activating mutations in CDK4 are oncogenic, since this kinase negatively 
regulates the retinoblastoma protein by phosphorylation, causing it to release 
transcription factors.
The majority of melanomas are sporadic, but up to 5% of melanoma 
patients have one or more first-degree relatives also affected (Hayward, 2003). 
Genetic analysis o f these melanoma families shows germline mutations of 
CDKN2A (MIM# 600160) in 20-30% of patients (Harland et al. 1997; Kefford et 
al. 1999; Hayward et al. 2000; Goldstein et al. 2001; Bishop et al. 2002). 
CDKN2A mutations are rare but highly penetrant and are transmitted in an 
autosomal dominant fashion. The estimated frequency of the mutated CDKN2A 
gene in the general population is 0.01% (Bishop et al. 2002). In a study of 
sporadic melanoma cases from Queensland, Australia, Aitken et al. (1999) 
estimated that 0.2% of all melanoma cases are caused by CDKN2A mutations.
The first germline mutation in CDKN2A was discovered in large 
melanoma pedigrees in 1994 by the Utah group. Hussussian et al. (1994) 
identified six probable disease-related mutations in the CDKN2A gene in families 
linked to 9p21. A variety of germline mutations within the coding sequences of 
exons l a  and 2 of CDKN2A have now been observed in affected members of 
more than 100 malignant melanoma families worldwide, including deletions, 
duplications and missense mutations (Harland et al. 1997; Pollock et al. 1998; 
Ruas and Peters 1998), a selection o f which will be discussed below. Mutations 
in exon l a  affect only the CDKN2A transcript, whereas those mutations in exon 
2 can affect both CDKN2A and ARF.
The International Melanoma Genetics Consortium has established an 
online locus-specific variant database for familial melanoma called eMelanoBase 
which is accessible at www.wmi.usyd.edu.au: 8080/melanoma.html (Fung et al. 
2003). More recently, Murphy et al. (2004) introduced the CDKN2A Database, 
which is again an online database of germline and somatic variants of the 
CDKN2A tumour suppressor gene recorded in human disease, annotated with 
evolutionary, structural, and functional information. It is accessible at 
http://biodesktop.uvm.edu/perl7p 16.
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1,10,1 Commonly Detected CDKN2A Allelic Variants
R24P
In a patient with multiple primary melanomas, Monzon et al. (1998) 
identified an arginine 24 to proline mutation in the CDKN2A gene. This 
mutation had previously been reported in melanoma-prone families and was 
found to cosegregate with cases o f melanoma (Holland et al. 1995). This 
mutation has also now been identified U.K. melanoma families (Harland et al. 
1997; MacKie et al. 1998). Functional studies have shown the R24P mutant to 
behave normally in a CDK4 binding assay, despite cosegregation of this mutation 
with disease in nine melanoma families (Becker et al. 2001).
24bp Duplication
Pollock et al. (1998) identified two new melanoma kindreds that carried a 
duplication of a 24bp repeat present in the 5-prime region of the CDKN2A gene. 
This brought the total number of melanoma families described with this mutation 
to five, from three continents: Europe, North America, and Australasia. Previous 
families were reported by Goldstein et al. (1995), Walker et al. (1995), and 
Flores et al. (1997). This suggested to Pollock et al. (1998) that there had been at 
least three independent 24bp duplication events. The duplication was 
hypothesized to have arisen due to an unequal crossing-over between the two 
24bp repeats naturally present in the wild-type sequence, possibly through 
polymerase slippage during replication. Further evidence that this repeat region 
is unstable and therefore prone to both meiotic and mitotic slippage was provided 
by the identification o f a somatic 24bp deletion o f one of these normally 
occurring repeats in a prostate tumour (Komiya et al., 1995).
Exon 1p Deletion
Randerson-Moor et al. (2001) described a family characterized by multiple 
melanoma and neural cell tumours segregating with a germline deletion of the 
y4RF-specific exon ip  of CDKN2A. The deletion was approximately 14kb and 
did not affect the coding or minimal promoter sequences of either CDKN2A or 
p!4A R F .
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G67S
Holland et al. (1999) analyzed 131 Australian melanoma probands. They 
identified a glycine 67 to serine mutation. Glycine 67 is conserved, lying within 
the second ankyrin repeat and shares secondary structure alignment with glycine 
101, a residue of proven significance to pl6INK4A function. Glycine 67 is the 
first residue of loop 2 of pl6INK4A (Byeon et al. 1998).
IVS2. A -G .-105
Harland et al. (2001) reported that affected individuals in six of 90 
English melanoma pedigrees screened carried a transition (IVS2-105 A-G) deep 
in intron 2 o f the CDKN2A gene. The mutation creates a false GT splice donor 
site 105 bases 5-prime of exon 3 and results in aberrant splicing of the mRNA. 
The authors proposed that this mutation and others similar to it might account for 
a significant proportion of 9p21-linked melanoma pedigrees with no detectable 
mutations in the coding region of CDKN2A.
R112G
Holland et al. (1999) analysed 131 Australian Melanoma Probands. They 
identified an arginine 112 to glycine mutation. Arginine 112, though not itself 
conserved in the INK4 family, is immediately flanked by several highly 
conserved residues. This mutation has also been observed as a somatic event in a 
sporadic metastatic melanoma (Platz et al. 1996a).
1.10.2 CDKN2A polymorphisms
In addition to mutations within the CDKN2A gene, the rare alleles in the 
3' untranslated region of the gene, the C500G (Aitken et al. 1999) or C540T 
polymorphism (Kumar et al. 2001) have also been associated with risk of 
developing melanoma. Aitken et al. (1999) showed the frequency of the C500G 
polymorphism to increase with increasing familial risk and in those carrying 
mutations of CDKN2A. Kumar et al. (2001) analysed the C540T polymorphism 
and found the frequency to be significantly higher in the melanoma cases than in 
controls. Further studies are needed to confirm a possible association between 
the polymorphisms and melanoma risk.
44
1.10.3 CDKN2A mutations in Patients with Multiple Primary Melanomas
CDKN2A mutations have been detected in 9%-15% of patients with 
multiple primary melanomas and a family history of melanoma (Hayward,
2003). CDKN2A germline mutations have also been detected in 5/33 (15%) 
multiple primary melanoma cases irrespective of family history (Monzon et al., 
1998) and in 2/17 (12%) multiple primary melanoma patients with a negative 
family history (MacKie et al., 1998).
1.10.4 CDKN2A AND UV Radiation
The exact sequence of the molecular changes in the melanocyte following 
UV induced damage is not yet understood. Pavey et al. (1999) reported 
increased levels of pl6INK4A when human skin was exposed to UV radiation. 
The presence of a pathway involving pl6INK4A, which can be stimulated by 
UV radiation, could provide a link between pl6INK4A, UV radiation and 
melanoma. UV radiation causes both G1 and G2 phase checkpoint arrest in vitro 
cultured cells. Pavey et al. (2001) investigated the cell cycle responses to UV 
exposure on skin. Using skin cultures they demonstrated that melanocytes 
undergo a G2 phase cell cycle arrest for up to 48 hours following exposure and 
showed increased pl6INK4A expression.
In addition Pavey et al. (2002) demonstrated that an increased expression 
of pl6INK4A after exposure to UV radiation is influenced by a-MSH, a ligand 
for MC1R (page 35). This link between pl6INK4A and MC1R may provide a 
molecular basis for the increased skin cancer risk associated with MC1R 
polymorphisms.
1.10.5 CDKN2A and Other Cancers
Somatic CDKN2A mutations have been reported in a number of different 
tumour types (Smith-Sorensen and Hovig 1996; Foulkes et al. 1997; Ruas and 
Peters 1998) and therefore it is possible that germline CDKN2A mutations could 
increase the risk of non-melanoma cancers in CDKN2A mutation-positive 
individuals. An increased risk of pancreatic cancer was first reported in 
melanoma families with CDKN2A mutations (Goldstein et al. 1995; Whelan et 
al. 1995).
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Several other groups have since reported the occurrence of pancreatic 
cancer in mutation-positive melanoma families (Bergman et al. 1996; Ciotti et al. 
1996; Soufir et al. 1998; Liu et al. 1999; Borg 2000; Lynch et al. 2002). The 
International Melanoma Genetics Consortium is currently collecting data on the 
risks of non-melanoma cancers in melanoma families carrying CDKN2A 
mutations.
1.11 Other Melanoma Susceptibility Genes
Familial melanoma is rare and the genes implicated in these melanoma 
families are likely to play a minor role in sporadic melanomas. Other high- 
penetrance melanoma predisposition genes are likely to exist and those that 
encode proteins involved in cell-cycle regulation will be strong candidates.
1.11.1 ARF
Melanoma segregates with chromosome 9p markers in a larger number of 
melanoma families than have been shown to carry mutations o f CDKN2A. This 
high degree of linkage to 9p could be due to mutations affecting pl4ARF, the 
product o f the alternative transcript arising from the CDKN2A locus. Hewitt et 
al. (2002) described a melanoma family in which both mother and daughter carry 
a mutation in the last nucleotide of exon lp. The substitution replaces a glycine 
with an arginine residue, which affects the splicing o f the ARF mRNA, and leads 
to complete deletion of the mutant transcript.
An insertion of 16bp within exon lp  causing a frameshift in ARF  but 
does not affect pl6INK4A has been reported in a sporadic melanoma patient 
with multiple primary melanomas (Rizos et al. 2001).
1.11.2 MC1R
The suggestion o f a low-penetrance susceptibility gene for sporadic 
melanoma was the association of variants of the MC1R gene with red hair and 
fair skin (Valverde et al. 1996).
The Melanocyte-stimulating hormone (MSH) regulates pigmentation by 
binding to its receptor Melanocortin 1 Receptor (MC1R) (MIM# 155555) as 
described previously. Chhajlani and Wikberg (1992) isolated the 317 amino acid
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MC1R protein from human melanoma cells. The MCIR  gene was mapped to 
chromosome 16q24.3 by fluorescence in situ hybridization (Gantz et al. 1994). 
This intronless gene encodes encodes a seven pass transmembrane G protein 
coupled receptor that controls melanogenesis (Figure 1.10). As described on 
pages 34-35, the relative proportions o f pheomelanin and eumelanin are 
regulated by melanocyte stimulating hormone, which acts via its receptor 
(MCI R) on melanocytes, to increase the synthesis o f eumelanin. Gene mutations 
that lead to a loss in function are associated with increased pheomelanin 
production, which leads to lighter skin and hair colour. Harding et al. (2000) 
have shown that there is extensive variation o f the MC1R gene in European and 
Asian populations, but hardly any variation in African populations. This 
suggests the evolutionary conservation o f the MCIR  gene in Africa to retain 
eumelanin production.
FIGURE 1.10 
The M C IR  Gene
The M C IR  gene has only one exon, which encodes a seven pass transm embrane G protein 
coupled receptor that controls melanogenesis.
Sequence variants in the MCIR  gene were identified in over 80% of 
individuals with red hair and/or fair skin that tan poorly but in fewer than 20% of 
individuals with brown or black hair, and in less than 4% of those who showed a 
good tanning response (Valverde et al. 1995).
This indicated that M CIR is a control point in the regulation of 
pigmentation phenotype and that variations in this protein are associated with a
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poor tanning response. From sequencing the entire M CIR  gene from 30 
unrelated British or Irish individuals with various degrees of red hair and 30 
brown or black haired control subjects, nine sequence variants were identified. 
53% of individuals with red hair were found to carry one variant allele and 29% 
had two variant M CIR  alleles. No individual with any other hair colour was 
found to carry two variants. The majority of individuals (76.5%) with skin type 
1 carried a M CIR  variant, whereas no individuals with skin type 4 carried a 
variant. The frequencies were intermediate for individuals with skin types 2 
(46.5%) and 3 (5%). 16 individuals carried the D294H variant, making it the 
most common variant identified. The variant was not present in the individuals 
with brown or black hair. D294 is in the seventh transmembrane domain and a 
mutation to D294H replaces an acidic residue with a basic one. Valverde also 
found that one of the most frequent mutations associated with red hair and a poor 
tanning capacity was V92M. Variant V92M and variants at codons 84 and 95, 
might be expected to alter the alpha-helix structure o f the second transmembrane 
domain of the MSH receptor.
The link between M CIR  and melanoma became apparent when Valverde 
et al. (1996) first reported certain variants of the M1CR gene to be more common 
in individuals with melanoma than in control subjects. They compared the 
M CIR  genotype between 43 melanoma cases and 44 controls. They found that 
M CIR variants were significantly more common in cases than controls 
(P=0.0094). They found the D84E variant in 10/43 patients with melanoma with 
two individuals being homozygous for this substitution. The aspartate at codon 
84 is highly conserved.
Following Valverde’s two publications, there have been a number of 
publications looking both at M CIR  variants in melanoma compared with healthy 
individuals, and also population studies looking at the association between 
M CIR  variants and skin type and hair colour. This work has been carried out by 
Box et al, (1997); Ichii-Jones et al. (1998); Smith et al. (1998); Flanagan et al. 
(2000); Healy et al. (2000); Palmer et al. (2000); Kennedy et al. (2001).
Studies have also explored possible interactions between CDKN2A 
mutations and the M CIR  variants by Box et al. (2001) in Australia and van der 
Velden et al. (2001) in The Netherlands.
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There are a large number o f MCIR  variants and the relationship between 
MCIR variants and skin type and hair colour, as well as the relationship between 
MCIR  variants and melanoma, are complex. Other genes responsible for 
pigmentation are likely to be involved as low-risk melanoma predisposition 
genes as well as modifier genes.
1.12 BR AF
In 1992 Eychene et al. identified two human BRAF loci by fluorescence 
in situ hybridization. The BRAF gene locus was mapped to chromosome 7q34 
and encodes the functional gene product. BRAF2, located on X ql3 , is an 
inactive pseudogene.
In 2002 Davies et al. reported for the first time BRAF (V-RAF Murine 
Sarcoma Viral Oncogene Flomolog B1 (MIM# 164757) mutations in human 
melanoma. They reported a T to A transversion at nucleotide 1796 in exon 15 of 
the BRAF gene that leads to a valine-to-glutamic acid substitution at codon 599 
(V599E) (Figure 1.11). This mutation accounted for 92% of the BRAF somatic 
mutations identified in the 20 o f 34 (59%) human melanoma cell lines, short­
term melanoma cultures, and 6/9 primary melanoma samples.
FIGURE 1.11 
BRAF S tructure
Kinase Domain
G-Loop Activation Segment
1
G465 T598 
|G 468 | T601
CR1 CR2 CR3
Codon
1
Codon
765
V599
Schem atic drawing o f BRAF showing the location o f  the G-loop (exon 11) and activation 
segment (exon 15) o f  the kinase domain. Codon 599 is highlighted in red. The glycine residues 
that make up the backbone o f  the glycine loop and the phosphorylation sites in the activation 
segment are also shown.
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No data was included either on cases o f familial melanoma or on the prevalence 
o f BRAF mutations in secondary melanoma tissue. We have therefore looked for 
exon 15 BRAF mutations in our material from these sources. We were 
particularly interested to see if exon 15 BRAF mutations were present in our 
families with no evidence o f CDKN2A mutations.
The BRAF gene encodes a proto-oncogenic serine/threonine-protein 
kinase. Its normal function is to control proliferation and differentiation through 
the MAP kinase pathway (Figure 1.12).
FIGURE 1.12
Melanocyte Signal Transduction
CAMP
Changes in Gene expression
BRAF functions downstream o f Ras in the M APK cascade. Signals from extracellular growth 
regulatory factors (pink) transduced through receptor tyrosine kinases (blue) or G protein- 
coupled receptors (yellow) result in activation o f  the M APK pathway. This illustration was taken 
from Pollock and M eltzer (2002).
In the course o f carrying out the studies reported in this thesis, further 
publications o f BRAF in relation to melanoma have come from Meyer et al. 
(2003), Pollock et al. (2003), Edwards et al. (2004) and Wan et al. (2004). These 
are fully reviewed in Chapter 11, in relation to the findings in this thesis.
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1.13 Aims of the Thesis
The aim of this study is to extend our knowledge of genetic factors in the 
development of melanoma. In this thesis I have investigated Scottish families 
with cutaneous malignant melanoma and also patients with sporadic melanoma 
for mutations in the CDKN2A, M CIR  and BRAF  genes using molecular genetic 
techniques. CDKN2A studies have been carried out in families with melanoma, 
and M CIR  and BRAF  variants investigated in familial melanoma, sporadic 
melanoma and phenotyped normal controls.
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CHAPTER 2
DETAILS OF MELANOMA PATIENTS 
STUDIED AND CONTROL SUBJECTS 
INCLUDING PHENOTYPIC 
CHARACTERISTICS
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2.1 Subjects
DNA for this study was extracted from peripheral blood and from tumour 
tissue of patients with melanoma, both with and without a family history of 
melanoma, from relatives in the case of familial melanoma, and from an 
appropriate control population. Ethical committee permission (reference number 
LREC 00/161(2)) was obtained to obtain peripheral blood and/or tumour tissue 
from all these groups and written informed consent given by all participants. To 
protect individual identity, no dates o f birth are presented. All individuals have 
given written permission for the publication of their family trees.
2.1.1 Melanoma Families
Index cases of melanoma families were referred to the West of Scotland 
melanoma clinic, Department of Dermatology in the Western Infirmary, 
Glasgow, U.K., and family histories of other affected members confirmed by 
examination of the pathology slides from the primary tumour of the second and 
subsequent family members by Prof. MacKie. All melanoma patients in the 
study have primary cutaneous melanoma invasive to Clark level 2 or deeper 
(Clark et al. 1969). It was decided not to include patients who only had in situ 
melanoma because of the lack of concordance among pathologists in the 
discrimination between in situ melanoma and severely atypical nevi. While this 
may have excluded some families, it ensures that all families studied do indeed 
have potentially fatal melanoma.
Where possible, second and subsequent melanoma patients in affected 
families, and also unaffected family members have been personally examined by 
Prof. MacKie to establish information on the family pedigree, hair and eye 
colour and skin type with regard to sun exposure, sun bed use, and of other 
reported non melanoma cancers within the family. Since 1985 to date peripheral 
blood DNA has been collected from 48 melanoma families comprising 78 
patients with melanoma and 28 currently unaffected family members. Forty-six 
families originated in the West of Scotland and two in the North East Grampian 
region who were referred by Dr M Nicholson of Aberdeen. Tumour DNA has 
also been obtained from secondary melanoma samples from two of these 
patients. In addition, DNA from five melanoma families from Toronto, four
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from Brisbane and three from Boston (25 individuals) were made available for 
the M53I founder mutation study.
2.1,2 Sporadic Melanoma Cases
As with familial cases, all patients were referred to the West of Scotland 
melanoma clinic. A family history of melanoma was excluded in each case. 
Information on skin type, eye and hair colour with regard to sun exposure and 
sun bed use was collected as previously described. DNA was extracted from the 
peripheral blood of 28 patients with sporadic melanoma for the MCIR  study. 
Peripheral blood DNA was also collected from eight patients with sporadic 
melanoma with three or more multiple primary melanomas for the CDKN2A 
study.
As with familial cases, all patients have invasive melanoma (Clark level 2 
or deeper). Thick primary melanomas were used for the DNA extraction from 
paraffin-processed tissue. Fifty-two sections each lOpM thick were cut from the 
block containing the greatest density of melanoma tissue. DNA extracted from 
these sections was then screened for mutations in exon 15 of the BRAF  gene.
DNA from patients with metastatic melanoma was obtained from frozen 
tumour tissue. In 22 cases this was from lymph nodes containing large 
melanoma metastases, and DNA was then extracted from the area in which nodal 
tissue was most obviously replaced by secondary melanoma. One of these 
patients gave two samples to the study because of two surgical procedures
several months apart. A further patient had large soft tissue melanoma
metastases and DNA was extracted both from two tumour deposits and also the 
peripheral blood.
All melanoma patients, both sporadic and familial, answered a detailed 
questionnaire at diagnosis. This included:
• Place of birth
• Whether or not childhood was spent in a high solar environment
• Occupational details, decade by decade, with regard to
geographical location and whether their occupation was indoors 
or outdoors
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• History of more than one sunny holiday per year
• History of any severe blistering or peeled sunburn
• Use of sunbeds
2,1.3 Control subjects
Individuals attending a local minor injury clinic were invited to 
contribute peripheral blood DNA to the study. They were from the same 
geographical area as the melanoma patients, and were matched for age and ethnic 
group. Past sun exposure and sun bed use, hair and eye colour was recorded, and 
skin type with regard to sun exposure was recorded. There is no need to believe 
that this population have any greater or lesser risk of melanoma than the general 
population.
2.2 Samples used in this study
2.2.1 Venous Blood Samples
Blood was collected by venous puncture into a 10ml EDTA coated 
vaccutainer or specimen tube (TEKLAB). Samples were routinely kept at room 
temperature for up to three hours then transferred to 4°C until extraction. 
Extraction was routinely carried out within 48 hours.
2.2.2 Paraffin Embedded Tissue Samples
Samples were obtained from the Department of Pathology at Glasgow 
Royal Infirmary. Routinely 10X lOpM sections of formalin fixed paraffin- 
embedded melanoma tissue were used for extraction. Samples were selected 
from thick melanomas to obtain adequate volumes of tumour tissue.
2.2.3 Fresh Tissue Samples
Frozen material was available from patients undergoing lymph node dissection 
for clinically enlarged lymph nodes or from patients having subcutaneous 
metastases excised at Gartnavel General Hospital. In every case the metastatic 
melanoma was confirmed by pathological examination. All samples were frozen 
and stored at -70°C.
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2.3 Numbering of Families
The 48 families were numbered F1-F48. Where a sample from a family 
member was available, the family member was numbered. For example in 
family FI 1 there were three family member’s samples available and therefore the 
family members were numbered FI 1.1, FI 1.2 and FI 1.3. A diagnosis of familial 
melanoma was made when two or more family members had a pathological 
confirmed diagnosis of invasive melanoma to Clark level 2 or deeper.
Of the 48 families in total, there are 106 family members with melanoma, 
66 females and 40 males. As of June 2004, one family F19 has five affected 
members, one family F2 has four affected members, five families FI, F8, F20, 
F21 and F29 have three affected members, and the remaining 41 families have 
two affected members.
Thirteen DNA samples were available from familial melanoma patients 
with multiple primary melanomas, 9/66 (13.6%) females, and 4/40 (10%) males. 
In families F I9, F30 and F31 there are a total of five cases of ovarian cancer, in 
families FI 1 and F21 there are a total of two cases of pancreatic cancer, in family 
F l l  there is a case of breast cancer, in family F14 there is a case of lymphoma 
and in family F2 there is a case of oesophageal cancer. Details of currently 
affected family members, gender, age at diagnosis and other malignancies are 
presented in table 2.1.
Available samples were collected for this study from 106 members of 
these families o f which 78 were affected members and 28 were currently 
unaffected members.
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TABLE 2.1
Details of Scottish Families with Two or More Members with Invasive Melanoma
Scottish
Family
Number
Family Members 
with Melanoma
Age at Diagnosis 
(years), Sex M/F
Other Malignancies 
in the Pedigree
1 3 F48, F37*, F? -
2 4 F39, M37, M31.M19 oesophagus
3 2 F55, F33* -
4 2 M46*, F46* -
5 2 M36*, F27 -
6 2 F34*, F21 -
7 2 F45, M43 -
8 3 F41, F23, M16 -
9 2 M56, F21 -
10 2 M53, F45 -
11 2 M63, F33* breast, pancreatic
12 2 M69, F37 -
13 2 M34, M3 6 -
14 2 F68, F31 lymphoma
15 2 F61, M48 -
16 2 M34, F16 -
17 2 M34, M3 6 -
18 2 F42, F49 -
19 5 F66, F33*, F49*, 
M40, F40
ovarian
20 2 M38, M51 -
21 3 M34, F35, M46 pancreatic
22 3 F38, M33, M29 -
23 2 F48, F53 -
24 2 F39, F41 -
25 2 M45, F50 -
26 2 M70, M49 -
27 2 M43, F61 -
28 2 M34*, M37 -
29 3 M27, F50, M62 -
30 2 F20, F24 ovarian
31 2 F43, M61 ovarian
32 2 F38, F76 -
33 2 F25*, F28* -
34 2 M23, M69 -
35 2 F44, F56 -
36 2 M43, F36 -
37 2 F24, F62 -
38 2 F43, F36 -
39 2 M27, F23 -
40 2 F27, F58 -
41 2 F18, F59 -
42 2 F39*, F62 -
43 2 F26*, M51* -
44 2 F29, M66 -
45 2 F48, F21 -
46 2 F71, F79 -
47 2 F33, M? -
48 2 F?, F? -
* denotes a patient with multiple primary melanomas.
? denotes age unknown.
- denotes no other malignancy.
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2.4 Phenotyping of Patient and Control C ohort
Sporadic cases are numbered S1-S28 and control subjects are numbered 
C1-C68.
2.4.1 Phenotype Grouping o f Patients and Control Subjects for MCIR Study
Patients were asked to identify their skin type with regard to sun exposure 
as one of four groups according to Fitzpatrick (1988):
1 = never tans, always bums
2 = bums easily, tans rarely
3 = bums rarely, tans easily
4 = never bums, always tans
Eye colour was assessed into one of four categories at clinical 
examination by Prof. R. MacKie:
1 = blue
2 = green
3 = brown
4 = other
Patients were asked to classify their hair colour at 20 years of age into 
one of four groups:
1 = red
2 = blonde
3 = light brown
4 = dark brown/black
The phenotypic characteristics of all patients with melanoma, unaffected family 
members and of control subjects are summarised in tables 2.2, 2.3 and 2.4 
respectively.
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TABLE 2.2
Phenotypes of Fam ilial M elanoma Patients & their Unaffected Relatives
Identifier Skin
Type
Eye
Colour
Hair
Colour
F l.l 1 1 2
F1.2 1 1 2
FI.3 2 1 3
F2.1 2 1 4
F2.2 2 1 3
F2.3 2 1 3
F2.4 2 1 2
F2.5 2 1 3
F2.6 2 4 2
F2.7 2 1 4
F2.8 2 1 3
F3.1 2 4 3
F3.2 2 1 3
F3.3 2 4 3
F4.1 2 4 3
F4.2 2 1 3
F4.3 2 1 3
F5.1 2 3 4
F5.2 2 4 4
F6.1 1 1 1
F6.2 1 1 1
F6.3 2 1 2
F6.4 2 1 2
F6.5 1 4 1
F7.1 1 4 1
F7.2 2 1 2
F8.1 2 3 4
F8.2 2 1 3
F9.1 1 1 1
F10.1 2 1 3
F10.2 2 1 2
F10.3 2 1 3
FI 1.1 1-2 1 1
F11.2 2 1 4
FI 1.3 2 4 2
F12.1 1 1 1
F13.1 3 3 4
F13.2 2 3 4
F13.3 2 4 2
F13.4 3 3 4
F14.1 2 1 3
F14.2 2 1 4
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Identifier Skin
Type
Eye
Colour
Hair
Colour
F15.1 2 1 2
F15.2 2 1 2
F16.1 1 1 2
F17.1 2 1 2
F17.2 2 1 2
F17.3 1 4 1
F17.4 2 1 2
F17.5 2 1 2
F18.1 2 1 3
F18.2 2 1 3
F19.1 1 1 4
F20.1 3 4 4
F21.1 2 1 4
F21.2 2 3 4
F22.1 1 1 3
F22.2 1 2 1
F22.3 2 1 4
F22.4 2 2 3
F22.5 2 1 3
F22.6 2 2 3
F23.1 2 1 2
F23.2 2 4 2
F23.3 2 1 2
F23.4 2 1 3
F24.1 2 1 3
F24.2 2 1 3
F25.1 2 4 4
F25.2 1 2 2
F26.1 2 1 3
F26.2
F27.1 1 1 1
F27.2 1 2 1
F28.1 2 1 3
F28.2 2 1 3
F29.1 2 1 3
F29.2 2 4 2
F30.1
F30.2
F31.1 1 1 1
F32.1 2 1 4
F32.2 1 1 3
F33.1 2 1 2
F33.2 2 1 2
F34.1 2 2 3
F35.1 2 2 3
F35.2 2 1 2
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Identifier Skin
Type
Eye
Colour
Hair
Colour
F36.1 2 1 2
F37.1 2 1 3
F37.2 2 1 3
F38.1 2 1 3
F38.2 2 1 4
F39.1 1 1 2
F40.1 1 1 1
F41.1 2 3 4
F41.2
F42.1 2 3 4
F42.2
F43.1 3 1 4
F43.2 1 1 3
F44.1 2 1 3
F45.1 2 3 3
F46.1 2 1 2
F47.1 1 1 1
F48.1 2 1 3
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TABLE 2.3
Phenotypes of Sporadic M elanoma Patients
Identifier Skin
Type
Eye
Colour
Hair
Colour
SI
S2 1 1 1
S3 2 2 3
S4 1 1 1
S5 1 2 1
S6
S7 2 1 3
S8 2 1 3
S9 2 1 2
S10 2 1 3
S ll 2 2 1
S12 1 1 2
S13 3 1 1
S14 2 1 3
S15 2 1 2
S16 2 1 3
S17 3 1 2
S18 2 1 1
S19 3 1 2
S20 2 1 2
S21 2 1 2
S22 2 3 3
S23 2 1 2
S24 1 3 3
S25 2 1 3
S26 1 1 2
S27 2 1 3
S28 3 3 3
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TABLE 2.4
Phenotypes of Control Subjects
Identifier Skin
Type
Eye
Colour
Hair
Colour
Cl 2 4 4
C2 2 2 2
C3 3 3 4
C4 2 1 2
C5 2 1 4
C6 2 2 1
Cl 2 1 4
C8 3 3 4
C9 3 3 4
CIO 3 3 4
C ll 2 1 2
C12 1 4 1
C13 2 4 4
C14 3 1 3
C15 2 1 3
C16 2 4 4
C17 2 1 3
C18 3 1 3
C19 2 1 2
C20 3 1 3
C21 3 1 2
C22 2 1 4
C23 1 1 1
C24 3 2 3
C25 3 1 2
C26 2 1 2
C l l 1 1 2
C28 3 1 2
C29 3 3 4
C30 3 3 4
C31 2 1 2
C32 3 3 2
C33 3 3 4
C34 2 1 2
C35 2 1 3
C36 2 1 3
C37 2 1 2
C38 2 1 4
C39 1 2 3
C40 2 4 3
C41 3 1 4
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Identifier Skin
Type
Eye
Colour
Hair
Colour
C42 1 3 1
C43 1 1 2
C44 2 3 2
C45 3 4 4
C46 2 1 2
C47 3 3 3
C48 1 1 1
C49 3 3 4
C50 1 1 1
C51 1 1 2
C52 3 3 3
C53 2 1 3
C54 3 3 4
C55 2 1 2
C56 3 1 2
C57 1 2 1
C58 3 3 4
C59 2 3 3
C60 2 1 3
C61 2 2 4
C62 3 1 2
C63 3 3 4
C64 1 1 2
C65 4 3 4
C66 2 1 2
C67 1 1 2
C68 4 1 2
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2.5 Correlation between Phenotype and Melanoma
This section describes the phenotypic characteristics of melanoma 
patients and control subjects, aimed at confirming that the characteristics of both 
patients and control subjects were reasonably representative by comparing with 
large epidemiological studies (Palmer et al. 2000; Box et al. 2001; discussed in 
section 10.1).
2.5.1 Statistical Analysis
Statistical analysis was performed using the methods described in method 
3.17. Due to the large quantity of results, all findings are reported in tabular 
form in Appendix 5. Significant results are only presented in this chapter.
2.5.2 Correlation between Skin Type and Melanoma
Among the four subsets o f skin type, the most frequent phenotype 
observed in the melanoma patients is to bum easily and tan rarely 60/88 (68.2%) 
and also in 29/68 (42.7%) control subjects. Only 7/88 (7.9%) cases compared 
with 25/68 (36.8%) control subjects have skin type 3. A 2 x 4 table was 
constructed to include the four skin phenotypes described in section 2.4.1. A 
chi-squared test was performed to compare melanoma cases, both familial (60 
cases) and sporadic melanoma patients (28 cases), with 68 control subjects. 
Familial and sporadic melanoma patients were pooled together as patient 
numbers are small. One of the potential problems o f investigating both familial 
and sporadic patients together is that the genetic background of the different 
groups cannot be easily pooled together, because both specific mutation and 
genes involved may differ between the two groups. The correlations discussed in 
these sections do not investigate genetics status and therefore the error rate in 
pooling these two groups is thought to be very small.
Table 2.5 shows the very highly significant difference in skin types 
between melanoma patients, both familial and sporadic, and control subjects (P < 
0.001). As expected, skin types 1 and 2 are significantly more common in 
patients than control subjects, compared with skin types 3 and 4, which are 
significantly more common in control subjects than in patients.
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TABLE 2.5
Skin Types in Familial and Sporadic Melanoma Patients Compared with
Control Subjects
1 Never 
Tans 
Always 
Burns
2 Burns 3 Burns 
Easily Rarely 
Tans Tans Easily 
Rarely
4 Never 
Burns 
Always 
Tans
No. of Cases 21 60 7 0
No. of Control 12 29 25 2
Subjects
P-value < 0.001 *** significant
Skin type can be thought to have a natural scale going from type 1 to 2 to 
3 to 4 and therefore to determine exactly which end of the skin type scale shows 
significance, similar skin types are grouped together, skin types 1 and 2 are 
grouped together and skin types 3 and 4 are grouped together, and compared 
against all melanoma patients, both familial and sporadic, and the control 
subjects by performing a two-tailed Fisher’s exact test. The following table 2.6 
shows the very highly significant difference between skin types 1 and 2 
compared with skin types 3 and 4 in melanoma patients, both familial and 
sporadic, compared with control subjects. 81/88 (92%) cases have skin type 1 or 
2 compared with 41/68 (60.3%) control subjects (P < 0.001; OR = 7.620; Cl 
3.060-18.974). These results confirm that skin types 1 and 2 are significantly 
seen more in patients than control subjects, compared with skin types 3 and 4, 
which are significantly seen more in control subjects than patients.
TABLE 2.6
Correlation between Skin Type 1 or 2 and Skin Type 3 or 4 and Melanoma 
Patients (Familial and Sporadic) and Control Subjects
No. of Cases No. of Control Subjects
Skin Type 1 or 2 81 41
Skin Type 3 or 4 7 27
P-value < 0.001 *** significant
OR = 7.620, Cl 3.060-18.974
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2.5.5 Correlation between Eye Colour and Melanoma
The most frequent eye colour observed in the melanoma patients is blue 
63/88 (71.6%). Blue is also the most common eye colour in control subjects 
38/68 (55.9%). 10/88 (11.4%) cases have brown eyes compared with 18/68 
(26.5%) control subjects. A 2 x 4 table was constructed to include the four eye 
phenotypes described in section 2.4.1. A chi-squared test was performed to 
compare melanoma cases, both familial and sporadic melanoma patients 
together, with the control subjects. Table 2.7 shows the nearly significant 
observation (P = 0.095) in all melanoma patients, both familial and sporadic, 
compared to the control subjects.
TABLE 2.7
Correlation between Eye Colour and Melanoma Patients (Familial and 
Sporadic) and Control Subjects
Blue Green Brown Other
No. of Cases 63 7 10 8
No. of Control Subjects 38 6 18 6
P-value = 0.095 (not significant)
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To further consider if there is an association between an individual 
having a particular eye colour and having melanoma, a two-tailed Fisher’s exact 
test was performed on cases and on control subjects for each eye colour against 
all other eye colours (Appendix 5, Table 9). The following table 2.8 shows the 
significant observations in all melanoma patients, both familial and sporadic, 
compared to the control subjects. Among the four different eye colours both 
blue and brown eyes returned a significant finding. 63/88 (71.6%) cases have 
blue eyes compared with 38/68 (55.9%) control subjects (P = 0.045; OR = 1.989; 
Cl 1.022-3.873). Only 10/88 (11.4%) cases have brown eyes compared with 
18/68 (26.5%) control subjects (P = 0.020; OR = 2.808; Cl 1.199-6.574).
TABLE 2.8
Eye Colour in Melanoma Patients (Familial and Sporadic) Compared with 
Control Subjects
No. of Cases No. of Control Sub jects
Blue Eyes 63 38
Other Eye Colour 25 30
P-value = 0.045 * significant 
OR = 1.989, Cl 1.022-3.873
Brown Eyes 10 18
Other Eye Colour 78 50
P-value = 0.020 * significant
OR =0.356, Cl 0.152-0.832
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2.5.4 Correlation between Hair Colour and Melanoma
The most frequent hair colour observed in the melanoma patients is light 
brown 32/88 (36.4%) compared with 15/68 (22.1%) control subjects. The most 
frequent hair colour observed in control subjects is blonde 24/68 (35.3%) 
compared with 24/88 (27.3%) cases. Sixteen out of 88 (18.2%) melanoma 
patients have red hair compared with 7/68 (10.3%) control subjects. A 2 x 4 
table was constructed to include the four hair phenotypes described in section 
2.4.1. A chi-squared test of association was performed on melanoma cases, both 
familial and sporadic melanoma patients together and on control subjects. The 
following table 2.9 shows the significant observation (P = 0.042) in all 
melanoma patients, both familial and sporadic, and in the control subjects.
TABLE 2.9
Hair Colour in Melanoma Patients (Familial and Sporadic) Compared with 
Control Subjects
Red Blonde Light Brown Dark Brown/Black
No. of Cases 16 24 32 16
No. of Control Subjects 7 24 15 22
P-value = 0.042 * significant
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To further investigate if there is a relationship between an individual 
having a particular hair colour and having melanoma, a two-tailed Fisher’s exact 
test was performed on cases and on control subjects for each hair colour 
(Appendix 5, Table 8). The following table 2.10 shows the almost significant 
observations in all melanoma patients, both familial and sporadic, and in the 
control subjects. Among the four different hair colours only light brown hair and 
dark brown or black hair returned a near significant result. 32/88 (36.4%) cases 
have light brown hair compared with 15/68 (22.1%) control subjects (P = 0.056; 
OR = 2.019; Cl 0.984-4.145). 16/88 (18.2%) cases have dark brown or black 
hair compared with 22/68 (32.4%) control subjects (P = 0.059; OR = 2.152; Cl 
1.024-4.523).
TABLE 2.10
Correlation between Hair Colour and Melanoma Patients (Familial and 
Sporadic) and Control Subjects
No. of Cases No. of Control Subjects
Light Brown Hair 32 15
Other Hair Colour 56 53
P-value = 0.056 (not significant) 
OR = 2.019, Cl 0.984-4.145
Dark Brown/Black Hair 16 22
Other Hair Colour 72 46
P-value = 0.059 (not significant)
OR = 0.465, Cl 0.221-0.976
The phenotyping carried out for the work in this thesis can reassure the reader 
that the melanoma population presented in this thesis is not atypical with regard 
to skin type, eye or hair colour.
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CHAPTER 3
LABORATORY METHODS
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3.1 Extraction of Genomic DNA
3.1.1 DNA Extraction from Venous Blood
DNA was extracted using the Whatman BioScience Genomic DNA 
Purification System (England) according to the manufacturer’s 
recommendations. The DNA was purified in approximately 30 minutes. 
Routinely 300pg of DNA per 10ml of blood was extracted with a concentration 
of 200ng/pl. The sample was stored at 4°C in a 2ml screw-cap tube (Sarstedt) 
for one month to allow complete dissolving of the sample. lOpl of each sample 
was loaded onto a 0.7% agarose gel containing ethidium bromide to estimate the 
amount of DNA of each sample. Samples were then transferred to -20°C for 
long-term storage.
3.1.2 DNA Extraction from Paraffin Embedded Tissue
Paraffin blocks of thick primary melanomas were selected from the files. 
These blocks were trimmed to remove as far as possible surrounding normal non 
melanoma tissue and 10 x lOpM sections were cut from the primary melanoma 
sample. Dissected tissue was deparaffinized in 1200pl o f Histo-Clear (National 
Diagnostics) and vortexed vigorously using a rotamixer (Hook & Tucker 
Instruments) in a 1.5ml microcentrifuge tube. This was followed by 
centrifugation using a Micro Centaur (Scotlab) at 5,000 x g for 5 minutes at room 
temperature. The supernatant was removed by pipetting. 1200pl o f 100% 
ethanol was added to the pellet and the sample vortexed at a low speed until the 
pellet was resuspended. This step was to ensure the removal of residual Histo- 
Clear. The sample was centrifuged at 5,000 x g for 5 minutes at room 
temperature to pellet the tissue and the ethanol was removed by pipetting. This 
step was repeated three times followed by incubation of the open microcentrifuge 
tube at 37°C for 15 minutes to evaporate residual ethanol. The tissue pellet was 
resuspended in 180pl of Buffer ATL from the QLAGEN QIAamp DNA Mini kit 
(England). 20pl of Proteinase K was added to the sample, mixed by vortexing 
and incubated at 56°C overnight until lysis had taken place. DNA was extracted 
using the QIAGEN QIAamp DNA Mini kit according to the manufacture’s 
instructions.
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3.1.3 DNA Extraction from Frozen Tissue
DNA was extracted from frozen tissue using the above method with the 
QIAGEN QIAamp DNA Mini kit.
3.1.4 DNA extraction from Bacterial Colonies
DNA was extracted from the cloning experiments using the QIAGEN 
QIAprep Spin Miniprep Kit according to the manufacture’s instructions.
3.2 Storage of DNA
Two separate aliquots of extracted DNA were stored:
1) Stored at 4°C for at least 24 hours to allow complete dissolving of DNA. This 
was used as the working aliquot.
2) Stored separately at -20°C as a backup sample kept in case of contamination 
of one tube and also to avoid continual freeze thawing.
3.3 Determination of Concentration of DNA
The concentration of DNA was measured by absorbance at 260nm using 
the GeneQuant II spectrophotometer (Pharmacia Biotech) according to the 
manufacturer’s instructions. 1ml of MqFbO was aliquoted into a 10mm Silica 
cuvette (Amersham Pharmacia Biotech, Cambridge) to zero the spectrometer. 
Readings were taken at wavelength 260 nm (OD260). The spectrometer was 
rezeroed between each wavelength reading. All DNA used has an absorbance 
reading at 260nm between the range of 1.5-2. An OD of 1 corresponded to 
approximately 50pg /ml for double stranded DNA.
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3.4 The Polymerase Chain Reaction
3.4.1 Primer Design
Individual primers and primer pairs (Appendix 1) were designed with the 
aid of the Primer3 web site (http://frodo.wi.mit.edu/cgi- 
bin/primer3/primer3_www.cgi). Several variables were taken into account when 
designing primers. All oligonucleotides were designed to have a length between 
18 and 24 bases in order for them to be sequence specific. When designing the 
primer pairs, both o f the oligonucleotide primers were designed such that they 
had similar melting temperatures to allow for efficient amplification and rule out 
mis-priming at lower temperatures. The melting temperatures of the oligos were 
calculated using Primer3 and also by the Wallace formula:
Tm = 2(A+T) + 4(G+C)
The lowest melting temperature of each primer pair was then used for choosing 
the annealing temperature for PCR. Optimisation o f PCR usually began with an 
annealing temperature 5°C lower than the melting temperature.
Primers were designed with no primer homology as partial homology in 
the middle regions of two primers could interfere with hybridization and no 
homology at the 3' end of either primer, as primer dimer formation would occur 
which could prevent the formation of the desired product via competition. The 
base composition of primers was designed to be between 45% and 55% GC with 
no polyG or polyC stretches as these could promote non-specific annealing. 
PolyA and PolyT stretches were also avoided as these would open up stretches of 
the primer-template complex, lowering the efficiency of amplification. Where 
possible a G or C residue at the 31 end of primers was included to help correct 
binding at the 3’ end due to the stronger hydrogen bonding of G/C residues.
3.4.2 Primer Synthesis
All primer sequences were synthesised commercially (Sigma-Genosys). 
All primers were desalted, deprotected and at 0.03pM except the forward 
haplotyping primers which were at 0.05pM and 5 '-end FAM fluorescently 
labelled.
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3.4.3 Resuspension o f Primers
Dried primers were resuspended in 1ml of sterile MqfbO. Once 
suspended, primers stocks were stored at -20°C. A 5pM working stock of each 
primer was kept separately at -20°C. However, to minimize degradation due to 
freeze/thaw, aliquots were sometimes kept at 4°C for immediate, short term use.
3.4.4 PCRMastermix
All PCR amplifications were carried out using the same mastermix made 
fresh each time. Each 25pi mastermix comprised the following reagents added 
to a 0.2ml sterile thin-walled tube with flat cap (ABgene). The master reaction 
mix was scaled up to provide sufficient quantities for the number of tubes 
required, plus a further tube was calculated for to allow for pippetting errors:
19pl MegaMix~W (Microzone Ltd, UK)
2.5pi Forward Primer (5pM)
2.5pi Reverse Primer (5pM)
24pl Total
3.4.5 Amplification
Routinely lp l of genomic DNA or 2pl of tissue DNA (approximately 
lOOng/pl) was used as a template. 24pl of master mix was aliquoted into tubes 
on ice and DNA added to each tube. Mixing was by pipette. When multipore 
plates were used, the master reaction mix was aliquoted out first and then the 
appropriate DNA template added and mixed by swirling the pipette tip in the 
mixture, no pipette pumping action was used to reduce aerosol-contamination. 
The cycling parameters were determined for each primer pair (Appendix 2). 
Amplifications were performed using a Primus 96 Plus (MWG Biotech) and 
stored at 4°C.
5 pi of PCR product was analysed by agarose gel electrophoresis for 
product amplification and size. When amplifying DNA from paraffin embedded 
tissue, the yield from a single PCR was insufficient to visualise in a gel, therefore 
a 2pl aliquot was used as a template for a second round of PCR amplification.
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3.5 Gel Electrophoresis
Size separation of DNA fragments using a range of techniques were 
performed in the course of this study. Agarose gels were used for routine 
amplification checking and sizing of PCR products. Agarose or Spreadex gels 
were used in the sizing of digested PCR products. Polyacrylamide gel 
electrophoresis was used to visualise sequencing fragments.
3.5.1 Agarose
a) Agarose Gel Preparation
Routinely two types of agarose gels were used, UltraPure Agarose 
(Invitrogen Life Technologies, UK) or a mixture o f UltraPure Agarose and 
NuSieve 3:1 agarose (BioWhittaker Molecular Applications, USA). IX  TAE 
buffer (Flowgen, UK) was used as a solute. The concentration of pure agarose 
gel varied depending upon the size of fragments to be separated. Both agarose 
and agarose/NuSieve were added to IX TAE buffer in a large beaker. The 
mixture was heated on a high microwave setting for 1-2 min or until all solids or 
viscous agar had melted and the solution had started to boil. The mixture was 
than left to cool until hand hot or 65°C and then ethidium bromide (EtBr) 
(Sigma) was added to a final concentration of 0.3pg/ml and the solution poured 
into the appropriate gel mould to set (20 to 30 min).
b) Agarose Gel Electrophoresis
Agarose gel electrophoresis was carried out using either a RunOne 
System (Embi Tec, USA) or Sub Cell GT (Bio Rad). The polymerized gel was 
submerged to a depth of around 1mm in the appropriate horizontal 
electrophoresis tank, either RunOne System (Embi Tec, USA) or Sub Cell GT 
(Bio Rad), containing IX TAE electrophoresis buffer. 2pl of loading mix was 
added to each sample and loaded into the sample wells. 1 Opl of an appropriate 
size marker, usually lkb, lkb plus or phi-X 174/Hinf I (Promega), was co- 
electrophoresed with the DNA samples to check for band presence, intensity and 
correct size. The DNA standards were loaded at one end o f a row of samples. 
Electrophoresis was typically run at 100V for 20 minutes at room temperature
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until the loading buffer dye front reached the base of the gel. During migration, 
the EtBr present in the gel intercalates with the amplicon nucleotides. The 
nucleotides are then visible when the gel is viewed under UV254 nm.
3.5.2 Spreadex
a) Snreadex Mini Gels
Ready prepared mini gels, Spreadex EL 600 and 1200, were purchased 
from Elchrom Scientific, Switzerland. These were used to separate digested 
PCR products, which were only a small number of bases difference. The gels 
were stored at 4°C until ready for use.
b) Spreadex Gel Electrophoresis
The gel was submerged to a depth of around 1cm in the submerged gel 
electrophoresis apparatus (Elchrom Scientific, Switzerland) containing 30mM 
TAE electrophoresis buffer. 3 pi of loading mix was added to each 7pl sample 
and loaded into the sample wells. lOpl of an appropriate size marker, usually 
lkb, lkb plus or phi-X 174/Hinf I (Promega), was co-electrophoresed with the 
DNA samples. Electrophoresis usually was at 120V for 90 minutes at room 
temperature.
c) Ethidium Bromide Staining
After electrophoresis, the gel was placed on a shaker filled with 6pi of 
EtBr and 100ml 30mM TAE buffer and left to stain for 10 minutes.
3.5.3 DNA Visualisation
After electrophoresis, gels were placed on a Dual-Intensity 
Transiluminator (Alpha Innotech Corporation) and a picture of the fluorescent 
EtBr-stained DNA was captured with the AlphaArchiver 600 Documentation and 
Archiving System with the Mitsubishi P96 printer and video processor.
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3.5.4 Polyacrylamide Gel Electrophoresis
Polyacrylamide gels for visualising sequencing products were prepared as 
follows:
50ml of Long Ranger PreMix Gel Solution (BioWhittaker Molecular 
Applications, USA), stored at -20°C in a falcon tube and thawed by placing in a 
beaker filled with warm water.
250pl of 10% ammonium persulfate, stored at -20°C.
30 j l x 1 of TEMED (National Diagnostics, USA), stored at room temperature.
The above solutions were mixed together at room temperature in a 500ml 
glass beaker and used immediately. The mixture was poured using a syringe and 
capillary action to spread the acrylamide solution between two clamped 36cm, 
boiling water-cleaned glass plates for use in an A BB77 with 0.5mm spacers in 
the cassette. The plates were tipped at an angle to allow the acrylamide to move 
down between the plates. Any bubbles were carefully removed by slowly 
dragging them to the edge of the gel before inserting the straight blunt edge o f a 
sharks tooth comb into the top of the gel. The gel was then left to polymerize for 
two hours. After 30 minutes paper towels soaked in electrophoresis buffer were 
placed over the ends of the plates to prevent moisture loss, which reduces the 
appearance of ‘red rain’ in the gel. The comb was removed from the gel and the 
wells flushed with copious amounts of dFLO using a syringe. The polymerized 
gel was assembled into the ABB77 apparatus for electrophoresis. 2pi o f sample 
was mixed with 3pl of loading dye and 5pi of formamide, denatured at 95°C for 
two minutes in a PCR block and then immediately placed on ice prior to loading. 
0.5 pi of each sample was loaded into the loading tray. A disposable comp was 
then dipped into the loading tray to soak up the sample. The comb was then 
inserted into the wells through the top buffer tank, which was filled with dFLO 
and Ficol 1% Dextran Blue. A pre run was carried out for two minutes then the 
Ficol was removed and replaced with 10X TBE. Electrophoresis was carried out 
in IX TBE for 9 hours.
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3.6 Denaturing High Performance Liquid Chromatography (dHPLC) 
Analysis
dHPLC identified mutations by detecting sequence variation in 
reannealed DNA strands (heteroduplexes). dHPLC analysis was carried out 
using the Transgenomic WAVE 3500 machine. Optimum dHPLC temperatures 
were determined by a temperature scan, using the WAVEMaker 4.0 melting 
profile as a starting point. Control samples were originally run at four 
temperatures due to the large distribution of GC-rich regions. For the proband 
samples the two best temperatures were chosen for the dHPLC runs for exons l a  
and 2. The amplicons were eluted with a linear acetonitrile (ACN) (Labscan, 
Ireland) gradient at a flow rate of 0.9 ml/min, 50% Buffer A:50% Buffer B. 
Using volumetric flasks the following buffer solutions were made up:
0.1M Triethylammonium acetate (TEAA) Buffer A 
0.1M TEAA:25% ACN Buffer B 
75% ACN cleaning solution Buffer C 
8% ACN syringe wash solution
The gradient duration was adjusted according to each PCR product 
length. Each elution profile or chromatogram was compared with the profiles 
associated with homozygous wild type and mutated sequence controls.
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3.7 Purification of PCR Products
Two methods of purification of PCR products were used during this study 
to remove nucleotides and primers from PCR products.
1) Amplified PCR products in microcentrifuge tubes were purified using the 
QuickStep PCR Purification Kit (Ver. 4) (EdgeBioSystems) according to the 
manufacturer’s instructions.
2) 96 well MicroAmp plates containing amplified PCR products were 
purified using a shrimp alkaline phosphatase (SAP) method. SAP 
dephosphorylates nucleotides and Exol degrades primers, which interfere with 
the primer extension reaction (Olsen et al. 1991).
3 pi of lp /p l of shrimp alkaline phosphatase (Promega) was added to each 
sample along with 3 pi of Exonuclease I which was diluted to 1:10 (Exonuclease 
I: 10X Exonuclease I Buffer (New England BioLabs)). The sample was then 
incubated at 37°C for 30 minutes, followed by 72°C for 15 minutes, followed by 
8°C for 5 minutes.
3.8 Sequencing Reaction
Fluorescence-based cycle sequencing reactions on PCR fragments were 
performed using the ABI PRISM BigDye Terminator v3.1 Ready Reaction Cycle 
Sequencing Kit and BetterBuffer (Microzone Ltd, UK). This kit included the 
dye terminators, deoxynucleoside triphosphates, AmpliTaq DNA Polymerase, 
FS, magnesium chloride, and buffer premixed in a single tube o f Ready Reaction 
Mix.
Each sample was mixed with 0.8pl of specific primer (5pM), 4pl o f 
BigDye, 4pl of BetterBuffer, and sterile dFLO to a final volume o f 20pl. 
Samples were subjected to cycling parameters specified in Appendix 2 and then 
stored at 4°C until ready to purify.
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3.9 Purification of Sequencing Products by Ethanol/EDTA Precipitation
All PCR products were purified to remove dNTPs, primers and 
unincorporated dye terminators before sequencing analysis.
5pi of 125 mM EDTA and 60pl of 100% ethanol was added to each well. 
The Micro Amp Optical 96-well reaction plate (ABI) was sealed with an adhesive 
plate seal (ThermoLife Sciences), mixed by inverting and then incubated at room 
temperature for 15 minutes. The plate was then spun at 3000 x g for 45 minutes. 
Following this, the plate was inverted and spun at 200 x g. 150pl of 70% ethanol 
was added to each well and the plate spun at 3000 x g for 15 minutes after which 
it was inverted and spun at 200 x g for about 10 seconds. The wells were 
covered with a paper towel and pellets left to dry for at least 30 minutes.
3.10 Sequence Analysis
12pl of Hi-Di Formamide was added to each cleaned pellet and incubated 
at room temperature for at least one hour before loading the plate into the ABI 
PRISM 3100 Genetic Analyzer. Sequence analysis was carried out using the 
ABI PRISM377 DNA Sequencer, and laterally the ABI PRISM 3100 Genetic 
Analyzer. Sequence analysis was performed with the ABI PRISM 3100 Genetic 
Analyzer because in contrast to the traditional slab-gel system which requires at 
least 9 hours of electrophoresis time for equivalent length of read in addition to 
significant time for pouring, setting up, loading and tracking lanes o f sequence 
on the gel. With the 3100 Genetic Analyzer System 96 samples were 
electrophoresed in 4.5 hours, with minimal hands-on time.
For sequence analysis Dye Set Z with Mobility file DT3100POP4 
(BDv3)vl, Run module UltraSeq36_POP4 and Analysis module BC3100UR 
were used. The ABI PRISM 3100 Genetic Analyzer contained 10X Buffer with 
EDTA, a 36cm capillary array length and POP-4 polymer. The total run time 
was 45 minutes per 16 samples.
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3.11 Electropherogram Analysis
Forward and reverse sequence electropherograms were generated by ABI 
Sequence Analysis 3.4.1 and studied with ABI SeqEd 1.0.3 or latterly ABI 
SeqScape versions 1.1 and 2.0. The SeqScape software program contains 
basecalling, sequence assembly, alignment, and sequence comparison tools for 
fast sequence comparisons and accurate variant identifications based on a 
reference sequence with or without known nucleotide variant information. 
Unique to this tool are features such as per base and per sample quality values 
that allow a user to precisely detect polymorphisms including heterozygotes. 
Each sequence was read at least twice.
3.12 Haplotype Analysis
PCR reactions, using 5 '-end fluorescently labelled primers (Appendix 1) 
were performed for eight microsatellite DNA markers, in the Genome Database 
(GDB) http://www.gdb.org/, D9S1604, D9S1748, D9S942, D9S974, RH103023, 
D9S2060, D9S2136 and D9S1749 from the region that contains the CDKN2A 
gene, which is localised on chromosome 9p21.
Microsatellite loci were PCR amplified (Appendix 2) and the PCR 
products were then analyzed by electrophoresis on an ABI PRISM 3100 Genetic 
Analyzer with GENESCAN Analysis 3.1 and GENOTYPER 1.1.1 software to 
size and quantitate DNA fragments. PCR-amplified microsatellite alleles were 
detected by fluorescent dye labeling.
The samples were placed in a thermal cycler for 3 minutes at 95°C to 
denature and then placed immediately on ice. lp l o f each PCR product and 
0.5pi of the GeneScan ROX 500 Internal Lane Size Standard were diluted in 9pl 
of deionized formamide. Some samples were highly concentrated giving off the 
scale readings and therefore these were diluted to 1:20 (PCR product: sterile 
dH20).
For fragment analysis Dye Set 6-FAM (Blue) and ROX (Red, std) with 
Virtual Filter Set D, Run module GeneScan 36 POP4 and Analysis module 
GS500 were used.
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3.13 Sizing of Fragments
The called size for a fragment can differ from its actual size due to 
different machinery setup, therefore fragment sizes were converted to alleles 
before comparing microsatellite data generated on different instruments used by 
other authors.
The ABI ROX 500 size standard was used to accurately calculate the 
sizes of the alleles. Alleles for each marker were numbered with allele 1 being 
the largest. The following table lists the lengths o f the 16 fragments comprising 
the GeneScan ROX 500 size standard:
TABLE 3.1
ABI ROX 500 Size Standard Fragment Lengths
Fragment Lengths (nt)
35 50 75 100
139 150 160 200
250 300 340 350
400 450 490 500
The accuracy o f the sizing of alleles using the ABI ROX size standard 
was checked to ensure that allele sizes quoted in this thesis were comparable to 
other published work. The AMXY (amelogenin) marker, located on 
chromosomes Xp22.1-22.31 and Y p ll.2 , carries a small deletion of 6bp in the 
first intron on the X chromosome, facilitating the design of distinct X and Y 
specific PCR primers (Appendix 1) (Mann et al., 2001). The AMXY fragment 
identifies an X-specific 104bp fragment and a Y-specific llObp (Appendix 2) 
(Nakahori et al. 1991). This AMXY marker of known size was checked against 
the ABI ROX size standard to confirm the ABI ROX size standard was sizing 
accurately.
Allele frequencies for the different markers were based on the typing of 
86 unrelated, ethnically matched, noncarrier chromosomes of European ancestry 
and from previously published papers. The sizes of the different alleles were 
established by comparison with the ROX 500 standard sequence.
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3.14 Digestion of Genomic DNA with Restriction Endonucleases
Restriction enzyme cutting sites were determined with the aid o f the 
internet site http://darwin.bio.geneseo.edu/~yin/WebGene/temp/remain261 .html. 
All enzymes were purchased from New England BioLabs (UK) and restriction 
enzyme digestion was performed according to the manufacturer’s instructions by 
incubating the PCR product with the appropriate amount of restriction enzyme, 
its buffer and at the temperature specific for that enzyme (Appendix 3). Partially 
digested samples were digested to completion by adding 1 pi of restriction 
enzyme and incubating the reaction at the specified temperature for a minimum 
of lh  30 min.
3.15 Cloning of PCR Products
50pl of PCR product and a 750bp control DNA template were cloned 
using the TOPO TA Cloning Kit for Sequencing Version H (Invitrogen Life 
Technologies) according to the manufacturer’s instructions to produce colonies 
of single alleles of exon 2 of the CDKN2A gene. For each transformation, two 
LB plates containing 50pg/ml of kanamycin were used. Colonies were grown on 
imMedia Kan Agar and Liquid (Invitrogen Life Technologies). The control 
template was a plasmid that encodes ampicillin resistance and so was grown on 
kanamycin plates. The pUC19 plasmid was grown on LB plates 
containing 100pg/ml of ampicillin to check the transformation efficiency o f the 
One Shot competent cells.
LB-agar medium was cooled to 50°C before adding to falcon tubes 
containing ampicillin. The mixture was then poured into sterile plates. The 
kanamycin/ampicillin plates were stored at 4°C until needed when they were 
warmed to 37°C. The competent One Shot cells were removed from -70°C and 
thawed on ice for 5 minutes. 4pl of PCR product, 1 pi of salt solution and 1 pi of 
TOPO vector were gently mixed together and incubated for five minutes at room 
temperature before placing on ice. At the same time, lp l of the control PCR 
product, 3pi of sterile water, lp l of salt solution and lp l of pCR4-TOPO were 
gently mixed together and incubated for five minutes at room temperature before 
placing on ice.
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A vector only reaction was set up in the same way but omitting the 
control PCR product from the reaction. 2pi of these TOPO Cloning reactions 
were then mixed gently into a vial of One Shot TOP 10 Chemically Competent 
E.coli. The vials were left on ice for 20 minutes. The vials were then heat- 
shocked by placing in a 42°C waterbath for 30 seconds. The vials were placed 
back immediately on ice for 2 minutes. The samples were taken off ice and 
250jal of room temperature SOC medium was added to each tube. The tubes 
were gently inverted and placed in a 37°C waterbath for 1 hour. During this 
period the LB-agar/ampicillin/kanamycin petri dishes were removed from 4°C.
lOOpl of each transformation was pipetted to the middle of the sterile 
petri dishes and the solution spread over the plate using a disposable plastic 
sterile spreader. The petri dishes were then inverted and placed at 37°C over 
night. Ten colonies were picked, five from each plate and cultured overnight in 
10ml of LB-kanamycin at 50pl/ml. The colonies were cultured in ten separate 
universals at 37°C in a shaker.
3.16 Molecular Modelling
Molecular Modelling was carried out in the laboratory of Professor 
William Hunter in the Division of Biological Chemistry and Molecular 
Microbiology in the School of Life Sciences at the University o f Dundee.
The computer graphics program “O” (Jones et al. 1991) was used to 
visualize the structure of the protein pl6INK4A and to investigate the potential 
effect of the mutations on the interactions formed between this tumour 
suppressor and the protein kinase CDK6. The crystalline structure for CDK4 is 
not yet available. Coordinates for the CDK6-pl6INK4A complex were retrieved 
from the Protein Data Bank (http://www.rcsb.org/pdb/; code 1BI7) and supplied 
to Prof. Hunter. Each mutation was inserted into the model and the affect was 
observed. Molecular diagrams were produced with the program MOLSCRIPT.
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3.17 Statistical analysis
Statistical analysis on the MC1R genotypes and phenotypes was carried 
out under the kind supervision of Dr. Vincent Macaulay, Department o f 
Statistics, University of Glasgow.
3.17.1 Calculating P-values
The computer software, DNA Sequence Polymorphism (DnaSP), version 
4 (University of Barcelona), www.ub.es/dnasp was used to perform Fisher's 
exact test, in order to test for associations between genetic and phenotypic 
variables. DnaSP allows testing of associations between 2 binary variables (in a 
2 x 2  contingency table). The British geneticist and biostatistician R. A. Fisher 
(1890-1962) devised Fisher’s exact test. Fisher's exact test tests the 
independence of rows and columns in a 2 x 2 contingency table (with two 
horizontal rows crossing two vertical columns creating four places for data) 
based on the exact sampling distribution of the observed frequencies. The test 
directly computes the probability, P, of getting a table less probable than the 
observed table, under the null hypothesis that the two variables are not 
associated. If this probability is sufficiently small, the null hypothesis can be 
rejected and a significant association declared. The well-known chi-squared test 
for independence in a 2 x 2 contingency table is an approximate form of this test. 
The probability o f observing a given set of frequencies A, B, C, and D in a 2 x 2 
contingency table, given fixed row and column marginal totals and sample size 
N, is:
p _ (A + B)!(C + D)!(A + C)!(B + D)!
A!B!C!D!N!
If P < 0.05 we reject the null hypothesis of independence. Since the 
whole population cannot be tested, the P-value attempts to make a judgment 
about the effects from a sample of the population. If the P-value is > 0.05, there 
is no statistically significant association. The test assumes random sampling and 
that each observation is independent.
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MINITAB Release 14 was used to perform a chi-squared test of 
independence in 2 x 4 contingency tables. P-values were only calculated when 
the expected frequency was > 5 in every cell in the table. Due to this small data 
set, this was not always the case and therefore P-values were not always 
calculated.
3.17.2 Bonferroni Correction
Every statistical test has a probability that it will find a significant 
association even when one does not exist. The more tests one performs the more 
likely it is that some false positives will be declared. To try to compensate for 
this effect, the Bonferroni correction adjusts the statistical significance level (the 
value 0.05 above) when multiple tests are performed. This study has many cases 
of multiple tests e.g., analysing the associations between the various MC1R 
variants and the phenotypes and so the Bonferroni adjustment was required. If n 
tests are performed the value against which each P-value is compared in each test 
is reduced as follows:
0.05
Bonferroni adjustment = — - —
The disadvantage of the Bonferroni method however is that it can be over 
conservative (since it assumes that each test is independent) and so the analysis is 
in danger of finding no significant differences when in fact they could be there. 
If there are many tests, the Bonferroni criterion becomes so strict that it is very 
difficult to reject any null hypothesis and an important finding may be 
overlooked. Thus in an exploratory analysis, it is wise not to rule out possible 
associations which are significant without the correction, but which just fail to be 
significant after the correction. This is particularly true in this context where 
there is every reason to suppose that the individual tests will not be independent, 
owing to the correlations induced by linkage disequilibrium because o f the 
shared ancestry of a short DNA segment.
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3.17.3 Calculating Odds Ratios and Confidence Intervals
The odds ratio (OR) was also used to assess the risk of a particular 
outcome if a certain factor was present. Odds are the probability for an outcome 
occurring divided by the probability of them not occurring. The OR is the ratio 
of the odds for the particular trait in cases divided by the odds in controls. If the 
OR is > 1 then the event is more likely to happen in cases than controls. If the 
OR is < 1 then the event is less likely to happen in cases than controls. Since the 
OR is subject to sampling error, it is helpful to construct a 95% confidence 
interval for its true value. If this interval includes 1 then there is no significant 
difference between cases and controls (cf. the results of the Fisher’s exact test). 
If the interval excluded 1 then there is a significant association and the 
magnitude of the OR gives a quantitative measure of the strength of the 
difference in risk. The following formulae were used to calculate an 
approximate 95% Cl of the OR (using the same notation as above):
OR = (A/B) / (C/D)
Upper limit of Cl for ln(OR) = ln(OR) + 1.96 x SE(lnOR)
Lower limit of Cl for ln(OR) = ln(OR) -  1.96 x SE(lnOR)
Upper limit of Cl for OR = exp(upper limit o f Cl for InOR)
Lower limit o f Cl for OR = exp(lower limit o f Cl for InOR)
Standard error (SE) o f ln(OR) = V [(l/A ) + (1/B) + (1/C) + (1/D)]
For each Test o f Independence in Chapter 6 a Two-tailed Fisher’s Exact Test was 
performed, unless stated otherwise. Odds ratios (OR) are indicated with 95% 
confidence interval (Cl) in all statistical analysis. Alleles were counted twice in 
homozygous individuals which increases the N value of subjects for certain 
variants.
CHAPTER 4
MUTATION SCREENING OF THE 
CDKN2A GENE
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4.1 Families in Study
Members of 48 families were used in this section of the work. The 
families for identification purposes are numbered from F1-F48 throughout this 
thesis. CDKN2A results for patients F I-F I6 have already been reported (MacKie 
et al. 1998). The CDKN2A studies carried out on these families in the course of 
work presented in this thesis is therefore confirmatory. All other results on 
families FI-FI 6 and all results on families F17-F48 are reported for the first 
time.
4.2 CDKN2A Mutation Detection
Familial cutaneous malignant melanoma can be caused by germline 
mutations in CDKN2A. The gene was therefore screened in Scottish familial 
melanoma patients. CDKN2A encodes a protein (pl6INK4A) of 156 amino 
acids. The coding region for this protein product spans three exons: 150 bp in 
exon la ;  306 bp in exon 2; and 12 bp in exon 3.
4.2.1 Mutation Detection Strategy Employed
Primers were designed (Methods 3.4.1-3.4.3) for independent 
amplification of the complete coding regions of exons la ,  2 and 3 and their 
splice sites. PCR primers were situated up and downstream of each exon. The 
final amplification conditions are presented in Appendix 2. Routinely a lp l 
aliquot of DNA (extracted as described in method 3.1a) from each patient was 
amplified (Method 3.4.5) with each of the three sets of primers. Fragment sizes 
of 347bp for exon la ,  458bp for exon 2 and 254bp for exon 3 were generated. 
Negative controls (no DNA) were run along with each reaction. Once all the 
DNA samples had been transferred to PCR tubes, the same reagents were used 
for the negative control. The absence of amplicons in the negative control meant 
that there had been no cross-contamination between the samples or into the 
reagents. The distinct bands obtained from amplification were resolved on 
ethidium bromide stained agarose gels (Method 3.5) to verify the size of the 
amplified band and are presented in figures 4.1, 4.2 and 4.3.
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FIG U RE 4.1
Amplification of Exon l a  of CDKN2A
The expected 347bp amplicons o f exon l a  o f CDKN2A were confirmed by 
resolution on a 1.5% agarose gel with ethidium bromide. The amplicons were 
electrophoresed in IX TAE buffer for 20 minutes. The size o f the amplicons 
which are represented below shown in base pairs were deduced by comparison to 
the migration o f the known size o f the DNA ladder fragments in lane 1. 1 pi of 
genomic DNA was routinely amplified by conditions specified in Appendix 2 
and with primers specified in Appendix 1. The am plicons’ size is consistent with 
the expected 347bp fragment and was sequenced to confirm this.
Lancs
1 2 3 4 5 6 7 8 9
Sample Band (bp)Ladder Bands (bp)
Electrophoresis Conditions: 1.5% agarose gel, IX TAE, lOpl size marker, 5pl
PCR product, 2pl loading mix, 100V, 20 minutes, 
room temperature 
Lane 1 -  lkb Plus size marker 
Lane 2 -  PCR product from individual F2.1 
Lane 3 -  PCR product from individual F2.2 
Lane 4 -  PCR product from individual F2.6 
Lane 5 -  PCR product from individual F3.1 
Lane 6 -  PCR product from individual F3.2 
Lane 7 -  PCR product from individual F 11.1 
Lane 8 -  PCR product from individual FI 1.2
Lane 9 -  negative control See page 60 for patient details.
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FIGURE 4.2
Amplification of Exon 2 of CDKN2A
The expected 458bp amplicons o f exon 2 o f CDKN2A were confirmed by 
resolution on a 1.2% agarose gel with ethidium bromide. The amplicons were 
electrophoresed in IX TAE buffer for 20 minutes. The size of the amplicons 
which are represented below shown in base pairs were deduced by comparison to 
the migration of the known size o f the DNA ladder fragments in lane 1. lp l o f 
genomic DNA was routinely amplified by conditions specified in Appendix 2 
and with primers specified in Appendix 1. The amplicons’ size is consistent with 
the expected 458bp fragment and was sequenced to confinn this.
Lanes
Ladder Bands (bp) Sample Band (bp)
Electrophoresis Conditions: 1.2% agarose gel, IX TAE, lOpl size marker, 5pl
PCR product, 2pl loading mix, 100V, 20 minutes, 
room temperature 
Lane 1 -  lkb Plus size marker 
Lane 2 -  PCR product from individual F l . l  
Lane 3 -  PCR product from individual F I7.1 
Lane 4 -  PCR product from individual F I9.1 
Lane 5 -  PCR product from individual F33.1
Lane 6 -  negative control See page 60 for patient details.
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FIG U RE 4.3
Amplification of Exon 3 of CDKN2A
The expected 254bp amplicons o f exon 3 o f CDKN2A were confirmed by 
resolution on a 1.5% agarose gel with ethidium bromide. The amplicons were 
electrophoresed in IX TAE buffer for 20 minutes. The size o f the amplicons 
which are represented below shown in base pairs were deduced by comparison to 
the migration o f the known size o f the DNA ladder fragments in lane 1. lp l of 
genomic DNA was routinely amplified by conditions specified in Appendix 2 
and with primers specified in Appendix 1. The am plicons’ size is consistent with 
the expected 254bp fragment and was sequenced to confirm this.
1
Lanes 
3 4
Ladder B ands(bp) Sample Band (bp)
300 
200 254
Electrophoresis Conditions: 1.5% agarose gel, IX TAE, lOpl size marker, 5pl
PCR product, 2pl loading mix, 100V, 20 minutes, 
room temperature 
Lane 1 -  lkb Plus size marker 
Lane 2 -  PCR product from individual F9.1 
Lane 3 -  PCR product from individual F I2.1 
Lane 4 -  PCR product from individual F I3.2 
Lane 5 -  PCR product from individual F I4.1
Lane 6 -  negative control See page 60 for patient details.
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4.3 dHPLC Analysis Conditions
To identify the presence o f mutant or polymorphic alleles a mutation 
screen o f exons l a  and 2 was carried out using dHPLC analysis (Method 3.6). 
dHPLC analysis with the Transgenomic WAVE machine was a new technique in 
the laboratory and therefore both dHPLC and sequencing was performed to 
compare the sensitivity o f dHPLC with sequencing. dHPLC analysis was not 
performed on exon 3 because exon 3 is only 12 bp long and direct sequencing o f 
this exon together with SNPs 500 and 540 was thought to be more appropriate.
The detection o f DNA changes by dHPLC is based on the formation of 
heteroduplexes o f wild type and mutant amplicons (Figure 4.4).
FIGURE 4.4 
Heteroduplex Form ation
H a p  k i d  S v s te  m
Wt + Mt
Horn oduplexesli nl i l i  .  li ii 
li l i^ n  JiV wA llele  A  A llele  BDip loid S ystem
H e ta o  duplexes
Mutations are detected by comparison between the wild type and the sample 
chromatograms (Figure 4.5). Optimum dHPLC temperatures were determined 
by a temperature scan, using the W AVEMaker 4.0 melting profile as a starting 
point, which allowed the entire fragment to be screened at a minimum number of 
temperatures. Mutation positive control samples were originally run at four 
temperatures due to the large distribution o f GC regions, 71.18% GC content for 
exon l a  and 66.15% GC content for exon 2. For the proband samples, the two 
temperatures that gave the clearest chromatogram results at which mutations 
were detected were chosen (Figures 4.6 and 4.7). For exon la ,  samples were run 
at 66°C and 68°C, although all mutations were detected at 68°C. For exon 2, 
samples were run at 63°C and 69°C. Mutations near the beginning o f the exon 2 
fragment were better detected at 63 °C whereas mutations near the end of the 
exon 2 fragment were better detected at 69°C.
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FIG U R E 4.5
Heteroduplex and Homoduplex Elution Profiles
7
Wild Type 
Homoduplexes
6
ye. 5
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o 3v>
1
0
6 7 80 1 2 3 4 5
Time (Minutes)
7
Mutated
Heteroduplexes
2
1
0
7 80 1 2 3 5 64
Time (Minutes)
Elution profiles that differ from the wild type indicate the presence of a mutation. 
Heteroduplex peaks elute earlier than homoduplex, and can be observed as 
separate peaks or as shoulders. The numbers on the x axis correspond to the 
column retention time in minutes.
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FIG U RE 4.6
Exon l a  Optim um  dHPLC Tem peratures
The melting characteristics o f the exon l a  fragment to determine the temperature 
at which mutations will resolve using dHPLC are illustrated. The software 
predicts the average Tm for the entire fragment was used as a midpoint for the 
temperature titration. Mutations are best detected if  the helical fraction ranges 
between 70-85%.
Helical Fraction vs. Temperature
5  100 r  0s
Temperature (*C)
Helical Fraction v Base Position
5  100
— 70 *C
—  71 °C
350150 200 250 30050 1000
Base Position
Predicted three temperature melting trial for exon la .  For exon la ,  samples 
were run at 66°C and 68°C as the temperatures in the above graph were too high 
for best mutation detection.
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FIG U RE 4.7
Exon 2 Optim um  dHPLC Tem peratures
The melting characteristics o f the exon 2 fragment to determine the temperature 
at which mutations will resolve using dHPLC is illustrated below.
Helical Fraction vs. Temperature
* 100
50
35 40 45
—I— 
50 55 60
Temperature (®C)
65 70 75 80
Helical Fraction v Base Position
S' 100
50
0
500450400350300250200150100500
Base Position
Helical Fraction v Base Position
59 °c
60 °c
61 *c
3  100
50 100 1 50 200 250 300
Base Position
350 400 450
—  63 °C
—  64 'C
—  65 °C
500
Helical Fraction v. Base Position
3  100 T
0 50 100 150 200 300250 350 400 450 500
69 4C
70 ®C
71 °C
Base Position
Predicted nine temperature melting trial for exon 2.
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For exon 2, samples were run at 63°C and 69°C. Mutations near the beginning 
of the exon 2 fragment were better detected at 63°C whereas mutations near the 
end of the exon 2 fragment were better detected at 69°C.
4.3.1 dHPL C A nalysis o f  Proband Samples
Amplified DNA samples from the 48 probands were subjected to dHPLC 
analysis (Method 3.6). Two optimum melting profiles were identified for use in 
the analysis of exons l a  (66°C and 68°C) and 2 (63°C and 69°C). Fifeteen 
abnormal chromatogram patterns were identified for exons l a  and 2 and their 
flanking sequences as shown in figure 4.8.
DNA from each abnormal sample was reamplified and subjected to direct 
sequence analysis to identify the cause of the chromatogram shift.
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FIG U R E 4.8
Detection of CDKN2A mutations by dH PL C
Elution profiles obtained in melanoma patients as compared with a wild-type 
elution profile are shown.
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Exon la  at 68°C is shown in panels A-D and exon 2 at 63°C and 69°C is 
shown in panels E-L. Representative normal profiles are depicted in each panel. 
Note the shoulder obtained for the sample in panel C which is shown more 
clearly in panel D. Additional peaks/shoulders were obtained in 15 proband 
samples. The numbers on the x  axis correspond to the column retention time in 
minutes.
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4.4 Direct Sequencing of Abnormal Amplicons
Each of the exons in which an aberrant chromatogram shift was identified was 
subjected to direct sequencing (Methods 3.7-3.11). The primers used for sequence 
analysis were the same as the amplification primers. DNA sequence of the complete 
exons and at least 20 base pairs of flanking DNA were routinely obtained and nucleic 
acid changes identified in all fragments sequenced. In total, 15 probands were found to 
have a nucleic acid change on sequencing. In exon la  three distinct mutations were 
identified and in exon 2 five were found. All changes were confirmed by 
reamplification and sequencing of the mutated exons. The nature of these changes were 
analysed with respect to the amino acid change and whether they had been previously 
reported in melanoma patients (Table 4.2). Exon 3 was sequenced directly. No exon 3 
mutations have been identified in any of these 48 families, however nine probands 
showed a change at SNP 500 and five probands showed a change at SNP 540.
4.5 Determining the Nature of the Nucleic Acid Change
The eight different nucleic acid changes were identified in samples from 15 
probands. In three of these proband samples, individuals F2.1, F3.1 and F28.1, an exon 
l a  mutation was identified and in 13 of these proband samples, individuals F l.l, F4.1, 
F5.1, F6.1, F7.1, F13.1, F17.1, F19.1, F22.1, F29.1, F30.1 and F33.1, an exon 2 
mutation was identified. No exon 3 mutations were identified in this study, however in 
individuals F7.1, F12.1, F13.1, F19.1, F25.1, F28.1, F31.1, F33.2 and F34.1, a 
polymorphism at the 3’ end of exon 3, SNP 500, was found, and in individuals F9.1, 
F14.1, F27.2, F32.1, F36.1, a further downstream polymorphism, SNP 540, was 
identified. In two proband samples, individuals F7.1 and FI3.1, the mutation identified, 
A148T, has been previously reported in melanoma families as a polymorphism (Bertram 
et al. 2002). The mutations 32-33ins9-32 24bp duplication, R24P, Y44stop, M53I, 
G67R and R112G, and SNPs 500C>G and 540OT have been previously reported 
(Holland et al. 1995; Walker et al. 1995; Platz et al. 1997; MacKie et al. 1998; Newton 
Bishop et al. 1999; Kumar et al. 2001; Bertram et al. 2002), however mutation H83N 
has not to date been reported in melanoma families. The exon la  32-33ins 9-32 24 base 
pair duplication has previously been incorrectly reported as a 1-8 24 base pair 
duplication (Hussussian et al. 1994; Harland et al. 1997; Monzon et al. 1998).
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4.6 Polymorphisms
The polymorphisms identified during this study have previously been 
reported (Ranade et al. 1995; Reymond and Brent 1995; Aitken et al. 1999). The 
site o f three polymorphisms are one G>A A148T in exon 2, one 500C>G at the 
3’ end of exon 3 and a third 540C>T 40 base pairs downstream from this.
4.7 Confirmation of Mutation M53I by Restriction Digestion
A restriction assay was developed to test for the M53I mutation (Method 
3.14), which is the most frequently occurring of the mutations in Scottish 
familial melanoma. Details of this assay are presented in Appendix 3.
The exonic sequence of both wild type and the heterozygous mutant was 
analysed to identify restriction enzyme sites (Method 3.14). For mutation M53I 
the sequence was altered such that a new restriction site was created. This assay 
allowed confirmation of the presence of the mutation and also permitted family 
studies to be carried out where the mutation was identified in the proband.
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4.8 Summary of Findings
A summary of all mutations identified is listed below in table 4.1.
TABLE 4.1
CDKN2A Mutations Identified in Scottish Melanoma Families
CDKN2A Mutation Number of Scottish Melanoma 
Families with Mutation
Exon la
32-33ins9-32 24bp dup 1
71G>C R24P 1
1 3 2 0 A Y44stop 1
Exon 2
159G>C M53I 6
199G>C G67R 1
2 4 7 0 A H83N 1
334C>G R112G 2
442G>A A148T (polymorphism) 2
Thirteen of the 48 families (27%) have a CDKN2A mutation. Three 
families have an exon l a  mutation, and ten have an exon 2 mutation. Two 
additional families have the exon 2 A148T suspected polymorphism. No exon 3 
mutations have been identified. Six of the 13 families with identified mutations 
carry the M53I mutation. In 33 families, families F8-F12, F14-F16, F I8, F20- 
F21, F23-F27, F31-F32, and F34-48, no CDKN2A mutation or polymorphism 
was detected. The new observation in this section o f the thesis is the 
identification of a previously undescribed mutation, H83N.
4.8.1 Results o f  Family Studies
The mutation data generated on each of the mutation positive families is 
presented in this section. The family pedigree, dHPLC analysis, sequencing 
results with the predicted amino acid change and where developed, the restriction 
enzyme assay are presented for each family. All exons of CDKN2A were 
screened by either dHPLC and/or sequencing for each of the probands. Where a 
mutation was not found, all other available affected members of each family 
were also sequenced. Where a mutation was identified, only the exon in which 
the mutation occurred was amplified and sequenced in available affected and 
currently unaffected individuals.
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4.9 The H83N M utation
4.9.1 Mutation Analysis in Family 33 (Figure 4.9)
Family 33 has two affected members with melanoma, both female, who 
presented with melanoma aged 25 and 28 years. Both individuals have multiple 
primary melanomas.
FIGURE 4.9
Scottish M elanoma Family 33
F 33. F 33 .2
4 m ultip le  3 m ultip le
p r im a ries pr im a r ies
111:1 lll:2 111:3 111:4
4.9.2 Identification o f  a Chromatogram WA VE Shift
Exons l a  and 2 o f the proband, individual F33.1 were amplified and 
subjected to dHPLC analysis (Figure 4.10). A chromatogram WAVE shift from 
the normal was identified in exon 2.
4.9.3 Identification o f  Mutation H83N
A new exon 2 amplicon was generated for direct sequencing o f the 
proband using both forward and reverse exon 2 primers.
A heterozygous C to A transition at nucleotide position 247C>A was 
identified (Figure 4.10). This base change is predicted to lead to the substitution 
o f histidine (H) for an asparagine (N) at codon 83 (H83N) (Figure 4.10). This 
mutation has not been previously reported. Exon 2 from another available family 
member was screened by direct sequencing. The predicted substitution observed 
in the proband was also found in the affected family member F33.2. No 
currently unaffected family members were available for screening.
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FIG U RE 4.10
Family 33 -  Identification of M utation H83N (247C>A)
NormalAbnormal elution 
profile> 6 
E
a 5
5 6 70 2 3 41
Time (M inutes)
dHPLC WAVE analysis o f PCR amplified genomic DNA from individual F33.1. 
Proband DNA was amplified using intronic primer pair CDKN2A exon 2 
(Appendix 1, 2).
Sequence analysis o f PCR amplified genomic DNA from individual F33.1. 
Proband DNA was amplified and sequenced using intronic primer pair CDKN2A 
exon 2 (Appendix 1, 2).
P V H D A
Wild Type CCC GTG CAC GAC GCT
Mutant CCC GTG AAC GAC GCT
N
(H83N)
Nucleic acid and derived amino acid sequences from the mutated region o f 
CDKN2A. The amino acid substitution o f a histidine (H) for an asparagine (N) at 
position 83, H83N is shown.
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4.10 The 32-33ins9-32 24bp Duplication
4.10.1 Mutation Analysis in Family 28 (Figure 4.11)
Family 28 has two affected members with melanoma, both male, who 
presented with melanoma aged 34 and 37 years. Individual 11:1 (F28.2) has 
multiple primary melanomas.
FIGURE 4.11
Scottish Melanoma Family 28
F28. F28
11:1 11:2
34 37
3 multiple 
primaries
4.10.2 Identification o f  a Chromatogram WA VE Shift
Exons l a  and 2 o f the proband, individual F28.1 were amplified and 
subjected to dHPLC analysis (Figure 4.12). A chromatogram WAVE shift from 
the normal was identified in exon la .
FIGURE 4.12
Familv 2 8 — Identification of  Mutation 32-33ins9-32 24hn Dnnlication
NormalAbnormal elution 
profile
3 6 70 1 2 4 5
Time (M inutes)
dHPLC W AVE analysis o f  PCR am plified genom ic DNA from individual F28.1. Proband DNA 
was am plified using intronic primer pair CDKN2A  exon l a  (Appendix 1, 2).
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Sequence analysis o f PCR amplified genomic DNA from individual F28.1. 
Proband DNA was amplified and sequenced using intronic primer pair CDKN2A 
exon l a  (Appendix 1, 2).
M EPAAGSSM EPSADW LATAAARGRVEEVRALLEAGALPNAPNSYGRRP
I Q
a t g g a g c c g g c g g c g g g g a g c a g c a t g g a g c c g g c g g c g g g g a g e a g c a t g g a g c c t t c g g c t g a c t g g c
tggccacggccgcggcccggggtcgggtagaggaggtgcgggcgctgctggaggcgggggcgctgcccaac
gcaccgaatagttacggtcggaggccgatccag
Nucleic acid and derived amino acid sequences from the mutated region o f 
CDKN2A. The 24bp fragment o f bases 9-32 (black bold underlined) inserted 
between bases 32-33 (red bold underlined), 32-33ins9-32 24bp duplication is 
shown.
4.10.3 Identification o f  Mutation 32-33ins9-32 24bp Duplication
A new exon l a  amplicon was generated for direct sequencing o f the 
proband using both forward and reverse exon l a  primers.
A heterozygous 24bp fragment o f bases 9-32 inserted between bases 32- 
33 was identified (Figure 4.12). This insertion is in frame. This mutation has 
been previously incorrectly reported as 1-8 24bp insertion (Goldstein et al. 1995; 
W alker et al. 1995; Flores et al. 1997; Pollock et al. 1998). Exon l a  from the 
other available family member was screened by direct sequencing. The 
predicted duplication observed in the proband was also found in the affected 
family member F28.2.
No currently unaffected family members were available for screening.
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4.10.4 Development o f  a Gel Based Assay
The insertion creates a mutant allele, which, identified by sequencing, is 
24bp larger than the normal allele (Figure 4.13). The duplication produces a 
fragment o f 371 bp in affected individual F28.1, see lanes 2-4 (Figure 4.14). The 
normal allele (347bp) is present, see lane 6.
FIGURE 4.13 
Development of a Gel Based Assay to Detect M utation 32-33ins 9-32 24bp 
Duplication
Diagrammatic representation of the 347bp PCR amplified fragment o f exon l a  
o f CDKN2A. The mutation creates a 24bp duplication o f base pairs 9-32 and 
inserts the 24bp at base pair 32 to give rise to a 371 bp PCR amplified fragment 
of exon 1 a  o f CDKN2A.
Duplication
S ’ ------------Intron E xonLq347bp
3 ’
32-33ins 9-32 24bp duplication
Intron 3 ’371bp
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FIGURE 4.14
Development of a Gel Based Assay to Detect M utation 32-33ins 9-32 24bp 
Duplication
a) The expected 371 bp and 347bp amplicons o f the 32-33ins 9-32 24bp
duplication were confirmed by resolution on a 4% agarose gel with ethidium
bromide. The amplicons were electrophoresed in IX TAE buffer for 20 minutes.
The size o f the amplicons which are represented below shown in base pairs were
deduced by comparison to the migration o f the known size of the DNA ladder
fragments in lanes 1 and 4. The am plicons’ sizes are consistent with the
expected 371 bp and 347bp fragments and was sequenced to confirm this.
Lanes
Ladder Bands (bp) Sample Bands (bp)
Electrophoresis C onditions:4% agarose gel, IX TAE, lOpl size markers, 5jul
PCR product, 2pl loading mix, 100V, 20 minutes, 
room temperature 
Lane 1 -  lkb  Plus size marker 
Lane 2 -  PCR product from a normal control 
Lane 3 -  PCR product from individual F28.1 
Lane 4 -  PhiXl 74-Mini I size marker
See page 60 for patient details.
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b) The expected 371 bp and 347bp amplicons of the 32-33ins 9-32 24bp 
duplication were confirmed by resolution on a Spreadex 600 gel with ethidium 
bromide. The amplicons were electrophoresed in 30mM TAE buffer for 10 
minutes. The size o f the amplicons which are represented below shown in base 
pairs were deduced by comparison to the migration o f the known size o f the 
DNA ladder fragments in lanes 1 and 4. The am plicons’ sizes are consistent with 
the expected 371 bp and 347bp fragments and was sequenced to confirm this.
Heterodulpex Lanes
Band (bp)
Ladder Bands (bp)
Sample Bands (bp)
3 7 1 ^
347
Electrophoresis Conditions: Spreadex 600 gel, 30mM TAE, lOpl size markers,
5pl PCR product, 2pl loading mix, 100V, 20 
minutes, room temperature
Lane 1 -  lkb size marker
Lane 2 -  PCR product from individual F28.1
Lane 3 -  PCR product from individual F28.1
Lane 4 -  PCR product from individual F28.1
Lane 5 -  PCR product from a normal control
Lane 6 -  1 kb size marker
Lane 7 -  PhiX 174///w f I size marker
Lane 8 -  lkb Plus size marker See page 60 for patient details.
Spreadex gels (Elchrom Scientific) are a novel synthetic matrix o f gel polymers 
arranged to selectively retard migration so that the bands remain sharp but are 
more spread out relative to each other.
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4.10.5 Heteroduplex Analysis
The resolution of the duplication is much clearer in the Spreadex 600 gel 
compared with the 4% agarose gel. The expected 371bp and 347bp amplicons of 
individuals F28.1 and F28.2 are resolved, however, there is also detection o f an 
extra slow moving band present. This extra band has thought to be caused by 
heteroduplex formation, which has less electrophoretic mobility than that of 
homoduplexes and therefore detected as an extra slow moving band. The 
formation of this heteroduplex band is likely to have occurred during the 
annealing step of the PCR programme or when the PCR products from these 
heterozygous individuals were cooled. This would have allowed the single 
mutant strands to base pair with the complementary strands from the wild type 
allele and form heteroduplexes rather than homoduplexes.
I l l
4.11 The R24P M utation
4.11,1 Mutation Analysis in Family 2 (Figure 4.15)
Family 2 has four affected members with melanoma, three male and one 
female, who presented with melanoma aged 19, 31, 37 and 39 years. There is 
also a member o f this family with oesophageal cancer.
FIGU RE 4.15
Scottish M elanom a Family 2
1:1
oesophageal
F 2 . ^
o
l:2
.
Il:4
39
F2.6
II :2
37
O
II :6
F2.5jj- F2.7
1:1 :2
2.1
11:3
31
O
11:7
F2.41+ F2.81 -
F 2 .^ +
111:3
19
11:5
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4A 1.2 Identification o f  a Chromatogram WAVE Shift
Exons l a  and 2 of the proband, individual F2.1 were amplified and 
subjected to dHPLC analysis (Figure 4.16). A chromatogram WAVE shift from 
the normal was identified in exon la .
4.11.3 Identification o f Mutation R24P
A new exon l a  amplicon was generated for direct sequencing of the 
proband using both forward and reverse exon l a  primers.
A heterozygous G to C transition at nucleotide position 71G>C was 
identified (Figure 4.16). This base change is predicted to lead to the substitution 
of arginine (R) for a proline (P) at codon 24 (R24P) (Figure 4.16). This mutation 
has been previously reported (Monzon et al. 1998; MacKie et al. 1998). Exon 
l a  from each of the family members was screened by direct sequencing. The 
predicted substitution observed in the proband was also found in the affected 
family members F2.2, F2.3 and F2.4, but no substitution was present in the 
currently unaffected family members F2.6, F2.7 and F2.8. The presence of the 
substitution in the affected individuals and not in unaffected individuals 
increases the chance that this identifies a pathological mutation. The predicted 
substitution was also identified in currently unaffected individual F2.5.
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FIG U RE 4.16
Family 2 -  Identification of M utation R24P (71G>C)
Abnormal elution 
profile —■
Normal
>
E
a)ocaj
XI
0 2 3 5 6 7 81 4
Time (Minutes)
dHPLC WAVE analysis o f PCR amplified genomic DNA from individual F2.1. 
Proband DNA was amplified using intronic primer pair CDKN2A exon l a  
(Appendix 1, 2).
Sequence analysis o f PCR amplified genomic DNA from individual F2.1.
Proband DNA was amplified and sequenced using intronic primer pair CDKN2A
exon l a  (Appendix 1, 2).
R G R V E
Wild Type CGG GGT CGG GTA GAG
Mutant CGG GGT CCG GTA GAG
P
(R24P)
Nucleic acid and derived amino acid sequences from the mutated region of 
CDKN2A. The amino acid substitution o f an arginine (R) for a proline (P) at 
position 24, R24P is shown.
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4.12 The Y44stop Mutation
4.12.1 Mutation Analysis in Family 3 (Figure 4.17)
Family 3 has two affected members with melanoma, both female, who 
presented with melanoma aged 33 and 55 years. Individual F3.1 has multiple 
primary melanomas.
FIGURE 4.17
Scottish Melanoma Family 3
F3.1
2 multiple primaries
F3.3F3.
111:1 l l l : 2
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4.12.2 Identification o f  a Chromatogram WAVE Shift
Exons l a  and 2 of the proband, individual F3.1 were amplified and 
subjected to dHPLC analysis (Figure 4.18). A chromatogram WAVE shift from 
the normal was identified in exon la .
4.12.3 Identification o f  Mutation Y44stop
A new exon l a  amplicon was generated for direct sequencing of the 
proband using both forward and reverse exon l a  primers.
A heterozygous C to A transition at nucleotide position 132C>A was 
identified (Figure 4.18). This base change is predicted to lead to the substitution 
of tyrosine (Y) for a stop codon at codon 44 (Y44stop) (Figure 4.18). This 
mutation has been previously reported (MacKie et al. 1998). Exon l a  from each 
of the family members was screened by direct sequencing. The predicted 
substitution observed in the proband was also found in the affected family 
member F3.2, but no substitution was present in the currently unaffected family 
member F3.3. The presence of the substitution in the affected individuals and 
not in unaffected individual increases the chance that this identifies a 
pathological mutation.
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FIG U RE 4.18
Family 3 -  Identification of M utation Y44stop (132C>A)
Normal
^  A0 4
0 21 3 4 5 6 7 8
Tb(WiIss)
Abnormal elution 
profile
5 6 74
dHPLC WAVE analysis o f PCR amplified genomic DNA from individual F3.1. 
Proband DNA was amplified using intronic primer pair CDKN2A exon l a  
(Appendix 1, 2).
Sequence analysis o f PCR amplified genomic DNA from individual F3.1.
Proband DNA was amplified and sequenced using intronic primer pair CDKN2A
exon l a  (Appendix 1, 2).
N S Y G R
Wild Type AAT AGT TAC GGT CGG
Mutant AAT AGT TAA GGT CGG
R
(Y44stop)
Nucleic acid and derived amino acid sequences from the mutated region of 
CDKN2A. The amino acid substitution o f a tyrosine (Y) for a stop codon at 
position 44, Y44stop is shown.
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4.13 The M53I M utation
4.13.1 Mutation Analysis in Families 1, 4, 5, 6, 29 and 30 (Figure 4.19)
Family 1 has three affected members with melanoma, all female, two of 
whom presented with melanoma at 37 and 48 years of age. Individual 111:1 
(F 1.1) has multiple primary melanomas. Family 4 has two affected members 
with melanoma, one male and one female, who both presented with melanoma at 
46 years o f age. Both individuals have multiple primary melanomas. Family 5 
has two affected members with melanoma, one male and one female, who 
presented with melanoma at 27 and 36 years of age. Individual 111:5 (F5.1) has 
multiple primary melanomas. Family 6 has two affected members with 
melanoma, both female, who presented with melanoma aged 21 and 34 years. 
Individual 1:2 (F6.1) has multiple primary melanomas. Family members F6.4 
and F6.5 who do not have melanoma do however carry the polymorphism 
A148T as described on page 105. Family 29 has three affected members with 
melanoma, two male and one female, who presented with melanoma aged 27, 50 
and 62 years. Family 30 has two affected members with melanoma, both female, 
who presented with melanoma aged 20 and 24 years. There is also a member of 
this family with ovarian cancer.
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FIGU RE 4.19
Scottish M elanoma Families 1, 4, 5, 6, 29 and 30
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4.13.2 Identification o f a Chromatogram WAVE Shift
Exons l a  and 2 of the probands, individuals F l . l ,  F4.1, F5.1, F6.1, F29.1 
and F30.1 were amplified and subjected to dHPLC analysis (Figure 4.20). 
Chromatogram WAVE shifts from the normal were identified in exon 2.
4.13.3 Identification o f Mutation M53I
New exon 2 amplicons were generated for direct sequencing of the 
probands using both forward and reverse exon 2 primers.
A heterozygous G to C transition at nucleotide position 159G>C was 
identified (Figure 4.20). This base change is predicted to lead to the substitution 
of methionine (M) for an isoleucine (I) at codon 53 (M53I) (Figure 4.20). This 
mutation has been previously reported (Harland et al. 1997; MacKie et al. 1998; 
Monzon et al. 1998; Pollock et al. 1998). Exon 2 from each of the family 
members was screened by direct sequencing. The predicted substitution 
observed in the probands was also found in the affected family members F4.2, 
F5.2, F6.3 and F30.2, but no substitution was present in the currently unaffected 
family members F I.3, F6.4 and F6.5. The presence of the substitution in the 
affected individuals and not in unaffected individuals increases the chance that 
this identifies a pathological mutation. The predicted substitution was also 
identified in currently unaffected individuals F I.2, F4.3 and F6.2 but it was not 
identified in affected individual F29.2 (see cloning method 3.15).
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FIG U R E  4.20
Families 1, 4, 5, 6, 29 and 30 -  Identification of M utation M53I (159G>C)
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dHPLC WAVE analysis of PCR amplified genomic DNA from individuals F l.l, F4.1, 
F5.1, F6.1, F29.1 and F30.1. Proband DNA was amplified using intronic primer pair
CDKN2A exon 2 (Appendix 1, 2).
Sequence analysis of PCR amplified genomic DNA from individuals F l.l, F4.1, F5.1, 
F6.1, F29.1 and F30.1. Proband DNA was amplified and sequenced using intronic 
primer pair CDKN2A exon 2 (Appendix 1, 2).
V M M M G
Wild Type GTC ATG ATG ATG GGC
Mutant GTC ATG ATC ATG GGC
I
(M53I)
Nucleic acid and derived amino acid sequences from the mutated region of CDKN2A. 
The amino acid substitution of a methionine (M) for an isoleucine (I) at position 53, 
M53I is shown.
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4.13.4 Cloning Analysis o f  F29.2
Mutation M53I, which was identified in individual F29.1, was screened 
for in the other affected family members. No DNA was available however from 
the deceased II: 1. Surprisingly the mutation was not identified in affected family 
member F29.2.
To rule out sample mix-up, a fresh blood sample was taken from both 
individuals F29.1 and F29.2, and once again the mutation was present in affected 
individual F29.1 but not in affected family member F29.2. Unfortunately in the 
exact place where the mutation should be in individual F29.2 a “dye blob” would 
appear on the chromatogram. “Dye blobs” are unincorporated dye terminator 
molecules that have remained in the sample by passing through the cleanup 
columns with the purified DNA. They make broad peaks at various points in the 
chromatogram, although “dye blobs” tend to be worst near the beginning of a 
read. In this case the “dye blob” would always appear over the mutation site no 
matter what purifying method was used to remove the unincorporated 
terminators, which meant that it was difficult to fully interpretate the 
electropherogram. Therefore the PCR amplicons of individual F29.2 were 
cloned using the TOPO TA Cloning Kit for sequencing (Method 3.15) to 
determine exactly whether or not affected individual F29.2 carried the familial 
mutation. TA Cloning was the chosen approach to obtain experience in this 
technique.
The primers used for the amplification of the fragment containing exon 2 
were the same set which were designed for independent amplification o f the 
complete coding region of exon 2 and its splice sites as previously described. 
The final amplification conditions are presented in Appendix 2. A 2pl aliquot of 
DNA (extracted as described using method 3.Id) from patient F29.2 was 
amplified with the set of primers in a 50 j l i 1 PCR reaction. A fragment size of 
458bp for exon 2 was generated. The single discrete band obtained from 
amplification was resolved on an ethidium bromide stained 1.2% agarose gel to 
verify the size o f the amplified band. In parallel with cloning of the patient’s 
DNA, 1 pi of control DNA, which was supplied with the kit, was also amplified. 
The supplied amplification conditions are presented in Appendix 2. A fragment 
size of 750bp was generated. The single discrete band obtained from
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amplification was resolved on an ethidium bromide stained 0.8% agarose gel to 
verify the size of the amplified band.
Seven LB plates were prepared, six of which contained 50pg/ml of 
kanamycin and one that contained lOOpg/ml of ampicillin. The kanamycin 
plates were used for the control transformation of vector only and vector plus 
insert and also for the transformation of the patient DNA. An ampicillin plate 
was only used for the pUC19 transformation because the control template is a 
plasmid that encodes an ampicillin resistance gene and transformants carrying 
this plasmid will also be ampicillin resistant, therefore upon analysis colonies 
would not contain the desired construct. The transformation control is a pUC19 
plasmid, which checks the transformation efficiency of the competent cells. 
Sodium chloride and magnesium chloride o f a concentration of 200mM NaCl, 
lOmM MgC12 was added to the chemically competent E. coli. Inclusion of salt 
allows for longer incubation times because it prevents topoisomerase I from 
rebinding and potentially nicking the DNA after ligating the PCR product and 
dissociating from the DNA. The result is more intact molecules leading to 
higher transformation efficiencies.
While an efficient cloning reaction should produce hundreds of colonies, 
the cells used were old and few colonies grew well. There were only about 30 
colonies on the ampicillin pUC19 transformation plate and therefore the 
transformation efficiency of the competent cells was quite poor. There were no 
colonies on the kanamycin vector-only reaction plates. There were about 160 
and 150 white colonies on the kanamycin vector plus PCR insert reaction plates, 
indicating that they contained the 750bp insert. There were about 105 and 60 
white colonies on the kanamycin vector plus PCR patient DNA insert reaction 
plates, indicating that they contained the 458bp exon 2 insert. Ten white 
colonies, five from each plate, were picked for analysis. DNA was extracted 
from the colonies using the QIAprep Spin Miniprep Kit and then sequenced in 
both directions. All ten colonies in both forward and reverse directions did not 
carry any mutation and therefore conclude that melanoma patient F29.2 must be 
a sporadic case of melanoma in family 29.
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4.13.5 Development o f  a Restriction Test
The 159G>C mutation creates a Bel I site when the mutant C base is 
present in amplified product (Figure 4.21a).
Digestion with Bel I, produces full fragment sizes o f 374bp and 84bp in 
affected individuals F l . l ,  F4.1, F5.1, F6.1, F29.2 and F30.1, see lanes 2-7 
(Figure 4.21b). The normal allele (458bp) and the undigested normal allele 
(458bp) are both present, see lanes 8-10.
FIGURE 4.21
Development of a Be11 Restriction Site Created by M utation M53I
a) Diagrammatic representation o f the 458bp PCR amplified fragment o f exon 2 
o f CDKN2A. The mutation creates a Bel I restriction site 84bp into the PCR 
fragment in the presence o f the 159G>C substitution.
Normal (m53)
5 ’ Intron Exon 2 •3’
458bp
M utant (153)
5 ’ Intron
Bel I* 
84bp \
Exon 2
374bp-
■3’
a
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b) The expected 458bp and 374bp DNA fragments from the Bel I digested 
amplicons were confirmed by resolution on a 3% agarose gel with ethidium 
bromide. The amplicons were electrophoresed in IX TAE buffer for 20 minutes. 
The size o f the digested amplicons which are represented below shown in base 
pairs were deduced by comparison to the migration o f the known size o f the 
DNA ladder fragments in lanes 1,11 and 12.
Lanes
1 2 3 4 5 6 7 8 9 10 11 12
Ladder Bands (bp) Sample Bands (bp)
— 458
— 374
Electrophoresis C onditions:3% agarose gel, IX TAE, lOpI size markers, 5pl
digest, 2pl loading mix, 100V, 20 minutes, room 
temperature
Lane 1 -  lkb  Plus size marker 
Lane 2 -  digested PCR product from individual F l. l  
Lane 3 -  digested PCR product from individual F4.1 
Lane 4 -  digested PCR product from individual F5.1 
Lane 5 -  digested PCR product from individual F6.2 
Lane 6 -  digested PCR product from individual F29.1 
Lane 7 -  digested PCR product from individual F30.1 
Lane 8 -  digested PCR product from individual F6.3 
Lane 9 -  digested PCR product from individual F29.2 
Lane 10 -  undigested PCR product from a normal control 
Lane 11 -  1 kb size marker
Lane 12 -  PhiX 174/Hinf I size marker See page 60 for patient details.
The 84bp fragment is unresolved on the 3% agarose gel; therefore the following 
6% polyacrylamide gel was prepared to further resolve the bands.
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c) The expected 458bp, 374bp and 84bp DNA fragments from the Bel I digested 
amplicons were confirmed by resolution on a 6% polyacrylamide gel with 
ethidium bromide. The amplicons were electrophoresed in IX TBE buffer for 10 
minutes. The size o f the digested amplicons which are represented below shown 
in base pairs were deduced by comparison to the migration o f the known size o f 
the DNA ladder fragments in lane 1.
Ladder B ands(bp) 
500 
413
L a n e s
Sample Bands (bp)
Electrophoresis Conditions: 6% polyacrylamide gel, IX TBE, lOpl size marker,
5pl digest, 2pl loading mix, 100V, 20 minutes, 
room temperature
Lane 1 -  PhiX 174/////7f I size marker 
Lane 2 -  digested PCR product from individual F l. l  
Lane 3 -  digested PCR product from individual F4.1 
Lane 4 -  digested PCR product from individual F5.
See page 60 for patient details.
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4.14 The G67R M utation
4.14.1 Mutation Analysis in Family 19 (Figure 4.22)
Family 19 has five affected members with melanoma, four female and 
one male, who presented with melanoma at 33, 2 x 40, 49 and 66 years of age. 
Individuals 11:1 (F I9.2) and 11:3 have multiple primary melanomas. There are 
also two members of this family with ovarian cancer.
FIGURE 4.22
Scottish M elanoma Family 19
ovarian
F19.2
2 multiple primaries ovarian 
3 multiple primaries
F19.1
111:1 lll:2 lll:3
4.14.2 Identification o f a Chromatogram WAVE Shift
Exons l a  and 2 o f the proband, individual F I9.1 were amplified and 
subjected to dHPLC analysis (Figure 4.23). A chromatogram WAVE shift from 
the normal was identified in exon 2.
4.14.3 Identification o f Mutation G67R
A new exon 2 amplicon was generated for direct sequencing of the 
proband using both forward and reverse exon 2 primers.
A heterozygous G to C transition at nucleotide position 199G>C was 
identified (Figure 4.23). This base change is predicted to lead to the substitution 
of glycine (G) for an arginine (R) at codon 67 (G67R) (Figure 4.23). This 
mutation has previously been reported in and English family (Newton Bishop et 
al. 1999). No other samples from family members were available to be screened.
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FIG U RE 4.23
Family 19 -  Identification of M utation G67R (199G>C)
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dHPLC WAVE analysis o f PCR amplified genomic DNA from individual F I9.1. 
Proband DNA was amplified using intronic primer pair CDKN2A exon 2 
(Appendix 1, 2).
Sequence analysis o f PCR amplified genomic DNA from individual F I9.1. 
Proband DNA was amplified and sequenced using intronic primer pair CDKN2A 
exon 2 (Appendix 1, 2).
L H G A E
Wild Type CTC CAC GGC GCG GAG
Mutant CTC CAC CGC GCG GAG
R
(G67R)
Nucleic acid and derived amino acid sequences from the mutated region of 
CDKN2A. The amino acid substitution o f a glycine (G) for an arginine (R) at 
position 67, G67R is shown.
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4.15 The R112G M utation
4.15.1 Mutation Analysis in Families 17 and 22 (Figure 4.24)
Family 17 has two affected male members with melanoma, who
presented with melanoma at 34 and 36 years of age. Family 22 has three 
affected members with melanoma, two of whom are male and one is female, they 
presented with melanoma at 29, 33 and 38 years of age.
4.15.2 Identification o f a Chromatogram WAVE Shift
Exons l a  and 2 of the probands, individuals F I7.1 and F22.1 were
amplified and subjected to dHPLC analysis (Figure 4.25). Chromatogram
WAVE shifts from the normal were identified in exon 2.
FIGURE 4.24
Scottish M elanom a Family 17
F17.4 + F17.5 _
1:1 l:2
F17. F17.2I +
O  ■
11:1 l l : 2 11:4 11:3
34 36
111:1 lll:2 111:3
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Scottish M elanoma Family 22
F22.3 + F22.4 .
F22. 2 l+  F22 F22.51 _ F22.6
111:1 lll:2 lll:3 lll:4
4.153 Identification o f Mutation R112G
New exon 2 amplicons were generated for direct sequencing of the 
probands using both forward and reverse exon 2 primers.
A heterozygous C to G transition at nucleotide position 334C>G was 
identified (Figure 4.25). This base change is predicted to lead to the substitution 
o f arginine (R) for a glycine (G) at codon 112 (R112G) (Figure 4.25). This 
mutation has been previously reported (Holland et el. 1999). Exon 2 from each 
of the family members was screened by direct sequencing. The predicted 
substitution observed in the probands was also found in the affected family 
members F I7.2 and F22.2, but no substitution was present in the currently 
unaffected family members F I7.5, F22.4, F22.5 and F22.6. The presence of the 
substitution in the affected individuals and not in unaffected individuals 
increases the chance that this identifies a pathological mutation. The predicted 
substitution was also identified in currently unaffected individuals F17.3, F I7.4 
and F22.3.
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FIG U R E 4.25
Families 17 and 22 -  Identification of M utation R112G (334C>G)
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dHPLC WAVE analysis of PCR amplified genomic DNA from individuals FI 7.1 
and F22.1. Proband DNA was amplified using intronic primer pair CDKN2A 
exon 2 (Appendix 1, 2).
Sequence analysis o f PCR amplified genomic DNA from individuals F I7.1 and 
F22.1. Proband DNA was amplified and sequenced using intronic primer pair 
CDKN2A exon 2 (Appendix 1, 2).
W G R L P
Wild Type TGG GGC CGT CTG CCC
Mutant TGG GGC GGT CTG CCC
G
(R112G)
Nucleic acid and derived amino acid sequences from the mutated region of 
CDKN2A. The amino acid substitution of an arginine (R) for a glycine (G) at 
position 112, R112G is shown.
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4.16 The A148T Suspected Polym orphism
4.16.1 Mutation Analysis in Families 7 and 13
Family 7 has two affected members with melanoma, one male and one 
female, who presented with melanoma aged 43 and 45 years. Family 13 has two 
male affected members with melanoma, who presented with melanoma aged 34 
and 36 years. As reported on page 122, two unaffected members of family 6 
(F6.4 and F6.5) also carry this polymorphism.
4.16.2 Identification o f a Chromatogram WAVE Shift
Exons l a  and 2 of the probands, individuals F7.1 and F I3.1 were 
amplified and subjected to dHPLC analysis (Figure 4.26). Chromatogram 
WAVE shifts from the normal were identified in exon 2.
4.16.3 Identification o f  the Suspected Polymorphism A148T
New exon 2 amplicons were generated for direct sequencing o f the 
probands using both forward and reverse exon 2 primers.
A heterozygous G to A transition at nucleotide position 442G>A was 
identified (Figure 4.26). This base change is predicted to lead to the substitution 
of alanine (A) for a threonine (T) at codon 148 (A148T) (Figure 4.26). This 
mutation has been previously reported as a polymorphism (Hussussian et al. 
1994). Exon 2 from each of the family members was screened by direct 
sequencing. The predicted substitution observed in the probands was not present 
in the currently unaffected family members F6.2 and F7.2. The presence o f the 
substitution in the affected individuals and not in unaffected individuals 
increases the chance that this identifies a pathological mutation. However, the 
predicted substitution was also identified in currently unaffected individuals 
F6.4, F6.5 and F I3.3 but it was not identified in affected individual F6.1, F6.3, 
and F I3.2, which leads us to believe that this predicted substitution is a 
polymorphism.
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FIG U RE 4.26
Families 7 and  13 -  Identification of M utation A148T (442G>A)
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dHPLC WAVE analysis o f PCR amplified genomic DNA from individuals F7.1 
and F I3.1. Proband DNA was amplified using intronic primer pair CDKN2A 
exon 2 (Appendix 1, 2).
Sequence analysis o f PCR amplified genomic DNA from individuals F7.1 and 
F I3.1. Proband DNA was amplified and sequenced using intronic primer pair 
CDKN2A exon 2 (Appendix 1, 2).
D A A E G
Wild Type GAT GCC GCG GAA GGT
Mutant GAT GCC ACG GAA GGT
1
(A148T)
Nucleic acid and derived amino acid sequences from the mutated region of 
CDKN2A. The amino acid substitution o f an alanine (A) for a threonine (T) at 
position 148, A148T is shown.
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4.17 Multiple Primary Melanomas
Approximately 5% of all melanoma patients develop additional primary 
melanomas, which suggests that a genetic predisposition or de novo mutations in 
predisposing genes may be involved with multiple primary melanomas (MPMs). 
This study therefore also included the identification of possible CDKN2A 
mutations in 13 cases o f MPM with familial melanoma and 11 sporadic 
melanoma cases (Tables 4.2, 4.3). There was no available DNA for individual 
F I9.2 who has two MPMs.
TABLE 4.2
Multiple Primary Melanomas -  Patients with Familial Melanoma
Family
Identifier
CDKN2A
Mutation
Number of Primary 
Melanomas
Age of 
Diagnosis
F l.l M531 3 37
F3.1 Y44stop 2 33
F4.1 M53I 3 46
F4.2 M53I 3 46
F5.1 M53I 2 36
F6.1 M53I 2 34
F11.2 None detected 2 33
F28.2 24bp Duplication 3 34
F33.1 H83N 4 28
F33.2 H83N 3 25
F42.1 None detected 3 21
F43.1 None detected 3 43
F43.2 None detected 2 19
TABLE 4.3
Multiple Primary Melanomas -  Patients with Sporadic Melanoma
Sporadic
Identifier
CDKN2A
Mutation
Number of Primary 
Melanomas
Age of 
Diagnosis
SMP1 M53I 5 31
SMP2 None detected 5 38
SMP3 M53I 9 23
SMP4 None detected 3 71
SMP5 None detected 3 33
SMP6 None detected 3 51
SMP7 -30G>T 3 64
SMP8 None detected 4 65
SMP9 None detected 5 62
SMP10 None detected 4 74
SMP11 None detected 4 50
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Germline mutations in the CDKN2A gene were identified in 12/24 (50%) 
of MPM cases, nine with a family history of melanoma and three sporadic cases. 
Four of the ten families with MPM have the M53I mutation, one family has the 
Y44stop mutation, one family has the exon l a  32-33ins9-32 24base pair 
duplication, one family has the H83N mutation, and the remaining three families 
have no detectable mutation. Three sporadic melanoma patients with MPM have 
CDKN2A mutations. Two individuals have the M53I mutation and one 
individual has a previously unreported -30G>T mutation. The remaining eight 
patients with sporadic melanoma and MPM have no detectable mutation.
The most frequently identified mutation in patients with MPM was M53I, 
found in five familial cases and in two sporadic cases. CDKN2A mutations were 
more frequent in those patients with a family history of melanoma (9/13 69.2%) 
than in those without a family history (3/11 27.3%). In the patients with a 
CDKN2A mutation the average number of primary melanomas was 3.5 and in 
those patients without a detected CDKN2A mutation it was slightly lower at 3.4. 
The mean age of diagnosis in the patients with a CDKN2A mutation was at 36.4 
years and in those patients without a detected CDKN2A mutation it was older at 
46.7 years.
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4.18 The use of Molecular Modelling to Identify Mutation Sites and their 
Possible Effects on Pathological Function
To investigate the potential effect of the newly identified H83N CDKN2A 
mutation and the potential effect of the G67R mutation with unknown function 
effects, the consequences of these mutations were investigated at the molecular 
level by consideration of the crystal structure of the CDK6-pl6 complex. This 
work was carried out in collaboration with Professor Hunter, Division of 
Biological Chemistry and Molecular Microbiology at the School of Life 
Sciences, University of Dundee (Method 3.16).
The computer graphics program “O” was used to visualize the structure 
of p i6, the interactions formed between this tumour suppressor and the protein 
kinase CDK6 and how the mutations were predicted to affect the structure and 
interactions.
The analysis could only be carried out for the CDK6 complexes, as the 
crystalline structure for CDK4 is not yet available. The structure of CDK6 
resembles other ATP-dependent protein kinases and consists of an N-terminal 
and a C-terminal domain with the active site formed in a crevice between these 
two lobes (Figure 4.27). The kinase inhibitor pl6INK4A consists of four 
ankyrin repeats, a 33-amino acid segment that folds into a p-hairpin-helix-loop- 
helix motif (Zhang and Peng 2000) and is a characteristic unit implicated in 
many protein-protein associations. The tumour suppressor pl6INK4A binds 
adjacent to the ATP-binding active site o f CDK6 and interacts with both N and 
C-terminal domains to distort the kinase structure. Binding of the suppressor 
prevents the kinase-cyclin associations required for progression through the cell 
cycle.
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FIGU RE 4.27
Ribbon Representation of p!6IN K 4A  and CDK6
CDK6 
active site
The computer graphics program “O” was used to visualize the pl6-CD K 6 
complex. The kinase is depicted as yellow ribbons, the tumour suppressor as 
grey. Six residues from pl6IN K 4A , discussed in text, as shown as van der 
Waals radii coloured according to atom type: C black, N blue, O red and S 
yellow. The single letter amino acid code is used in labelling.
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A newly reported mutation H83N is presented in this thesis. H83 is 
buried within the core of pl6INK4A and the side chain of histidine participates 
in three hydrogen bonds to different parts of the tumour suppressor molecule 
main chain (the carbonyl groups of V I96 and R 112, and the amide group of R80) 
that serve to stabilise the conformation of two loops that interact with residues 31 
to 38 of CDK6. Replacing the basic histidine with asparagine would ensure the 
loss of at least one hydrogen bond within the core of the molecule, which might 
destabilise the pl6INK4A structure.
The side chain of residue R24 of pl6INK4A forms hydrogen bond 
interactions with Q149 and E l04 of CDK6. The crystal structure shows the side 
chain of Q149 placed so that the NE2 group contacts the R24 guanidinium 
group, however it is more likely that it is the Q149 OE1 group that participates in 
the association. If R24 was mutated to P then this would remove the strong 
electrostatic interactions and reduce the affinity for complex formation between 
the two proteins.
Within 6°A of amino acid R24 is M53 (Figure 4.28). The side chain of 
this hydrophobic residue makes van der Waals interactions with the main chain 
atoms of D102, E l03 and T107 of CDK6. A mutation to I would likely reduce 
the area of interaction and therefore be slightly disruptive of complex formation. 
Mutations to the R and M residues of either pl6INK4A or pl4ARF would be 
predicted to have similar effects on binding to either CDK4 or CDK6.
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FIGURE 4.28 
The Site of M53
\  H10°
D104
D102
Specific residues discussed in text, as shown as ball-and-stick models coloured 
according to atom type: C grey, N blue, O red and S yellow. The replacement of 
isoleucine for methionine is highlighted by representing the isoleucine as black 
sticks.
One mutation reported in this thesis is G67R, which has only been 
reported once before (Newton Bishop et al. 1999). G67 is situated on the
opposite side o f the pl6IN K 4A  inhibitor kinase interface and is not involved in 
the protein:protein contacts between the tumour suppressor and kinase. This 
residue is however an important component o f the helix-tum-strand m otif of the 
ankyrin repeats. It is situated at the end o f the helix on a tight turn into the (3- 
sheet. A mutation at this point o f the protein may affect the secondary structure 
and perhaps the folding o f the protein. Four ankyrin repeat units span exons 1 
and 2 o f CDKN2A, and are essential to pl6IN K 4A  binding and function. G67 is 
a strictly conserved amino acid and the first residue o f the second ankyrin repeat 
and shares secondary structure alignment with G101 (not shown), the latter is a 
residue o f proven significance to pl6IN K 4A  function (Hussussian et al. 1994; 
Kamb et al. 1994; Ciotti et al. 2000). Any mutation at this point would be likely 
to impair function as replacing glycine with arginine could influence the fold and
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alter the position of adjacent helices, which taper down to the binding site with 
CDK6. This G67R substitution could also change the binding sites to other as 
yet unidentified proteins. A mutation at the same residue G67S has been 
observed previously (Holland et al., 1999) and is likely to affect pl6INK4A 
function as shown by site-directed mutagenesis (Tevelev et al. 1996; Zhang and 
Peng 1996) by the described pl6INK4A structure (Byeon et al. 1998) and also 
reduced binding to CDK4 (Rizos et al., 2001).
R112 makes a salt bridge interaction with E l20, which helps to stabilise 
the structure of the loops that interact with CDK6. A mutation from R to G 
would disrupt this part o f the structure and also complex formation.
While molecular modelling is an important lead, functional studies are 
still required to confirm the functional consequences of any mutation. We would 
like to determine whether the mutation inhibits cell cycle progression, if 
pl6INK4A is still able to bind to CDK4 and whether pRB phosphorylation 
inhibition is reduced. We have therefore agreed collaboration with the 
University o f Toronto who have functional assays to determine cell proliferation 
and protein-protein interactions and yeast-two-hybrid assays to evaluate 
functional importance as part o f their battery of research techniques. We have 
supplied them with a sample of the H83N mutant DNA for testing.
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4.19 Statistical Analysis of the Correlation between Phenotype and Familial 
Melanoma Patients with and without a CDKN2A Mutation
All 62 familial melanoma patients were assessed for their CDKN2A 
genotype with regard to skin type, eye and hair colour as previously described in 
2.4.1. The phenotypic characteristics of all patients are summarised in table 2.1. 
Statistical analysis was performed using the methods described in method
3.17.
No association between skin type, eye or hair colour and the presence or 
absence o f a CDKN2A mutation within familial melanoma patients was observed 
in this data set (Tables 4.4-4.6). Due to the large quantity of results, all findings
are reported in tabular form in Appendix 5 (Skin Type - tables 15, 18; Eye
Colour - tables 14, 17; Hair Colour - tables 13, 16).
TABLE 4.4
Correlation between Skin Type and Familial Melanoma Patients with and without
a CDKN2A Mutation
Never Tans Burns Burns Never
Always Easily Rarely Burns
Burns Tans Tans Easily Always
Rarely Tans
CDKN2A Mutation 5 15 0 0
Positive
CDKN2A Mutation 10 29 3 0
Negative
P-value = 0.957 (not significant)
TABLE 4.5
Correlation between Eye Colour and Familial Melanoma Patients with and without
a CDKN2A Mutation
Blue Green Brown Other
CDKN2A Mutation Positive 15 1 1 3
CDKN2A Mutation Negative 28 3 6 5
P-value = 0.713 (not significant)
TABLE 4.6
Correlation between Hair Colour and Familial Melanoma Patients with and
without a CDKN2A Mutation
Red Blonde Light Brown Dark Brown/Black
CDKN2A Mutation 2 7 7 4
Positive
CDKN2A Mutation 8 8 14 12
Negative
P-value = 0.475 (not significant)
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CHAPTER 5
STUDIES TO ESTABLISH A COMMON 
FOUNDER OF THE M53I MUTATION
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5.1 Haplotyping of M53I Scottish Melanoma Families
The most common CDKN2A mutation identified in this thesis from the 
cohort of Scottish melanoma families is the M53I mutation. The M53I mutation 
was originally detected in an Australian melanoma kindred, and has now been 
reported in three additional Australian families, two American kindreds, two 
English kindreds and one family each in, Canada (Ontario) and France. Table
5.1 gives details of all currently reported M53I melanoma families worldwide.
TABLE 5.1
Currently Reported Melanoma Families Worldwide with M53I Mutations
Number of M53I Country Population
Families (millions)
6 Scotland (MacKie et al. 1998; this 
thesis)
5
4 Australia (Walker et al. 1995; Flores et 
al. 1997; Holland et al. 1999)
19.5
2 U.S.A
(FitzGerald et al. 1996; Tsao et al. 2000)
286.8
2 England (Harland et al. 1997; Newton 
Bishop et al. 1999)
49.9
1 Canada, Ontario (Monzon et al. 1998) 11
1 France (Soufir et al. 1998) 60.1
Previous examination of five melanoma families from Australia and 
North America with the M53I mutation suggested the possibility of a common 
haplotype (Pollock et al., 1998). The high prevalence of reported M53I mutation 
positive families per head of population in Scotland led this study to investigate 
the possibility that the M53I mutation is o f Scottish origin.
In addition to the six M53I families from Scotland, DNA from five M53I 
families from Toronto, Canada, four from Brisbane, Australia, three from 
Boston, U.S.A and two Scottish patients with sporadic melanoma with multiple 
primaries were studied.
143
5.2 Families
Details and pedigrees of the six Scottish families have already been given 
in Chapter 4. Table 5.2 shows details o f the Scottish, Canadian, Australian and 
American M53I melanoma families.
TABLE 5.2
Details of Melanoma Families with M53I Mutations
M53I
Family
Identifier
Country Ancestry Number of 
Individuals 
in the 
Pedigree with 
Melanoma
Number of 
M53I Carriers 
Available for 
Haplotyping
1 Scotland Scottish 3 2
4 Scotland Scottish 2 2
5 Scotland Scottish 2 2
6 Scotland Scottish 2 2
29 Scotland Scottish 3 1
30 Scotland Scottish 2 2
FAM-1 Canada Scottish 5 4
FAM-2 Canada Scottish 2 1
FAM-3 Canada Scottish 2 1
FAM-4 Canada Scottish 4 1
FAM-5 Canada Scottish 3 1
41001 Australia Scottish 14 2
41031 Australia Irish/English/Chinese 5 2
60001 Australia Scottish 15 4
41156 Australia Irish 5 2
L25 America Scottish/Irish/French 8 1
637 America Scottish/French
Canadian
3 1
590 America Irish/English 5 1
The six Scottish families have either two or three melanoma patients per 
family. In addition, patients from four of the families had multiple primary 
melanomas. Members o f the six Scottish families with M53I mutations have 
been questioned about their family history, and in no family can a link to any of 
the other M53I Scottish families be traced, going back to generations bom 
around 1900. All six families give a history o f Scottish ancestry. Two 
individuals from each of the M53I Scottish families were available for 
haplotyping except family 29 in which only one individual was available.
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O f the five Canadian families, two families have two melanoma patients 
per family, one family has three melanoma patients, one family has four 
melanoma patients and one family has five melanoma patients. In addition, 
patients from four of the families had multiple primary melanomas. All five 
Canadian families are thought to have Scottish ancestries. One individual from 
each of the M53I Canadian families was available for haplotyping except family 
FAM-1 in which four carriers and two non-carriers were available.
Two of the four Australian families have five melanoma patients, one 
family has 14 melanoma patients and one family has 15 melanoma patients. In 
addition, patients from all four of the families have multiple primary melanomas. 
Members of the four Australian families with M53I mutations have been 
questioned about their family history. Two families are thought to have Scottish 
ancestries, one family is thought to have mixed Irish, English and Chinese 
ancestry and one family is thought to have Irish ancestry. Two individuals from 
two o f the M53I Australian families (41001 and 41156) were available for 
haplotyping. Family 41031 had two carriers and two non-carriers available and 
in family 60001 there were four carriers available.
The three American families have three, five and eight melanoma patients 
per family. In addition, patients from all three of the families have multiple 
primary melanomas. Members of the three American families with M53I 
mutations have been questioned about their family history. One family is 
thought to have Scottish, Irish and French ancestry, one family is thought to have 
Irish and English ancestry and one family is thought to have Scottish and French 
Canadian ancestry. One individual from each of the M53I American families 
was available for haplotyping.
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5.3 Determination of Allele Length Employed
Eight markers, D9S1604, D9S1748, D9S942, D9S974, RH103023, 
D9S2060, D9S2136 and D9S1749, as illustrated in figure 5.1, were genotyped to 
determine which alleles from loci flanking CDKN2A were transmitted with 
melanoma in each of the 18 M53I families. Ninety chromosomes from 45 
Scottish control subjects were also characterised to determine the allele 
frequency of the markers in the general Scottish population.
FIGURE 5.1
Physical Map of the Eight Markers used in Haplotype Analysis
500 
5401
Jjcon lb Exon la Exon 2 Exon 3
12 11 11 12 13 21 22 23 24
E m■ 11Chromosome 9
The location o f the M53I mutation and CDKN2A locus with respect to these 
markers is shown. Distances are not shown to scale.
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Primers were designed for independent amplification of each of the eight 
markers (Methods 3A2-3.4.5). The sequences of the primers used for 
amplification of the microsatellite markers at 9p21 were from the Genome 
Database (http://gdbwww.gdb.org/). All forward primers were 5’ labelled with 
fluorescent dye FAM. The final amplification conditions are presented in 
Appendix 2. Routinely a lp l aliquot of DNA at lOOng/pl (extracted as described 
using method 3.1a) from each patient was amplified with each of the sets of 
primers. DNA samples sent from Canada, Australia and America were diluted to 
a concentration of lOOng/pl (Method 3.3).
Fragment sizes of approximately 190bp for D9S1604, 115bp for 
D9S1748 and D9S942, 210bp for D9S974, 120bp RH103023, 145bp for 
D9S2060, 130bp for D9S2136 and 135bp for D9S1749 were generated. 
Negative controls (no DNA) were run along with each reaction. Once all the 
DNA samples had been transferred to PCR tubes, the same reagents were used 
for the negative control. The absence of amplicons in the negative control meant 
that there had been no cross-contamination between the samples or into the 
reagents. The distinct bands obtained from amplification were resolved on 
ethidium bromide stained agarose gels to verify amplification and estimate the 
size of the amplified band (Method 3.5). The distinct bands are presented in 
figure 5.2.
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FIGU RE 5.2
Amplification of M arkers  S urrounding  the CDKN2A Locus
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The approximate sizes o f the amplicons o f each marker were determined by 
resolution on 2% agarose gels with ethidium bromide staining in IX TAE buffer 
for 20 minutes. The size o f the amplicons shown in base pairs were deduced by 
comparison to the migration o f the known size o f the DNA ladder fragments in 
lane 1. lp l o f genomic DNA was routinely amplified by conditions specified in 
Appendix 2 and with primers specified in Appendix 1. The am plicons’ sizes are 
consistent with the approximate sizes o f fragments as detailed in the Genome 
Database.
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5.4 Accuracy of Allele Sizing
The ABI ROX 500 size standard was used to accurately calculate the 
sizes o f the alleles. The accuracy o f the sizing of alleles using the ABI ROX size 
standard was checked to ensure that allele sizes quoted in this thesis were 
comparable to other published work (Method 3.13). The AMXY (amelogenin) 
marker, located on chromosomes X p22.1-22.31 and Y p ll.2 , carries a small 
deletion o f 6bp in the first intron on the X chromosome, facilitating the design o f 
distinct X and Y specific PCR primers. The AMXY fragment identifies an X- 
specific 104bp fragment and a Y-specific llObp (Nakahori et al. 1991). Ten 
male DNAs and ten female DNAs were amplified (Mann et al., 2001) and the 
fragments o f known bp composition were sized by comparison with ROX 
standards using the same analysis conditions as used in the sizing o f the alleles. 
One fluorescent peak o f 1 lObp (Y) and one fluorescent peak o f 104bp (X) were 
observed when samples from males were tested. Only one fluorescent peak o f 
104bp (XX) was observed when samples from females were tested (Figure 5.3). 
Each o f the male and female specific fragments was accurately sized using the 
ABI ROX 500 size standard. This confirms that the methods used in this thesis 
for allele sizing accurately identify the bp composition o f the alleles.
FIGURE 5.3 
GeneScan Results of Male and Female AMXY Controls
Male Female
120 iso 30 so
Two peaks One peak
The ABI ROX 500 size standard, shown here in red, was used to accurately 
calculate the sizes o f the alleles o f the AMXY (amelogenin) marker. One 
fluorescent peak o f llO bp (Y) and one fluorescent peak o f 104bp (X) were 
observed when samples were male. Only one fluorescent peak o f 104bp (XX) 
was observed when samples were female.
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5.5 Genotyping
Amplicons of each individual marker, from each patient and control, 
were genotyped to determine each individual allele size (Method 3.12). In total 
32 M53I mutation carriers, four non-carrier relatives and 45 control subjects 
were haplotyped. Ninety chromosomes from the 45 geographically matched 
control subjects were genotyped to determine the allele frequency of the markers 
in the general Scottish population. These allele frequencies are given in table 
5.3. Figure 5.4 shows the GeneScan electropherograms of PCR amplified 
genomic DNA for each 9p21 marker from Scottish family member F30.1 as an 
example of the M53I carriers’ results.
TABLE 5.3
Allele Frequencies in Scottish Control Chromosomes at each Marker
Allele D9S1604 D9S1748 D9S942 D9S974 D9S2060 D9S2136 D9S1749
1 0.300 0.050 0.056 0.023 0.022 0.012 0.000
2 0.700 0.050 0.111 0.000 0.756 0.000 0.000
3 0.100 0.667 0.104 0.222 0.035 0.000
4 0.223 0.157 0.012 0.163 0.000
5 0.200 0.009 0.105 0.035 0.000
6 0.150 0.000 0.256 0.232 0.000
7 0.113 0.000 0.174 0.070 0.000
8 0.038 0.186 0.372 0.012
9 0.076 0.093 0.081 0.012
10 0.000 0.012 0.036
11 0.000 0.059
12 0.023 0.095
13 0.000 0.143
14 0.000 0.095
15 0.000 0.036
16 0.012 0.083
17 0.107
18 0.048
19 0.024
20 0.036
21 0.012
22 0.071
23 0.024
24 0.048
25 0.012
26 0.036
27 0.000
28 0.012
Size of 
allele 1 190bp 123bp 121bp 223bp 148bp 141bp 165bp
Allele 1 is the largest allele observed either in M53I family members or in the 90
control chromosomes. The size o f allele 1 is given for each marker.
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FIGU RE 5.4
GeneScan Results of the Eight M arkers used in Haplotype Analysis
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GeneScan electropherograms o f PCR amplified genomic DNA for each 9p21 
marker from Scottish family member F30.1. Peaks are labeled with the assigned 
allele number.
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5.6 S tutter Products
During the PCR amplification of the dinucleotide microsatellite loci, minor 
products that were between one and four repeat units shorter than the main allele were 
sometimes produced as illustrated in figure 5.5. These “stutter” peaks may have been 
caused by polymerase slippage during the elongation step of PCR. When evaluating the 
data with multiple stutter products present, particularly in samples with two alleles close 
in size, analysis was complicated. For example, peaks in a position one repeat unit 
smaller than the main allele could have been interpreted either as a stutter band or as an 
allele. The amount of stutter did not depend on the quantity of DNA amplified during 
PCR. The largest peak in each sample represents the “true” allele.
Amplification of the dinucleotide repeat markers yielded allele peaks and 
associated PCR stutter bands within a maximum range of six base pairs from the allele 
peak. The number of allele peaks depended on whether the individual tested was a 
heterozygote or homozygote. For example, the GeneScan electropherogram of 
dinuclcotide repeat marker D9S974 from a heterozygous individual (213bp, 219bp) is 
shown in figure 5.5. Allele sizes differ by 6bp. The 2bp stutter peak to the left of each 
allele peak was always of lower intensity than the allele peak itself. The larger 219bp 
allele peak is of lower intensity than the smaller 213bp allele. In heterozygotes, the 
higher molecular weight allele often produced a fluorescent signal of lower intensity 
than the lower molecular weight peak perhaps because of a less efficient amplification 
of the larger fragment.
FIGURE 5.5
GeneScan Electropherogram of a Dinucleotide Repeat Marker from a 
Heterozygous Individual with Stutter Peaks
4000 4400 4800
1200 D9S974 6
1000
800 |
600
400 i
200
0 ...... ............ .... ........................ ........ aA/*' Hill
The GeneScan electropherogram from dinucleotide repeat marker D9S974 of a 
heterozygous control individual (213bp, 219bp). Peaks are labeled with the assigned 
allele number.
Stutter products were not a problem in the microsatellite analysis as they 
allowed the true allele peaks to be distinguished from non-specific PCR products, as 
non-specific PCR products are not associated with stutter bands.
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5.7 Haplotype Analysis
Haplotype analysis using eight polymorphic markers spanning the 
CDKN2A locus was interpreted by eye on available M53I carriers from each 
family to determine whether carriers from the 18 families harbored the same 
mutation identically by descent. Table 5.4 shows the disease haplotypes for the 
six Scottish M53I families. Both alleles are indicated for each marker with the 
segregating allele shown in blue type. Results are displayed in the same format 
as others publishing in this field.
TABLE 5.4
Haplotype Analysis of Scottish M53I M utation C arriers for 9p M arkers
Haplotype for each Marker 
Family Identifier
Markers F l.l FI.2* F4.1 F4.3* F5.1 F5.2 F6.2* F6.3 F29.1 F30.1 F30.2
D 9S1749 8/9 8/9 8/10 8/9 8/9 8/9 10/11 10/11 12/13 10/11 10/11
D9S2136 4/4 4/9 4/5 5/6 4/6 4/8 4/6 4/6 4/8 4/7 4/7
D9S2060 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2
RH 103023 1/1 1/1 1/1 1/1 1/1 1/1 1/1 1/1 1/1 1/1 1/1
M53I G /C G /C G /C G /C G /C G /C G /C G /C G /C G /C G /C
D9S974 3/8 5/8 6/8 8/9 5/8 4/8 1/8 1/8 6/8 6/8 8/9
D9S942 4/5 4/5 4/5 4/5 4/5 4/5 4/5 4/5 4/5 4/5 4/5
D9S1748 6/8 6/9 6/7 6/7 6/6 6/8 6/8 6/8 5/6 6/7 3/6
D9S1604 1/2 1/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 1/2 2/2
The position of the mutation relative to the markers is shown 
FI, F4, F5, F6, F29 and F30 refer to family identifiers 
Blue denotes consensus haplotype
Grey shaded area denotes individuals who do not carry the consensus allele for that 
marker
* denotes M53I carriers who are currently unaffected
Data collected from marker R H 103023 was not informative as all families and 
control subjects share the one allele.
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All six Scottish families showed a haplotype consistent with a single 
genetic origin for the M53I mutation. The D9S2136 - D9S1604 haplotype 4-2-8- 
4-6-2 appears to be common across all six Scottish families. One currently 
unaffected carrier of Scottish family F4 (F4.3) had the 5/6 alleles at marker 
D9S2136, rather than the allele 4 seen in all other families and in affected family 
member F4.1 of the same family. All but one Scottish family showed co­
segregation of either the 9 or 10 allele for marker D9S1749. Family 29 showed 
alleles 12/13 to co-segregate with the M53I melanoma mutation. D9S1749 has 
previously been shown to vary in allele size because of replication slippage 
resulting in the loss or gain of one or more repeat units during meiosis (Pollock 
et al, 1998).
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In addition to the 18 M53I families, two Scottish patients with sporadic 
melanoma and no family history o f melanoma were haplotyped (Table 5.5). 
Both these individuals have multiple primary melanomas and also have the M53I 
mutation. Both o f the M53I Scottish patients with sporadic melanoma carried 
the core disease haplotype.
TABLE 5.5
Haplotype Analysis of Scottish M53I M utation C arriers with Sporadic 
Melanoma with Multiple Prim ary Melanomas
Haplotype for each Marker 
Sporadic Identifier 
Markers SMP1 SMP3
D9S1749 8/9 8/9
D9S2136 4/4 4/9
D9S2060 2/2 2/2
RH 103023 1/1 1/1
M53I G /C G /C
D9S974 3/8 5/8
D9S942 4/5 4/5
D9S1748 6/8 6/9
D9S1604 1/2 1/2
The position of the mutation relative to the markers is shown
SMP1 and SMP3 refer to patients with sporadic melanoma with multiple primaries and
the M53I mutation
Blue denotes consensus haplotype
Grey shaded area denotes individuals who do not carry the consensus allele for that 
marker
Data collected from marker RH 103023 was not informative as all patients and control 
subjects share the one allele.
Table 5.6 shows the disease haplotypes for the 12 M53I families from 
Canada, Australia and America. Both alleles are indicated for each marker with 
the segregating allele shown in blue type. The two non-carriers from Canadian 
family FAM-1 and the two non-carriers from Australian family 41031 were also 
haplotyped and alleles are indicated in table 1 in Appendix 4.
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Eight o f the twelve M53I families from DNA samples from Canada, 
Australia and America showed a haplotype consistent with a single genetic origin 
for the M53I mutation. The D9S1749 - D9S1604 haplotype 10-4-2-8-4-6-2 
appears to be common across eight of these twelve families. One Canadian 
family FAM-4 (T9) had the 7/9 alleles at D9S2136, rather than the allele 4 seen 
in all other haplotype sharing families. Three families, Australian families 41031 
and 60001 and American family 637, showed co-segregation of allele 4 instead 
of the consensus allele 6 for marker D9S1748. This could be accounted for by 
replication slippage of marker D9S1748 gaining one repeat unit during meiosis. 
All but one of the haplotype sharing families showed co-segregation of the 4 
allele for marker D9S942. Australian family 60001 showed allele 6 to co- 
segregate with the M53I melanoma mutation. Australian families 41031 and 
60001 could not be assigned the consensus haplotype, as has been previously 
reported by Pollock et al, 1998. Their study accounted for these families not 
sharing the disease haplotype by replication slippage.
Analysis of the 18 melanoma families from around the world carrying the 
M53I mutation showed that 14 of them share a common haplotype for markers 
D9S2136 - D9S1604 4-2-8-4-6-2. This haplotype was found consistently in all 
tested M53I mutation carriers in 13 families (F I, F5, F6, F29, F30, FAM-1, 
FAM-2, FAM-3, FAM-5, 41001, 41156, L25 and 590).
After allowing for a high mutation rate at D9S1749, the most common 
allele observed was allele 10. Among the 18 families’ haplotypes, 11 families 
carry the 10 allele and nine families carry the 9 allele. Analysis of the 18 
melanoma showed that 10 of them share a common haplotype for markers 
D9S1749 - D9S1604 10-4-2-8-4-6-2. This haplotype was found consistently in 
all tested M53I mutation carriers in eight families (F6, F30, FAM-1, FAM-2, 
41001,41156, L25 and 590).
Forty-five controls were typed for the same markers to determine the 
frequency of alleles at each marker in the Scottish population. The consensus 
M53I haplotype D9S1749 - D9S1604 10-4-2-8-4-6-2 or D9S2136-D9S1604 4-2- 
8-4-6-2 was not determined in any of the control subjects and therefore the 
probability o f finding the M53I haplotype in the general Scottish population is 
extremely low. The frequencies of the M53I common haplotype for markers 
D9S1749-D9S1604 were 0.036, 0.163, 0.756, 0.186, 0.157, 0.150 and 0.700.
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The probability of finding the M53I haplotype in the general population is 
therefore extremely low (1.4 x 10-5) and even if the D9S1749 marker was not 
included in the haplotype, the frequency is still very low (3.8 x KT4). These 
results confirm that all cases are distantly related.
Six o f the 18 families all live in Scotland and have a Scottish ancestry. In 
addition, nine o f the families from out-with Scotland has a history of Scottish 
ancestry. Therefore the mutation that arose on a chromosome carrying a 
common ancestral haplotype probably occurred in Scotland due to the majority 
o f families having a Scottish ancestry.
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CHAPTER 6
MC1R VARIANTS IN FAMILIAL 
MELANOMA, UNAFFECTED FAMILY 
MEMBERS, SPORADIC MELANOMA 
AND CONTROL SUBJECTS
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6.1 MC1R Sequence Variation Detection
It has been postulated that variants of the MC1R gene are common low 
penetrance melanoma susceptibility alleles in sporadic melanoma (Valverde et 
al. 1996; Ichii-Jones et al. 1998; Palmer et al. 2000; Kennedy et al. 2001). The 
study of this thesis therefore sequenced the entire MC1R gene for variants in 60 
familial melanoma patients, 25 unaffected family members, 28 cases of sporadic 
melanoma and 67 healthy phenotyped control subjects. All patients, unaffected 
family members and control subjects were phenotyped. In all groups, the 
relationship o f the MC1R variants to other risk factors such as skin type, hair and 
eye colour was also investigated.
6.2 Mutation Detection Strategy Employed
A set o f primers was designed for amplification of the single 951 
nucleotide coding region of MC1R and its splice sites (Method 3.4). The final 
amplification conditions are presented in Appendix 2. Routinely a lp l aliquot of 
DNA (extracted as described using method 3.1a) from each patient was 
amplified with the set of primers. Fragment sizes of 1242bp were generated. 
Negative controls (no DNA) were run along with each reaction. Once all the 
DNA samples had been transferred to PCR tubes, the same reagents were used 
for the negative control. The absence of amplicons in the negative control meant 
that there had been no cross-contamination between the samples or into the 
reagents. The distinct bands obtained from amplification were resolved on 
ethidium bromide stained agarose gels to verify the size o f the amplified band 
(Method 3.5) and are presented in figure 6.1.
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FIGU RE 6.1
Amplification of MC1R
The expected 1242bp amplicons o f MC1R were confirmed by resolution on a 
0.6% agarose gel with ethidium bromide. The amplicons were electrophoresed 
in IX TAE buffer for 20 minutes. The size o f the amplicons which are 
represented below shown in base pairs were deduced by comparison to the 
migration o f the known size o f the DNA ladder fragments in lane 1. lp l o f 
genomic DNA was routinely amplified by conditions specified in Appendix 2 
and with primers specified in Appendix 1. The am plicons’ size is consistent with 
the expected 1242bp fragment.
Lanes
1 2 3 4 5 6 7
L adder Bands (bp)
1650------
1000------
Electrophoresis C onditions:0.6% agarose gel, IX TAE, lOpl size marker, 5pl
PCR product, 2pl loading mix, 100V, 20 minutes, 
room temperature 
Lane 1 -  lkb Plus size marker 
Lane 3 -  PCR product from individual F IT  
Lane 4 -  PCR product from individual F 2 .1 
Lane 5 -  PCR product from individual F 3 .1 
Lane 6 -  PCR product from individual F4.1
Lane 7 -  negative control See page 60 for patient details.
r ' e T T  58 j
Sample Band (bp)
 1242
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6.3 Direct Sequencing of All Amplicons
MC1R was sequenced directly (Methods 3.7-3.10) rather than performing 
an initial screen such as dHPLC because the gene is highly polymorphic with 
over 35 variants in the published literature and therefore the majority of samples 
would have shown an abnormal chromatogram and would need to be sequenced. 
Each chromatogram was analysed using SeqScape (Method 3.11). The primers 
used for sequence analysis included the same amplification primers but also an 
additional three primers that gave rise to five overlapping sequenced fragments. 
Briefly, the MC1R-F primer binds nucleotides -135- -116 and sequences in the 
forward direction, the MC1R-NT-F primer binds nucleotides 377-358 and 
sequences in the reverse direction, the MC1R-TM-F primer binds nucleotides 
202-221 and sequences in the forward direction, the MC1R-CT-F primer binds 
nucleotides 518-537 and sequences in the forward direction and the MC1R-R 
primer binds nucleotides 1108-1083 and sequences in the reverse direction. 
DNA sequence of the complete coding region and flanking DNA were routinely 
obtained and nucleic acid changes identified in all fragments sequenced.
6.4 Sequence Analysis
In total, 13 MC1R variants leading to an amino acid substitution were 
detected among the 180 samples sequenced (Table 6.1). Three of these (L44I, 
M128K, A171G) have not been described elsewhere and appear to be very rare. 
L44I is present in only one sporadic melanoma patient, M128K is present in only 
one currently unaffected member of a melanoma family and A171G is present in 
only one familial melanoma patient. Three silent nucleotide changes (G239G, 
T314T, C315C) were also detected but these have not been included in the 
statistical analysis, as they do not lead to an amino acid substitution.
Figure 6.2 illustrates each of the MC1R variants identified in this Scottish
study.
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TABLE 6.1
MC1R V ariants Identified in this Scottish Study
180 samples were sequenced in total.
Nucleotide
Variation
Amino Acid 
Substitution
No. of M elanoma 
Patients o r Unaffected 
Family M embers in 
which V ariant was 
Detected
No. of C ontrol 
Subjects in 
which V arian t 
was Detected
1 3 0 O A L44I 1 0
178G>T V60L 35 19
2 5 2 0 A D84E 8 1
274G>A V92M 18 10
284C>T T95M 1 0
383T>A M128K 1 0
425G>A R142H 3 2
451C>T R151C 32 12
464T>C I155T 4 4
478C>T R160W 28 14
488G>A R163Q 11 7
5 1 2 0 G A171G 2 0
717C>T *G239G 1 0
880G>C D294H 11 3
942A>G *T314T 24 6
945C>T *C315C 1 0
Italics denote variants that have not previously been published.
* denotes a silent amino acid substitution and have not been included in the 
statistical analysis.
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FIGU RE 6.2
Identification of MC1R V ariants
Sequence analysis o f PCR amplified genomic DNA using intronic primer pair 
MC1R-F, MC1R-R followed by sequencing using primers MC1R-F, MC1R-NT- 
F, MC1R-TM-F, MC1R-CT-F and MC1R-R (Appendix 1) are shown in the left 
hand column. Nucleic acid and derived amino acid sequences from the mutated 
region o f MC1R are shown in the right hand column.
D G L F L
Wild Type GAC GGG CTC TTC CTC
Variant GAC GGG ATC TTC CTC
I
(L44I)
L44I has not previously been published
L V V A T 
Wild Type CTG GTG GTG GCC ACC 
Variant CTG GTG TTG GCC ACC
L
(V60L)
L S D L L 
Wild Type TTG TCG GAC CTG CTG 
Variant TTG TCG GAA CTG CTG
E
(D84E)
V ariant D84E (252C>A)
V ariant V60L(178G>T)
V ariant L44I (130C>A)
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V arian t V92M (274G>A) S N V L E 
Wild Type AGC AAC GTG CTG GAG 
Variant AGC AAC ATG CTG GAG
M
(V92M)
V ariant T95M (284C>T)
G g A G A G G C C G
L E t  a  v  
Wild Type CTG GAG ACG GCC GTC 
Variant CTG GAG ATG GCC GTC
M
(T95M)
V ariant M128K (383T>A) S S M L S 
Wild Type AGC TCC ATG CTG TCC 
Variant AGC TCC AAG CTG TCC
K
(M128K)
M128K has not previously been published
V ariant R142H (425G>A) V D R Y
Wild Type GTG GAC CGC TAC ATC 
Variant GTG GAC CGC TAC ATC
(R142H)
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V ariant R151C (451C>T) A L R Y H 
Wild Type GCA CTG CGC TAC CAC 
Variant GCA CTG TGC TAC CAC
C
(R151C)
V ariant I155T (464T>C)
C G T G A
H S I V T 
Wild Type CAC AGC ATC GTG ACC 
Variant CAC AGC ACC GTG ACC
1
(I155T)
Variant R160W (478C>T) L R A R
Wild Type CTG CCG CGG GCG CGG 
Variant CTG CCG TGG GCG CGG
(R160W)
V ariant R163Q (488G>A) R R V
Wild Type GCG CGG CGA GCC GTT 
Variant GCG CGG CAA GCC GTT
(R163Q)
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V ariant A171G (512C>G) W V A S V
Wild Type TGG GTG GCC AGT GTC
Variant TGG GTG GGC AGT GTC
G
(A171G)
A171G has not previously been published
L K G A V 
Wild Type CTT AAA GGC GCT GTC 
Variant CTT AAA GGT GCT GTC
G
(G239G)
G239G is a silent amino acid substitution, 
not included in the statistical analysis
I I D P L 
Wild Type ATC ATC GAC CCC CTC 
Variant ATC ATC CAC CCC CTC
H
(D294H)
V L T C S 
Wild Type GTG CTG ACA TGC TCC 
Variant GTG CTG ACG TGC TCC
1
(T314T)
T314T is a silent amino acid substitution, 
not included in the statistical analysis
V ariant T314T (942A>G)
V ariant D294H (880G>C)
T C A T  C
V ariant G239G (717C>T)
A A A G G G C T  G T
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V ariant C315C (945C>T) L T C S W 
Wild Type CTG ACA TGC TCC TGG 
Variant CTG ACA TGT TCC TGG
C
(C315C)
C 3 15C is a silent amino acid substitution, 
not included in the statistical analysis
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6.5 Results of Phenotyping & Genotyping of Patient and Control Cohort for 
MC1R Study
Information on the presence of variants of the MC1R gene was obtained 
for 180/202 (89.1%) of the study participants. Tables 6.2, 6.3 and 6.4 gives 
details of the MC1R variants in relation to melanoma status (yes, Y or no, N), 
skin type, eye and hair colour and CDKN2A mutations of all patients with 
melanoma, unaffected family members and o f control subjects.
MC1R variants were recorded by sequencing of the entire coding region o f the 
gene.
Thirteen distinct variants were established for MC1R as follows:
a = V60L h = I155T
b = D84E i = R160W
c = V92M j = R163Q
d = T95M k = A171G
e = M128K 1 = D294H
f  = R142H m = L44I
g = R151C None = no variants identified
CDKN2A variants were recorded by sequencing of the entire coding region of the 
gene. Nine distinct variants were established for CDKN2A as follows:
A = Duplication 
B = R24P 
C = Y44stop 
D = M53I 
E = G67R 
F = H83N 
G = R112G 
H = D125H 
1 = A148T
None = no variants identified
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TABLE 6.2
MC1R V ariants, Skin Type, Eye and H air Colour and CDKN2A M utations 
in Familial M elanoma Patients & their Unaffected Relatives
Identifier Melanoma Skin
Type
Eye
Colour
H air
Colour
MC1R
Variant(s)
CDKN2A
V ariant
F l.l Y 1 1 2 a, i D
F1.2 N 1 1 2 i D
F1.3 N 2 1 3 None
F2.1 Y 2 1 4 a,g B
F2.2 Y 2 1 3 a B
F2.3 Y 2 1 3 B
F2.4 Y 2 1 2 a,g B
F2.5 N 2 1 3 B
F2.6 N 2 4 2 a ,g None
F2.7 N 2 1 4 j None
F2.8 N 2 1 3 g>j None
F3.1 Y 2 4 3 g ,l C
F3.2 Y 2 1 3 g ,l C
F3.3 N 2 4 3 1 None
F4.1 Y 2 4 3 1 D
F4.2 Y 2 1 3 D
F4.3 N 2 1 3 e D
F5.1 Y 2 3 4 a D
F5.2 Y 2 4 4 a D
F6.1 Y 1 1 1 D
F6.2 N 1 1 1 a, c D
F6.3 Y 2 1 2 a ,g D
F6.4 N 2 1 2 c, i I
F6.5 N 1 4 1 a, i I
F7.1 Y 1 4 1 g>i I
F7.2 N 2 1 2 g ,i H
F8.1 Y 2 3 4 g j None
F8.2 Y 2 1 3 None
F9.1 Y 1 1 1 g ,i None
F10.1 Y 2 1 3 a, a None
F10.2 Y 2 1 2 a ,g None
F10.3 N 2 1 3 a
FI 1.1 Y 1-2 1 1 c None
FI 1.2 Y 2 1 4 c ,j None
FI 1.3 Y 2 4 2 None None
F12.1 Y 1 1 1 U None
F13.1 Y 3 3 4 a ,g I
F13.2 Y 2 3 4 a, a None
F13.3 N 2 4 2 a I
F13.4 N 3 3 4 a
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Identifier M elanoma Skin
Type
Eye
Colour
H air
Colour
MC1R
V ariant(s)
CDKN2A
V ariant
F14.1 Y 2 1 3 c, i,i None
FI 4.2 Y 2 1 4 c,j,j None
F15.1 Y 2 1 2 c None
F15.2 N 2 1 2 a, c
FI 6.1 Y 1 1 2 c,g None
F17.1 Y 2 1 2 a, a G
F17.2 Y 2 1 2 a, a G
F17.3 N 1 4 1 a G
F17.4 N 2 1 2 a, i G
F17.5 N 2 1 2 a None
F18.1 Y 2 1 3 a None
F18.2 Y 2 1 3 a None
F19.1 Y 1 1 4 a, d E
F20.1 Y 3 4 4 b None
F21.1 Y 2 1 4 c, 1 None
F21.2 Y 2 3 4 c, 1 None
F22.1 Y 1 1 3 i,k G
F22.2 Y 1 2 1 i G
F22.3 N 2 1 4 k G
F22.4 N 2 2 3 c, i None
F22.5 N 2 1 3 c None
F22.6 N 2 2 3 i None
F23.1 Y 2 1 2 j None
F23.2 N 2 4 2 g None
F23.3 N 2 1 2 None None
F23.4 N 2 1 3 g,j None
F24.1 Y 2 1 3 h, i None
F24.2 Y 2 1 3 i, i None
F25.1 Y 2 4 4 c None
F25.2 Y 1 2 2 None
F26.1 Y 2 1 3 i None
F26.2 Y None
F27.1 Y 1 1 1 f None
F27.2 Y 1 2 1 b , f None
F28.1 Y 2 1 3 b,g A
F28.2 Y 2 1 3 A
F29.1 Y 2 1 3 a D
F29.2 Y 2 4 2 c None
F30.1 Y g,l D
F30.2 Y g,J D
F31.1 Y 1 1 1 g,g None
F32.1 Y 2 1 4 None None
F32.2 Y 1 1 3 a None
F33.1 Y 2 1 2 c,g F
F33.2 Y 2 1 2 g, i F
F34.1 Y 2 2 3 a, a None
171
Identifier Melanoma Skin
Type
Eye
Colour
Hair
Colour
MC1R
Variant(s)
CDKN2A
Variant
F35.1 Y 2 2 3 h None
F35.2 Y 2 1 2 g None
F36.1 Y 2 1 2 h None
F37.1 Y 2 1 3 None
F37.2 Y 2 1 3 None
F38.1 Y 2 1 3 None
F38.2 Y 2 1 4 None
F39.1 Y 1 1 2 None
F40.1 N 1 1 1 None None
F41.1 Y 2 3 4 None
F41.2 Y 2 1 2 None
F42.1 Y 2 3 4 None
F42.2 Y None
F43.1 Y 3 1 4 b, j , j None
F43.2 Y 1 1 3 b, i None
F44.1 Y 2 1 3 c ,g None
F45.1 Y 2 3 3 g None
F46.1 Y None
F47.1 Y 1 1 1 None
F48.1 N 2 1 3 None
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TABLE 6.3
M C1R  Variants, Skin Type, Eye and Hair Colour and CDKN2A Mutations 
in Sporadic Melanoma Patients
Identifier Melanoma Skin
Type
Eye
Colour
Hair
Colour
MC1R
Variant(s)
CDKN2A
Variant
SI Y a, h None
S2 Y 1 1 1 g>i None
S3 Y 2 2 3 j>j None
S4 Y 1 1 1 a, i, m D
S5 Y 1 2 1 i,g D
S6 Y 1 None
S7 Y 2 1 3 i, 1 None
S8 Y 2 1 3 None None
S9 Y 2 1 2 a ,g None
S10 Y 2 1 3 f, i None
S ll Y 2 2 1 None None
S12 Y 1 1 2 i None
S13 Y 3 1 1 a, b None
S14 Y 2 1 3 b None
S15 Y 2 1 2 None None
S16 Y 2 1 3 i None
S17 Y 3 1 2 g None
S18 Y 2 1 1 a None
S19 Y 3 1 2 i None
S20 Y 2 1 2 a None
S21 Y 2 1 2 g None
S22 Y 2 3 3 i, i None
S23 Y 2 1 2 1 None
S24 Y 1 3 3 b None
S25 Y 2 1 3 c, i None
S26 Y 1 1 2 g None
S27 Y 2 1 3 g None
S28 Y 3 3 3 1 None
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TABLE 6.4
MC1R V ariants, Skin Type, Eye and H air Colour in Control Subjects
Identifier Skin
Type
Eye
Colour
H air
Colour
MC1R
V ariant(s)
C l 2 4 4 None
C2 2 2 2 None
C3 3 3 4 None
C4 2 1 2 h, 1
C5 2 1 4 None
C6 2 2 1 None
C l 2 1 4 c, c
C8 3 3 4 g
C9 3 3 4 None
CIO 3 3 4 h
C ll 2 1 2 h, i
C12 1 4 1 g ,i
C13 2 4 4 a, i
C14 3 1 3 a
C15 2 1 3 g
C16 2 4 4 j
C17 2 1 3 a
C18 3 1 3 j
C19 2 1 2 a
C20 3 1 3 i,j
C21 3 1 2 a, 1
C22 2 1 4 None
C23 1 1 1 f j
C24 3 2 3 a
C25 3 1 2 c
C26 2 1 2 i
C27 1 1 2 i
C28 3 1 2 a
C29 3 3 4 i
C30 3 3 4 h
C31 2 1 2 a, i
C32 3 3 2 None
C33 3 3 4 g
C34 2 1 2 g
C35 2 1 3 None
C36 2 1 3 c
C37 2 1 2 c ,g
C38 2 1 4 None
C39 1 2 3 a, a
C40 2 4 3 c
C41 3 1 4 f
C42 1 3 1
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Identifier Skin
Type
Eye
Colour
H air
Colour
MC1R
Variant(s)
C43 1 1 2 a, i
C44 2 3 2 c
C45 3 4 4 a,j
C46 2 1 2 g
C47 3 3 3 None
C48 1 1 1 a, i
C49 3 3 4 a,j
C50 1 1 1 a
C51 1 1 2 c, i
C52 3 3 3 c
C53 2 1 3 a, i
C54 3 3 4 a, c
C55 2 1 2 g
C56 3 1 2 a, b
C57 1 2 1 g ,i
C58 3 3 4 g
C59 2 3 3 c ,g
C60 2 1 3 i
C61 2 2 4 None
C62 3 1 2 1
C63 3 3 4 a
C64 1 1 2 j
C65 4 3 4 None
C66 2 1 2 a
C67 1 1 2 g
C68 4 1 2 None
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6.6 MC1R Variants and Statistical Analyses
Statistical analysis was performed using the methods described in method 
3.17. Due to the large quantity of results, only significant and approaching
significant results are presented in this chapter. Results not presented in this 
chapter are reported in tabular form in Appendix 5.
To investigate whether there is a relationship between an individual 
having any particular MC1R variant and melanoma, a two-tailed Fisher’s exact 
test was performed on cases and on control subjects for each MC1R variant 
identified in the entire data set (Appendix 5, Tables 1-4).
Among the 13 different variants identified in all sequenced individuals, 
the most frequently occurring variant in the melanoma patients is V60L. V60L 
was found in 25/88 (28.4%) melanoma patients and 19/67 (28.4%) control 
subjects. R151C occurred in 27/88 (30.7%) of patients compared with 12/67 
(17.9%) of control subjects and R160W in 21/88 (23.9%) compared with 14/67 
(20.9%) of control subjects. D84E was found in 8/88 (9.1%) patients compared 
with 1/67 (1.5%) controls subjects.
Table 6.5 shows the significant and nearly significant observations in 
familial and sporadic melanoma patients, and in the control subjects. 83/88 
(94.3%) of patients and 53/88 (79.1%) of control subjects carry an MC1R 
variant.
TABLE 6.5
MC1R Variants Found in Familial and Sporadic Melanoma Patients 
Compared with Control Subjects
No. of Cases No. of Controls
Any variant 
No variant
83
5
53
14
P-value = 0.006 ** significant (not significant after Bonferroni correction) 
OR = 4.385, Cl 1.492-12.883
D84E present 
D84E absent
8 1
6680
P-value = 0.079 (not significant) 
OR = 6.600, Cl 0.805-54.128
R151C present 
R151C absent
28
61
12
55
P-value = 0.065 (not significant)
OR = 2.104, Cl 0.976-4.536 
Bonferroni adjusted significance level for multiple tests = 0.004
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There is a significant difference between carrying an MC1R variant or not 
between the melanoma cases and control subjects (P = 0.006; OR = 4.385; Cl 
1.492-12.883.
There is a nearly significant difference between carrying the R151C 
variant or not between the melanoma cases and control subjects (P = 0.065; OR 
= 2.104; Cl 0.976-4.536).
There is a nearly significant difference between carrying the D84E 
variant or not between the cases and control subjects (P = 0.079; OR = 6.600; Cl 
0.805-54.128). However the Bonferroni adjusted significance level for multiple 
tests in this case is 0.004 and therefore these results do not remain significant.
The most commonly occurring variants in the familial melanoma patients
are:
• V60L in 19/60 (31.7%) compared with 19/67 (28.4%) control subjects.
• V92M in 12/60 (20%) compared with 10/67 (14.9%) control subjects.
• R151C in 20/60 (33.3%) compared with 12/67 (17.9%) control subjects.
• R160W in 11/60 (18.3%) compared with 14/67 (20.9%) control subjects.
• 58/60 (96.7%) familial melanoma patients and 53/67 (79.1%) control 
subjects carry at least one MC1R variant.
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Table 6.6 shows only the significant observations o f MC1R variants in 
familial melanoma patients, compared with the control subjects. There is again a 
significant difference between carrying any MC1R variant or none between the 
familial cases and control subjects (P = 0.003; OR = 7.660; Cl 1.663-35.296). 
There is a significant difference between carrying the R151C variant or not 
between the familial cases and control subjects (P = 0.043; OR = 2.406; Cl 
1.062-5.452). The Bonferroni adjusted significance level for multiple tests in 
this case is 0.004 and hence carrying any MC1R variant remains significant, 
although carrying the R151C variant loses significance.
TABLE 6.6
Correlation between MC1R  V ariants in Familial M elanoma Patients and 
Control Subjects
__________________________ No. of Cases_________ No. of Control
Any variant 58 53
No variant 2 14
P-value = 0.003 ** significant 
OR = 7.660, Cl 1.663-35.296
R151C present 21 12
R151C absent 40 55
P-value = 0.043 * significant (not significant after Bonferroni correction)
OR = 2.406, Cl 1.062-5.452
Bonferroni adjusted significance level for multiple tests = 0.004
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6.6.1 MC1R Variants in Familial Melanoma Patients with CDKN2A 
Mutations Compared with those with no Detectable CDKN2A Mutation
The following results show MC1R variants in CDKN2A positive and 
negative patients before statistical analysis. The most frequently occurring 
variants in the CDKN2A positive patients are:
•  V60L in 12/23 (52.2%) CDKN2A positive patients compared with 7/37 
(18.9%) CDKN2A negative patients.
• R151C in 12/23 (52.2%) CDKN2A positive patients compared with 8/37
(21.6%) CDKN2A negative patients.
• R160W in 5/23 (21.7%) CDKN2A positive patients compared with 6/37 
(16.2%) CDKN2A negative patients.
• D294H in 4/23 (17.4%) CDKN2A positive patients compared with 2/37 
(5.4%) CDKN2A negative patients.
• The V92M variant is only present in 1/23 (4.3%) CDKN2A positive patients 
compared with 11/37 (29.7%) CDKN2A negative patients.
• The R163Q variant is only present in 1/23 (4.3%) CDKN2A positive patients 
compared with 6/37 (16.2%) CDKN2A negative patients.
• 23/23 (100%) CDKN2A positive patients and 35/37 (94.6%) CDKN2A 
negative patients carry an MC1R variant.
It should be noted that relatively small numbers are included in some of 
these comparisons.
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Table 6.7 shows the significant observations in familial melanoma 
patients with and without a CDKN2A mutation, excluding CDKN2A 
polymorphisms. There is a significant difference between carrying the V60L 
variant or not between the CDKN2A positive cases and CDKN2A negative cases 
(P = 0.017; OR = 3.818; Cl 1.315-11.084). There is also a significant difference 
between carrying the R151C variant or not between the CDKN2A positive cases 
and CDKN2A negative cases (P = 0.029; OR = 3.515; Cl 1.160-10.650). There 
is a significant difference between carrying the V92M variant or not between the 
CDKN2A negative cases and CDKN2A positive cases (P = 0.021; OR = 9.308; Cl 
1.112-77.888), although the Cl is wide. This is perhaps unexpected in that there 
are more patients without a CDKN2A mutation with the V92M variant than in 
those patients with a CDKN2A mutation. There is a nearly significant difference 
between carrying the R163Q variant or not between the CDKN2A positive cases 
and CDKN2A negative cases (P = 0.078; OR = 0.157; Cl 0.018-1.327).
Unfortunately the Bonferroni adjusted significance level for multiple tests 
in this case is 0.004 and therefore none of these results remain significant after 
correction.
TABLE 6.7
Correlation between MC1R Variants in Familial Melanoma Patients with 
and without a CDKN2A Mutation
CDKN2A Mutation Positive CDKN2A Mutation Negative
V60L present 
V60L absent
14
11
10
30
P-value = 0.017 * significant (not significant after Bonferroni correction)
OR = 3.818, Cl 1.315-11.084 
V92M present 
V92M absent 22
11
26
P-value = 0.021 * significant (not significant after Bonferroni correction) 
OR = 0.107, Cl 0.013-0.899
R151C present 
R151C absent
12
11
9
29
P-value = 0.029 * significant (not significant after Bonferroni correction)
OR = 3.515, Cl 1.160-10.650 
R163Q present 
R163Q absent 22
9
31
P-value = 0.078 (not significant) 
OR = 0.157, Cl 0.018-1.327
Bonferroni adjusted significance level for multiple tests = 0.004
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6.6.2 MC1R Variants in Non- Familial Melanoma Cases
The most frequently occurring variants in the 28 sporadic melanoma 
patients are:
•  V60L in 6/28 (21.4%) compared with 19/67 (28.4%) control subjects.
• R151C in 7/28 (25%) compared with 12/67 (17.9%) control subjects.
•  R160W in 10/28 (35.7%) compared with 14/67 (20.9%) control subjects.
• 25/28 (89.3%) patients and 53/67 (79.1%) control subjects carry at least one
MC1R variant.
Table 6.8 below shows the nearly significant finding in sporadic melanoma 
patients, compared with in the control subjects. D84E was found in 3/28 
(10.7%) compared with 1/67 (1.5%) control subjects (P = 0.075; OR = 7.920; Cl 
0.787-79.753).
TABLE 6.8
Correlation between MC1R Variants in Sporadic Melanoma Patients and 
Control Subjects
______________ No. of Cases No. of Controls
D84E present 3 1
D84E absent 25 66
P-value = 0.075 (not significant)
OR = 7.920, Cl 0.787-79.753
6.7 Comparison to the Number of MC1R variants in Melanoma Patients 
and Control Subjects
The number o f MC1R variants was compared between all melanoma 
patients, both familial and sporadic, and in the control subjects by performing a 
two-tailed Fisher’s exact test. Table 6.9 below shows that there is a significant 
relationship between melanoma cases and having two or more MC1R variants 
with 48/87 (55.2%) cases with two or more variants compared with 21/67 
(31.3%) control subjects (P = 0.003; OR 2.696; Cl 1.384-5.253).
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All variants were heterozygous, except for V60L which was detected in 
five homozygous familial melanoma patients and one control, V92M which was 
detected in one homozygous control, R151C which was detected in one 
homozygous familial melanoma patient, R160W which was detected in two 
homozygous familial melanoma patients and one sporadic patient and R163Q 
which was detected in three homozygous familial melanoma patients and one 
sporadic patient.
TABLE 6.9
Correlation between the Number of MC1R  Variants and Melanoma 
(Familial and Sporadic Patients) and Control Subjects
^ One M C1R  Variant > Two MC1R  Variants
No. of Cases 39 48
No. of Controls 46 21
P-value = 0.003 ** significant
OR = 2.696, Cl 1.384-5.253
The number of MC1R variants was then compared in melanoma families 
studying both affected and unaffected family members, and in the control 
subjects by performing a two-tailed Fisher’s exact test. Table 6.10 below shows 
that there is a significant relationship between melanoma family members and 
having two or more MC1R variants with 47/84 (56%) members with two or more 
variants compared with 21/67 (31.3%) control subjects (P = 0.003; OR 2.782; Cl 
1.421-5.450).
TABLE 6.10
Correlation between the Number of MC1R  Variants in Familial Melanoma 
(Affected and Unaffected) and Control Subjects
< One MC1R  
Variant
> Two MC1R  
Variants
Affected and Unaffected Family 37 47
Members
No. of Controls 46 21
P-value = 0.003 ** significant
OR = 2.782, Cl 1.421-5.450
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The number o f MC1R variants was then compared between melanoma 
patients from affected families and the control subjects by performing a two- 
tailed Fisher’s exact test. Table 6.11 below shows that there is a very highly 
significant relationship between familial melanoma cases and having two or 
more MC1R variants with 37/59 (62.7%) cases with two or more variants 
compared with 21/67 (31.3%) control subjects (P = 0.001; OR 3.684; Cl 1.761- 
7.707).
TABLE 6.11
Correlation between the Number of MC1R Variants in Familial Melanoma 
Patients and Control Subjects
< One MC1R Variant > Two MC1R Variants
No. of Cases 22 37
No. of Controls 46 21
P-value = 0.001 *** significant
OR = 3.684, Cl 1.761-7.707
The number of MC1R variants was compared between unaffected family 
members o f familial melanoma patients and the control subjects by performing a 
two-tailed Fisher’s exact test (Appendix 5, Table 19). There is no significant 
difference between unaffected family members and control subjects and how 
many MC1R variants they carry.
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6.8 Comparison of the Number of MC1R  variants in CDKN2A Positive 
Melanoma Patients and Control Subjects
The number of MC1R variants was compared between familial melanoma 
patients with a CDKN2A mutation and in the control subjects by performing a 
two-tailed Fisher’s exact test. Table 6.12 below shows that there is a significant 
relationship between CDKN2A positive melanoma cases and having two or more 
MC1R variants with 15/21 (71.4%) cases with two or more variants compared 
with 21/67 (31.3%) control subjects (P = 0.002, OR 5.476, Cl 1.863-16.099).
TABLE 6.12
Correlation between the Number of MC1R  Variants in Familial Melanoma 
Patients with a CDKN2A Mutation and Control Subjects
< One M C1R  Variant < Two M C1R  Variants
No. of Cases 6 15
No. of Controls 46 21
P-value = 0.002 ** significant
OR = 5.476, Cl 1.863-16.099
6.9 Comparison of the Number of M C1R  variants in CDKN2A Negative 
Melanoma Patients and Control Subjects
The number of MC1R variants was compared between familial melanoma 
patients without a CDKN2A mutation and in the control subjects by performing a 
two-tailed Fisher’s exact test. Table 6.13 below shows that there is a significant 
relationship between CDKN2A negative melanoma cases and having two or more 
MC1R variants with 22/38 (57.9%) cases with two or more variants compared 
with 21/67 (31.3%) control subjects (P = 0.013; OR 3.012; Cl 1.319-6.875).
TABLE 6.13
Correlation between the Number of MC1R  Variants in Familial Melanoma 
Patients without a CDKN2A Mutation and Control Subjects
< One M C1R  Variant > Two MC1R  Variants
No. of Cases 16 22
No. of Controls 46 21
P-value = 0.013 * significant
OR = 3.012, Cl 1.319-6.875
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The number of MC1R variants was compared between familial melanoma 
patients with a CDKN2A mutation and familial melanoma patients without a 
CDKN2A mutation by performing a two-tailed Fisher’s exact test (Appendix 5, 
Table 20).
There is no significant association between CDKN2A status in melanoma 
cases and having two or more MC1R variants.
The number o f MC1R variants was compared between familial melanoma 
patients and currently unaffected family members by performing a two-tailed 
Fisher’s exact test. Table 6.14 below shows that there is almost a significant 
difference between melanoma cases and having two or more MC1R variants with 
37/59 (62.7%) patients with two or more variants compared with 10/25 (40%) 
unaffected family members (P = 0.091; OR 2.523; Cl 0.967-6.579).
TABLE 6.14
Number of MC1R Variants in Familial Melanoma Patients Compared with 
their Unaffected Relatives
<, One MC1R Variant t  Two MC1R Variants
No. of Familial Melanoma Patients 22 37
No. of Unaffected Relatives 15 10
P-value = 0.091 (not significant) 
OR = 2.523, Cl 0.967-6.579
The number o f MC1R variants was compared between sporadic
melanoma patients and the control subjects by performing a two-tailed Fisher’s 
exact test. There is no significant difference between sporadic melanoma 
patients and control subjects and how many MC1R variants they carry in this 
small data set (Table 6.15).
TABLE 6.15
Correlation between the Number of MC1R Variants in Sporadic Melanoma 
Patients and Control Subjects
<L One MC1R Variant > Two MC1R Variants
No. of Cases 17 11
No. of Control Subjects 46 21
P-value = 0.482 (not significant)
OR = 1.417, Cl 0.566-3.547
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The number of MC1R variants was compared between familial melanoma 
patients and sporadic melanoma patients by performing a two-tailed Fisher’s 
exact test. Table 6.16 below shows that there is almost a significant difference 
between familial melanoma cases and having two or more MC1R variants with 
37/59 (62.7%) familial melanoma patients with two or more variants compared 
with 11/28 (39.3%) sporadic cases (P = 0.064; OR 2.599; Cl 1.032-6.548).
TABLE 6.16
Correlation between the Number of MC1R  Variants in Familial and 
Sporadic Melanoma Patients
< One MC1R  Variant > Two M C1R  Variants
No. of Familial Cases 22 37
No. of Sporadic Cases 17 11
P-value = 0.064 (not significant)
OR = 2.599, Cl 1.032-6.548
6.10 Correlation Between M C1R  Variants and Phenotype
The following sections look at phenotype in relation to MC1R variants.
6.10.1 Skin Type
In order to determine whether there is any significant relationship 
between having a particular MC1R variant and a particular skin type, 2 x 4  tables 
were constructed to include the four skin types and the MC1R variants detected 
in the control subjects. Statistical analysis was performed on phenotyped control 
subjects only (Appendix 5, Table 7). This table only shows data for which a P- 
value could be calculated. The following table 6.17 shows the significant 
observation in the phenotyped control subjects. Among the variants identified 
the only one to show a significant finding is R160W (P = 0.007). The 
Bonferroni adjusted significance level for multiple tests here is 0.0071 and 
therefore R160W remains significantly correlated with skin type after correction.
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TABLE 6.17
Correlation between Skin Type and MC1R variants in Control Subjects
Chi-squared Test
Never Tans Burns Burns Never Burns
Always Easily Rarely Always
___________________ Burns_____ Tans Rarely Tans Easily______Tans
R160W 6 6 2 0
present
R160W absent 5 23 23 2
P-value = 0.007 ** significant
Bonferroni adjusted significance level for multiple tests = 0.0071
Therefore it can be seen that the presence o f the R160W variant in normal 
Scottish individuals is significantly associated with paler skin type.
To investigate in more detail as to which MC1R variant correlates with 
skin type 1, a two-tailed Fisher’s exact test was performed for each variant on all 
cases, relatives and control subjects, with skin type 1 (Appendix 5, Table 31).
The following table 6.18 shows the significant and nearly significant 
observations. Among the variants identified the only one to show a significant 
finding with skin type 1 is R160W (P < 0.001). The Bonferroni adjusted 
significance level for multiple tests here is 0.005 and therefore R160W remains 
significantly correlated with skin type 1 after correction. R142H (P = 0.052) is 
nearly significant.
TABLE 6.18
Correlation between MC1R Variants and Skin Type 1
Skin Type 1 Other Skin Type
R160W present 18 24
R160W absent 16 116
P-value < 0.001 *** significant
OR =5.438, Cl 2.433-12.152
R142H present 3 2
R142H absent 31 138
P-value = 0.052 (not significant)
OR =6.677, Cl 1.070-41.674
Bonferroni adjusted significance level for multiple tests = 0.005
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6.10.2 Eye Colour
With the intention of determining whether there is any significant 
relationship between having a particular MC1R variant and a particular eye 
colour, 2 x 4  tables were constructed to include the four eye colours and the 
MC1R variants detected in the control subjects. Statistical analysis was 
performed on phenotyped control subjects (Appendix 5, Table 6) and all blue­
eyed individuals (Appendix 5, Table 32). No significant relationship could be 
identified between eye colour and MC1R variants in this data set.
6.10.3 Hair Colour
In order to determine whether there is any significant relationship 
between having a particular MC1R variant and a particular colour of hair, 2 x 4  
tables were constructed to include the four hair colours and the MC1R variants 
detected in the control subjects. Statistical analysis was performed on 
phenotyped control subjects only (Appendix 5, Table 5). This table only shows 
data for which a P-value could be calculated. No significant relationship could 
be identified between hair colour and MC1R variants in this data set.
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6.11 Correlation between the MC1R Variants, Red Hair and Melanoma
To investigate in more detail as to which MC1R variant correlates with 
red hair in these Scottish individuals, a two-tailed Fisher’s exact test was 
performed for each variant on all individuals, cases, relatives and control 
subjects, with red hair (Appendix 5, Table 33).
The following table 6.19 shows the significant observations. Among the 
variants identified, both R142H (P = 0.019) and R160W (P = 0.018) show a 
significant positive association with red hair. Unfortunately the Bonferroni 
adjusted significance level for multiple tests in this case is 0.006 and therefore 
these two observations lose significance.
TABLE 6.19
Correlation between MC1R Variants and Red Hair in all DNA Samples 
Available
________________________Red Hair_______ Other than Red Hair
R142H present 3 2
R142H absent 21 148
P-value = 0.019 * significant (not significant after Bonferroni correction)
OR = 10.571, Cl 1.668-67.009
R160W present 11 31
R160W absent 13 119
P-value = 0.018 * significant (not significant after Bonferroni correction)
OR = 3.248, Cl 1.327-7.949 
Bonferroni adjusted significance level for multiple tests = 0.006
Some previous studies have associated the R142H, R151C, R160W and 
D294H variants with red hair (Valverde et al. 1995; Smith et al. 1998; Flanagan 
et al. 2000). Numbers are small and statistical analysis has not always been 
rigorous. This is discussed further on page 274. In this thesis, a significant 
association with melanoma and R151C and a significant association with skin 
type 1 and R160W have been found.
Among the 67 control subjects tested for MC1R variants, two individuals 
are compound heterozygotes for R151C/R160W. Both individuals have red hair 
and skin type 1. Among the 88 melanoma cases, four have red hair and also are 
compound heterozygotes R151C/R160W. Two are homozygous; one for R151C 
and one for R160W, both of whom have red hair.
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6.11.1 Correlation Between Having Melanoma and Carrying a Postulated 
Red Hair Variant
In order to identify whether or not there is a correlation between having 
melanoma and carrying a postulated red hair variant of MC1R, a two-tailed 
Fisher’s exact test was performed on all red haired melanoma patients, both 
familial and sporadic, and in the red haired control subjects (Appendix 5, Table 
21). No significant relationship could be determined in this small data set.
6.11.2 Correlation Between Having Red Hair and Carrying a Postulated 
Red Hair Variant
To establish if there is an association between the postulated red hair 
variants and having red hair, a two-tailed Fisher’s exact test was performed on all 
red haired individuals whether they are melanoma patients, family members or 
control subjects (Appendix 5, Table 22). O f the seven red headed control 
subjects, four were found to be compound heterozygotes for at least one of the 
postulated red hair variants (R142H, R151C, R160W). DNA from one of the red 
haired control subjects failed on sequence analysis. The D294H variant was not 
seen in any red haired control or melanoma patient. From the sample of 27 red 
haired individuals (seven control subjects, six sporadic melanoma patients, ten 
familial melanoma patients and four currently unaffected family members) a 
significant association between red hair and the presence of the high-penetrance 
MC1R alleles R142H, R151C, R160W and D294H could not be demonstrated 
with this data. The control red haired individuals were tested, but again no 
significant relationship could be determined between carrying these variants and 
having red hair (Appendix 5, Table 23).
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The possible correlation between carrying any of the variants R142H, 
R151C, R160W and D294H and having melanoma was considered by 
performing a two-tailed Fisher’s exact test on all melanoma patients, both 
familial and sporadic, and the control subjects. Table 6.20 below shows a nearly 
significant association as 51/88 (58%) patients one or more of these variants 
compared with 29/67 (43.3%) control subjects (P = 0.077; OR = 1.806; Cl 0.950- 
3.434).
TABLE 6.20
Correlation between the Presence of MC1R R142H, R151C, R160W or 
D294H Variant in Melanoma (Familial and Sporadic Patients) and Control 
Subjects
No. of Cases No. of Controls
R142H, R151C, R160W or D294H Present 51 29
R142H, R151C, R160W and D294H Absent 37 38
P-value = 0.077 (not significant)
OR = 1.806, Cl 0.950-3.434
To determine if there is a possible correlation between carrying any of 
these variants and having familial melanoma a two-tailed Fisher’s exact test was 
performed on all familial melanoma patients compared to the control subjects 
(Appendix 5, Table 24). No significant differences were identified between the 
two groups.
191
The possible correlation between carrying a R142H, R151C, R160W or 
D294H variant and having sporadic melanoma was considered by performing a 
two-tailed Fisher’s exact test on sporadic melanoma patients compared to the 
control subjects. Table 6.21 below shows the nearly significant connection as 
18/28 (64.3%) patients carry one or more o f these variants compared with 29/67 
(43.3%) control subjects (P = 0.074; OR = 2.359; Cl 0.948-5.869).
TABLE 6.21
Correlation between MC1R R142H, R151C, R160W or D294H Variant and 
Sporadic Melanoma Patients and Control Subjects
No. of Cases No. of Controls
R142H, R151C, R160W or D294H Present 18 29
R142H, R151C, R160W and D294H Absent 10 38
P-value = 0.074 (not significant)
OR =2.359, Cl 0.948-5.869
To determine if  there is a possible correlation between carrying a R142H, 
R151C, R160W or D294H variant and having familial melanoma with a 
CDKN2A mutation, a two-tailed Fisher’s exact test was performed on all familial 
melanoma patients with a CDKN2A mutation and the control subjects. Table 
6.22 below shows the nearly significant association as 14/21 (66.7%) patients 
carry a R142H, R151C, R160W or D294H variant compared with 29/67 (43.3%) 
control subjects (P = 0.081; OR = 2.621; Cl 0.937-7.326).
TABLE 6.22
Correlation between MC1R R142H, R151C, R160W or D294H Variant and 
Familial Melanoma Patients with a CDKN2A Mutation and Control 
Subjects
No. of Cases No. of Controls
R142H, R151C, R160W or D294H Present 14 29
R142H, R151C, R160W and D294H Absent 7 38
P-value = 0.081 (not significant)
O R = 2.621, Cl 0.937-7.326
The possible correlation between carrying a R142H, R151C, R160W or 
D294H variant and having familial melanoma without a CDKN2A mutation was 
considered by performing a two-tailed Fisher’s exact test on all familial
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melanoma patients without a CDKN2A mutation and the control subjects 
(Appendix 5, Table 25). No significant differences were identified between the 
two groups.
To determine if there is a possible correlation between carrying a R142H, 
R151C, R160W or D294H variant and having familial melanoma compared with 
sporadic melanoma, a two-tailed Fisher’s exact test was performed on all familial 
melanoma patients and on all sporadic melanoma patients (Appendix 5, Table
26). No significant differences were identified between the two groups.
In order to determine if  there is a significant difference between familial 
melanoma patients and their currently unaffected family members, and carrying a 
R142H, R151C, R160W or D294H variant, a two-tailed Fisher’s exact test was 
carried out on all family members, affected and unaffected (Appendix 5, Table
27). No significant differences were identified between the two groups.
To investigate whether there is a difference between carrying a CDKN2A 
mutation and a R142H, R151C, R160W or D294H variant or not, a two-tailed 
Fisher’s exact test was carried out on both CDKN2A positive and negative 
familial melanoma patients (Appendix 5, Table 28). No significant differences 
were identified between the two groups.
To determine if  there is a possible correlation between carrying a R142H, 
R151C, R160W or D294H variant and being an unaffected family member, a 
two-tailed Fisher’s exact test was performed on all currently unaffected family 
members and in the control subjects (Appendix 5, Table 29). No significant 
differences were identified between the two groups.
In order to determine if  there is a significant difference between familial 
melanoma patients taken together with their currently unaffected family 
members and carrying a R142H, R151C, R160W or D294H variant, and control 
subjects, a two-tailed Fisher’s exact test was carried out on all family members, 
affected and unaffected and control subjects (Appendix 5, Table 30). No 
significant differences were identified between the two groups.
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6.12 Summary of Statistically Significant Findings
This section o f work has given rise to many observations. The following 
points summarise the statistically significant findings.
• Collectively, both familial and sporadic melanoma patients are more 
likely to carry a MC1R variant than normal control subjects (P = 0.006; 
OR = 4.485; Cl 1.492-12.883).
• Melanoma patients carry significantly more MC1R variants than control 
subjects (P = 0.003; OR = 2.696; Cl 1.384-5.253).
• Familial melanoma patients are more likely to carry the R151C variant 
than normal control subjects (P = 0.043; OR = 2.406; Cl 1.062-5.452) 
and are more likely to carry any MC1R variant than normal control 
subjects (P = 0.003; OR = 7.660; Cl 1.663-35.296).
• CDKN2A positive familial melanoma patients are more likely to carry the 
V60L and R151C variants than CDKN2A negative familial melanoma 
patients (P = 0.017; OR = 3.818; Cl 1.315-11.084 and P = 0.029; OR = 
3.515; Cl 1.160-10.650, respectively). Conversely, CDKN2A negative 
familial melanoma patients are more likely to carry the V92M variant 
than CDKN2A positive familial melanoma patients (P = 0.021; OR = 
9.308; Cl 1.112-77.888).
• Variant R160W is significantly correlated with skin type 1 (P < 0.001).
• Variants R142H (P = 0.019) and R160W (P = 0.018) are significantly 
correlated with red hair, although this significance is lost after the 
Bonferroni correction.
It should however be noted that this study has used greater statistical rigor 
than any other previously published paper, and that numbers are relatively small. 
Larger confirmatory studies using the same degree o f statistical rigor are needed.
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CHAPTER 7
MUTATION SCREENING OF EXON 15 OF
THE BRAF GENE
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7.1 Exon 15 BRAF Mutation Detection
Recent studies have identified that the exon 15 V599E BRAF  mutation is 
common in primary melanoma tissue (Davies et al. 2002). At the time Davies 
published in Nature, no data was available on BRAF mutations in germline DNA 
from familial melanoma patients, and the number o f melanoma tissue samples 
investigated for BRAF  mutations was low. I therefore searched for exon 15 
BRAF  mutations in germline DNA from patients with familial melanoma, both 
with and without identified CDKN2A mutations. I then investigated frozen 
melanoma tissue from secondary tumours for exon 15 BRAF  mutations. Finally, 
I looked for exon 15 BRAF mutations in a large panel of primary melanomas of 
which there was details of body site and histogenetic type.
7.2 Exon 15 BRAF Studies on Germline DNA from Patients with Familial 
Melanoma
7.2.1 Source o f DNA
Blood samples were obtained from 42 patients with familial melanoma. 
DNA was extracted, stored and used (Methods 3.1a, 3.2). DNA was also 
available from fresh secondary melanoma tissue from two familial probands F4.1 
and F10.1.
7.2.2 Mutation Strategy Employed
The exon 15 set of primers taken from Davies et al were designed to 
amplify the complete coding region of exon 15 and its splice sites. The final 
amplification conditions are presented in Appendix 2. Routinely a lp l aliquot of 
genomic DNA (extracted as described using method 3.1a) from each patient was 
amplified with the set o f primers (Method 3.4). Fragment sizes of 224bp for 
exon 15 were generated. Negative controls (no DNA) were run along with each 
reaction. Once all the DNA samples had been transferred to PCR tubes, the 
same reagents were used for the negative control. The absence of amplicons in 
the negative control meant that there had been no cross-contamination between 
the samples or into the reagents. The distinct bands obtained from amplification 
were resolved on ethidium bromide stained agarose gels to verify the size of the 
amplified band (Method 3.5) and are presented in figure 7.1.
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FIGURE 7.1
Amplification of Exon 15 of BR AF
The expected 224bp amplicons o f exon 15 o f BRAF were confirmed by 
resolution on a 1.5% agarose gel with ethidium bromide. The amplicons were 
electrophoresed in IX TAE buffer for 20 minutes. The size o f the amplicons 
which are represented below shown in base pairs were deduced by comparison to 
the migration o f the known size o f the DNA ladder fragments in lane 1. lp l of 
genomic DNA or 2pl o f somatic DNA was routinely amplified by conditions 
specified in Appendix 2 and with primers specified in Appendix 1. The 
am plicons’ size is consistent with the expected 224bp fragment and was 
sequenced to confirm this.
8 9 10
Ladder B ands(bp)
300
200
L an es
Sample Band (bp)
—  224
Electrophoresis Conditions: 1.5% agarose gel, IX TAE, lOpl size marker, 5pl
PCR product, 2pl loading mix, 100V, 20 minutes, 
room temperature
Lane 1 -  lkb Plus size marker 
Lane 2 -  PCR product from individual F l.l 
Lane 3 -  PCR product from individual F2.1 
Lane 4 -  PCR product from individual F3.1 
Lane 5 -  PCR product from individual F4.1 
Lane 6 -  PCR product from individual F5.1 
Lane 7 -  PCR product from individual F6.2 
Lane 8 -  PCR product from individual F7.1 
Lane 9 -  PCR product from individual F8.1
Lane 10 -  negative control See page 60 for patient details.
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7.2.3 Direct Sequencing o f all Amplicons
Exon 15 of BRAF was subjected to direct sequencing (Methods 3.7-3.11). 
The primers used for sequence analysis were the same as the amplification 
primers. DNA sequence of the complete exon and at least 20 base pairs of 
flanking DNA were routinely obtained. In total, only one nucleic acid change 
was found during sequencing of the samples. Any changes were confirmed by 
reamplification and sequencing of the mutated exon and the resulting amino acid 
change identified.
7.2.4 Sequence Analysis o f  Amplicons
Genomic DNA from familial melanoma cases
DNA from the peripheral blood o f the 42 familial melanoma cases 
contained no exon 15 BRAF mutations. This result was irrespective of the 
number of affected family members. Secondly, this result was irrespective of 
whether the families are CDKN2A mutation positive or CDKN2A mutation 
negative.
Somatic DNA from familial melanoma cases
The DNA from the two samples of secondary melanoma from individuals 
F4.1 and F I0.1 with a family history of melanoma also failed to show exon 15 
BRAF mutations.
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7.3 Detection of B R A F  Mutations in Frozen Melanoma Tissue from 
Secondary Tumours from Patients with Sporadic Melanoma
7.3.1 Source o f  Material
DNA was available from 24 tumour samples from 22 cases of sporadic 
melanoma (Methods 3.1c, 3.2). All samples were from secondary tumour. 
Twenty-two of these cases were from lymph nodes and two from soft tissue 
metastases. Table 7.1 details the age at diagnosis, sex of the patient, DNA 
source, histology of the primary melanoma, body site and thickness of the frozen 
secondary melanoma tumours.
Blood samples were obtained from two patients with sporadic melanoma. 
DNA was extracted, stored and used (Methods 3.1a, 3.2).
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TABLE 7.1
Details of Secondary M elanoma Samples O btained from  Sporadic 
M elanoma Patients Assessed for Exon 15 B R A F  mutations
Sample
Identifier
Age Sex DNA
Source
Prim ary  Type 
Histology
Body
Site
Thickness
(mm)
*96037 50 F 2 x Soft 
Tissue
SSM Calf 4.3
87004 52 F Nodal SSM Calf 1.6
92017 47 M Nodal SSM Back 0.2
88137 45 M Nodal SSM Trunk 1.0
94330 55 M Nodal SSM Arm 4.0
*91054 52 F Nodal SSM Thigh 2.0
94126 54 F Nodal SSM Leg 0.6
99067 78 F Nodal SSM Calf 4.3
97165 76 F Nodal Nodular Leg 7.0
96150 48 M Nodal Nodular Leg 1.0
96250 48 F Nodal Nodular Thigh 5.0
91065 68 F Nodal Nodular Leg 3.7
996156 49 M Nodal Nodular Arm 2.8
85207 52 F Nodal Nodular Leg 2.5
97263 78 M Nodal Nodular Leg 13.0
94098 68 F Nodal Nodular Knee 12.0
93087 66 F Nodal Nodular Arm 5.0
96161 65 F Nodal Nodular Sole 8.0
94186 84 F Nodal Nodular Leg 5.0
86240 72 F Nodal Nodular Leg 5.3
97260 79 F Nodal Acral Heel 3.0
95015 56 F 2 x Nodal Acral Toe 6.0
Abbreviations for melanoma type are:
SSM = Superficial Spreading Melanoma
Nodular = Nodular Melanoma
Acral = Acral Lentiginous Melanoma
* = Blood samples were also obtained
See pages 36-38 for a description of the melanoma type.
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A typical secondary melanoma is illustrated in figure 7.2. 
FIGURE 7.2
Secondary M elanoma Cells in a Lymph Node
Example of the pathology o f invasive secondary melanoma cells in a lymph 
node.
7.3.2 Mutation Strategy Employed
Primers and amplification conditions were used as previously described 
in the familial section (page 204). Routinely a 2pl aliquot o f somatic DNA 
(extracted as described using method 3.1c) was amplified.
7.3.3 Sequence A nalysis o f  A mplicons 
Genomic DNA -  Two Samples
Blood samples from patient 96037, taken at the same time as tumour 
excision, were negative for the V599E mutation, which was identified in the 
corresponding two tumour samples (see following section). A second patient 
91054, where both tumour and blood were available, did not carry the V599E 
mutation or any other exon 15 mutations in either o f the samples.
Somatic Secondary M elanoma Tissue DNA -  24 Samples 
Identification of M utation V599E
A heterozygous T to A transition at nucleotide position 1796T>A 
was identified (Figure 7.3). This base change is predicted to lead to the 
substitution o f a valine (V) for a glutamic acid (E) at codon 599 (V599E) 
(Figure 7.3). This mutation has been previously reported (Davies et al).
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FIG U RE 7.3
Identification of M utation V599E (1796T>A) in M elanom a T um our Tissue
Sequence analysis o f PCR amplified somatic DNA from tumour samples Braf30 
and 96037. Tumour DNA was amplified and sequenced using intronic primer 
pair BRAF exon 15 (Appendix 1, 2). Tumour DNA that has lost 1 allele, the wild 
type allele, will amplify only the remaining allele, the mutant allele, as shown in 
the right hand side panel.
A T V K S
Wild Type GCT ACA GTG AAA TCT
Mutant GCT ACA GAG AAA TCT
E
(V599E)
Nucleic acid and derived amino acid sequences from the mutated region o f 
BRAF. The amino acid substitution o f a valine (V) for a glutamic acid (E) at 
position 599, V599E is shown.
202
The V599E substitution was detected in secondary melanoma DNA from 
6/22 cases (27%) of secondary melanoma as shown in table 7.2. Four of the 
samples of secondary melanoma which contained this BRAF  mutation were from 
DNA extracted from metastatic deposits in lymph nodes, all from different 
individuals and 2 were from soft tissue metastatic nodules both from the same 
individual 96037, taken approximately 9 months apart. The average age at 
primary melanoma diagnosis of patients with these secondary tumours is 61 
years, and those that carry the V599E mutation have an average age at diagnosis 
of 58 years. Six of the samples came from male patients with one being 
mutation positive and 16 came from female patients with four being mutation 
positive. The average thickness of these primary tumours from which these 
secondary tumours came from is 4.5mm and those with the V599E mutation 
have an average thickness of 4.2mm. These results are not significant.
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TABLE 7.2
Sum m ary of Sequence Analysis of Frozen Secondary M elanoma Tum ours
Sample
Identifier
Age Sex DNA
Source
Prim ary
Type
Histology
Body
Site
Thickness
(mm)
Sequence 
Result 1
Sequence 
Result 2
96037 50 F 2 x Soft 
Tissue
SSM Calf 4.3 V599E V599E
87004 52 F Nodal SSM Calf 1.6 WT WT
92017 47 M Nodal SSM Back 0.2 WT WT
88137 45 M Nodal SSM Trunk 1.0 WT WT
94330 55 M Nodal SSM Arm 4.0 WT WT
91054 52 F Nodal SSM Thigh 2.0 WT WT
94126 54 F Nodal SSM Leg 0.6 WT WT
99067 78 F Nodal SSM Calf 4.3 WT WT
97165 76 F Nodal Nodular Leg 7.0 V599E V599E
96150 48 M Nodal Nodular Leg 1.0 V599E V599E
96250 48 F Nodal Nodular Thigh 5.0 V599E V599E
91065 68 F Nodal Nodular Leg 3.7 V599E V599E
996156 49 M Nodal Nodular Arm 2.8 WT WT
85207 52 F Nodal Nodular Leg 2.5 WT WT
97263 78 M Nodal Nodular Leg 13.0 WT WT
94098 68 F Nodal Nodular Knee 12.0 WT WT
93087 66 F Nodal Nodular Arm 5.0 WT WT
96161 65 F Nodal Nodular Sole 8.0 WT WT
94186 84 F Nodal Nodular Leg 5.0 WT WT
86240 72 F Nodal Nodular Leg 5.3 WT WT
97260 79 F Nodal Acral Heel 3.0 WT WT
95015 56 F Nodalx2 Acral Toe 6.0 WT WT
Abbreviations for melanoma type are:
SSM = Superficial Spreading Melanoma
Nodular = Nodular Melanoma
Acral = Acral Lentiginous Melanoma
See pages 36-38 for a description of the melanoma type.
WT denotes a wild type sequence 
F denotes female 
M denotes male
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7.4 Confirmation of Mutation V599E in Tumour Tissue by Restriction 
Digestion
A restriction assay was developed to test for the V599E mutation 
(Method 3.14). Details of this assay are presented in Appendix 3.
The exonic sequence of both wild type and the heterozygous mutant was 
analysed to identify restriction enzyme sites. For mutation V599E the sequence 
was altered such that a restriction site was destroyed. This assay allowed 
confirmation of the presence of the mutation in the secondary tumours and was 
also used as a screen for the large number of paraffin embedded primary 
melanoma tissues.
7.4.1 Development o f a Restriction Test
The 1796T>A mutation removes a TspR I site when the mutant A base is 
present in amplified product (Figure 7.4a).
Digestion with TspR I produces fragments of 202bp and 22bp in affected 
secondary tumour samples 96250 and 97165, see lanes 2 and 3 (Figure 7.4b). 
The normal allele (124bp, 78bp and 22bp) and the undigested normal allele 
(224bp) are both present, see lanes 2-5.
205
FIGURE 7.4
Development of a TspR  I Restriction Site C reated by M utation V599E for 
Secondary M elanoma Tum our Samples
a) Diagrammatic representation o f the 224bp PCR amplified fragment o f exon 15 
o f BRAF. The mutation deletes a TspR 1 restriction site 124bp into the PCR 
fragment that is present in the wild type in the absence o f the 1796T>A 
substitution.
Normal (v599)
5 ’ Tiitron , E xoliT 5~ .' m  p 3 ’
TspR I* TspR I
^-------- 1 2 4 b p -------------- \ -----------7 8 b p ---------- \2 2 b p ^
Mutant (E599)
5’ T f ^  W LZi EmnJS Z ^ m  p 3 ’
I
^-------------------------2 0 2 b p ------------------------------- \ 2 2 b p ^
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b) The expected 202bp and 124bp DNA fragments from the TspR I digested 
amplicons of secondary tumour were confirmed by resolution on a 3% agarose 
gel with ethidium bromide. The fragments were electrophoresed in IX TAE 
buffer for 20 minutes. The size o f the digested amplicons which are represented 
below shown in base pairs were deduced by comparison to the migration of the 
known size o f the DNA ladder fragments in lanes 1 and 6.
Lanes
1 2 3 4 5 6
Sample Bands (bp)Ladder Bands (bp)
Electrophoresis Conditions: 3% agarose gel, IX TAE, lOpl size markers, 5pl
digest, 2pl loading mix, 100V, 20 minutes, room 
temperature
Lane 1 -  lkb Plus size marker 
Lane 2 -  digested PCR product from tissue 96250 
Lane 3 -  digested PCR product from tissue 97165 
Lane 4 -  digested PCR product from a normal control 
Lane 5 -  undigested PCR product from a normal control 
Lane 6 -  ?h\X\74/H inf I size marker
See page 208 for tissue details.
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7.5 Detection of B R A F  Mutations in Formalin Fixed and Paraffin Processed 
Tissue from Primary Melanomas from Patients with Sporadic Melanoma
7.5.1 Source o f  Material
DNA was extracted, stored and used from 52 paraffin embedded primary 
melanoma samples (Methods 3.1b, 3.2). The samples are described in table 7.3, 
which gives details o f the age at which diagnosis was first given, sex o f the 
patient, pathological type, body site and thickness of the tumour.
TABLE 7.3
Primary Tumours from Sporadic Melanoma Patients Assessed for Exon 15 
B R A F  Mutations
Sample Identifier Age Sex Histology Body Site Thickness
(mm)
Brafl 53 M SSM Scalp 6.8
Braf2 70 M SSM Trunk 6.0
Braf3 58 M SSM Trunk 3.8
Braf4 48 M SSM Neck 5.7
Braf5 66 M SSM Back 3.5
Braf6 69 F SSM Leg 6.3
Braf7 76 F SSM Arm 2.0
Braf8 65 F SSM Leg 2.9
Braf9 75 F SSM Leg 18.0
Brafl 0 53 M SSM Back 2.6
Brafl 1 76 M SSM Face 5.4
Brafl 2 80 M SSM Ear 5.8
Brafl 3 76 F SSM Face 15.2
Brafl 4 45 M SSM Cheek 2.5
Brafl 5 52 F SSM Leg 11.8
Brafl 6 62 M SSM Leg 9.9
Brafl 7 54 F SSM Leg 4.9
Brafl 8 71 F Nodular Leg 10.0
BraH 9 69 M Nodular Upper Arm 6.0
Braf20 70 F Nodular Thigh 4.9
Braf21 76 F Nodular Face 3.5
Braf22 86 F Nodular Leg 14.6
Braf23 87 F Nodular Buttock 5.0
Braf24 82 F Nodular Back 6.0
Braf25 66 M Nodular Foot 22.0
Braf26 82 M Nodular Scalp 6.0
Braf27 51 F Nodular Ear 3.0
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Sample Identifier Age Sex Histology Body Site Thickness
(mm)
Braf28 71 M Nodular Scalp 9.0
Braf29 72 M Acral Toe 3.5
BrafiO 65 F Acral Leg 4.2
Braf31 61 M Acral Ankle 5.8
Braf32 77 M Acral Leg 10.0
Braf33 69 F Acral Sole 11.5
Braf34 66 M Acral Toe 3.3
Braf35 45 F Acral Leg 4.2
Braf36 87 F Acral Sole 6.1
Braf37 74 M Acral Sole 9.3
Braf38 78 F Acral Leg 0.6
Braf39 63 F Acral Leg 7.5
Braf40 80 M Acral Sole 5.5
Braf41 74 M Acral Leg 4.2
Braf42 72 M Mucosal Lip 7.5
Braf43 40 F LMM Face 1.0
Braf44 79 M LMM Foot 1.2
Braf45 76 M LMM Face 6.1
Braf46 61 M LMM Face 9.5
Braf47 88 M LMM Face 4.3
Braf48 74 M LMM Face 8.4
Braf49 73 F LMM Face 2.7
Braf50 58 F LMM Neck 1.0
Braf51 73 M LMM Ear 1.1
Braf52 72 M LMM Face 3.9
Abbreviations for melanoma type are:
SSM = Superficial Spreading Melanoma
Nodular = Nodular Melanoma
Acral = Acral Lentiginous Melanoma
Mucosal = Mucosal Melanoma
LMM = Lentigo Maligna Melanoma
In addition to the above 52 samples, tissue from five further primary 
melanomas from five individuals were available, but the DNA from these failed 
to amplify on repeated occasions. These were one 3.5mm Superficial Spreading 
Melanoma from a male back aged 72 years and four Acral Lentiginous 
Melanomas melanomas, three from females and one from a male, all from the 
foot. Thicknesses ranged from 1.6mm-7.0mm. The reason for this failure to 
amplify is not clear. All samples selected were less than two years old but it is 
possible that these five samples remained in formalin for longer than the others 
before processing. Unfortunately the details in the pathology records do not 
allow confirmation or refute of this hypothesis.
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7.5.2 Mutation Strategy Employed
The same set of primers and amplification conditions as previously 
described in the familial section were used. Routinely a 2pi aliquot of somatic 
DNA (extracted as described using method 3.1b) was amplified with the set of 
primers. When paraffin embedded DNA was amplified and was not present on 
the check gel, a 2pl aliquot of PCR product was reamplifed using the same set of 
primers and amplification conditions.
7.5.3 Paraffin Embedded Primary Melanoma Tissue -  52 Samples
The TspR I digest, as described in section 7.4 above, did not work well 
for the paraffin embedded primary melanoma tissues. Unfortunately the 202bp 
and the 124bp fragments were unresolved for the paraffin embedded primary 
melanoma tissues (Figure 7.5). All samples were therefore sequenced directly 
(Methods 3.7-3.11).
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FIG U R E 7.5
TspR I Restriction Assay for Paraffin Embedded Prim ary M elanoma 
Tissues
The expected 202bp and 124bp DNA fragments from the TspR I digested 
paraffin embedded primary melanoma tissue 2nd round PCR products were 
unable to be resolved on a 3% (2% agarose / 1% Nesieve) gel with ethidium 
bromide. The fragments were electrophoresed in IX TAE buffer for 20 minutes. 
The size of the digested amplicons which are represented below shown in base 
pairs were deduced by comparison to the migration o f the known size o f the 
DNA ladder fragments in lane 1.
Lanes
1 2 3 4 5 6
■■yi 
— ; um
Ladder Bands (bp) Sample Band (bp)
249  
200
224
Electrophoresis C onditions:3% agarose gel, IX TAE, lOpl size markers, 5pl
digest, 2pl loading mix, 100V, 20 minutes, room 
temperature 
Lane 1 -  PhiX 174/////7f I size marker 
Lane 2 -  undigested PCR product from a normal control 
Lane 3 -  digested PCR product from a normal control 
Lane 4 -  digested PCR product from tissue Brafl 
Lane 5 -  digested PCR product from tissue Braf42 
Lane 6 -  negative control
See pages 216-217 for tissue details.
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7.5.4 Sequence Analysis o f  Amplicons 
Identification of Mutation V599E
Five samples failed to amplify possibly because of degradation. The 
V599E substitution was detected in tumour DNA from 13 of the remaining 52 
samples (25%) of paraffin embedded primary melanoma. A new exon 15 
amplicon was generated for direct sequencing of the mutation positive samples 
using both forward and reverse exon 15 primers to confirm the presence of the 
mutation. When sequencing for the second time, two of the mutation positive 
paraffin embedded primary melanoma samples, Braf4 and Braf42, showed a wild 
type sequence. All samples, whether positive or negative, were therefore 
sequenced again. A sample, Braf5, which had shown to be wild type during the 
first sequence analysis, was mutation positive on the second sequence analysis. 
All samples were sequenced until two concurring mutation positive results were 
obtained as shown in table 7.4. While samples Braf4, Braf5 and Braf42 all gave 
two wild type and two mutated sequence results, in all three cases the results 
using the two additional techniques described below showed the DNA to be 
mutated, illustrating the value of using additional confirmatory techniques.
TABLE 7.4
Summary of Sequence Analysis of Paraffin Embedded Primary Melanoma 
Tumours
Sample
Identifier
Sequence 
Result 1
Sequence 
Result 2
Sequence 
Result 3
Sequence 
Result 4
Brafl V599E V599E
Braf2 V599E V599E
Braf3 V599E V599E
*Braf4 V599E WT V599E WT
*Braf5 WT V599E WT V599E
Braf6 WT WT
Braf7 WT WT
BrafS WT WT
Braf9 WT WT
Brafl 0 WT WT
Brafl 1 WT WT
Brafl 2 WT WT
Brafl 3 WT WT
Brafl 4 WT WT
Brafl 5 WT WT
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Sample Sequence Sequence Sequence Sequence
Identifier Result 1______ Result_2______ Result_3______ Result 4
Brafl 6 WT WT
Brafl 7 WT WT
Brafl 8 V599E V599E
Brafl 9 V599E V599E
Braf20 V599E V599E
B r a d  WT WT
B r a d  WT WT
B r a d  WT WT
B r a d  WT WT
B r a d  WT WT
B r a d  WT WT
Braf27 WT WT
B r a d  WT WT
B r a d  V599E V599E
Braf30 V599E V599E
Braf31 WT WT
B r a d  WT WT
B r a d  WT WT
B r a d  WT WT
B r a d  WT WT
Braf36 WT WT
Braf37 WT WT
B r a d  WT WT
B r a d  WT WT
Braf40 WT WT
Braf41 WT WT
*Braf42 V599E WT WT V599E
Braf43 V599E V599E
Braf44 V599E V599E
Braf45 WT WT
Braf46 WT WT
Braf47 WT WT
Braf48 WT WT
Braf49 WT WT
Braf50 WT WT
Braf51 WT WT
Braf52 WT WT
WT denotes wild type
* denotes samples which produced two WT and two mutated sequence results
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7.5.5 Allele Specific PCR fo r  the Detection o f  Mutation V599E in Paraffin 
Embedded Primary Melanoma Tissue
In order to validate the above sequencing results by only amplifying 
mutant DNA and to be able to perform a rapid screen of paraffin embedded 
primary melanoma tissues, an allele specific PCR was designed. For this study, 
the same reverse primer as used previously and taken from Davies et al was used 
along with an allele specific forward primer designed to only amplify DNA 
where the mutant V599E allele was present. To confirm that amplification has 
been performed, a second reaction was set up in parallel using the same reverse 
primer along with an allele specific forward primer designed to amplify DNA 
where the normal allele was present. This would therefore amplify all samples, 
however the reaction using the mutant primer, which has an A instead of a T as 
its end base, would only anneal to DNA containing the V599E mutation. The 
final developed amplification conditions are presented in Appendix 2. A 2 pi 
aliquot of somatic DNA from each sample was amplified with each set of 
primers. A 2pl aliquot of PCR product was then reamplifed using the same sets 
of primers and amplification conditions. The distinct bands obtained from 
amplification are presented in figure 7.6.
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FIGURE 7.6
Development of an Allele Specific PCR for the Detection of M utation V599E 
in Paraffin Embedded Prim ary M elanoma Tissue
The expected 130bp amplicons o f the V599E allele specific PCR were confirmed 
by resolution on a 2% agarose gel with ethidium bromide. The amplicons were 
electrophoresed in IX TAE buffer for 20 minutes. The size o f the amplicons 
which are represented below shown in base pairs were deduced by comparison to 
the migration o f the known size o f the DNA ladder fragments in lanes 1 and 8. 
2pl o f somatic DNA was routinely amplified by conditions specified in 
Appendix 2 and with primers specified in Appendix 1. The am plicons’ size is
consistent with the expected 130bp fragment.
Lanes
1 2 
IS C: 50
5 6
** SHARPENED **
Ladder Bands (bp)
7 8
| | 11:49 02/28
Sample Band (bp)
200
100
130
Electrophoresis Conditions: 2% agarose gel, IX TAE, lOpl size marker, 5pl
PCR product, 2pl loading mix, 100V, 20 minutes, 
room temperature 
Lane 1 -  lkb Plus size marker
Lane 2 -  PCR product from normal B rafl2 tissue for v599
Lane 3 -  PCR product from mutation positive tissue Braf4 for v599
Lane 4 -  negative control for v599
Lane 5 -  PCR product from normal Brafl 2 tissue for E599 
Lane 6 -  PCR product from mutation positive tissue Braf4 for E599 
Lane 7 -  negative control for E599 
Lane 8 -  1 kb size marker
See page 216-217 for tissue details.
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For V599E mutation negative samples the reactions amplified with the 
normal forward primer, however no product amplified with the mutant forward 
primer. Samples in which the mutation was present, both normal and mutant 
forward primers amplified the DNA. The results of the allele specific PCR are 
detailed in table 7.5. All previously sequenced mutation positive and negative 
samples were confirmed with the allele specific PCR
TABLE 7.5
Summary of V599E Allele Specific PCR on Paraffin Embedded Primary 
Melanoma Tumours
Sample Identifier Allele Specific PCR Result
Brafl 
Braf2 
Braf3 
*Braf4 
*Braf5 
Braf6 
Braf7 
Braf8 
Braf9 
Brafl 0 
Brafl 1 
Brafl 2 
Brafl 3 
Brafl 4 
Brafl 5 
Brafl 6 
Brafl 7
V599E
V599E
V599E
V599E
V599E
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
Brafl 8 
Brafl 9 
Braf20 
Braf21 
Braf22 
Bra£23 
Braf24 
Braf25 
Braf26 
Braf27 
Braf28
V599E
V599E
V599E
WT
WT
WT
WT
WT
WT
WT
WT
Braf29
Braf30
V599E
V599E
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Sample Identifier Allele Specific PCR Result
Braf31 WT
Braf32 WT
Braf33 WT
Braf34 WT
Braf35 WT
Braf36 WT
Braf37 WT
Braf38 WT
Braf39 WT
Braf40 WT
Braf41 WT
*Braf42 V599E
Braf43 V599E
Braf44 V599E
Braf45 WT
Braf46 WT
Braf47 WT
Braf48 WT
Braf49 WT
Braf50 WT
Braf51 WT
Braf52 WT
See table 7.3 for pathological details.
WT denotes wild type
* denotes samples which produced two WT and two mutated sequence results
7.5.6 dHPLC Analysis o f  Paraffin Embedded Primary Melanoma Tissue 
Samples
As a second method to resolve the somatic mutations detected in the 
sequencing results, and to be able to perform a rapid screen and most importantly 
to identify low-level mutant heteroduplex peaks in the paraffin embedded 
primary melanoma tissues dHPLC analysis was performed.
Optimum dHPLC temperatures were determined by a temperature scan, 
using the WAVEMaker 4.0 melting profile as a starting point for this 37.5% GC 
rich fragment. Three mutation positive samples were originally run at four 
temperatures to determine the profile o f the mutated samples. The two best 
temperatures were chosen (Figure 7.7). For exon 15 of BRAF, samples were run 
at 56°C and 58°C, although all mutations were detected at 56°C.
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FIGURE 7.7
Optim um  dHPLC Tem peratures
H elica l F raction  v s  T e m p e r a tu r e
A \
—(-----------1-----------1-----------1---------- i r i -----  i-----------1
40 45 50 55 60 65 70 75 80
Temperature (°C)
Helical Fraction v. Base Position
£  100 O'
CQts
E 50L
I
1 0
0
DNA from all 52 paraffin embedded primary melanoma tissue was amplified 
using the Davies’ primers as previously described and 50pl PCR products were 
then subjected to dHPLC analysis. Each elution profile was compared with the 
profiles associated with homozygous wild type and mutated sequence controls as 
shown previously in figure 4.4.
,V599E
25020050 100 150
Base Position
^  100 r
9Z
$ 50
35
7.5.7 Identification o f  a Chromatogram WA VE Shift
Thirteen abnormal chromatogram patterns were identified for exon 15 
and its flanking sequences (Figure 7.8). The more sensitive dHPLC WAVE 
analysis returned a mutation positive finding in the three cases that had shown 
both positive and negative mutation status on sequencing, table 7.6. All 
sequenced mutation negative samples were also dHPLC mutation negative.
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FIGU RE 7.8
Identification of M utation V599E (1796T>A) by dH PL C
NormalAbnormal elution 
profile \
Time (Minutes)
dHPLC WAVE analysis o f PCR amplified somatic DNA from tumour sample 
Brafl 9. Tumour DNA was amplified using intronic primer pair BRAF exon 15 
(Appendix 1). All elution profiles which were abnormal were identical in pattern 
to each other.
TABLE 7.6
Summary of dHPLC Results of Paraffin Embedded Prim ary Melanoma 
Tum ours
Sample Identifier dHPLC Result
Brafl Abnormal
Braf2 Abnormal
Braf3 Abnormal
*Braf4 Abnormal
*Braf5 Abnormal
Braf6 WT
Braf7 WT
BrafS WT
Braf9 WT
Brafl 0 WT
Brafl 1 WT
Brafl 2 WT
Brafl 3 WT
Brafl 4 WT
Brafl 5 WT
Brafl 6 WT
Brafl 7 WT
Brafl 8 Abnormal
Brafl 9 Abnormal
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Sample Identifier dHPLC Result
Braf20 Abnormal
Braf21 WT
Braf22 WT
Braf23 WT
Braf24 WT
Braf25 WT
Braf26 WT
Braf27 WT
Braf28 WT
Braf29 Abnormal
Braf30 Abnormal
Braf31 WT
Braf32 WT
Braf33 WT
Braf34 WT
Braf35 WT
Braf36 WT
Braf37 WT
Braf38 WT
Braf39 WT
Braf40 WT
Braf41 WT
*Braf42 Abnormal
Braf43 Abnormal
Braf44 Abnormal
Braf45 WT
Braf46 WT
Braf47 WT
Braf48 WT
Braf49 WT
Braf50 WT
Braf51 WT
Braf52 WT
WT denotes wild type
* denotes samples which produced two WT and two mutated sequence results
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7.5.8 Contamination
At one point during the analysis of the paraffin embedded primary 
melanoma tissues there was an incident of PCR product carryover. The PCR 
product carryover contaminated the second round of amplification. This was 
obviously a concern because the amplified PCR product served as an ideal 
template for the subsequent amplifications of that same target. The transfer of 
aerosol o f the amplified product meant on one occasion significant 
contamination, which resulted in false-positives, and the detection and 
amplification o f the contaminating sequence at the expense of the target 
sequence in every tissue sample. To minimize PCR product carryover in the 
subsequent reactions, reactions were physically separated prior to and following 
amplification, new reagents were used and separate sets o f pipettes, filter- 
plugged pipette tips, microcentrifuge tubes and gloves were used when handling 
pre- and post-PCR solutions.
7.5.9 Summary o f Paraffin Embedded Primary Melanoma Tissue Studies
The complete set of mutation data generated on each of the paraffin 
embedded primary melanoma tissue is presented in table 7.7. The sequencing 
results, allele specific PCR and dHPLC analysis are presented for each tissue 
sample. All paraffin embedded primary melanoma tissue DNAs were screened 
for mutations in exon 15 of BRAF  firstly by direct sequencing. Where a 
mutation was identified, the sample was reamplified and sequenced again to 
confirm the mutation. In the majority o f cases the mutation was confirmed, 
however in two cases the mutation was not confirmed and therefore the sample 
was reamplified and sequenced again for a third time. In three samples the pick 
up rate for the mutation was 50%, therefore all samples, positive or negative for 
the mutation were reamplified and sequenced until a positive or negative result 
was obtained twice. Due to this pick up rate in paraffin embedded primary 
melanoma tissue other screening methods, dHPLC and allele specific PCR, were 
investigated.
The V599E substitution was detected in primary tumour DNA from 
13/52 cases (25%). Five of the samples of primary melanoma which contained 
this BRAF  mutation were from DNA extracted from 17 Superficial Spreading 
Melanomas, three from 11 Nodular Melanomas, two from 13 Acral Lentiginous
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Melanomas, one from one Mucosal Melanoma and two from ten Lentigo 
Maligna Melanomas. The average patient’s age at diagnosis of these primary 
tumours is 68.6 years, and those that carry the V599E mutation have an average 
age at diagnosis of 64.1 years (NS). Twenty-nine of the samples came from 
male patients with nine (31 %) being mutation positive and 23 came from female 
patients with four (17.4) being mutation positive. The average thickness of these 
primary tumours is 6.3mm and those with the V599E mutation have an average 
thickness of 4.9mm.
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7.5.10 Summary o f  all Exon 15 B R A F  Frozen and Paraffin Embedded 
Melanoma Tissue Studies
In summary, the exon 15 1796T>A BRAF  mutation has been detected in 
13/52 (25%) of primary melanoma samples and 6/24 (25%) of secondary 
melanoma samples, giving an overall mutation pickup rate for somatic mutations 
of 19/76 (25%). The percentage of Superficial Spreading Melanomas showing 
the exon 15 BRAF mutation was 7/26 (26.9%), in 7/23 (30.4%) Nodular 
Melanomas, in 2/16 (12.5%) Acral Lentiginous Melanomas, in 1/1 (100%) 
Mucosal Melanoma and 2/10 (20%) Lentigo Maligna Melanomas.
The average age at diagnosis of these tumours is 66.3 years, and those 
that carry the V599E mutation have an average age at diagnosis of 62.4 years. 
Thirty-five of the samples came from male patients with ten being mutation 
positive and 39 came from female patients with eight being mutation positive. 
The average thickness o f these tumours is 5.7mm and those with the V599E 
mutation have an average thickness of 4.7mm. The tissue samples analyzed in 
this study were chosen for their thickness and do not represent the normal 
thickness of tissue samples for the Scottish population. The body site of the 
tissues of the BRAF mutation positive samples do not differ from those of the 
BRAF negative population sampled (Table 7.8).
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TABLE 7.8a
Summary of Mutation Positive Paraffin Embedded Primary Melanoma 
Tissue Studies
Sample
Identifier
Age Sex Histology Body
Site
Thickness Mutation
Analysis
Brafl 53 M SSM Scalp 6.8 V599E
Braf2 70 M SSM Trunk 6.0 V599E
Braf3 58 M SSM Trunk 3.8 V599E
Braf4 48 M SSM Neck 5.7 V599E
Braf5 66 M SSM Back 3.5 V599E
Brafl 8 71 F Nodular Leg 10.0 V599E
Brafl 9 69 M Nodular Upper
Arm
6.0 V599E
Braf20 70 F Nodular Thigh 4.9 V599E
Braf29 72 M Acral Toe 3.5 V599E
BrafiO 65 F Acral Leg 4.2 V599E
Braf42 72 M Mucosal Lip 7.5 V599E
Braf43 40 F LMM Face 1.0 V599E
Braf44 79 M LMM Foot 1.2 V599E
TABLE 7.8b
Summary of Mutation Positive 
Studies
Frozen Secondary Melanoma Tumour
Sample
Identifier
Age Sex DNA
Source
Primary
Type
Histology
Body Thickness 
Site
Mutation
Analysis
96037 50 F 2 x Soft 
Tissue
SSM Calf 4.3 V599E
97165 76 F Nodal Nodular Leg 7.0 V599E
96150 48 M Nodal Nodular Leg 1.0 V599E
96250 48 F Nodal Nodular Thigh 5.0 V599E
91065 68 F Nodal Nodular Leg 3.7 V599E
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CHAPTER 8
DISCUSSION OF 
MUTATION SCREENING OF THE 
CDKN2A GENE
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8.1 CDKN2A Discussion
The work presented in this thesis adds 32 new melanoma families to the 
16 already reported from Scotland (MacKie et al. 1998) (population 5 million). 
In total, 13/48 (27%) Scottish families have detectable CDKN2A mutations. One 
of the mutations detected (H83N) have not previously been reported in 
melanoma, and molecular modelling suggests the likely functional result of this 
mutation. Function results are awaited from an active collaboration with the 
University o f Toronto. O f the 48 Scottish families, one family, F I 9, has five 
affected family members and carries a CDKN2A mutation. One family, F2, has 
four affected members and is mutation positive. Five families, F I, F8, F20, F21 
and F29 have three affected members in each family and three o f these families 
(60%) carry a CDKN2A mutation. The remaining 41 families have only two 
affected members, with eight (20%) of these families mutation positive.
8.2 Detection of CDKN2A mutations by dHPLC
Fifteen abnormal chromatogram patterns were identified for exons l a  
and 2 of the CDKN2A gene using dHPLC analysis. To validate dHPLC, all 
probands from each family were sequenced whether or not the chromatogram 
was abnormal or wild type. No false negatives or false positives were obtained 
by dHPLC in any sample. All of the 15 amplicons that showed a non wild type 
profile were sequenced and all 15 amplicons contained a nucleic acid change.
Orlow et al. (2001) has also validated dHPLC as a rapid detection method 
for the identification of CDKN2A mutations. They screened exons la ,  2, and 3 
from 129 samples and 13 known mutants, yielding 347 products that were 
examined at different temperatures. Forty-two of the amplicons showed a 
distinct non-wild-type chromatogram. Sequencing of all 129 samples identified 
16 different nucleotide variations. Most importantly, as in this thesis, no false 
negatives or false positives were obtained by dHPLC in samples with mutations 
or polymorphisms.
Thus the work presented in this thesis confirms that o f Orlow et al. 
dHPLC is a reliable method for the screening of a large number of samples for 
CDKN2A mutations and polymorphisms and is fast, sensitive, and cost-efficient.
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Another useful application o f dHPLC rather than direct sequencing is that 
individual profiles from amplicons containing different mutations are generated. 
For example, in elution profile E (Figure 8.1) there are amplicons from two 
melanoma patients and one from a control subject. Both patients have identical 
elution profiles and both carry the same mutation. These identical profiles could 
be used when screening additional family members for an already identified 
familial mutation.
The results from the dHPLC analysis gave rise to 15 abnormal elution 
profiles. It was found that each different profile was the result o f amplicons each 
with a different mutation. For example, elution profiles E and L (Figure 8.1) 
show a different elution profile from each other. Profile E has two spaced out 
tall peaks of almost equal height in comparison to profile L that has two peaks 
very close together and o f different heights. The different profiles o f each 
different mutation could be used as a guide to which mutation will be present 
upon sequencing.
FIGURE 8.1
Applications of dHPLC analysis
E L
Abnormal elution 
profiles^
Normal 
Wild Type
2 30 1 4 5 6 7
Abnormal elution 
profiles
Normal 
Wild Type
<x>oc
to-Q
o(/)
<
0 1 2 3 4 5 6 7
___________________ Time (Mins) _____________  Time (Mins)
Elution profiles obtained in melanoma patients as compared with a wild-type 
elution profile are shown.
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8.3 Determining the Nature of the Nucleic Acid Change
Eight different nucleic acid changes were identified in samples from 15 
probands. Three families carry an exon l a  mutation and ten families carry an 
exon 2 mutation. Two additional families have the exon 2 A148T suspected 
polymorphism. No exon 3 mutations were identified in this study. Nine 
probands showed a change at SNP 500 and five probands showed a change at 
SNP 540.
8.3.1 The H8 3N  Mutation
A previously unreported mutation was identified within the Scottish 
melanoma families presented in this thesis. A heterozygous C to A transition at 
nucleotide position 247C>A was identified in family 33. This base change is 
predicted to lead to the substitution of histidine (H) for an asparagine (N) at 
codon 83 (H83N). Family 33 has two affected members with melanoma. Both 
family members have multiple primary melanomas. Both affected family 
members carry the H83N mutation. No currently unaffected family members 
were available for screening.
Molecular modelling was used to investigate the potential effects on the 
pathological function of the H83N mutation. H83 is buried within the core of 
pl6INK4A and the side chain of histidine participates in three hydrogen bonds to 
different parts o f the tumour suppressor molecule main chain that serve to 
stabilise the conformation of two loops that interact with residues 31 to 38 of 
CDK6. Replacing the basic histidine with asparagine would ensure the loss of at 
least one hydrogen bond within the core of the molecule, which might destabilise 
the pl6INK4A structure. This molecular modelling and the fact that the 
mutation was identified in both affected members o f the one family would 
suggest that the H83N mutation has a pathological effect on pl6INK4A.
8.3.2 The 32-33ins9-32 24bp Duplication
A heterozygous 24bp fragment of bases 9-32 inserted between bases 32- 
33 was identified in a family with two affected members, one o f whom has 
multiple primary melanomas. This insertion is in frame. This mutation has been 
previously incorrectly reported as a 1-8 24bp insertion by Goldstein et al. (1995),
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Walker et al. (1995), and Flores et al. (1997). Pollock et al. (1998) identified two 
new melanoma kindreds that carried the duplication. This brought the total 
number o f melanoma families described with this mutation to five, from three 
continents: Europe, North America, and Australasia. This suggested to Pollock 
et al. (1998) that there had been at least three independent 24bp duplication 
events. The duplication may have arisen due to an unequal crossing-over 
between the two 24bp repeats naturally present in the wild-type sequence, 
possibly through polymerase slippage during replication. Further evidence that 
this repeat region is unstable and prone to slippage was provided by the 
identification o f a somatic 24bp deletion of one of the normally occurring repeats 
in a prostate tumour (Komiya et al. 1995)
8.3.3 The R24P Mutation
A heterozygous G to C transition at nucleotide position 71G>C was 
identified in family 2. This base change is predicted to lead to the substitution of 
arginine (R) for a proline (P) at codon 24 (R24P). Family 2 is the second largest 
family in the Scottish cohort with four affected members with melanoma. There 
is also a member of this family with oesophageal cancer. The predicted 
substitution was also identified in a currently unaffected family member.
In a patient with multiple primary melanomas, Monzon et al. (1998) 
identified a R24P mutation in the CDKN2A gene. This mutation had previously 
been reported in an Australian melanoma family and was found to cosegregate 
with cases of melanoma (Holland et al. 1995). This mutation has also been 
identified in an English melanoma family (Harland et al. 1997).
Molecular modelling was used to investigate the potential effects on the 
pathological function of the R24P mutation. The side chain o f R24 of 
pl6INK4A forms hydrogen bond interactions with CDK6. If R24 mutated to 
R24P this would remove strong electrostatic interactions and reduce the affinity 
for complex formation between the two proteins.
Functional studies have shown the R24P mutant to behave normally in a 
CDK4 binding assay, but the cell cycle-inhibitory activity of the R24P mutant 
was reduced. Therefore this mutation may be defective in interaction with 
proteins other than CDKs (Becker et al. 2001).
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8.3.4 The Y44X Mutation
A heterozygous C to A transition at nucleotide position 132C>A was 
identified in family 3. This base change is predicted to lead to the substitution of 
tyrosine (Y) for a stop codon at codon 44 (Y44X). Both affected members in 
this family carry the mutation.
8.3.5 The G67R Mutation
A heterozygous G to C transition at nucleotide position 199G>C was 
identified in family 19. This base change is predicted to lead to the substitution 
of glycine (G) for an arginine (R) at codon 67 (G67R). Family 19 is the largest 
family in the Scottish cohort with five affected members with melanoma. Family 
members with multiple primary melanomas are present in this G67R family and 
there is also a member of this family with ovarian cancer.
Molecular modelling was used to investigate the potential effects on the 
pathological function of the G67R mutation. The G67 residue is situated at the 
end of the helix-tum-strand motif on a tight turn into the p-sheet of the ankyrin 
repeats. Glycine 67 is highly conserved, lying within the second ankyrin repeat 
and shares secondary structure alignment with glycine 101, a residue of proven 
significance to pl6INK4A function. Glycine 67 is the first residue of loop 2 of 
pl6INK4A (Byeon et al. 1998). A mutation at this point of the protein may 
affect the secondary structure and perhaps the folding of the protein. Any 
mutation at this point would be likely to impair function and replacing glycine 
with arginine could influence the fold and alter the position of adjacent helices, 
which taper down to the binding site with CDK6. This G67R substitution could 
also change the binding sites to other as yet unidentified proteins.
Newton Bishop et al. (1999) screened 42 English families for CDKN2A 
mutations. They identified the single base pair substitution G67R in one 
melanoma family.
Holland et al. (1999) analyzed 131 Australian melanoma probands. They 
identified a mutation at the same glycine 67 residue to serine (G67S). G67S is 
likely to affect pl6INK4A function as shown by site-directed mutagenesis 
(Tevelev et al. 1996; Zhang and Peng 1996) and also by reduced binding to 
CDK4 (Rizos et al., 2001). The fact that there are two mutations at the G67
233
residue in melanoma families shows that this residue is important and that a 
mutation at this amino acid may have an effect on the pathological function of 
pl6INK4A.
8.3.6 The R112G Mutation
A heterozygous C to G transition at nucleotide position 334C>G was 
identified in two Scottish families, families 17 and 22. This base change is 
predicted to lead to the substitution of arginine (R) for a glycine (G) at codon 112 
(R112G). The predicted substitution observed in the probands was also found in 
other affected family members and also in three currently unaffected family 
members.
Molecular modelling was used to investigate the potential effects on the 
pathological function of the R112G mutation. R112 makes a salt bridge 
interaction with residue E l 20, which helps to stabilise the structure of the loops 
that interact with CDK6. A mutation from R to G would disrupt this part of the 
structure and also complex formation.
In 1999 Holland et al. analysed 131 Australian melanoma probands. 
They identified an R112G mutation. Arginine 112, is not conserved but is 
immediately flanked by several highly conserved residues. This mutation has 
also been observed as a somatic event in a sporadic metastatic melanoma (Platz 
et al. 1996).
8.3.7 The A 148T  Suspected Polymorphism
A heterozygous G to A transition at nucleotide position 442G>A was 
identified in three families. This base change is predicted to lead to the 
substitution o f alanine (A) for a threonine (T) at codon 148 (A148T). The 
presence of this substitution in affected family members and not in unaffected 
family members increases the chance that this is a pathological mutation. 
However, A148T was also identified in currently unaffected family members and 
most importantly was not identified in a number o f affected family members 
from the same families. This would lead us to believe that this predicted 
substitution is a polymorphism.
Bertram et al. (2002) investigated the role of A148T as a low penetrance 
melanoma or nevus susceptibility variant in 488 adults from 179 English families
234
of patients with the atypical nevus phenotype and/or a family history of 
melanoma, and a population-based sample of 599 women. They found a very 
similar prevalence of A148T (4.9% and 5.2%) in both the atypical nevus 
phenotype and/or a family history of melanoma patients, and the population- 
based control samples. In addition, they showed no association between the 
A148T variant and nevus number or history of melanoma. Therefore this data 
does not suggest that the A148T variant is a low penetrance melanoma allele or 
nevus susceptibility allele.
8.3.8 SN P  500 and SN P 540
No exon 3 mutations were identified in this study, but nine probands 
showed a change at SNP 500 C>G and five probands showed a change at SNP 
540 C>T in the 3'UTR of the CDKN2A gene. The number of individuals typed 
for these two polymorphisms is too small to draw any definite conclusions about 
these two polymorphisms. However, it is possible that these variants could 
either be in linkage disequilibrium with an unidentified variant directly 
responsible for the increased melanoma risk or alter either the stability o f the 
CDKN2A transcript or the level o f CDKN2A transcription.
Kumar et al. (2001) genotyped the 500 C>G and 540 C>T 
polymorphisms in 44 Swedish melanoma cases, 187 Norwegian melanoma cases 
and 235 Nordic population controls. The T-allele frequency (for 540 C>T 
polymorphism) in melanomas was significantly higher than in controls (0.14 vs. 
0.08; p = 0.01; OR = 1.71, 95% Cl = 1.11-2.66). The heterozygote frequency for 
this polymorphism was 0.26 (59/229) in melanomas compared to 0.13 (30/235) 
in healthy controls (p = 0.0007; OR = 2.34, 95% Cl = 1.40-3.92). The frequency 
of the 500 C>G polymorphism was not significantly higher in melanomas 
compared to healthy controls. The 500 C>G polymorphism, however, was in 
linkage disequilibrium with approximately 50 kb from the C>A intronic 
polymorphism in the CDKN2B gene (determined in 44 melanomas and 90 
controls; Fisher exact test, p<0.0001).
Straume et al. (2002) investigated the impact of the 540 C>T 
polymorphism of CDKN2A in vertical growth phase melanomas from Norwegian 
patients. Forty-seven cases (25%) were heterozygous for the 500 C>G 
polymorphism. The 540 C>T polymorphism was found in 42/185 (23%) of
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melanomas and was also associated with improved survival (P = 0.03). There 
was no association with the clinicopathological variables studied and these 
polymorphisms. These results suggest a role for the 540 C>T polymorphism of 
CDKN2A in the initiation or early progression of a subset of cutaneous 
melanomas with less aggressive behaviour.
A summary of all CDKN2A mutations currently identified in Scotland is listed 
below in table 8.1.
TABLE 8.1
Mutations Detected in the CDKN2A Gene in 48 Scottish Melanoma Families
CDKN2A Mutation Number of Scottish Melanoma 
Families with Mutation
Exon la
32-33ins9-32 24bp dup 1
71G>C R24P 1
132C> A Y44X 1
Exon 2
159G>C M53I 6
199G>C G67R 1
247C>A H83N 1
3 3 4 0 G R112G 2
442G>A A148T (polymorphism) 2
The overall mutation rate o f 27% is relatively high for small families by 
comparison with other parts o f the world. For example, in the Australian states 
of Victoria and New South Wales, the mutation rate in melanoma families is 
reported as 11/131 or 8.4% (Holland et al., 1999) and in Israel it is 2/30 or 7% 
(Yakobson et al., 2000).
Mantelli et al. (2002) screened for CDKN2A mutations in Italian families with 
two melanoma patients, one of whom was younger than 50 years at onset, the 
other either being a first-degree relative, or having an additional relative with 
pancreatic cancer, or having multiple primary melanomas. 62/67 (80%) of 
families met this criteria. Four CDKN2A mutations (G101W, R24P, V126D, and 
N71S) were found in 21/62 (34%) families. The percentage of families with two 
melanoma cases/family carrying a mutation was low (7%, 2/27), but rose to 45%
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(9/20) if one of the melanoma patients carried multiple melanomas or if 
pancreatic cancer was present in that family. In the 15 families with three 
melanoma cases the presence of a mutation was higher (67%, 10/15) and reached 
100% in the 4 families with four or more melanoma cases.
The results in this thesis suggest that CDKN2A screening is worthwhile 
even for families with only two melanoma cases, in research settings, 
irrespective of the presence of multiple primary melanomas or of pancreatic 
cancer.
8.4 CDKN2A M utations and Age at M elanoma Diagnosis
In the Scottish families with CDKN2A mutations, the mean age of 
melanoma diagnosis is 35 years, and in families with no detected mutations it is 
46 years. This difference is significant (P = 0.008) and there is also a highly 
significant difference between both of these ages at diagnosis and the mean age 
of 56.7 years at diagnosis for the geographically matched sporadic cases 
(MacKie et al., 2002). As questioning of the familial melanoma cases (page 57) 
does not indicate excessive sun exposure by comparison with age matched 
sporadic cases, it would appear that there may be an interaction between 
CDKN2A mutations and environmental factors including sun exposure and no 
doubt other genes which accelerates the pathway to melanoma development.
8.5 CDKN2A and O ther Cancers
In families F I 9, F30 and F31 there are five cases of ovarian cancer, in 
families F l l  and F21 there are two cases of pancreatic cancer, in family F l l  
there is also a case of breast cancer, in family F14 there is a case of lymphoma 
and in family F2 there is a case of oesophageal cancer. It has been previously 
reported that melanoma families with CDKN2A mutations have a higher than 
expected incidence of pancreatic cancer (Goldstein et al. 1995; Bergman et al. 
1996; Ghiorzo et al. 1999; Borg et al. 2000; Vasen et al. 2000). The relationship 
between the CDKN2A gene and pancreatic cancer is however unknown.
8.5.1 Pancreatic Cancer
The Scottish families presented in this thesis do not confirm the 
association between familial melanoma, CDKN2A mutations and pancreatic
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cancer, as only two melanoma families also have members with pancreatic 
cancer (families 11 and 21), neither of whom have detectable CDKN2A 
mutations. It may be of significance that a Scandinavian report (Whelan et al., 
1995) finds coexistent pancreatic cancer only in families with the CDKN2A 
113insR mutation, a mutation that has not been detected in Scottish families.
Borg et al. (2000) analyzed an affected member from each of 52 families 
from southern Sweden with two or more cases of melanoma for germline 
mutations in CDKN2A and CDK4 to reveal the contribution of these gene 
mutations to familial melanoma and to the occurrence of other cancer types. 
They found CDKN2A mutations in 10/52 (19%) families. Nine families carried 
the insl 13R mutation and one family carried a VI15G missense mutation. Six of 
the nine 113insR families had at least one member with multiple primary 
melanomas; the 113insR families also had a high frequency of other cancer 
types, in particular, breast cancer (a total of eight cases compared with the 
expected 2.1; P = 0.0014) and pancreatic cancer (a total of six cases compared 
with the expected 0.16; P < 0.0001). These findings show that families with the 
CDKN2A 113insR mutation have an increased risk of multiple primary 
melanomas, pancreatic cancer and breast cancer.
Bartsch et al. (2002) evaluated the prevalence of mutations in the 
CDKN2A gene in 18 German familial pancreatic cancer families and five 
German families with at least one patient with pancreatic cancer and another 
first-degree relative with malignant melanoma. None of 18 familial pancreatic 
cancer families carried a CDKN2A mutation. Two of the five families with 
pancreatic cancer and melanoma carried a truncating CDKN2A mutation (Q50X 
and E l 19X). Neither o f these mutations were detected in the Scottish families.
Ghiorzo et al. (2004) investigated the association between CDKN2A 
mutations and the occurrence of pancreatic cancer in 49 Italian familial 
melanoma patients, 66 sporadic pancreatic cancer patients and 54 control 
subjects. As compared with the general population, the risk o f pancreatic cancer 
was increased 9.4-fold (95% Cl 2.7-33.4) in G101W familial melanoma patients 
and 2.2-fold (95% Cl 0.8-5.7) in G101W negative familial melanoma patients. 
One G101W familial melanoma patient also had a germline deletion o f the 
second allele, including exon lp. This deletion could mean that pl4A RF is
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involved in the development of pancreatic cancer and a mutation in both 
pl6INK4A and pl4ARF may result in an increased risk of pancreatic cancer in a 
familial melanoma setting. The G101W mutation was not identified in the 
Scottish melanoma families.
Goldstein (2004) examined the relationships between familial melanoma, 
pancreatic cancer and germline CDKN2A mutations using published data. She 
identified 67 different CDKN2A mutations in 189 melanoma families. Forty-two 
melanoma families also had cases of pancreatic cancer in the family. Eighteen 
mutations were identified in these 42 melanoma families with pancreatic cancer. 
Comparison of the 147 melanoma families without pancreatic cancer with the 42 
families that had pancreatic cancer showed no significant differences in the types 
or locations of mutations identified. There was however, a significant difference 
(p=0.002) in the distribution of the mutations from each group across the four 
ankyrin repeats of pl6INK4A. The third ankyrin repeat is where most mutations 
occur in mutation positive melanoma families with pancreatic cancer. Nine of 
22 (41%) G101W melanoma families also had pancreatic cancer. Three of ten 
(30%) V126D melanoma families also had pancreatic cancer. No M53I 
melanoma families also had pancreatic cancer. The M53I mutation is Scotland’s 
most common melanoma CDKN2A mutation.
8.5.2 Breast Cancer
Epidemiologic studies have provided suggestive evidence of a link 
between melanoma and breast cancer. Goggins et al. (2004) found a significant 
increased risk o f melanoma among female breast cancer survivors and vice versa 
by following U.S. female breast cancer patients registered in the 1973-1999 
Surveillance, Epidemiology and End Result (SEER) database. Among breast 
cancer patients aged 50 years or under, they also observed a 46% elevated risk of 
a subsequent melanoma, suggesting that mutations identified in high-risk 
melanoma groups may also be present at a much lower level in the general breast 
cancer population. One Scottish melanoma family also has a case of breast 
cancer. No significant increased risk of melanoma with breast cancer has been 
observed in Scottish melanoma patients (MacKie and Hole, personal 
communication).
239
8.5.3 Ovarian Cancer
In the Scottish families, the commonest additional malignancy is ovarian 
cancer with three families affected. One family has a G67R CDKN2A mutation, 
one an M53I mutation and one no detectable CDKN2A mutation. Clearly further 
correlation is required with all melanoma families worldwide with and without 
CDKN2A mutations currently recorded to evaluate any significant coexistence of 
malignancies in addition to melanoma in these families.
Ovarian cancer is one of the most common cancers among women. 
Arcellana-Panlilio et al. (2002) studied the role of pl6INK4 in ovarian granulosa 
cell tumours. Granulosa cell tumours of the ovary are relatively rare ovarian 
cancers. Seven of twelve (58%) adult ovarian granulosa cell tumours lacked 
expression of pl6INK4A. In one of these cases, there was a homozygous 
deletion o f the CDKN2A locus, and in the other tumours they found 
hypermethylation o f the promoter region, which can lead to gene inactivation.
Kudoh et al. (2002) identified homozygous deletions of the CDKN2A 
gene in 8/45 (18%) cases o f primary epithelial ovarian cancer.
8.5.4 Lymphoma
There is a case o f lymphoma in one Scottish melanoma family F I4. This 
family has two affected members but no CDKN2A mutation identified.
8.6 Multiple Primary Melanomas
Many melanoma families also have members with multiple primary 
melanomas, and in Scotland there is now a record of 10 such families (1, 3, 4, 5, 
6, 11, 28, 33, 42 and 43) with 13 family members affected with MPMs for which 
there was DNA available. In total, 24 patients with MPM were screened for 
CDKN2A mutations, 13 are classed as familial melanoma and 11 as sporadic 
melanoma.
Germline mutations in the CDKN2A gene were identified in 12/24 (50%) 
of MPM cases, nine with a family history o f melanoma and three sporadic cases. 
Seven of these families have CDKN2A mutations.
The most frequently identified mutation in patients with MPM was M53I, 
found in five familial cases and in two sporadic cases. CDKN2A mutations were
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more frequent in those patients with a family history of melanoma (9/13 69.2%) 
than in those without a family history (3/11 27.3%).
Hashemi et al. (2000) screened 80 Swedish individuals with at least two 
primary melanomas, for germ-line CDKN2A mutations. In 15 patients, at least 
one additional family member with melanoma was identified. These 15 
individuals belonged to 13 separate kindreds with melanoma as two kindreds 
each had two additional affected relatives. Nine (11%) patients carried a 
CDKN2A mutation, seven of which had a family history of melanoma. Two 
patients without a family history of melanoma had CDKN2A mutations. One had 
a mutation in the 5' noncoding sequence (-14C/T) and the other had an insertion 
of an extra T in codon 28, which results in a stop signal in codon 43.
Blackwood et al. (2002) in Pennsylvania identified germline mutations in 
the CDKN2A gene in 9/96 (9%) MPM cases. Six of the mutation positive 
individuals with MPMs had a family history of melanoma.
8.7 Future Studies
Future studies would include screening for germline deletions of the 
region on 9p21 containing the CDKN2A gene and exon 1 p. Mutation screening 
o f the non-coding region of the CDKN2A gene suggests that mutations in the 
promoter region are unlikely to play a significant role in linked 9p21 families 
without CDKN2A exonic mutations (Pollock et al. 2001). It is however possible 
that mutations in noncoding regions may be responsible for predisposition to 
melanoma. Harland et al. (2000) screened the promoter region of CDKN2A in 
107 melanoma families. They identified four variants. Two of these (A-191G 
and A-493T) did not segregate with disease and were present in a control 
population, indicating that they are unlikely to predispose to melanoma. The A- 
493T variant appeared to be in linkage disequilibrium with the previously 
described CDKN2A polymorphism A148T. The variant G-735A was detected in 
the control population, but segregation of this variant with melanoma within 
families could not be discounted. The fourth variant (G-34T), located in the 5’ 
UTR, creates an aberrant initiation codon. This variant appeared to segregate 
with melanoma and was not detected in a control population. G-34T has recently 
been identified in a subset o f Canadian melanoma families and was concluded to 
be associated with predisposition to melanoma.
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The creation of an aberrant initiation site in the 5' UTR may have an 
important role in carcinogenesis in a small percentage of families; however, 
mutations in the CDKN2A promoter appear to have a limited role in 
predisposition to melanoma.
8.7.1 IVS2, A-G, -105
Harland et al. (2001) reported that affected individuals in six o f 90 
English melanoma pedigrees screened carried a transition (IVS2-105 A-G) deep 
in intron 2 o f the CDKN2A gene. The mutation creates a false GT splice donor 
site 105 bases 5-prime of exon 3 and results in aberrant splicing of the mRNA. 
The authors proposed that this mutation and others similar to it might account for 
a significant proportion of 9p21-linked melanoma pedigrees with no detectable 
mutations in the coding region of CDKN2A.
The intronic sequence of CDKN2A has not been investigated for 
mutations in Scottish melanoma families; however, in the light o f the IVS2-105 
deep intronic mutation being the most common CDKN2A mutation identified in 
English melanoma families this mutation should now be screened for in those 
Scottish melanoma pedigrees where coding mutations o f CDKN2A cannot be 
identified.
The CDKN2A 500 and 540 3’ UTR variants and any other SNPs adjacent 
to CDKN2A require further investigation not only in the familial melanoma 
patients but in sporadic cases too and of course a general population study of 
their frequency would need to be obtained. It would be useful to obtain the 
genotype of these SNPs in families with CDKN2A mutations to determine the 
carrier haplotype of any ancestral mutations and also in families without 
CDKN2A mutations to look for haplotypes suggestive of carrying a common, yet 
currently unrecognised mutation.
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8.8 International Collaboration
Mutations in the CDKN2A gene are found in 27% of all Scottish 
melanoma families. Clearly, additional melanoma predisposition genes must 
exist. Melanoma is not a common tumour, and families are even rarer, so future 
progress will need worldwide collaboration. The International Melanoma 
Genetics Consortium is currently carrying out genetic and epidemiological 
studies and genome-wide scans in melanoma families to localize genes 
predisposing to melanoma. When new melanoma genes are discovered, 
interactions with CDKN2A and gene-environmental interactions can be 
investigated more closely. The identification of other genes contributing to 
melanoma predisposition will increase the ability to identify who might be a 
target for early detection and prevention campaigns.
8.9 CDKN2A Screening
Routine screening for CDKN2A mutations in melanoma families is 
currently not recommended in Scottish clinical practice outside of research 
settings. This is because a patient’s mutation status does not affect the lifetime 
follow-up strategies. Undetected mutations, other undetected genes, and 
incomplete penetrance of CDKN2A means that predictive DNA testing for 
melanoma outside of the defined research protocols would be premature. There 
is a possibility of sporadic melanoma in non-mutation carriers in melanoma 
families, o f which we have one family. Programs of sun protection and skin 
surveillance should be followed by all high risk individuals irrespective of their 
mutation status. Although the frequency of CDKN2A mutations in Scottish 
patients with melanoma who have two or more family members with melanoma 
is 27%, the frequency among all melanoma patients is low, estimated at about 
0*2-2'0% (Hansen et al. 2004). Therefore genetic testing would only be 
appropriate only in well-defined categories of patients with melanoma.
Myriad Genetic Laboratories launched a predictive test, MELARIS™, for 
malignant melanoma in 2001. This test detects inherited mutations in the 
CDKN2A gene by sequencing. This test aims at providing an assessment of risk 
in family members who have not so far shown any sign or symptom of the 
disease. However, a negative result in an unaffected family member could mean
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that they are a non-carrier in a CDKN2A-mutation family or that they are a 
carrier o f a mutation of another yet unidentified gene in a melanoma family that 
does not have a CDKN2A mutation or that they are a non-carrier in a family that 
does not have a CDKN2A mutation. In families in whom no CDKN2A mutation 
is identified, there should be careful interpretation of false-negative results as the 
family is still at increased risk of melanoma on the basis of the family history. A 
negative result in a family member who has melanoma indicates that their family 
is unlikely to have a CDKN2A mutation that is identifiable by the current 
screening techniques. They may however have a mutation in another melanoma- 
predisposition gene that has not yet been identified.
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CHAPTER 9
DISCUSSION OF THE M53I FOUNDER
MUTATION
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9.1 Founder Mutation Discussion
The most common CDKN2A mutation identified in this thesis from the 
Scottish melanoma families studied is a heterozygous G to C transition at 
nucleotide position 159G>C. This base change is predicted to lead to the 
substitution of methionine (M) for an isoleucine (I) at codon 53 (M53I). It was 
identified in six Scottish families, families 1, 4, 5, 6, 29 and 30. All affected 
family members from these six families carry the M53I mutation except affected 
individual F29.1 (see cloning method 3.15). No CDKN2A mutation could be 
identified in this individual and therefore is thought to be a sporadic melanoma 
patient within a familial setting.
Reports from a number of countries suggest that apparent founder 
mutations explain a substantial fraction of hereditary melanoma. These 
mutations and their suggested country o f origin are indicated in table 9.1.
TABLE 9.1
Currently Reported Melanoma Founder Mutations
Study Mutation Main Population Ancestry
Gruis et al. (1995) ‘p i 6-Leiden’ The Netherlands Dutch
Borg et al. (1996) insR113 Southern Sweden Swedish
MacKie et al. (1998) M53I Scotland Scottish
Liu et al. (1999) G-34T Canada British
Ciotti et al. (2000) G101W Liguria, Italy ‘Celtic’
Goldstein et al. (2001) V126D North America German/English
Yakobson et al. (2003) V59G European Israeli
9.1.1 19bp Deletion ‘p i  6-Leiden ’
Most Dutch melanoma families appear to originate from a unique founder 
mutation (pi6-Leiden). Gruis et al. (1995) analyzed 15 Dutch FAMMM
syndrome pedigrees in the Netherlands, and identified a 19bp deletion in exon 2 
CDKN2A germline deletion in 13 of them with Dutch ancestry. The 19bp 
deletion has also been documented outside the Netherlands, in an Australian 
family, however the proband has distant Dutch ancestors (Holland et al. 1999).
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The deletion causes a reading-frame shift, which encodes a truncated non­
functional pl6INK4A protein consisting of the N-terminal of pl6INK4A and the 
C-terminal of pl4ARF (van der Velden et al. 1999).
9.1.2 3bp Duplication, 113insR
In ten melanoma kindreds from southern Sweden, Borg et al. (1996) 
identified a novel germline mutation in two families, constituting an inffame 3bp 
duplication at nucleotide 332 in exon 2. The mutation resulted in an insertion of 
an extra arginine at codon 113, which interrupts the last of the four ankyrin 
repeats of the pl6INK4A protein, motifs which have been demonstrated as 
important in binding and inhibiting the activity o f CDK4 and CDK6 in cell cycle 
G1 phase regulation. Analysis of microsatellite markers adjacent to the 
CDKN2A gene at chromosomal region 9p21 in the two families with the 
mutation showed that they shared a common haplotype, in keeping with a 
common ancestor. 113insR has been identified in 17 Swedish melanoma 
families (Hashemi et al, 2001).
9.1.3 -34G-T
CDKN2A coding mutations cosegregate with melanoma in 20-30% of 
families with melanoma but there are also a number o f CDKN2A mutation- 
negative families that demonstrate linkage of inherited melanoma to 9p21 
markers (Hayward 1996). Liu et al. (1999) showed that 4/59 (7%) Canadian 
melanoma kindreds possess a G to T transversion at nucleotide -34 of CDKN2A, 
designated -34G-T. The mutation gives rise to a novel AUG translation initiation 
codon that decreases translation from the wild-type AUG. The -34G-T mutation 
was not seen in controls but segregated with melanoma in families. From 
haplotyping studies, it appeared to have arisen from a common founder in the 
U.K. Liu et al. (1999) suggested that screening for mutations in the promoter 
region o f the CDKN2A gene should be useful in populations in which a low 
incidence of germline coding mutations of CDKN2A has been found in familial 
melanoma cases.
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9.1.4 G101W
In three families with melanoma, Hussussian et al. (1994) identified a 
glycine 101 to tryptophan mutation in the CDKN2A gene. Ciotti et al. (1996) 
detected the G101W mutation in seven unrelated families from the eastern coast 
of Liguria, Italy. Ciotti et al. (2000) reported G101W to be the most common 
CDKN2A missense mutation, having been reported in numerous families, with a 
particularly high prevalence in France and Italy. Soufir et al. 1998 reported the 
GlylOlTrp mutation in five apparently unrelated French families. In all families 
studied, the mutation appeared to have been derived from a single ancestral 
haplotype.
G101W was found to be temperature sensitive for binding to CDK4 and 
CDK6 in vitro, for inhibiting cyclin D1-CDK4 in a reconstituted pRb-kinase 
assay, and for increasing the proportion of G1-phase cells following transfection 
(Parry and Peters 1996). Ruas et al. (1999) considered the effects G101W might 
have on the three dimensional structure of the protein. G101 is one o f several 
glycine residues that are critical for the formation of the ankyrin repeat structure. 
Substitution with any other residue would be energetically unfavourable.
9.1.5 V126D
One of the most common melanoma-related CDKN2A mutations reported 
in North America is valine 126 to aspartic acid (V126D) (Hussussian et 1994). 
Goldstein et al. (2001) examined nine markers surrounding the CDKN2A gene in 
three American and four Canadian families carrying this mutation. All seven 
families had a haplotype consistent with a common ancestor/founder. Six o f the 
seven families were shown to have German/English ancestries.
V126D was found to be temperature sensitive for binding to CDK4 and 
CDK6 in vitro, for inhibiting cyclin D1-CDK4 in a reconstituted pRb-kinase 
assay, and for increasing the proportion of G1-phase cells following transfection 
(Parry and Peters 1996). The CDK4-binding ability of the V126D mutant 
decreases with increasing temperature. In a study by Becker et al. (2001), CDK4 
binding of the V126D mutation was reduced to only 20-25%.
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9.1.6 V59G
A valine 59 to glycine mutation in the CDKN2A gene was found in four 
families segregating with melanoma. These were an Israeli family o f Moroccan 
Jewish ancestry (Yakobson et al. 2001), two French families (one of Tunisian 
Jewish ancestry and another without known Jewish roots) (Soufir et al. 1998), 
and a Spanish family (Ruiz et al. 1999). Yakobson et al. (2003) found that all 
but one of those affected in these families were heterozygous for the mutation; 
one affected member of the Israeli family was homozygous. Haplotype analysis 
indicated a single ancestral founder. The mutation, which occurs in a 
hydrophobic region with the second ankyrin repeat, impairs pl6INK4A function, 
as shown by studies of protein-protein interactions and cell proliferation assays.
No Ashkenazi melanoma family has been reported to have a mutation in 
either CDKN2A or CDK4 (Yakobson et al. 1998).
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9.2 The M53I Mutation
The M53I mutation was originally detected in an Australian melanoma 
kindred (Walker et al. 1995). It has now been reported in three additional 
Australian families (Flores et al. 1997; Holland et al. 1999), two US kindreds 
(FitzGerald et al. 1996; Tsao et al. 2000) two English kindreds (Harland et al. 
1997; Newton Bishop et al. 1999) and one family each in Canada (Ontario) 
(Monzon et al. 1998) and France (Soufir et al. 1998) (table 9.2). MacKie et al. 
(1998) identified this mutation in four Scottish melanoma families and also in 
one patient with multiple primary melanomas with a negative family history 
(Burden etal. 1999).
TABLE 9.2
Currently Reported Melanoma Families Worldwide with M53I Mutations
Number of M53I Country Population
Families (millions)
6 Scotland (MacKie et al. 1998; this 
thesis)
5
4 Australia (Walker et al. 1995; Flores et 
al. 1997; Holland et al. 1999)
19.5
2 U.S.A
(FitzGerald et al. 1996; Tsao et al. 2000)
286.8
2 England (Harland et al. 1997; Newton 
Bishop et al. 1999)
49.9
1 Canada, Ontario (Monzon et al. 1998) 11
1 France (Soufir et al. 1998) 60.1
Pollock et al. (1998) noted that the M53I mutation had been described in 
four melanoma families from Australia and one from Canada. Previous 
examination of these five M53I melanoma families suggested the possibility of a 
common haplotype (Pollock et al., 1998). The work in this thesis has extended 
this examination with the investigation o f 18 families, six from Scotland, five 
from Canada, four from Australia (including the previously reported 41001, 
41031 and 60001 families) and three from America, all carrying an identical 
M53I CDKN2A mutation. This thesis also includes two additional informative 
markers close to the CDKN2A locus, D9S2136 and D9S2060.
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In total, 32 M53I mutation carriers, four non-carrier relatives and 45 
control subjects were haplotyped. Ninety chromosomes from the 45 
geographically matched control subjects were genotyped to determine the allele 
frequency of the markers in the general Scottish population. These Scottish 
control subjects are appropriate in view of the fact that the majority of the 
families studied are Scottish. The consensus M53I haplotype was not 
determined in any of the control subjects and therefore the probability of finding 
the M53I haplotype in the general Scottish population is extremely low.
Haplotype analysis, with seven informative markers surrounding 
CDKN2A at 9p21, of 18 geographically diverse melanoma families carrying the 
M53I mutation clearly indicates that 14 of them share a common haplotype for 
markers D9S2136 - D9S1604 4-2-8-4-6-2.
One Canadian family FAM-4 had the 7/9 alleles at D9S2136, rather than 
the allele 4 seen in all other haplotype sharing families. Three families, 
Australian families 41031 and 60001 and American family 637, showed co­
segregation of allele 4 instead of the consensus allele 6 for marker D9S1748. 
Family 41031 has a Chinese/English/Irish ancestry so perhaps the M53I mutation 
has arisen independently in this family. It is more likely however that the 
difference in allele size could be accounted for by replication slippage of marker 
D9S1748 gaining two repeat units during meiosis. All but one of the haplotype 
sharing families showed co-segregation of the 4 allele for marker D9S942. 
Australian family 60001 showed allele 6 to co-segregate with the M53I 
melanoma mutation. Australian families 41031 and 60001 could therefore not be 
assigned the consensus haplotype, as previously shown by Pollock et al, 1998. 
Their study accounted for these families not sharing the disease haplotype by 
replication slippage. Gain or loss of one repeat unit is much more likely than 
gain or loss of two repeat units as shown in these families. Larger mutations can 
however occur (Primmer et al. 1996). The loss of two repeat units is a rare event 
and therefore it is possible that the M53I mutation has arisen independently in 
these families and the haplotype sharing observed around CDKN2A occurred by 
chance. However, the low frequency of this haplotype in the control individuals 
leads to the conclusion that it is not chance and that these families do not share 
the disease haplotype because of replication slippage.
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9.3 Functional Studies of M53I
Molecular modelling was used to investigate the potential effects of the 
M53I mutation. The side chain of this highly conserved hydrophobic residue 
makes van der Waals interactions with main chain atoms of CDK6. A mutation 
M to I would likely reduce the area of interaction and therefore be slightly 
disruptive of complex formation.
Functional studies have shown that the protein expressed from the M53I 
mutation has loss of function and does not bind to CDK4/CDK6, confirming its 
role as a causal mutation in melanoma (Harland et al. 1997). Sun et al. (1997) 
also revealed that M53I CDKN2A mutant protein was functionally deleterious as 
it was unable to bind effectively to CDK4, confirming that this mutation is of 
pathological significance.
Becker et al. (2001) examined the relationship between the loss of CDK 
binding by the M53I mutant protein in melanoma cells. The cell cycle-inhibitory 
activity o f the M53I mutant was reduced, and may also be defective in 
interaction with cellular targets other than CDKs.
Recently Yang et al. (2004) reported a novel germline M53V mutation in 
CDKN2A from a large U.S. melanoma family. The M53I affects ARF  at D68H 
but the M53V mutation affects ARF  at D67G. The occurrence of a second, 
independent CDKN2A M53 alteration highlights M53I as an important causal 
mutation in melanoma.
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In conclusion, this study provides further evidence that the M53I 
mutation appears to have originated from a common founder and together with 
work quoted above, gives further evidence demonstrating common founders for 
most of the recurrent mutations in the CDKN2A gene. This suggests that the 
CDKN2A gene is relatively stable and mutation hotspots in the CDKN2A gene are 
uncommon.
The CDKN2A M53I mutation appears to play a significant role in 
melanoma families with a Scottish ancestry. Six of the 18 families studied reside 
in Scotland and at least 15/18 families have Scottish ancestry. It is therefore 
reasonable to infer that the M53I mutation arose on a chromosome carrying a 
common ancestral haplotype and occurred in Scotland. It is likely that the M53I 
mutation will be found in other populations with ancestral connections to 
Scotland. In the meantime the 18 known distantly related M53I families are a 
valuable resource for in depth studies on age o f onset, ultraviolet exposure, 
multiple primary tumours and other details.
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CHAPTER 10
DICSUSSION OF MC1R VARIANTS IN 
PHENOTYPED FAMILIAL MELANOMA 
PATIENTS, UNAFFECTED FAMILY 
MEMBERS, SPORADIC MELANOMA 
AND CONTROL SUBJECTS
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10.1 Correlation between Phenotype and Melanoma
In chapter 2 the phenotypic characteristics of the melanoma patients and 
control subjects presented in this thesis were compared with the large 
epidemiological studies (Palmer et al. 2000; Box et al. 2001) and confirmed that 
the characteristics of both patients and control subjects were reasonably 
representative. This allowed both patients and controls to be analysed for their 
MC1R status in chapter 6 and compared to published data.
10.1.1 Correlation between Skin Type and Melanoma
Among the four subsets of different skin type the most frequent 
phenotype observed in the melanoma patients is to bum easily and tan rarely 
60/88 (68.2%) and also in 29/68 (42.7%) controls. Only 7/88 (7.9%) cases 
compared with 25/68 (36.8%) controls have a bums rarely and tans easily skin 
type, which is a very highly significant difference between skin types in cases 
and controls (P < 0.001). Valverde et al. (1996) studied 43 unrelated patients 
with cutaneous melanoma and of 44 unrelated control. They found a weak 
association between melanoma and skin type.
When similar skin types were grouped together, and compared against all 
melanoma patients, both affected familial and sporadic, and the control panel 
81/88 (92%) melanoma cases have skin type 1 or 2 compared with 41/68 
(60.3%) controls (P < 0.001; OR = 7.620; Cl 3.060-18.974). Palmer et al.,
(2000) also found that individuals with melanoma were significantly more likely 
to have a skin colour lighter than that seen in controls. Therefore the individuals 
presented in this thesis correlate with that of the larger epidemiological studies.
The work from this thesis has shown that there is no association of skin 
type and the presence or absence o f a CDKN2A mutation within affected familial 
melanoma patients. This is in agreement with Box et al. (2001) who showed that 
CDKN2A mutations showed no association with skin type in their data set.
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10.1.2 Correlation between Eye Colour and Melanoma
Risk of melanoma with a specific eye colour was investigated by 
grouping similar eye colours together and comparing against all melanoma 
patients, both affected familial and sporadic, and the control panel. 70/88 
(79.5%) cases have lighter coloured eyes compared with 44/68 (64.7%) controls 
(P = 0.046; OR = 2.212; Cl 1.034-4.350). Palmer et al., (2000) found individuals 
with melanoma were significantly more likely to have blue/grey eyes (OR =1.8; 
Cl 1.2-2.7) or hazel/green (OR = 1.6; Cl 1.1-2.3). Thus the individuals presented 
in this thesis correlate with that of the larger epidemiological studies.
10.1.3 Correlation between Hair Colour and Melanoma
Among the four subsets of different hair colour the most frequent colour 
observed in the melanoma patients is light brown 32/88 (36.4%) compared with 
15/68 (22.1%) controls (P = 0.056; OR = 2.019; Cl 0.984-4.145). Similarly 
Palmer et al. (2000) found that individuals with melanoma were significantly 
more likely to have fair hair (OR = 2.0; Cl 1.5-2.8).
The work presented in this study shows that no significant difference was 
observed between patients who are CDKN2A positive or negative and having a 
particular hair colour. Box et al. (2001) also showed that CDKN2A mutations 
showed no association with hair colour in their data set.
The phenotyping carried out for the work in this thesis can therefore 
reassure the reader that the melanoma population presented in this thesis is not 
atypical with regard to skin type, eye or hair colour.
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10.2 MC1R Discussion
The aim of the analysis of the MC1R gene was to try to examine any 
underlying genetic relationship between MC1R variants and familial melanoma. 
Variants o f MC1R may confer a low melanoma risk in both familial and sporadic 
cases but could also modify the risk of melanoma in individuals carrying a 
CDKN2A mutation. The frequencies o f the MC1R variants identified in Scottish 
familial melanoma patients, both CDKN2A mutation positive and CDKN2A 
mutation negative and also a small number o f cases of sporadic melanomas were 
examined and compared with phenotyped Scottish controls.
In total, 13 MC1R variants leading to an amino acid substitution were 
detected among the 180 individuals available for sequence analysis, three of 
which have not been described elsewhere (L44I, M128K, A171G) and appear to 
be very rare. L44I is present in only one sporadic melanoma patient. Both 
leucine and isoleucine are hydrophobic residues very similar in size and weight 
and so it is difficult to determine if this substitution would have a functional 
effect. M128K is present in only one currently unaffected family member. 
Methionine is a hydrophobic residue whereas lysine is a basic residue o f very 
similar shape to methionine, however they both have very different side chains 
and so it is probable that this rare substitution has some functional effect. 
A171G is present in only one familial melanoma patient. Alanine is a small 
amino acid as is glycine. Although they are very similar in size and weight, they 
do have different side chains and it is therefore possible this substitution would 
have a functional effect. Three silent nucleotide changes were also detected 
(G239G, T314T, C315C).
The sequencing of the entire coding region compared with screening only 
the most frequently occurring variants has allowed for the detection of 
unreported MC1R variants and also the calculation of frequencies o f all variants 
identified in the Scottish melanoma and general population.
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10.2.1 MC1R Variants in Familial and Sporadic Melanoma Patients 
Combined
This study has identified that 83/88 (94.3%) patients and 53/67 (79.1%) 
controls carry at least one MC1R variant, which is a significant difference 
between the two groups (P = 0.006; OR = 4.385; Cl 1.492-12.883).
Among the 13 different variants identified in the complete set of 
sequenced individuals, the most frequently occurring variant in the melanoma 
patients is V60L 25/88 (28.4%). V60L was also found in 19/67 (28.4%) of 
controls and therefore is thought to be a common polymorphism in the Scottish 
general population and not contribute to melanoma risk. R151C occurred in 
27/88 (30.7%) patients compared with 12/67 (17.9%) controls, which is nearly 
significant (P = 0.065; OR = 2.104; Cl 0.976-4.536). The Australian study of 
Dwyer et al. (2004) has shown however that carriers of the V60L, R151C and 
D294H variants were not at a substantially increased risk.
The work of this thesis shows R160W was identified in 21/88 (23.9%) 
patients and in 14/67 (20.9%) controls (NS). In contrast, Dwyer et al. (2004) 
showed in an Australian population that carriers of the R160W and the rare 
D84E variant were at an increased risk of melanoma.
Ichii-Jones et al. (1998) looked at the three variants (D84E, V92M and 
D294H) in a larger data set o f 306 sporadic melanoma cases and 190 basal cell 
papilloma patients as controls. The allele frequencies were not significantly 
different between patients and controls. Other alleles were not included in this 
study. Our data confirms this observation, as does the English report of Hearle et 
al. 2003.
Palmer et al. (2000) have also reported no significant difference between 
D84E in melanoma and controls in an Australian population, which may be the 
same population as the report by Healy et al. (2000), which consisted of 460 
melanoma patients and 399 control individuals. Their controls consisted of 218 
parents of twins involved in a genetic study of mole formation and 181 controls 
who were involved in an alcohol use study. MC1R variants were present in 72% 
of melanoma cases and in 56% of control individuals (P < 0.01), compared with 
94.3% and 79.1% in this Scottish study. These differences could be because 
some MC1R variants, in particular V60L, are much more common in the Scottish
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population overall and therefore would increase variant frequency in both 
controls and patients.
10.2.2 MC1R Variants in Familial Melanoma Patients
When looking at the familial melanoma patients separately from sporadic 
melanoma patients, 58/60 (96.7%) affected melanoma patients compared with 
53/67 (79.1%) controls carry an MC1R variant (P = 0.003; OR = 7.660; Cl
1.663-35.296). Not all MC1R alleles however conferred the same familial 
melanoma risk. The most commonly occurring variants in the familial 
melanoma patients are V60L in 19/60 (31.7%) compared with 19/67 (28.4%) 
controls (NS). The V92M variant was identified in 12/60 (20%) familial cases 
compared with 10/67 (14.9%) controls, R151C in 20/60 (33.3%) patients 
compared with 12/67 (17.9%) controls (P = 0.043; OR = 2.406; Cl 1.062-5.452), 
and R160W in 11/60 (18.3%) cases compared with 14/67 (20.9%) controls. The 
Bonferroni adjusted significance level for multiple tests in this case is 0.004 and 
hence carrying any MC1R variant remains significant, although carrying the 
R151C variant loses significance.
For comparison, Box et al. (2001) identified the R151C variant in 26% of 
family members from 15 melanoma pedigrees (67 affected and 69 unaffected 
individuals) but in only 10% (2017 individuals) of the southeastern Queensland, 
Australia general population. This thesis shows the R151C variant to be present 
in 33.3% of familial melanoma cases in Scotland compared with 17.9% of 
controls. These frequencies may be higher in both melanoma cases and controls 
because the Scottish population has a higher degree of Celtic ancestry than 
Australia.
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10.2.3 MC1R Variants in CDKN2A Positive Familial Melanoma Patients
All 23/23 (100%) CDKN2A positive familial melanoma patients and 
35/37 (94.6%) CDKN2A negative familial melanoma patients carry an MC1R 
variant. Individual allele frequencies differ between the two groups. The most 
frequently occurring variants in the CDKN2A positive patients are V60L in 12/23 
(52.2%) compared with 7/37 (18.9%) CDKN2A negative patients (P = 0.017; OR 
= 3.818; Cl 1.315-11.084). There is also a significant difference between the two 
groups with carrying the R151C variant in 12/23 (52.2%) CDKN2A positive 
cases compared with 8/37 (21.6%) CDKN2A negative patients (P = 0.029; OR = 
3.515; Cl 1.160-10.650).
In this study, the V92M variant is only present in 1/23 (4.3%) CDKN2A 
positive patients compared with 11/37 (29.7%) CDKN2A negative patients (P = 
0.021; OR = 9.308; Cl 1.112-77.888). Thus, there are more patients without a 
CDKN2A mutation with the V92M variant than there are patients with a 
CDKN2A mutation. The Cl in this case however is wide and therefore does not 
allow definite conclusions to be drawn about the magnitude of risk o f carrying or 
not carrying the V92M variant. Although maybe the V92M variant does play a 
part in increasing melanoma risk because the CDKN2A mutation negative 
patients still have melanoma. V92M could however just be a neutral 
polymorphism.
In Australia, Box et al. (2001) screened the MC1R gene of 15 CDKN2A 
mutation-carrying melanoma pedigrees in which nine different CDKN2A 
mutations were present. Melanoma risk was increased in individuals carrying 
both a CDKN2A mutation and a MC1R variant. The R151C, R160W, and 
D294H MC1R variants were largely responsible for increased risk of melanoma.
van der Velden et al. (2001) carried out a similar study looking at the 
frequencies of MC1R variants in melanoma and non-melanoma pl6-Leiden 
carriers. The pl6-Leiden mutation is the most common mutation of the 
CDKN2A gene in Dutch familial melanoma pedigrees. It is a 19-bp germline 
deletion causing a reading-frame shift, predicted to result in a severely truncated 
p l6  protein as described previously on page 254. van der Velden et al. (2001) 
compared the frequencies of MC1R variants in 101 pl6-Leiden carriers, who 
consisted of 38 melanoma patients and 63 individuals without melanoma with 
385 opthalmology patient controls. The only significant difference was the
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frequency of the R151C variant, which was found at an increased frequency in 
14% of the pl6-Leiden carriers, compared with the control group of 5%. They 
stated that the excess of the R151C allele in the pl6-Leiden carriers was mostly 
due to a high frequency in the melanoma patients (21%). Carriers without 
melanoma also presented a higher frequency (10%) of the R151C variant than in 
the control group (5%). They found that within the families, the R151C allele 
was transmitted from heterozygous parents carrying pl6-Leiden to affected 
offspring more often than by chance.
In this Scottish study and studies from other countries, there are no p i6- 
Leiden mutation families and therefore no comparison can be made.
10.2.4 MC1R Variants in Sporadic Melanoma Patients
The English study of Valverde et al. (1996) was the first to report certain 
variants o f MC1R to increase the risk o f melanoma. They compared the MC1R 
genotype of the second and seventh transmembrane domains in 43 sporadic 
melanoma cases and 44 psoriasis patients as controls. They found that MC1R 
variants were significantly more common in cases than controls. 20/43 (46.5%) 
melanoma patients, but only 8/44 (18.2%) controls were carriers of variant 
alleles (P = 0.0094).
A recent report by Matichard et al. (2004) studying the French 
population, show MC1R variants to be present in 73/108 (67.6%) melanoma 
patients compared with 33/105 (31.4%) controls (p<0.0001), again confirming 
the association of MC1R variants with melanoma.
In contrast, this thesis shows that carrying an MC1R variant is high both 
in 25/28 (89.3%) sporadic melanoma patients and in 53/67 (79.1%) controls 
(NS). This could be because of the high frequency of the V60L variant in the 
Scottish population increasing the control frequency.
Matichard et al. (2004) found three frequent variants to be significantly 
associated with melanoma risk, V60L, R151C and R160W with the strongestrisk 
being for R151C (OR = 6.26). The V60L variant, which was weakly associated 
with melanoma risk in Australia (Palmer et al. 2000) and The Netherlands 
(Kennedy et al. 2001), was one of the most frequent variants to be associated 
with melanoma risk (OR = 3.99, Cl 2.03-7.82) in the French study. They did not 
find D84E, R142H, I155T or D294H to be associated with melanoma.
261
Likewise, the most frequently occurring variants in the sporadic 
melanoma patients in this thesis are R160W in 10/28 (35.7%) compared with 
14/67 (20.9%) controls, R151C in 7/28 (25%) compared with 12/67 (17.9%) 
controls and V60L in 6/28 (21.4%) compared with 19/67 (28.4%) controls. 
None of the differences are significant in this small data set.
Valverde et al. (1996) identified the D84E variant in 10/43 (23%) 
sporadic melanoma cases with two of these individuals being homozygous for 
this change, whereas no control subject showed this alteration.
Kennedy et al. (2001) investigated the relationship between MC1R gene 
variants and cutaneous melanoma in a cohort of 123 Dutch sporadic melanoma 
patients, using 385 opthalmology patients as control subjects. They found the 
D84E variant in 3/123 (2.4%) melanoma patients compared with 3/385 (0.8%) 
controls. They identified the D84E variant to be the most significantly 
associated variant with melanoma OR = 10.4; Cl 1.2-68.5 but the wide Cl does 
not allow definite conclusions to be drawn about the magnitude of risk of 
melanoma. They also showed that while carrying one variant allele was found to 
give an increased risk of melanoma, two variants doubled this risk.
In this thesis, only 3/28 (10.7%) sporadic melanoma cases carry the D84E 
variant, which was also identified in 1/67 (1.5%) control individual (P = 0.075; 
OR = 7.920; Cl 0.787-79.753).
Aspartate at codon 84 is highly conserved throughout the melanocortin 
receptor family and also other G protein coupled receptors making it a probable 
candidate as to play a direct causal role in melanoma A further possibility is that 
D84 could be in linkage disequilibrium with another variant outside the MC1R 
coding region.
Valverde et al. (1996) also identified the D294H variant in three sporadic 
melanoma cases but in none of their control population. In contrast, this thesis 
has found the D294H variant in four sporadic melanoma patients but also in three 
controls. These results are similar to those from France (Matichard et al. 2004) 
who were also unable to significantly associate the D294H variant with 
melanoma. Both Matichard’s data set o f 108 cases and 105 controls, and the 
numbers in this thesis are greater than that of the small Valverde study, giving 
increased statistical power.
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Both the work presented in this thesis and by others (Valverde et al. 
1996; Matichard et al. 2004) identify the V92M variant at a similar frequency in 
sporadic melanoma cases and also in the control group showing that there is no 
association with melanoma risk for the variant V92M.
10.3 Correlation between the Number of MC1R variants and Melanoma 
Status
In this study all variants were heterozygous, except for V60L which was 
detected in five homozygous familial melanoma patients and one control, V92M 
which was detected in one homozygous control, R151C which was detected in 
one homozygous familial melanoma patient, R160W which was detected in two 
homozygous familial melanoma patients and one sporadic patient and R163Q 
which was detected in three homozygous familial melanoma patients and one 
sporadic patient.
In a study of 123 patients with sporadic melanoma and 385 controls in 
The Netherlands, compound heterozygote and homozygote carriers of the V60L, 
V92M, R142H, R151C, R160W and R163Q variants had OR = 4 to develop 
melanoma, whereas heterozygotes for these variants had half the risk (Kennedy et 
al. 2001).
There is a significant relationship between both familial and sporadic 
melanoma and having two or more MC1R variants in this thesis, with 48/87 
(55.2%) cases carrying two or more variants compared with 21/67 (31.3%) 
controls (P = 0.003; OR 2.696; Cl 1.384-5.253). Kennedy et al. (2001) found 
that carriers of two variant alleles had a relative risk for melanoma of 4.8 (95% 
Cl 2.5-9.4) compared with carriers of two wild-type alleles, and carriers of one 
variant allele had again half the risk.
There is a very highly significant relationship between affected familial 
melanoma cases whether they are CDKN2A mutation positive or not, and having 
two or more MC1R variants with 37/59 (62.7%) cases with two or more variants 
compared with 21/67 (31.3%) controls (P = 0.001; OR 3.684; Cl 1.761-7.707).
There is no significant difference between unaffected family members of 
familial melanoma patients and controls and how many MC1R variants they 
carry.
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No significant difference between sporadic melanoma patients and controls and 
how many MC1R variants they carry was identified from this data set.
10.4 Correlation Between MC1R Variants and Phenotype
10.4.1 Correlation Between MC1R Variants and Skin Type
Mutation screening of a variety of control groups who do not have
melanoma has shown that MC1R variants are common among all skin types, 
although some are particularly associated with fair skin and melanoma, for 
example, R151C, R160W and D294H (Valverde et al. 1995; Smith et al. 1998; 
Flanagan et al. 2000; Healy et al. 2000; Palmer et al. 2000). Valverde et al. 
(1995) reported 76.5% of individuals with skin type 1 carried a variant MC1R 
allele, whereas no individuals with skin type 4 carried a variant. The frequencies 
were intermediate for individuals with skin types 2 (46.5%) and 3 (5%).
In 1997 Box et al. reported an association between the V60L variant of 
the MC1R gene and fair skin. They also showed that variants R151C, R160W 
and D294H were most significantly associated with fair skin.
In a study by Smith et al. (1998), 75% of an Irish population with a fair 
skin type carried an MC1R variant and 30% carried two variants.
Healy et al. (2000) investigated the number of variants carried in the
MC1R gene in individuals from the U.K and Ireland. Individuals with one
variant allele had an intermediate skin type 2 or 3, whereas individuals two 
variant alleles tended to have skin type 1 and those with no variants most often 
had a shin type 4.
Among the variants identified in the phenotyped controls in this thesis, 
the only one to show a significant finding is R160W (P = 0.007), which still 
remains significant after the Bonferroni correction. No other variant showed a 
significant correlation.
Kennedy et al. (2001) found that the D84E, R142H, R151C, R160W and 
D294H variants were strongly associated with fair skin whereas like this study, 
the V60L, V92M and R163Q variant alleles, were much weaker or not at all 
associated with fair skin type. Ichii-Jones et al. (1998) also show no difference 
of frequencies of the V92M, D294H, or D84E variants in controls with skin 
types 1, 2, 3 or 4, and therefore suggest that a polymorphism in MC1R does not 
appear to be a major determinant of skin type.
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10.4.2 Correlation Between MC1R Variants and Eye Colour
No significant relationship could be identified between eye colour and 
MC1R variants from the data in this thesis, confirming the lack of an association 
between eye colour and MC1R genotype reported by Palmer et al. (2000).
10.4.3 Correlation Between MC1R Variants and Hair Colour
No significant relationship could be identified between hair colour and 
MC1R variants in this thesis. Ichii-Jones et al. (1998) also showed no significant 
association between MC1R variants and hair colour, although the D84E variant 
was more common in subjects with blonde hair. Palmer et al. (2000) reported a 
strong relationship between MC1R variants and hair colour and Kennedy et al.
(2001) found that the D84E, R142H, R151C, R160W and D294H variants were 
strongly associated with red hair whereas the V60L, V92M and R163Q variant 
alleles, were much weaker or not at all associated with red hair.
10.5 Correlation between the MC1R Variants, Red Hair and Melanoma
10.5.1 Correlation between the MC1R Variants and Red Hair
Among the 67 controls tested for MC1R variants, two individuals are 
compound heterozygotes for variants R151C/R160W. Both individuals have red 
hair and a skin type that never tans and always bums. Among the 88 melanoma 
cases, 12 are compound heterozygotes carrying two postulated red hair variants; 
of these only four (R151C/R160W) have red hair. Two are homozygous for 
variants; one R151C and one R160W, both of whom have red hair. One 
currently unaffected family member is a compound heterozygote for postulated 
red hair variants (R151C/R160W) but does not have red hair.
In a study by Smith et al. (1998), they associated red hair with the 
R151C, R160W and D294H variants. All individuals carrying two of these 
variants had red hair, but some red-haired individuals carried only one of these 
variants. Transfection and binding studies have been carried out to establish the 
functional significance of the R151C, R160W and D294H MC1R variants 
(Schioth et al. 1999). The R151C, R160W and D294H variants caused reduced 
binding of the MC1R to MSH, which reduced cAMP production compared with 
the wildtype MC1R.
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The R151C, R160W, D294H, R142H, 86insA, and 537insC variants were 
found to be associated with red hair from a study involving 174 individuals from 
11 red hair pedigrees and 99 unrelated red haired individuals (Flanagan et al. 
2000). The V60L variant was associated with red hair but did not reach 
significance. Flanagan et al. (2000) also identified an overrepresentation of red 
hair together with R151C in the families studied.
Palmer et al. (2000) found three variants (R151C, R160W and D294H) to 
each give a 2.2-fold increased risk of melanoma (Cl 1.6-3.0) in a study 
comprising of 460 melanoma patients and 399 controls.
Duffy et al., 2004 concluded that the D84E, R151C, R160W and D294H 
variants are strong red hair colour alleles and the V60L, V92M and R163Q 
variants are relatively weak red hair colour alleles, although each of these alleles 
can occur with red hair. At least one of these three alleles R151C, R160W or 
D294H was found in 93% of individuals with red hair. They show that 
significant numbers of red-haired individuals are only seen in homozygous and 
heterozygous strong/weak red hair colour genotypes with 67.1 and 10.8%, 
respectively. They report the frequency of red hair in those with a heterozygous 
strong/other variant genotype is only 1.5%, and less than 1% in those with a 
homozygous weak red hair colour genotype or a heterozygous weak/other variant 
genotype, while no redhead was observed with a homozygous other variant or 
consensus genotype. The only allele that was not seen to be highly associated 
with red hair in their study was R142H, although neither this nor I155T were 
found in sufficient numbers in their sample to determine their effect on hair 
colour.
Among the 67 controls in this thesis, seven have red hair, one o f which 
failed on sequencing. O f the six sequenced red headed control subjects, four 
were found to be compound heterozygotes for at least one o f the postulated red 
hair variants (R142H, R151C, R160W). The D294H postulated red hair variant 
was not seen in any red haired control or melanoma patient.
In the sample of 27 red haired individuals in this thesis (seven controls, 
six sporadic melanoma patients, ten affected familial melanoma patients and four 
currently unaffected family members) a significant association of red hair with 
the common high-penetrance MC1R alleles (R142H, R151C, R160W, D294H) 
could not be demonstrated. However, there is a nearly significant association
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between carrying a so called red hair variant and having melanoma as 51/88 
(58%) patients carry one of these variants compared with 29/67 (43.3%) controls 
(P = 0.077; OR = 1.806; Cl 0.950-3.434).
10.5.2 Correlation between the MC1R Variants and Melanoma
There is a nearly significant correlation between carrying a red hair 
variant and having sporadic melanoma as 18/28 (64.3%) patients carry a red hair 
variant compared with 29/67 (43.3%) controls (P = 0.074; OR = 2.359; Cl 0.948- 
5.869). This significance could not be demonstrated in familial melanoma 
patients, but those patients with a CDKN2A mutation show a nearly significant 
association as 14/21 (66.7%) patients carry a red hair variant compared with 
29/67 (43.3%) controls (P = 0.081; OR = 2.621; Cl 0.937-7.326). This 
association could not be identified in those familial melanoma patients without a 
CDKN2A mutation.
In conclusion, the presence o f one or more MC1R variant appears to 
increase the risk of melanoma, although the mechanisms underlying this risk are 
unknown. To understand the significance MC1R variants have on melanoma 
risk, future studies will have to investigate the functional effects these variants 
have on the melanocyte and also investigate other genes involved in 
pigmentation. It is possible that in the future, if  routine melanoma susceptibility 
screening is introduced for selected subjects, that a combination of phenotypic 
characteristics and MC1R polymorphism information could be part of the 
evaluation.
While CDKN2A mutations to date appear to be associated with a 
proportion of familial melanoma cases, it may well be that MC1R variants, 
although a weaker predisposing factor than CDKN2A mutations, play a part in 
melanoma susceptibility in a very much higher number of melanoma patients 
both with the familial and sporadic forms of the disease.
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CHAPTER 11
DISCUSSION OF MUTATION 
SCREENING OF EXON 15 OF THE BRAF
GENE
268
11.1 Exon 15 BRAF Mutation Discussion
During the time of this study Davies et al. (2002) reported that the most 
frequently targeted gene in melanoma is BRAF. Davies found BRAF  gene 
mutations in 20/34 (59%) melanoma cell lines, 12/15 (80%) short-term cultures 
and 6/9 (67%) primary melanomas. All mutations were within the kinase 
domain, with a single substitution (V599E) accounting for 80% of mutations. 
BRAF  mutations in germline DNA from familial melanoma patients had not been 
investigated, and the number of melanoma tissue samples investigated for BRAF 
mutations was low. Only nine primary melanoma samples had been screened 
and no secondary melanoma samples were reported. One of the aims of this 
thesis therefore was to screen exon 15 of BRAF  to determine if the V599E 
mutation would contribute to melanoma predisposition in familial melanoma as a 
germline mutation. The study of this thesis also investigated primary and 
secondary melanomas for exon 15 BRAF  mutations.
11.2 V600E
In all publications on mutations in the BRAF  gene, the nucleotide and 
codon numbers have been based on the NCBI gene bank accession number 
NM 004333. However, according to NCBI gene bank sequence with accession 
number NT 007914, there is a discrepancy of one codon (three nucleotides) in 
exon 1 in the sequence with accession number NM 004333. The sequence 
analysis o f exon 1 of the BRAF  gene by Kumar et al. (2003) has shown that the 
sequence derived from NT_007914 is correct. Due to this the sequence 
numbering of mutation V599E should now be changed to V600E.
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11.3 Exon 15 BRAF Studies on Germline DNA from Patients with Familial 
Melanoma
DNA from the peripheral blood of 42 familial melanoma cases contained 
no exon 15 BRAF  mutations, in families with any number of affected family 
members and regardless of whether the families are CDKN2A mutation positive 
or CDKN2A mutation negative.
The DNA from the two samples of secondary melanoma from individuals 
F4.1 and F I0.1 with a family history of melanoma also failed to show exon 15 
BRAF  mutations.
Meyer et al. (2003) confirmed the work presented in this thesis as they 
found no V599E mutations in 172 melanoma patients comprising 46 familial 
cases, 21 multiple melanoma patients and 106 cases with at least one first-degree 
relative suffering from other cancers.
Laud et al. (2003) have now also screened the BRAF  gene for germline 
mutations in 80 patients either from melanoma families or from patients with 
multiple primary melanomas without a familial history to determine whether 
BRAF  mutations could be an earlier event occurring at the germline level. They 
identified 13 BRAF  variants, 4 of which were silent mutations in coding regions 
and 9 nucleotide substitutions in introns. Importantly none of the variants 
segregated with melanoma in the 11 melanoma families studied.
Most recently, Casula et al. (2004) investigated the contribution of BRAF  
to melanoma susceptibility in 569 melanoma patients from Italy by dHPLC and 
sequencing. Three BRAF  germline sequence variants (M l 16R in exon 3, V599E, 
and 2 x G608H, exon 15) were identified in 4/569 (0.7%) patients. The V599E 
mutation was detected in one germline DNA sample only. No BRAF  variant 
(either mutation or polymorphism) was found in individuals with CDKN2A 
mutations.
The results of this thesis and that of those described therefore suggest that 
exon 15 BRAF  mutations are not causative germline mutations in melanoma. 
The investigation in this thesis did not include a study of the entire BRAF  gene 
therefore mutations in the BRAF  gene cannot be ruled out in melanoma patients.
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11.4 Exon 15 BRAF Studies on Formalin Fixed and Paraffin Processed 
Tissue from Primary Melanomas from Patients with Sporadic Melanoma
A heterozygous T to A transition at nucleotide position 1796T>A was 
identified. This base change is predicted to lead to the substitution of a valine 
(V) for a glutamic acid (E) at codon 599 (V599E). The V599E substitution was 
detected in primary tumour DNA from 13/52 cases (25%). Five of the samples 
of primary melanoma which contained this BRAF  mutation were from DNA 
extracted from 17 SSM, three from 11 Nodular, two from 13 Acral, one from one 
Mucosal and two from ten LMM (Table 11.1).
TABLE 11.1
Mutation Positive Primary Tumours from Sporadic Melanoma Patients
Sample
Identifier
Age Sex Histology Body
Site
Thickness
(mm)
Exon 15 
Mutation
Brafl 53 M SSM Scalp 6.8 V599E
Braf2 70 M SSM Trunk 6.0 V599E
Braf3 58 M SSM Trunk 3.8 V599E
Braf4 48 M SSM Neck 5.7 V599E
Braf5 66 M SSM Back 3.5 V599E
Brafl 8 71 F Nodular Leg 10.0 V599E
Brafl 9 69 M Nodular Upper
Arm
6.0 V599E
Braf20 70 F Nodular Thigh 4.9 V599E
Braf29 72 M Acral Toe 3.5 V599E
Braf30 65 F Acral Leg 4.2 V599E
Braf42 72 M Mucosal Lip 7.5 V599E
Braf43 40 F LMM Face 1.0 V599E
Braf44 79 M LMM Foot 1.2 V599E
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11.5 Exon 15 BRAF Studies on Frozen Melanoma Tissue from Secondary 
Tumours from Patients with Sporadic Melanoma
The V599E substitution was detected in secondary tumour DNA from 
6/22 cases (27%) of secondary melanoma (Table 11.2). Four of the samples of 
secondary melanoma which contained this BRAF  mutation were from DNA 
extracted from metastatic deposits in lymph nodes, all from different individuals 
and 2 were from soft tissue metastatic nodules both from the same individual 
96037, taken approximately 9 months apart.
TABLE 11.2
Mutation Positive Secondary Melanoma Tumours from Sporadic Melanoma 
Patients
Sample
Identifier
Age Sex DNA
Source
Primary
Type
Histology
Body
Site
Thickness
(mm)
Exon 15 
Mutation
96037 50 F 2 x Soft 
Tissue
SSM Calf 4.3 V599E
97165 76 F Nodal Nodular Leg 7.0 V599E
96150 48 M Nodal Nodular Leg 1.0 V599E
96250 48 F Nodal Nodular Thigh 5.0 V599E
91065 68 F Nodal Nodular Leg 3.7 V599E
Laud et al. (2003) also detected T1796A mutations in 6/24 (25%) 
secondary melanoma samples from sporadic cases. This frequency of mutation 
detection in the BRAF  gene is similar to the observations in this thesis (27%).
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Table 11.3 indicates the number of primary melanomas studied to date and 
the proportion which contain a BRAF  mutation.
TABLE 11.3
Prim ary M elanomas Analysed for B R A F  M utations
P rim ary  M elanomas N um ber with B R A F Reference
Studied M utation
9 6 (67%) Davies et al. (2002)
5 4 (80%) Pollock et al. (2003)
10 2 (20%) Cruz et al. (2003)
28 7 (25%) Dong et al. (2003)
25 13 (52%) Uribe et al. (2003)
71 42 (59%) Omholt et al. (2003)
97 28 (29%) Yazdi et al. (2003)
15 8 (53%) Reifenberger et al.
(2004)
59 18 (30%) Shinozaki et al. (2004)
35 9 (26%) Sasaki et al. (2004)
354 137 (39%) TOTAL
52 13 (25%) Lang (this thesis)
Pollock et al. (2003) carried out mutation analysis on microdissected
melanoma. They reported the V599E mutation in 4/5 (80%) primary melanomas 
and 41/60 (68%) melanoma metastases.
Cruz et al. (2003) has examined exons 11 and 15 of the BRAF  gene for 
mutations in ten primary melanomas and 34 metastatic melanomas. Mutations in 
BRAF  exon 15 were detected in 2/10 (20%) primary melanomas and 14/34 
(41%) metastatic melanomas. The most common mutation identified was the 
V599E mutation, but a novel point mutation (L596Q) was identified in two cases 
and an in-frame deletion/insertion (VKSRWK599-604D) was discovered in one 
case. The presence o f exon 15 mutations is at a lower percentage than in this 
thesis for the primary melanomas but at a higher percentage for secondary 
melanomas.
Omholt et al. (2003) screened 71 primary melanomas and 88 
corresponding metastases from 71 patients for BRAF  exon 11 and exon 15 
mutations. They identified mutations in 42/71 patients (59%). Thirty-seven 
patients had the V599E mutation, and mutations resulting in G468S, V599R, 
V599K, and K600E changes were detected in one patient each. Furthermore, 
one patient had a 6-bp insertion between codons 598 and 599, encoding two
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threonine residues. In most cases, mutations present in the primary tumours were 
also found in the corresponding metastases, and mutations did not arise at the 
metastatic stage if they were not present in the primary lesion.
Reifenberger et al. (2004) investigated 37 sporadic malignant melanomas 
(15 primary cutaneous melanomas and 22 melanoma metastases) and six 
melanoma cell lines for mutations in the BRAF  gene. Eight (53%) primary 
melanomas, six (27%) melanoma metastases and four (67%) melanoma cell lines 
carried the V599E BRAF  mutation. This is a much higher percentage o f 
mutations in their primary melanomas compared with this thesis but the 
percentage of mutations in the sporadic melanomas is identical.
Shinozaki et al. (2004) assessed BRAF mutation frequency in exons 11 
and 15 in 59 primary and 68 metastatic melanomas. They found 18/59 (31%) 
primary melanomas to have a BRAF  mutation in exon 15 with a significantly 
higher frequency in patients < 60 years old (P = 0.001). The incidence of BRAF  
mutations did not correlate with Breslow thickness. The population o f tumours 
sampled for this thesis came from older patients than average for the Scottish 
patient database (MacKie et al., 2002), and represent a thick subset o f primary 
melanomas because of the need to obtain an adequate melanoma cell volume for 
DNA extraction from paraffin blocks.
11.6 Melanoma Subtypes
This thesis shows a prevalence of BRAF  mutations in 13/52 (25%) 
melanomas overall comprising of 5/17 (29%) Superficial Spreading Melanomas, 
3/11 (27%) Nodular Melanomas, 2/13 (15%) Acral Lentiginous Melanomas, 1/1 
(100%) Mucosal Melanoma and 2/10 (20%) Lentigo Maligna Melanomas.
Sasaki et al. (2004) searched for mutations o f BRAF  in 35 primary 
sporadic melanomas from 35 Japanese patients and detected the V599E BRAF  
point mutation in nine (26%), which is very similar to this thesis (25%). They 
found differences in mutation frequency among the four histological subtypes; 
4/8 (50%) Superficial Spreading Melanomas and 5/15 (33%) Acral Lentiginous 
Melanomas had the mutation, but none of six Nodular Melanomas, five Lentigo 
Maligna Melanomas, or one Mucosal Melanoma.
Further larger studies are required to further investigate the relationship 
between the V599E mutation in specific melanoma subtypes.
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11.7 B R A F  and UV Radiation
The T1796A mutation is not a common UV-induced base change. The 
V599E mutation is not a C-to-T or CC-to-TT mutation, which are usually 
associated with UV exposure. Mutational mechanisms other than UV induced 
damage must therefore be important for the aetiology of the mutation.
Maldonado et al. (2003) reported that BRAF  mutations were present in 
23/43 melanomas occurring on intermittent sun-exposed skin. BRAF  mutations 
in melanomas on chronically sun-damaged skin (1/12 patients) and melanomas 
on skin relatively unexposed to sun, such as palms, soles, subungual sites (6/39 
patients), and mucosal membranes (2/21 patients) were rare.
Edwards et al. (2004) determined the BRAF  mutation frequency in 13 
mucosal melanomas and compared their findings with the published data. None 
of the 13 mucosal melanomas carried an exon 15 BRAF  mutation, as compared 
to 54/165 (33%) primary cutaneous melanomas with BRAF  mutations in 
published reports. The absence of BRAF  mutations identified in mucosal sites 
suggests that the prevalence of BRAF  mutations in melanoma may vary 
depending upon the extent of sun exposure for the tissue of origin.
Cohen et al. (2004) tested 17 malignant mucosal melanomas o f the head 
and neck, 21 cutaneous melanomas, including 13 arising from sun-exposed sites 
and eight from vulvar skin, for the V599E mutation. They detected the mutation 
in one (6%) sinonasal melanoma, eight (62%) sun-exposed melanomas but in 
none of the vulvar melanomas. They concluded that in contrast to cutaneous 
melanomas arising in sun-exposed sites, mucosal melanomas of the head and 
neck do not frequently harbour the V599E BRAF  mutation.
The higher mutation frequency in melanomas arising on intermittently 
sun-exposed skin suggests a complex causative role of UV radiation requiring 
further investigation.
It could be that UV radiation causes a greater proliferative response in 
melanocytes with the V599E BRAF  mutation than in surrounding cells with wild- 
type BRAF , further promoting melanocytic tumour progression in sun-exposed 
sites.
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11.8 The Presence of BRAF Mutations in Benign Melanocytic Nevi
There are a very large number of melanocytic nevi in the general 
population compared with the relatively low incidence of melanoma. Pollock et 
al. (2003) therefore investigated exon 15 BRAF  mutations on microdissected 
melanoma and nevi samples to evaluate the timing of mutations in BRAF during 
melanocyte development. They found the V599E mutation in 41/60 (68%) 
melanoma metastases, 4/5 (80%) primary melanomas, and, unexpectedly, in 
63/77 (82%) nevi. Many of those nevi were of types not thought to be potential 
precursors to melanoma. The mutation was not present in normal melanocytes in 
eight cases for which adjacent normal skin to the nevi was available. This 
suggests that the V599E mutation occurs during the development of melanocytic 
nevi but is insufficient for progression to melanoma.
Dong et al. (2003) screened BRAF mutations in 65 melanocytic lesions 
and 25 melanoma cell lines. BRAF  mutations were identified in 17/24 (71%) 
benign melanocytic nevi, 5/8 (63%) vertical growth phase melanomas, 8/13 
(61%) metastatic melanomas and 18/25 (72%) melanoma cell lines. In contrast, 
they found BRAF  mutations in only 2/20 (10%) of early stage or radial growth 
phase melanomas.
Uribe et al. (2003) investigated the stage in which BRAF  mutations occur 
in the malignant transformation of melanocytes. They examined DNA extracted 
from microdissected formalin-fixed and paraffin-embedded tissues from 22 
benign melanocytic nevi, 23 atypical melanocytic nevi, and 25 primary 
cutaneous melanomas from 63 different patients for BRAF mutations. Sixteen 
benign nevi (73%), 11 atypical melanocytic nevi (48%), and 13 melanomas 
(52%) had the V599E mutation. No mutations were found in microdissected 
epidermal keratinocytes and melanocytes adjacent to melanocytic lesions having 
BRAF  mutations. No correlation was detected between BRAF mutational status 
and age, sun exposure, or Clark levels in malignant melanoma. Again these 
findings of a high frequency of BRAF  mutations in benign melanocytic lesions 
indicate that the V599E mutation is not sufficient by itself for malignant 
transformation.
Yazdi et al. (2003) screened primary melanomas, nevi and lesions where 
a melanoma developed in an underlying nevus. They detected the mutation in
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28/97 (29%) melanomas and in 39/187 (21%) nevi. Four of 14 of these 
melanomas developed in a nevus.
Loewe et al. (2004) analysed 49 melanocytic lesions, which were not 
considered melanoma at first examination, but showed growth or structural 
changes within 12 months. The V599E mutation was detected in 16/36 (11 
melanomas and five nevi) growing lesions and 4/13 (three melanomas and one 
nevus) lesions with structural changes. Statistics revealed odds for the presence 
of the V599E mutation being 13 times higher in growing nevi as compared with 
nevi without changes and seven times higher in nevi with structural changes.
These five studies all indicate that in some situations BRAF  mutations are 
found in stable benign melanocytic lesions and that BRAF  mutations are neither 
necessary nor sufficient for melanoma development.
11.9 Possible Function of the V599E Mutation
The V599E substitution is an activating mutation within the kinase 
domain. Mutated BRAF  proteins have elevated kinase activity. Wan et al. 
(2004) analyzed 22 BRAF  mutants and found that 18 had elevated kinase activity 
and signalled to ERK in vivo, whereas three mutants had reduced kinase activity 
towards MEK in vitro. Perhaps the V599E mutations could accelerate tumour 
growth.
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11.10 Loss of Heterozygosity in Tum our Cells
Loss o f heterozygosity (LOH) in tumour cells can reveal recessive 
mutations, which predispose to tumourgenesis. One allele is mutated and the 
other is lost by a large chromosomal deletion. LOH represents the second 
mutational hit in a particular cell. Allele loss in a tumour must be that o f the 
wild type allele therefore allowing the mutant allele to be dominant and cause the 
tumour. If the mutant allele was lost then there would be no tumour. LOH or 
perhaps homozygosity for the mutation occurred in one secondary melanoma in 
this study (Figure 11.1).
FIGURE 11.1
Possible LOH in Melanoma Tum our Tissue
Sequence analysis o f  PCR amplified somatic DNA from a secondary melanoma tumour sample 
96037. Tumour DNA that has lost one allele, the wild type allele, will amplify only the 
remaining allele, the mutant allele.
dHPLC was used as a second screen in the analysis o f the primary 
melanoma tissues. If there was a single mutant allele (i.e. wild type loss) no 
heteroduplex would be formed and the chromatogram profile would be identical 
to the wild type profile. Therefore, a mutation could have been missed and 
mistaken for being wild type. However, all the samples presented in this thesis 
were sequenced prior to dHPLC and therefore any mutant cells present would 
have been identified. The only reason a mutation would not have been identified 
would have been if  the proportion o f wild type cells greatly outnumbered the 
number o f mutant cells in the tumour sample. There probably were a small 
number o f normal cells in the tissue sample allowing for a mixture o f wild type 
and mutant cells, therefore allowing heteroduplex formation to occur in dHPLC. 
Any mutation would then have been identified with dHPLC even if there had 
been loss o f the normal allele.
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CHAPTER 12
SYNTHESIS AND CONCLUSIONS
I
[
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Prevention and possibly treatment of all cancers depends on a clear 
understanding o f their aetiology. In the majority of solid tumours in adults, this 
appears to involve complex interactions between environmental agents and 
individual susceptibility governed by genetic factors. This appears to be true, 
even in tumours such as lung cancer where although there is a very strong case 
for tobacco as the environmental carcinogen, there are individual variations in 
the response to excessive exposure. These individual variations are likely to be 
under genetic control.
In the case o f cutaneous melanoma, the environmental agent most 
strongly incriminated is excessive exposure to ultraviolet radiation, mainly in 
natural sunlight. However this association is complex, as short episodes of 
intense UV overexposure appear to be more damaging than lower level long­
term exposure. In addition, Armstrong et al. (1997) has calculated that in up to 
one third o f all cutaneous melanoma cases worldwide, the evidence for 
ultraviolet exposure being a major aetiological agent is lacking. This clearly 
suggests either a second environmental agent, or genetic factors. No second 
environmental agent has yet been incriminated, and attention has therefore 
moved to genetic factors.
In other tumour types such as colon cancer, study of familial cases has 
helped identify genes involved in their development and then led to study of the 
role of these genes in the more common sporadic cases. 2-5% of all melanoma 
cases have a positive family history, and the gene identified to date, which 
appears mutated in 25-30% of familial cases, is the CDKN2A gene. However, 
extensive studies on large numbers of sporadic cases of melanoma have so far 
failed to identify CDKN2A mutations in the great majority o f cases.
Studies o f MC1R polymorphisms in sporadic melanoma cases appear 
more promising in identifying a possible genetic variant affecting the likelihood 
o f melanoma development in the majority of cases. In addition, the known 
function o f the M SH  gene in determining pigment response to ultraviolet 
radiation provides an attractive link between environmental and individual 
genetic aetiological factors. Two previous studies (van der Velden et al. 2001; 
Box et al. 2001) and the work described in this thesis suggest a possible 
interaction between some CDKN2A mutations and MC1R polymorphisms in
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familial melanoma, but it is not clear whether or not this has any relevance to the 
larger body of sporadic cases.
The normal function of the BRAF  gene suggests that mutations are highly 
likely to increase cancer risk, and BRAF  mutations have been reported in a 
variety o f malignancies to date. The first report of BRAF  mutations in sporadic 
melanoma cases suggested that the major melanoma susceptibility gene had been 
identified, but subsequent studies on larger numbers of melanoma cases and also 
on benign melanocytic lesions indicate that the situation is more complex, and 
that a BRAF  mutation is neither necessary nor sufficient for melanoma 
development. Despite this, studies are currently in progress evaluating Raf 
kinase inhibitors such as BAY 43-9006 in the management o f melanoma. Early 
results suggest minimal activity as a single agent but better responses when used 
in combination with chemotherapy.
The aim of many working in melanoma genetics worldwide is to show a 
pathway to melanoma development linking the currently known abnormalities in 
CDKN2A, MC1R, BRAF  and other genes including the DNA repair family. To 
date neither the work in this thesis nor in o f any other laboratory worldwide has 
achieved this, but it remains a very worthwhile objective.
There clearly still remains much to learn about familial melanoma as 
genetic analysis o f these families shows germline mutations o f CDKN2A in 20- 
30% of patients. Therefore, in at least 70% of familial melanoma cases a 
pathological mutation still needs to be identified. Familial melanoma cases, 
although rare in comparison to sporadic melanoma cases, provide an opportunity 
to study the aetiology of melanoma, and may therefore help in devising new 
strategies for the early detection and effective treatment. They will also allow us 
to isolate other genes thought to be involved in the development o f melanoma, 
both of the familial and sporadic form.
Future research will require the use o f new high-throughput technologies, 
such as dHPLC as used in this thesis, to enable rapid large-scale screening of 
newly identified genes.
In conclusion, due to the relatively small numbers of familial melanoma 
families worldwide, international collaboration is necessary to pool data sets 
together that perhaps individually would not reach any statistical significance. 
For example, a collaborative approach is required to obtain the sample numbers
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required to achieve statistical power for linkage to a common disease region and 
localisation of new candidate genes. This is the primary aim of the International 
Melanoma Genetics Consortium, Genomel.
282
References
Aitken, J., Welch, J., Duffy, D., Milligan, A., Green, A., Martin, N., & Hayward, 
N. 1999, "CDKN2A variants in a population-based sample of Queensland 
families with melanoma", J.Natl. Cancer Inst., vol. 91, no. 5, pp. 446-452.
Anderson, D. E., Smith, J. L., Jr., & McBride, C. M. 1967, "Hereditary aspects of 
malignant melanoma", JAMA , vol. 200, no. 9, pp. 741-746.
Anderson, D. E. 1971, "Clinical characteristics of the genetic variety of 
cutaneous melanoma in man", Cancer, vol. 28, no. 3, pp. 721-725.
Andrews, J. C. 1968, "Malignant melanoma in siblings", Arch.Dermatol., vol. 
98, no. 3, pp. 282-283.
Arcellana-Panlilio, M. Y., Egeler, R. M., Ujack, E., Magliocco, A., Stuart, G. C., 
Robbins, S. M., & Coppes, M. J. 2002, "Evidence of a role for the INK4 family 
of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors", Genes 
Chromosomes.Cancer, vol. 35, no. 2, pp. 176-181.
Armstrong, B. K., Kricker, A., & English, D. R. 1997, "Sun exposure and skin 
cancer. ", Australas.J.Dermatol., vol. 38, Suppl 1 :S 1-6.
Bale, S. J., Dracopoli, N. C., Tucker, M. A., Clark, W. H., Jr., Fraser, M. C., 
Stanger, B. Z., Green, P., Donis-Keller, H., Housman, D. E., & Greene, M. H. 
1989, "Mapping the gene for hereditary cutaneous malignant melanoma- 
dysplastic nevus to chromosome lp", N.Engl.J.Med., vol. 320, no. 21, pp. 1367- 
1372.
Bartsch, D. K., Sina-Frey, M., Lang, S., Wild, A., Gerdes, B., Barth, P., Kress, 
R., Grutzmann, R., Colombo-Benkmann, M., Ziegler, A., Hahn, S. A., 
Rothmund, M., & Rieder, H. 2002, "CDKN2A germline mutations in familial 
pancreatic cancer", Ann.Surg., vol. 236, no. 6, pp. 730-737.
Becher, R., Gibas, Z., & Sandberg, A. A. 1983, "Chromosome 6 in malignant 
melanoma", Cancer Genet. Cytogenet., vol. 9, no. 2, pp. 173-175.
Becker, T. M., Rizos, H., Kefford, R. F., & Mann, G. J. 2001, "Functional 
impairment of melanoma-associated pl6(INK4a) mutants in melanoma cells 
despite retention o f cyclin-dependent kinase 4 binding", Clin. Cancer Res., vol. 7, 
no. 10, pp. 3282-3288.
Bergman, W., Palan, A., & Went, L. N. 1986, "Clinical and genetic studies in six 
Dutch kindreds with the dysplastic naevus syndrome", Ann.Hum.Genet., vol. 50 ( 
Pt 3), pp. 249-258.
Bergman, W., Gruis, N. A., Sandkuijl, L. A., & Frants, R. R. 1994, "Genetics of 
seven Dutch familial atypical multiple mole-melanoma syndrome families: a 
review of linkage results including chromosomes 1 and 9", J.Invest Dermatol., 
vol. 103, no. 5 Suppl, pp. 122S-125S.
283
Bergman, W. & Gruis, N. 1996, "Familial melanoma and pancreatic cancer", 
N.Engl.J.Med., vol. 334, no. 7, pp. 471-472.
Bertram, C. G., Gaut, R. M., Barrett, J. H., Pinney, E., Whitaker, L., Turner, F., 
Bataille, V., Dos, S. S., I, Swerdlow, J., Bishop, D. T., & Newton Bishop, J. A. 
2002, "An assessment of the CDKN2A variant Alal48Thr as a nevus/melanoma 
susceptibility allele", J.Invest Dermatol, vol. 119, no. 4, pp. 961-965.
Bishop, D. T., Demenais, F., Goldstein, A. M., Bergman, W., Bishop, J. N., 
Bressac-de Paillerets, B., Chompret, A., Ghiorzo, P., Gruis, N., Hansson, J., 
Harland, M., Hayward, N., Holland, E. A., Mann, G. J., Mantelli, M., 
Nancarrow, D., Platz, A., & Tucker, M. A. 2002, "Geographical variation in the 
penetrance of CDKN2A mutations for melanoma", J.Natl.Cancer Inst., vol. 94, 
no. 12, pp. 894-903.
Blackwood, M. A., Holmes, R., Synnestvedt, M., Young, M., George, C., Yang, 
H., Elder, D. E., Schuchter, L. M., Guerry, D., & Ganguly, A. 2002, "Multiple 
primary melanoma revisited", Cancer, vol. 94, no. 8, pp. 2248-2255.
Borg, A., Johannsson, U., Johannsson, O., Hakansson, S., Westerdahl, J., 
Masback, A., Olsson, H., & Ingvar, C. 1996, "Novel germline p l6  mutation in 
familial malignant melanoma in southern Sweden", Cancer Res., vol. 56, no. 11, 
pp. 2497-2500.
Borg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., 
Westerdahl, J., Olsson, H., & Ingvar, C. 2000, "High frequency of multiple 
melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive 
melanoma families", J.Natl.Cancer Inst., vol. 92, no. 15, pp. 1260-1266.
Box, N. F., Wyeth, J. R., O'Gorman, L. E., Martin, N. G., & Sturm, R. A. 1997, 
"Characterization of melanocyte stimulating hormone receptor variant alleles in 
twins with red hair", Hum.Mol.Genet., vol. 6, no. 11, pp. 1891-1897.
Box, N. F., Duffy, D. L., Chen, W., Stark, M., Martin, N. G., Sturm, R. A., & 
Hayward, N. K. 2001, "MC1R genotype modifies risk of melanoma in families 
segregating CDKN2A mutations", Am.J.Hum.Genet., vol. 69, no. 4, pp. 765-773.
Breslow, A. 1970, "Thickness, cross-sectional areas and depth of invasion in the 
prognosis of cutaneous melanoma", Ann.Surg., vol. 172, no. 5, pp. 902-908.
Burchill, S. A., Ito, S., & Thody, A. J. 1993, “Effects of melanocyte-stimulating 
hormone on tyrosinase expression and melanin synthesis in hair follicular 
melanocytes of the mouse”, J.Endocrinol., vol. 137, no. 2, pp. 189-195.
Burden, A. D., Newell, J., Andrew, N., Kavanagh, G., Connor, J. M., & MacKie, 
R. M. 1999, "Genetic and environmental influences in the development of 
multiple primary melanoma", Arch.Dermatol., vol. 135, no. 3, pp. 261-265.
284
Byeon, I. J., Li, J., Ericson, K., Selby, T. L., Tevelev, A., Kim, H. J., O'Maille, 
P., & Tsai, M. D. 1998, "Tumor suppressor pl6INK4A: determination of 
solution structure and analyses of its interaction with cyclin-dependent kinase 4", 
Mol.Cell, vol. 1, no. 3, pp. 421-431.
Casula, M., Colombino, M., Satta, M. P., Cossu, A., Ascierto, P. A., Bianchi- 
Scarra, G., Castiglia, D., Budroni, M., Rozzo, C., Manca, A., Lissia, A., Carboni, 
A., Petretto, E., Satriano, S. M., Botti, G., Mantelli, M., Ghiorzo, P., Stratton, M. 
R., Tanda, F., & Palmieri, G. 2004, "BRAF gene is somatically mutated but does 
not make a major contribution to malignant melanoma susceptibility: the Italian 
Melanoma Intergroup Study", J.Clin.Oncol., vol. 22, no. 2, pp. 286-292.
Cawley, E. P., Kruse, W. T., & Pinkus, H. K. 1952, "Genetic aspects of 
malignant melanoma", AMA.Arch.Derm.Syphilol., vol. 65, no. 4, pp. 440-450.
Chhajlani, V. & Wikberg, J. E. 1992, "Molecular cloning and expression of the 
human melanocyte stimulating hormone receptor cDNA", FEBS Lett., vol. 309, 
no. 3, pp. 417-420.
Ciotti, P., Strigini, P., & Bianchi-Scarra, G. 1996, "Familial melanoma and 
pancreatic cancer. Ligurian Skin Tumor Study Group", N.Engl.J.Med., vol. 334, 
no. 7, pp. 469-470.
Ciotti, P., Struewing, J. P., Mantelli, M., Chompret, A., Avril, M. F., Santi, P. L., 
Tucker, M. A., Bianchi-Scarra, G., Bressac-de Paillerets, B., & Goldstein, A. M. 
2000, "A single genetic origin for the G101W CDKN2A mutation in 20 
melanoma-prone families", Am.J.Hum.Genet., vol. 67, no. 2, pp. 311-319.
Clark, W. H., Jr., From, L., Bernardino, E. A., & Mihm, M. C. 1969, "The 
histogenesis and biologic behavior of primary human malignant melanomas of 
the skin", Cancer Res., vol. 29, no. 3, pp. 705-727.
Clark, W. H., Jr., Reimer, R. R., Greene, M., Ainsworth, A. M., & Mastrangelo, 
M. J. 1978, "Origin of familial malignant melanomas from heritable melanocytic 
lesions. ’The B-K mole syndrome'", Arch.Dermatol., vol. 114, no. 5, pp. 732- 
738.
Cohen, Y., Rosenbaum, E., Begum, S., Goldenberg, D., Esche, C., Lavie, O., 
Sidransky, D., & Westra, W. H. 2004, "Exon 15 BRAF mutations are uncommon 
in melanomas arising in nonsun-exposed sites", Clin.Cancer Res., vol. 10, no. 
10, pp. 3444-3447.
Cruz, F., Ill, Rubin, B. P., Wilson, D., Town, A., Schroeder, A., Haley, A., 
Bainbridge, T., Heinrich, M. C., & Corless, C. L. 2003, "Absence of BRAF and 
NRAS mutations in uveal melanoma", Cancer Res., vol. 63, no. 18, pp. 5761- 
5766.
285
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, 
J., Woffendin, H., Gamett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, 
R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, 
A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., 
Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard- 
Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., 
Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., 
Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., 
Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A. 2002, "Mutations 
of the BRAF gene in human cancer", Nature, vol. 417, no. 6892, pp. 949-954.
Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z., & Aaronson, S. 
A. 2003, "BRAF oncogenic mutations correlate with progression rather than 
initiation of human melanoma", Cancer Res., vol. 63, no. 14, pp. 3883-3885.
Dracopoli, N. C., Harnett, P., Bale, S. J., Stanger, B. Z., Tucker, M. A., 
Housman, D. E., & Kefford, R. F. 1989, "Loss o f alleles from the distal short 
arm of chromosome 1 occurs late in melanoma tumor progression", 
Proc.Natl.Acad.Sci.U.S.A, vol. 86, no. 12, pp. 4614-4618.
Duffy, D. L., Box, N. F., Chen, W., Palmer, J. S., Montgomery, G. W., James, 
M. R., Hayward, N. K., Martin, N. G., & Sturm, R. A. 2004, "Interactive effects 
of MC1R and OCA2 on melanoma risk phenotypes", Hum.Mol.Genet., vol. 13, 
no. 4, pp. 447-461.
Dwyer, T., Stankovich, J. M., Blizzard, L., FitzGerald, L. M., Dickinson, J. L., 
Reilly, A., Williamson, J., Ashbolt, R., Berwick, M., & Sale, M. M. 2004, "Does 
the addition o f information on genotype improve prediction of the risk of 
melanoma and nonmelanoma skin cancer beyond that obtained from skin 
phenotypqT \  Am.J.Epidemiol, vol. 159, no. 9, pp. 826-833.
Edwards, R. H., Ward, M. R., Wu, H., Medina, C. A., Brose, M. S., Volpe, P., 
Nussen-Lee, S., Haupt, H. M., Martin, A. M., Herlyn, M., Lessin, S. R., & 
Weber, B. L. 2004, "Absence of BRAF mutations in UV-protected mucosal 
melanomas", J.Med.Genet., vol. 41, no. 4, pp. 270-272.
Elwood, J. M. & Jopson, J. 1997, "Melanoma and sun exposure: an overview of 
published studies", Int.J.Cancer, vol. 73, no. 2, pp. 198-203.
Eychene, A., Bamier, J. V., Apiou, F., Dutrillaux, B., & Calothy, G. 1992, 
"Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- 
raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene", 
Oncogene, vol. 7, no. 8, pp. 1657-1660.
FitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, 
L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., 
Sober, A. J., & Haber, D. A. 1996, "Prevalence of germ-line mutations in p i 6, 
pl9ARF, and CDK4 in familial melanoma: analysis o f a clinic-based 
population", Proc.Natl.Acad.Sci.U.S.A, vol. 93, no. 16, pp. 8541-8545.
286
Fitzpatrick, T. B. 1988, "The validity and practicality of sun-reactive skin types I 
through VI", Arch.Dermatol, vol. 124, no. 6, pp. 869-871.
Flanagan, N., Healy, E., Ray, A., Philips, S., Todd, C., Jackson, I. J., Birch- 
Machin, M. A., & Rees, J. L. 2000, "Pleiotropic effects of the melanocortin 1 
receptor (MC1R) gene on human pigmentation", Hum.Mol.Genet., vol. 9, no. 17, 
pp. 2531-2537.
Flores, J. F., Pollock, P. M., Walker, G. J., Glendening, J. M., Lin, A. H., Palmer, 
J. M., Walters, M. K., Hayward, N. K., & Fountain, J. W. 1997, "Analysis of the 
CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds", 
Oncogene, vol. 15, no. 24, pp. 2999-3005.
Foulkes, W. D., Flanders, T. Y., Pollock, P. M., & Hayward, N. K. 1997, "The 
CDKN2A (p i6) gene and human cancer", Mol.Med., vol. 3, no. 1, pp. 5-20.
Fung, D. C., Holland, E. A., Becker, T. M., Hayward, N. K., Bressac-de 
Paillerets, B., & Mann, G. J. 2003, "eMelanoBase: an online locus-specific 
variant database for familial melanoma", Hum.Mutat., vol. 21, no. 1, pp. 2-7.
Gantz, I., Yamada, T., Tashiro, T., Konda, Y., Shimoto, Y., Miwa, H., & Trent, 
J. M. 1994, "Mapping of the gene encoding the melanocortin-1 (alpha- 
melanocyte stimulating hormone) receptor (MC1R) to human chromosome 
16q24.3 by Fluorescence in situ hybridization", Genomics, vol. 19, no. 2, pp. 
394-395.
Ghiorzo, P., Ciotti, P., Mantelli, M., Heouaine, A., Queirolo, P., Rainero, M. L., 
Ferrari, C., Santi, P. L., De Marchi, R., Farris, A., Ajmar, F., Bruzzi, P., & 
Bianchi-Scarra, G. 1999, "Characterization of ligurian melanoma families and 
risk of occurrence of other neoplasia", Int.J.Cancer, vol. 83, no. 4, pp. 441-448.
Ghiorzo, P., Pastorino, L., Bonelli, L., Cusano, R., Nicora, A., Zupo, S., 
Queirolo, P., Sertoli, M., Pugliese, V., & Bianchi-Scarra, G. 2004, 'TNK4/ARF 
germline alterations in pancreatic cancer patients", Ann.Oncol., vol. 15, no. 1, pp. 
70-78.
Gilchrest, B. A., Eller, M. S., Geller, A. C., & Yaar, M. 1999, "The pathogenesis 
of melanoma induced by ultraviolet radiation", N.Engl. J.Med., vol. 340, no. 17, 
p p .1341-1348.
Gillanders, E., Juo, S. H., Holland, E. A., Jones, M., Nancarrow, D., Freas-Lutz, 
D., Sood, R., Park, N., Faruque, M., Markey, C., Kefford, R. F., Palmer, J., 
Bergman, W., Bishop, D. T., Tucker, M. A., Bressac-de Paillerets, B., Hansson, 
J., Stark, M., Gruis, N., Bishop, J. N., Goldstein, A. M., Bailey-Wilson, J. E., 
Mann, G. J., Hayward, N., & Trent, J. 2003, "Localization of a novel melanoma 
susceptibility locus to lp22", Am.J.Hum.Genet., vol. 73, no. 2, pp. 301-313.
287
Goggins, W., Gao, W., & Tsao, H. 2004, "Association between female breast 
cancer and cutaneous melanoma", IntJ.Cancer, vol. 111, no. 5, pp. 792-794.
Goldstein, A. M., Dracopoli, N. C., Ho, E. C., Fraser, M. C., Kearns, K. S., Bale, 
S. J., McBride, O. W., Clark, W. H., Jr., & Tucker, M. A. 1993, "Further 
evidence for a locus for cutaneous malignant melanoma-dysplastic nevus 
(CMM/DN) on chromosome lp, and evidence for genetic heterogeneity", 
Am.J.Hum.Genet., vol. 52, no. 3, pp. 537-550.
Goldstein, A. M., Fraser, M. C., Struewing, J. P., Hussussian, C. J., Ranade, K., 
Zametkin, D. P., Fontaine, L. S., Organic, S. M., Dracopoli, N. C., & Clark, W. 
H., Jr. 1995, "Increased risk of pancreatic cancer in melanoma-prone kindreds 
with pl6INK4 mutations", N.Engl.J.Med., vol. 333, no. 15, pp. 970-974.
Goldstein, A. M., Liu, L., Shennan, M. G., Hogg, D., Tucker, M. A., & 
Struewing, J. P. 2001, "A common founder for the V126D CDKN2A mutation in 
seven North American melanoma-prone families", Br.J.Cancer, vol. 85, no. 4, 
pp. 527-530.
Goldstein, A. M. 2004, "Familial melanoma, pancreatic cancer and germline 
CDKN2A mutations", Hum.Mutat., vol. 23, no. 6, p. 630.
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver- 
Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. 1995, "Homozygotes for 
CDKN2 (p i6) germline mutation in Dutch familial melanoma kindreds", 
Nat.Genet., vol. 10, no. 3, pp. 351-353.
Hansen, C. B., Wadge, L. M., Lowstuter, K., Boucher, K., & Leachman, S. A. 
2004, "Clinical germline genetic testing for melanoma", Lancet Oncol., vol. 5, 
no. 5, pp. 314-319.
Harding, R. M., Healy, E., Ray, A. J., Ellis, N. S., Flanagan, N., Todd, C., Dixon,
C., Sajantila, A., Jackson, I. J., Birch-Machin, M. A., & Rees, J. L. 2000, 
"Evidence for variable selective pressures at MC1R", Am.J.Hum.Genet., vol. 66, 
no. 4, pp. 1351-1361.
Harland, M., Meloni, R., Gruis, N., Pinney, E., Brookes, S., Spurr, N. K., 
Frischauf, A. M., Bataille, V., Peters, G., Cuzick, J., Selby, P., Bishop, D. T., & 
Bishop, J. N. 1997, "Germline mutations of the CDKN2 gene in UK melanoma 
families", Hum.Mol.Genet., vol. 6, no. 12, pp. 2061-2067.
Harland, M., Holland, E. A., Ghiorzo, P., Mantelli, M., Bianchi-Scarra, G., 
Goldstein, A. M., Tucker, M. A., Ponder, B. A., Mann, G. J., Bishop, D. T., & 
Newton, B. J. 2000, "Mutation screening of the CDKN2A promoter in melanoma 
families", Genes Chromosomes. Cancer, vol. 28, no. 1, pp. 45-57.
Harland, M., Mistry, S., Bishop, D. T., & Bishop, J. A. 2001, "A deep intronic 
mutation in CDKN2A is associated with disease in a subset o f melanoma 
pedigrees", Hum.Mol.Genet., vol. 10, no. 23, pp. 2679-2686.
288
Hashemi, J., Platz, A., Ueno, T., Stiemer, U., Ringborg, U., & Hansson, J. 2000, 
"CDKN2A germ-line mutations in individuals with multiple cutaneous 
melanomas", Cancer Res., vol. 60, no. 24, pp. 6864-6867.
Hashemi, J., Bendahl, P. O., Sandberg, T., Platz, A., Linder, S., Stiemer, U., 
Olsson, H., Ingvar, C., Hansson, J., & Borg, A. 2001, "Haplotype analysis and 
age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma 
families", Genes Chromosomes. Cancer, vol. 31, no. 2, pp. 107-116.
Hayward, N. K. 1996, "The current situation with regard to human melanoma 
and genetic inferences", Curr.Opin.Oncol., vol. 8, no. 2, pp. 136-142.
Hayward, N. 2000, "New developments in melanoma genetics", 
Curr.Oncol.Rep., vol. 2, no. 4, pp. 300-306.
Hayward, N. K. 2003, "Genetics of melanoma predisposition", Oncogene, vol. 
22, no. 20, pp. 3053-3062.
Healy, E., Flannagan, N., Ray, A., Todd, C., Jackson, I. J., Matthews, J. N., 
Birch-Machin, M. A., & Rees, J. L. 2000, "Melanocortin-1-receptor gene and 
sun sensitivity in individuals without red hair", Lancet, vol. 355, no. 9209, pp. 
1072-1073.
Hearle, N., Humphreys, J., Damato, B. E., Wort, R., Talaban, R., Wixey, J., 
Green, H., Easton, D. F., & Houlston, R. S. 2003, "Role of MC1R variants in 
uveal melanoma", BrJ. Cancer, vol. 89, no. 10, pp. 1961-1965.
Hecht, F. 1989, "The annals of cancer genetics. The description by Norris of 
hereditary malignant melanoma of the skin in 1820", Cancer Genet. Cytogenet., 
vol. 42, no. 1, pp. 153-156.
Hewitt, C., Lee, W. C., Evans, G., Howell, A., Elies, R. G., Jordan, R., Sloan, P., 
Read, A. P., & Thakker, N. 2002, "Germline mutation of ARF in a melanoma 
kindred", Hum.Mol.Genet., vol. 11, no. 11, pp. 1273-1279.
Holland, E. A., Beaton, S. C., Becker, T. M., Gmlet, O. M., Peters, B. A., Rizos, 
H., Kefford, R. F., & Mann, G. J. 1995, "Analysis of the p l6  gene, CDKN2, in 
17 Australian melanoma kindreds", Oncogene, vol. 11, no. 11, pp. 2289-2294.
Holland, E. A., Schmid, H., Kefford, R. F , & Mann, G. J. 1999, "CDKN2A 
(P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma 
probands: effect of family history and multiple primary melanomas", Genes 
Chromosomes. Cancer, vol. 25, no. 4, pp. 339-348.
Hunt, G., & Thody, A. J., 1995, “Agouti protein can act independently of 
melanocyte-stimulating hormone to inhibit melanogenesis”, J.Endocrinol., vol. 
147, no. 2, pp. 1-4.
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., 
Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., & Dracopoli, N. C. 1994, 
"Germline p i 6 mutations in familial melanoma", Nat.Genet., vol. 8, no. 1, pp. 
15-21.
289
Ichii-Jones, F., Lear, J. T., Heagerty, A. H., Smith, A. G., Hutchinson, P. E., 
Osbome, J., Bowers, B., Jones, P. W., Davies, E., Oilier, W. E., Thomson, W., 
Yengi, L., Bath, J., Fryer, A. A., & Strange, R. C. 1998, "Susceptibility to 
melanoma: influence of skin type and polymorphism in the melanocyte 
stimulating hormone receptor gene", J.Invest Dermatol., vol. 111, no. 2, pp. 218- 
221 .
Jemal, A., Devesa, S. S., Hartge, P., & Tucker, M. A. 2001, "Recent trends in 
cutaneous melanoma incidence among whites in the United States", 
J.Natl. Cancer Inst., vol. 93, no. 9, pp. 678-683.
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard. 1991, “Improved methods 
for building protein models in electron density maps and the location of errors in 
these models”, Acta.Crystallogr.A., vol. 1, no. 47, pp. 110-119.
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, 
S. V., Stockert, E., Day, R. S., Ill, Johnson, B. E., & Skolnick, M. H. 1994, "A 
cell cycle regulator potentially involved in genesis of many tumor types", 
Science, vol. 264, no. 5157, pp. 436-440.
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., 
Hussey, C., Tran, T., Miki, Y., & Weaver-Feldhaus, J. 1994, "Analysis o f the 
p l6  gene (CDKN2) as a candidate for the chromosome 9p melanoma 
susceptibility locus", Nat.Genet., vol. 8, no. 1, pp. 23-26.
Kefford, R. F., Salmon, J., Shaw, H. M., Donald, J. A., & McCarthy, W. H. 
1991, "Hereditary melanoma in Australia. Variable association with dysplastic 
nevi and absence of genetic linkage to chromosome lp", Cancer 
Genet.Cytogenet., vol. 51, no. 1, pp. 45-55.
Kefford, R. F., Newton Bishop, J. A., Bergman, W., & Tucker, M. A. 1999, 
"Counseling and DNA testing for individuals perceived to be genetically 
predisposed to melanoma: A consensus statement of the Melanoma Genetics 
Consortium", J.Clin.Oncol., vol. 17, no. 10, pp. 3245-3251.
Kennedy, C., ter Huume, J., Berkhout, M., Gruis, N., Bastiaens, M., Bergman, 
W., Willemze, R., & Bavinck, J. N. 2001, "Melanocortin 1 receptor (MC1R) 
gene variants are associated with an increased risk for cutaneous melanoma 
which is largely independent of skin type and hair color", J.Invest Dermatol., 
vol. 117, no. 2, pp. 294-300.
Komiya, A., Suzuki, H., Aida, S., Yatani, R., & Shimazaki, J. 1995, "Mutational 
analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human 
prostate cancer", Jpn.J. Cancer Res., vol. 86, no. 7, pp. 622-625.
Kudoh, K., Ichikawa, Y., Yoshida, S., Hirai, M., Kikuchi, Y., Nagata, I., Miwa, 
M., & Uchida, K. 2002, "Inactivation of pl6/CDKN2 and pl5/M TS2 is 
associated with prognosis and response to chemotherapy in ovarian cancer", 
Int.J.Cancer, vol. 99, no. 4, pp. 579-582.
290
Kumar, R., Smeds, J., Berggren, P., Straume, O., Rozell, B. L., Akslen, L. A., & 
Hemminki, K. 2001, "A single nucleotide polymorphism in the 3'untranslated 
region of the CDKN2A gene is common in sporadic primary melanomas but 
mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare", 
Int.J.Cancer, vol. 95, no. 6, pp. 388-393.
Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka-Kemppinen, M., 
Pyrhonen, S., & Hemminki, K. 2003, "BRAF mutations in metastatic melanoma: 
a possible association with clinical outcome", Clin.Cancer Res., vol. 9, no. 9, pp. 
3362-3368.
Lang, J., Boxer, M., & MacKie, R. 2003, "Absence of exon 15 BRAF germline 
mutations in familial melanoma", Hum.Mutat., vol. 21, no. 3, pp. 327-330.
Laud, K., Kannengiesser, C., Avril, M. F., Chompret, A., Stoppa-Lyonnet, D., 
Desjardins, L., Eychene, A., Demenais, F., Lenoir, G. M., & Bressac-de 
Paillerets, B. 2003, "BRAF as a melanoma susceptibility candidate gene?", 
Cancer Res., vol. 63, no. 12, pp. 3061-3065.
Liu, L., Dilworth, D., Gao, L., Monzon, J., Summers, A., Lassam, N., & Hogg,
D. 1999, "Mutation of the CDKN2A 51 UTR creates an aberrant initiation codon 
and predisposes to melanoma", Nat.Genet., vol. 21, no. 1, pp. 128-132.
Liu, Q., Yan, Y. X., McClure, M., Nakagawa, H., Fujimura, F., & Rustgi, A. K. 
1995, "MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in 
esophagus squamous cancer and pancreatic adenocarcinoma cell lines", 
Oncogene, vol. 10, no. 3, pp. 619-622.
Loewe, R., Kittler, H., Fischer, G., Fae, I., Wolff, K., & Petzelbauer, P. 2004, 
"BRAF kinase gene V599E mutation in growing melanocytic lesions", J.Invest 
Dermatol., vol. 123, no. 4, pp. 733-736.
Lynch, H. T., Frichot, B. C., Ill, & Lynch, J. F. 1978, "Familial atypical multiple 
mole-melanoma syndrome", J.Med.Genet., vol. 15, no. 5, pp. 352-356.
Lynch, H. T., Fusaro, R. M., Pester, J., & Lynch, J. F. 1980, "Familial atypical 
multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and 
malignant melanoma", Br.J.Cancer, vol. 42, no. 1, pp. 58-70.
Lynch, H. T., Brand, R. E., Hogg, D., Deters, C. A., Fusaro, R. M., Lynch, J. F., 
Liu, L., Knezetic, J., Lassam, N. J., Goggins, M., & Kern, S. 2002, "Phenotypic 
variation in eight extended CDKN2A germline mutation familial atypical 
multiple mole melanoma-pancreatic carcinoma-prone families: the familial 
atypical mole melanoma-pancreatic carcinoma syndrome", Cancer, vol. 94, no. 
l ,p p . 84-96.
MacKie, R. M., Andrew, N., Lanyon, W. G., & Connor, J. M. 1998, "CDKN2A 
germline mutations in U.K. patients with familial melanoma and multiple 
primary melanomas", J.Invest Dermatol., vol. 111, no. 2, pp. 269-272.
291
MacKie, R. M., Bray, C. A., Hole, D. J., Morris, A., Nicolson, M., Evans, A., 
Doherty, V., & Vestey, J. 2002, "Incidence of and survival from malignant 
melanoma in Scotland: an epidemiological study", Lancet, vol. 360, no. 9333, 
pp. 587-591.
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., 
Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. 2003, "Determinants of 
BRAF mutations in primary melanomas", J.Natl Cancer Inst., vol. 95, no. 24, pp. 
1878-1890.
Mann, K., Fox, S. P., Abbs, S. J., Yau, S. C., Scriven, P. N., Docherty, Z., & 
Ogilvie, C. M. 2001, "Development and implementation of a new rapid 
aneuploidy diagnostic service within the UK National Health Service and 
implications for the future of prenatal diagnosis", Lancet, vol. 358, no. 9287, pp. 
1057-1061.
Mantelli, M., Barile, M., Ciotti, P., Ghiorzo, P., Lantieri, F., Pastorino, L., 
Catricala, C., Torre, G. D., Folco, U., Grammatico, P., Padovani, L., Pasini, B., 
Rovini, D., Queirolo, P., Rainero, M. L., Santi, P. L., Sertoli, R. M., Goldstein, 
A. M., & Bianchi-Scarra, G. 2002, "High prevalence of the G101W germline 
mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma 
families", Am.J.Med.Genet., vol. 107, no. 3, pp. 214-221.
Marrett, L. D., Nguyen, H. L., & Armstrong, B. K. 2001, "Trends in the 
incidence o f cutaneous malignant melanoma in New South Wales, 1983-1996", 
Int. J.Cancer, vol. 92, no. 3, pp. 457-462.
Matichard, E., Verpillat, P., Meziani, R., Gerard, B., Descamps, V., Legroux, E., 
Bumouf, M., Bertrand, G., Bouscarat, F., Archimbaud, A., Picard, C., Ollivaud, 
L., Basset-Seguin, N., Kerob, D., Lantemier, G., Lebbe, C., Crickx, B., 
Grandchamp, B., & Soufir, N. 2004, "Melanocortin 1 receptor (MC1R) gene 
variants may increase the risk of melanoma in France independently of clinical 
risk factors and UV exposure", J.Med.Genet., vol. 41, no. 2, p. e l3.
Meyer, P., Klaes, R., Schmitt, C., Boettger, M. B., & Garbe, C. 2003, "Exclusion 
of BRAFV599E as a melanoma susceptibility mutation", Int.J.Cancer, vol. 106, 
no. 1, pp. 78-80.
Monzon, J., Liu, L., Brill, H., Goldstein, A. M., Tucker, M. A., From, L., 
McLaughlin, J., Hogg, D., & Lassam, N. J. 1998, "CDKN2A mutations in 
multiple primary melanomas", N.Engl.J.Med', vol. 338, no. 13, pp. 879-887.
Murphy, J. A., Barrantes-Reynolds, R., Kocherlakota, R., Bond, J. P., & 
Greenblatt, M. S. 2004, "The CDKN2A database: Integrating allelic variants 
with evolution, structure, function, and disease association", Hum.Mutat., vol. 
24, no. 4, pp. 296-304.
Nakahori, Y., Hamano, K., Iwaya, M., & Nakagome, Y. 1991, "Sex 
identification by polymerase chain reaction using X-Y homologous primer", 
Am.J.Med.Genet., vol. 39, no. 4, pp. 472-473.
292
Newton Bishop, J. A., Harland, M., Bennett, D. C., Bataille, V., Goldstein, A. 
M., Tucker, M. A., Ponder, B. A., Cuzick, J., Selby, P., & Bishop, D. T. 1999, 
"Mutation testing in melanoma families: INK4A, CDK4 and INK4D", 
Br.J.Cancer, vol. 80, no. 1-2, pp. 295-300.
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. 
1994, "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple 
human cancers", Nature, vol. 368, no. 6473, pp. 753-756.
Olsen, R., Overbo, K., & Mymes, B. 1991, "Alkaline phosphatase from the 
hepatopancreas of Shrimp (Pandalus borealis): A dimeric enzyme with 
catalytically active subunits.", Comp.Biochem.Physiol, vol. 99, no. B, pp. 755- 
761.
Omholt, K., Platz, A., Kanter, L., Ringborg, U., & Hansson, J. 2003, "NRAS and 
BRAF mutations arise early during melanoma pathogenesis and are preserved 
throughout tumor progression", Clin.Cancer Res., vol. 9, no. 17, pp. 6483-6488.
Orlow, I., Roy, P., Barz, A., Canchola, R., Song, Y., & Berwick, M. 2001, 
"Validation of denaturing high performance liquid chromatography as a rapid 
detection method for the identification of human INK4A gene mutations", 
J.Mol.Diagn., vol. 3, no. 4, pp. 158-163.
Osterlind, A., Tucker, M. A., Stone, B. J., & Jensen, O. M. 1988, "The Danish 
case-control study of cutaneous malignant melanoma. II. Importance of UV-light 
exposure", Int.J.Cancer, vol. 42, no. 3, pp. 319-324.
Palmer, J. S., Duffy, D. L., Box, N. F., Aitken, J. F., O’Gorman, L. E., Green, A. 
C., Hayward, N. K., Martin, N. G., & Sturm, R. A. 2000, "Melanocortin-1 
receptor polymorphisms and risk of melanoma: is the association explained 
solely by pigmentation phenotype?", Am.J.Hum.Genet., vol. 66, no. 1, pp. 176- 
186.
Parry, D. & Peters, G. 1996, "Temperature-sensitive mutants of pl6CDKN2 
associated with familial melanoma", Mol.Cell Biol., vol. 16, no. 7, pp. 3844- 
3852.
Pavey, S., Conroy, S., Russell, T., & Gabrielli, B. 1999, "Ultraviolet radiation 
induces pl6CDKN2A expression in human skin", Cancer Res., vol. 59, no. 17, 
pp. 4185-4189.
Pavey, S., Russell, T., & Gabrielli, B. 2001, "G2 phase cell cycle arrest in human 
skin following UV irradiation", Oncogene, vol. 20, no. 43, pp. 6103-6110.
Pavey, S. & Gabrielli, B. 2002, "Alpha-melanocyte stimulating hormone 
potentiates pl6/CDKN2A expression in human skin after ultraviolet irradiation", 
Cancer Res., vol. 62, no. 3, pp. 875-880.
Platz, A., Ringborg, U., Lagerlof, B., Lundqvist, E., Sevigny, P., & Inganas, M. 
1996, "Mutational analysis of the CDKN2 gene in metastases from patients with 
cutaneous malignant melanoma", Br.J.Cancer, vol. 73, no. 3, pp. 344-348.
293
Platz, A., Hansson, J., Mansson-Brahme, E., Lagerlof, B., Linder, S., Lundqvist,
E., Sevigny, P., Inganas, M., & Ringborg, U. 1997, "Screening of germline 
mutations in the CDKN2A and CDKN2B genes in Swedish families with 
hereditary cutaneous melanoma", J.Natl.Cancer Inst., vol. 89, no. 10, pp. 697- 
702.
Pollock, P. M., Spurr, N., Bishop, T., Newton-Bishop, J., Gruis, N., van der 
Velden, P. A., Goldstein, A. M., Tucker, M. A., Foulkes, W. D., Barnhill, R., 
Haber, D., Fountain, J., & Hayward, N. K. 1998, "Haplotype analysis of two 
recurrent CDKN2A mutations in 10 melanoma families: evidence for common 
founders and independent mutations", Hum.Mutat., vol. 11, no. 6, pp. 424-431.
Pollock, P. M., Stark, M. S., Palmer, J. M., Walters, M. K., Aitken, J. F., Martin, 
N. G., & Hayward, N. K. 2001, "Mutation analysis of the CDKN2A promoter in 
Australian melanoma families", Genes Chromosomes.Cancer, vol. 32, no. 1, pp. 
89-94.
Pollock, P. M. & Meltzer, P. S. 2002, "A genome-based strategy uncovers 
frequent BRAF mutations in melanoma", Cancer Cell, vol. 2, no. 1, pp. 5-7.
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. 
M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., 
Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, 
P. S. 2003, "High frequency of BRAF mutations in nevi", Nat.Genet., vol. 33, 
no. 1, pp. 19-20.
Primmer, C. R., Saino, N., Moller, A. P., & Ellegren, H. 1996, "Directional 
evolution in germline microsatellite mutations", Nat.Genet., vol. 13, no. 4, pp. 
391-393.
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., 
Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. 1995, 
"Mutations associated with familial melanoma impair pl6INK4 function", 
Nat.Genet., vol. 10, no. 1, pp. 114-116.
Randerson-Moor, J. A., Harland, M., Williams, S., Cuthbert-Heavens, D., 
Sheridan, E., Aveyard, J., Sibley, K., Whitaker, L., Knowles, M., Bishop, J. N., 
& Bishop, D. T. 2001, "A germline deletion of pl4(ARF) but not CDKN2A in a 
melanoma-neural system tumour syndrome family", Hum.Mol.Genet., vol. 10, 
no. 1, pp. 55-62.
Reifenberger, J., Knobbe, C. B., Sterzinger, A. A., Blaschke, B., Schulte, K. W., 
Ruzicka, T., & Reifenberger, G. 2004, "Frequent alterations of Ras signaling 
pathway genes in sporadic malignant melanomas", Int.J.Cancer, vol. 109, no. 3, 
pp. 377-384.
Reymond, A. & Brent, R. 1995, "p i6 proteins from melanoma-prone families are 
deficient in binding to Cdk4", Oncogene, vol. 11, no. 6, pp. 1173-1178.
294
Rizos, H., Puig, S., Badenas, C., Malvehy, J., Darmanian, A. P., Jimenez, L., 
Mila, M., & Kefford, R. F. 2001, "A melanoma-associated germline mutation in 
exon lbeta inactivates pl4ARF", Oncogene, vol. 20, no. 39, pp. 5543-5547.
Ruas, M. & Peters, G. 1998, "The pl6INK4a/CDKN2A tumor suppressor and its 
relatives", Biochim.Biophys.Acta, vol. 1378, no. 2, p. F115-F177.
Ruas, M., Brookes, S., McDonald, N. Q., & Peters, G. 1999, "Functional 
evaluation of tumour-specific variants of pl6INK4a/CDKN2A: correlation with 
protein structure information", Oncogene, vol. 18, no. 39, pp. 5423-5434.
Ruiz, A., Puig, S., Malvehy, J., Lazaro, C., Lynch, M., Gimenez-Amau, A. M., 
Puig, L., Sanchez-Conejo, J., Estivill, X., & Castel, T. 1999, "CDKN2A 
mutations in Spanish cutaneous malignant melanoma families and patients with 
multiple melanomas and other neoplasia", J.Med.Genet., vol. 36, no. 6, pp. 490- 
493.
Sasaki, Y., Niu, C., Makino, R., Kudo, C., Sun, C., Watanabe, H., Matsunaga, J., 
Takahashi, K., Tagami, H., Aiba, S., & Horii, A. 2004, "BRAF point mutations 
in primary melanoma show different prevalences by subtype", J.Invest 
Dermatol, vol. 123, no. l,p p . 177-183.
Schioth, H. B., Phillips, S. R., Rudzish, R., Birch-Machin, M. A., Wikberg, J. E., 
& Rees, J. L. 1999, "Loss of function mutations of the human melanocortin 1 
receptor are common and are associated with red hair", 
Biochem.Biophys.Res.Commun., vol. 260, no. 2, pp. 488-491.
Serrano, M., Hannon, G. J., & Beach, D. 1993, "A new regulatory motif in cell- 
cycle control causing specific inhibition of cyclin D/CDK4", Nature, vol. 366, 
no. 6456, pp. 704-707.
Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. 2004, "Incidence of 
BRAF oncogene mutation and clinical relevance for primary cutaneous 
melanomas", Cl in. Cancer Res., vol. 10, no. 5, pp. 1753-1757.
Smith-Sorensen, B. & Hovig, E. 1996, "CDKN2A (pl6INK4A) somatic and 
germline mutations", Hum.Mutat., vol. 7, no. 4, pp. 294-303.
Smith, F. E., Henly, W. S., Knox, J. M., & Lane, M. 1966, "Familial melanoma", 
Arch.Intern.Med., vol. 117, no. 6, pp. 820-823.
Smith, R., Healy, E., Siddiqui, S., Flanagan, N., Steijlen, P. M., Rosdahl, I., 
Jacques, J. P., Rogers, S., Turner, R., Jackson, I. J., Birch-Machin, M. A., & 
Rees, J. L. 1998, "Melanocortin 1 receptor variants in an Irish population", 
J.Invest Dermatol. , \  ol. I l l ,  no. l,p p . 119-122.
Soufir, N., Avril, M. F., Chompret, A., Demenais, F., Bombled, J., Spatz, A., 
Stoppa-Lyonnet, D., Benard, J., & Bressac-de Paillerets, B. 1998, "Prevalence of 
p i6 and CDK4 germline mutations in 48 melanoma-prone families in France. 
The French Familial Melanoma Study Group", Hum. Mo I. Genet., vol. 7, no. 2, 
pp. 209-216.
295
Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., 
Peters, G., & Kamb, A. 1995, "Complex structure and regulation of the P16 
(MTS1) locus", Cancer Res., vol. 55, no. 14, pp. 2988-2994.
Straume, O., Smeds, J., Kumar, R., Hemminki, K., & Akslen, L. A. 2002, 
"Significant impact of promoter hypermethylation and the 540 C>T 
polymorphism of CDKN2A in cutaneous melanoma of the vertical growth 
phase", Am.J.Pathol., vol. 161, no. 1, pp. 229-237.
Sun, S., Pollock, P. M., Liu, L., Karimi, S., Jothy, S., Milner, B. J., Renwick, A., 
Lassam, N. J., Hayward, N. K., Hogg, D., Narod, S. A., & Foulkes, W. D. 1997, 
"CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites 
results in a functionally abnormal protein", IntJ.Cancer, vol. 73, no. 4, pp. 531 - 
536.
Tevelev, A., Byeon, I. J., Selby, T., Ericson, K., Kim, H. J., Kraynov, V., & Tsai, 
M. D. 1996, "Tumor suppressor pl6INK4A: structural characterization of wild- 
type and mutant proteins by NMR and circular dichroism", Biochemistry, vol. 
35, no. 29, pp. 9475-9487.
Thody, A. J., Higgins, E. M., Wakamatsu, K., Ito, S., Burchill, S. A., & Marks, J. 
M. 1991, “Pheomelanin as well as eumelanin is present in human epidermis”, 
J.Invest.Dermatol., vol. 97, no. 2, pp. 340-344.
Trent, J. M., Rosenfeld, S. B., & Meyskens, F. L. 1983, "Chromosome 6q 
involvement in human malignant melanoma", Cancer Genet. Cytogenet., vol. 9, 
no. 2, pp. 177-180.
Tsao, H., Zhang, X., Kwitkiwski, K., Finkelstein, D. M., Sober, A. J., & Haluska,
F. G. 2000, "Low prevalence of germline CDKN2A and CDK4 mutations in 
patients with early-onset melanoma", Arch.Dermatol., vol. 136, no. 9, pp. 1118- 
1122.
Uribe, P., Wistuba, 1.1., & Gonzalez, S. 2003, "BRAF mutation: a frequent event 
in benign, atypical, and malignant melanocytic lesions o f the skin", 
Am.J.Dermatopathol., vol. 25, no. 5, pp. 365-370.
Valverde, P., Healy, E., Jackson, I., Rees, J. L., & Thody, A. J. 1995, "Variants 
of the melanocyte-stimulating hormone receptor gene are associated with red 
hair and fair skin in humans", Nat.Genet., vol. 11, no. 3, pp. 328-330.
Valverde, P., Healy, E., Sikkink, S., Haldane, F., Thody, A. J., Carothers, A., 
Jackson, I. J., & Rees, J. L. 1996, "The Asp84Glu variant o f the melanocortin 1 
receptor (MC1R) is associated with melanoma", Hum.Mol.Genet., vol. 5, no. 10, 
pp. 1663-1666.
van der Velden, P. A., Sandkuijl, L. A., Bergman, W., Hille, E. T., Frants, R. R., 
& Gruis, N. A. 1999, "A locus linked to p i6 modifies melanoma risk in Dutch 
familial atypical multiple mole melanoma (FAMMM) syndrome families", 
Genome Res., vol. 9, no. 6, pp. 575-580.
296
van der Velden, P. A., Sandkuijl, L. A., Bergman, W., Pavel, S., van Mourik, L., 
Frants, R. R., & Gruis, N. A. 2001, "Melanocortin-1 receptor variant R151C 
modifies melanoma risk in Dutch families with melanoma", Am.J.Hum.Genet., 
vol. 69, no. 4, pp. 774-779.
Vasen, H. F., Gruis, N. A., Frants, R. R., Der Velden, P. A., Hille, E. T., & 
Bergman, W. 2000, "Risk of developing pancreatic cancer in families with 
familial atypical multiple mole melanoma associated with a specific 19 deletion 
of p l6  (pl6-Leiden)", Int.J.Cancer, vol. 87, no. 6, pp. 809-811.
Walker, G. J., Hussussian, C. J., Flores, J. F., Glendening, J. M., Haluska, F. G., 
Dracopoli, N. C., Hayward, N. K., & Fountain, J. W. 1995, "Mutations of the 
CDKN2/pl6INK4 gene in Australian melanoma kindreds", Hum. Mo I. Genet., 
vol. 4, no. 10, pp. 1845-1852.
Walker, G. J., Indsto, J. O., Sood, R., Faruque, M. U., Hu, P., Pollock, P. M., 
Duray, P., Holland, E. A., Brown, K., Kefford, R. F., Trent, J. M., Mann, G. J., & 
Hayward, N. K. 2004, "Deletion mapping suggests that the lp22 melanoma 
susceptibility gene is a tumor suppressor localized to a 9-Mb interval", Genes 
Chromosomes. Cancer, vol. 41, no. 1, pp. 56-64.
Walter, S. D., King, W. D., & Marrett, L. D. 1999, "Association o f cutaneous 
malignant melanoma with intermittent exposure to ultraviolet radiation: results of 
a case-control study in Ontario, Canada", Int.J.Epidemiol, vol. 28, no. 3, pp. 
418-427.
Wan, P. T., Gamett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. 
M., Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., & Marais, R. 2004, 
"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic 
mutations of B-RAF", Cell, vol. 116, no. 6, pp. 855-867.
Weinstock, M. A. 1998, "Issues in the epidemiology of melanoma", 
Hematol.Oncol.Clin.North Am., vol. 12, no. 4, pp. 681-698.
Whelan, A. J., Bartsch, D., & Goodfellow, P. J. 1995, "Brief report: a familial 
syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 
tumor-suppressor gene", N.Engl.J.Med., vol. 333, no. 15, pp. 975-977.
Yakobson, E. A., Zlotogorski, A., Shafir, R., Cohen, M., Icekson, M., Landau, 
M., Brenner, S., Usher, S., & Peretz, H. 1998, "Screening for tumour suppressor 
pl6(CDKN2A) germline mutations in Israeli melanoma families", 
Clin.Chem.Lab Med., vol. 36, no. 8, pp. 645-648.
Yakobson, E., Shemesh, P., Azizi, E., Winkler, E., Lassam, N., Hogg, D., 
Brookes, S., Peters, G., Lotem, M., Zlotogorski, A., Landau, M., Safro, M., 
Shafir, R., Friedman, E., & Peretz, H. 2000, "Two p l6  (CDKN2A) germline 
mutations in 30 Israeli melanoma families", Eur.J.Hum.Genet., vol. 8, no. 8, pp. 
590-596.
297
Yakobson, E., Eisenberg, S., Isacson, R., Halle, D., Levy-Lahad, E., Catane, R., 
Safro, M., Sobolev, V., Huot, T., Peters, G., Ruiz, A., Malvehy, J., Puig, S., 
Chompret, A., Avril, M. F., Shafir, R., Peretz, H., & Bressac-de Paillerets, B. 
2003, "A single Mediterranean, possibly Jewish, origin for the Val59Gly 
CDKN2A mutation in four melanoma-prone families", Eur.J.Hum.Genet., vol. 
11, no. 4, pp. 288-296.
Yang, G., Niendorf, K. B., & Tsao, H. 2004, "A novel methionine-53-valine 
mutation of p l6  in a hereditary melanoma kindred", J.Invest Dermatol., vol. 123, 
no. 3, pp. 574-575.
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rutten, A., 
Mentzel, T., Hugel, H., Hantschke, M., Schmid-Wendtner, M. H., Kutzner, H., & 
Sander, C. A. 2003, "Mutations of the BRAF gene in benign and malignant 
melanocytic lesions", J.Invest Dermatol., vol. 121, no. 5, pp. 1160-1162.
Zhang, B. & Peng, Z. 1996, "Defective folding of mutant pl6(INK4) proteins 
encoded by tumor-derived alleles", J.Biol.Chem., vol. 271, no. 46, pp. 28734- 
28737.
Zhang, B. & Peng, Z. 2000, "A minimum folding unit in the ankyrin repeat 
protein pl6(INK4)", J.Mol.Biol., vol. 299, no. 4, pp. 1121-1132.
Zhang, Y., Xiong, Y., & Yarbrough, W. G. 1998, "ARF promotes MDM2 
degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb 
and p53 tumor suppression pathways", Cell, vol. 92, no. 6, pp. 725-734.
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., 
Hayward, N., & Dracopoli, N. C. 1996, "Germline mutations in the pl6INK4a 
binding domain of CDK4 in familial melanoma", Nat.Genet., vol. 12, no. 1, pp. 
97-99.
298
APPENDIX 1
PRIMER SEQUENCES
Prim er Sequences
Gene:
Name
CDKN2A exon l a
Prim ers:
P rim er Name Prim er Sequence
CDKN2A IF ACCGGAGGAAGAAAGAGGAG
CDKN2A 1R GCGCTACCTGATTCCAATTC
Gene:
Name
CDKN2A exon 2
Prim ers:
Prim er Name Prim er Sequence
CDKN2A 2F GTGAGGGGGCTCTACACAAG
CDKN2A 2R CT GT GCT GG AAAAT G A AT GC
Gene:
Name
CDKN2A exon 3
Prim ers:
Prim er Name Prim er Sequence
CDKN2A 3F TGCCACACATCTTTGACCTC
CDKN2A 3R TTT ACGGT AGT GGGGGAAGG
Gene:
Name
MC1R
Prim ers:
Prim er Name Prim er Sequence
M C1RF AGAT GGAAGGAGGCAGGCAT
M C1RR CCGCGCTTCAACACTTTCAGAGATCA
Gene:
Name
MC1R sequencing
Prim ers:
Prim er Name Prim er Sequence
M C1R N TF CTGCAGGTGATCACGTCAAT
M C1R TM F AACCTGCACTCACCCATGTA
M C 1R C TF TCGTCTTCAGCACGCTCTTC
Gene:
Name
AMXY
Prim ers:
Prim er Name Prim er Sequence
AMXY F *CCCTGGGCTCTGTAAAGAATAGTG
AMXY R ATCAGAGCTTAAACTGGGAAGCTG ;
Gene:
Name
BRAF  exon 15
Prim ers:
Prim er Name Prim er Sequence
BRAF 15F T CAT AAT GCTT GCT CT GAT AGG A
BRAF 15R GGCCAAAAATTTAATCAGTGG
Gene:
Name
BRAF  V599E
Prim ers:
Prim er Name Prim er Sequence
V599E F AATAGGTGATTTTGGTCTAGCTAC A G T;
V599E R AATAGGTGATTTTGGTCTAGCTACAGA
M arker:
Name
D9S1749
Prim ers:
P rim er Name Prim er Sequence
PkY6.F *AGGAGAGGGTACGCTTGCAA
PkY6.R TACAGGGTGCGGGTGCAGATAA;
M arker:
Name
D9S2136
Prim ers:
Prim er Name Prim er Sequence
1069.IF *ATTCAACGAGTGGGATGAAG
1069.1R TCCAGGTTGCTGCAAATGCC
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M arker:
Name
D9S2060
Prim ers:
Prim er Name Prim er Sequence
SHGC-9726.PrG-19451 *CATCAGTCACCGAAGGTCCT
SHGC-9726.PrG-19452 AAT GG AC ATTT ACGGT AGT GGG
M arker:
Name
RH 103023
Prim ers:
Prim er Name Prim er Sequence
stSG54862.A * TTT ATT C ATTT GCTT GT GGCC
stSG54862.B GGTCCCGATTTAGAAGGAGC |
M arker:
Name
D9S974
Prim ers:
Prim er Name Prim er Sequence
B4CA *GAGCCTGGTCTGGATCATAA
B4TG AAGCTT AC AG AACC AG AC AG
M arker:
Name
D9S942
Prim ers:
Prim er Name Prim er Sequence
CT.29.F *GCAAGATTCCAAACAGTA j
CT.29.R c t c a t c c t g c g g a a a c c a t t !
303
M arker:
Name
D9S1748
Prim ers:
P rim er Name Prim er Sequence
PkY3.F *CACCTCAGAAGTCAGTGAGT
PkY3.R GTGCTTGAAATACACCTTTCC
M arker:
Name
D9S1604
Prim ers:
Prim er Name Prim er Sequence
CT18-F *CCTGGGTCTCCAATTTGTCA
CT18-R AGC ACATGAC ACTGTGTGTG
* denotes fluorescently labelled primer
APPENDIX 2
THERMOCYCLING CONDITIONS
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Thermocycling Conditions
CDKN2A Exon la
94°C 5 minutes 1 cycle
94°C 1 minute
61°C 1 minute 30 cycles
72°C 1 minute
72°C 10 minutes 1 cycle
4°C soak
CDKN2A Exon 2
94°C 5 minutes 1 cycle
94°C 1 minute
58°C 1 minute 30 cycles
72°C 1 minute
72°C 10 minutes 1 cycle
4°C soak
CDKN2A Exon 3
94°C 5 minutes 1 cycle
94°C 1 minute
60°C 1 minute 30 cycles
72°C 1 minute
72°C 10 minutes 1 cycle
4°C soak
MC1R Entire Coding Region
94°C 5 minutes 1 cycle
94°C
65°C
72°C
1 minute 
1 minute 
90 seconds
35 cycles
72°C 10 minutes 1 cycle
4°C soak j
AMXY Entire Coding Region
95 °C 15 minutes 1 cycle
94°C 30 seconds
56.5°C 1 minute 30 cycles
72°C 90 seconds
72°C 10 minutes 1 cycle
8°C soak
BRAF Exon 15
\94°C 5 minutes 1 cycle
94°C 1 minute
60°C 1 minute 30 cycles
72°C 1 minute
72°C 10 minutes 1 cycle
4°C soak
BRAF V599E Allele Specific
94°C 5 minutes 1 cycle
94°C 1 minute (
57°C 1 minute 30 cycles
72°C 1 minute
72°C 10 minutes 1 cycle
4°C soak
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CDKN2A D9S1749
94°C 3 minutes 1 cycle
94°C 45 seconds
55°C 45 seconds 30 cycles
72°C 45 seconds
4°C soak
CDKN2A D9S2060
94°C 3 minutes 1 cycle
94°C 1 minute
62°C 1 minute 30 cycles
72°C 1 minute
4°C soak
CDKN2A D9S974
94°C 5 minutes 1 cycle
94°C 1 minute
55°C 1 minute 30 cycles
72°C 1 minute
4°C soak
CDKN2A D9S1748
94°C 5 minutes 1 cycle
94°C 1 minute
53°C 1 minute 35 cycles
72°C 1 minute
4°C soak
CDKN2A D9S2136
94°C 5 minutes 1 cycle
94°C 30 seconds
60°C 1 minute 35 cycles
72°C 30 seconds
72°C 5 minutes 1 cycle
4°C soak
CDKN2A RH103023
94°C 5 minutes 1 cycle
94°C 1 minute
61°C 1 minute 35 cycles
72°C 1 minute
72°C 10 minutes 1 cycle
4°C soak
CDKN2A D9S942
94°C 5 minutes 1 cycle
94°C
53°C
72°C
1 minute 
1 minute 
1 minute
35 cycles
4°C soak
CDKN2A D9S1604
94°C 5 minutes 1 cycle
94°C 1 minute
55°C 1 minute 30 cycles
72°C 1 minute
4°C soak
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PCR clean up SHRIMP
37°C 30 minutes 1 cycle
72°C 15 minutes 1 cycle
8°C 5 minutes 1 cycle
Sequencing BigDye 3
96°C 10 seconds
50°C 5 seconds 25 cycles
60°C 4 minutes
4°C soak
TOPO Cloning Control PCR Product
94°C 2 minutes 1 cycle
94°C
55°C
72°C
1 minute 
1 minute 
1 minute
25 cycles
72°C 7 minutes 1 cycle
Denature
95°C 10 minutes 1 cycle
Renature
95°C 5 minutes 1 cycle
95°C -  0.7°C 25 seconds 90 cycles
25°C soak
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APPENDIX 3
RESTRICTION ENZYME DIGESTS
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Restriction Enzyme Digests
Prim ers:
Prim er Name Prim er Sequence
CDKN2A 2F GT G AGGGGGCTCT AC AC AAG
CDKN2A 2R CTGTGCT GG AAAAT G AAT GC
CDKN2A Exon 2
M53I
B el I 50°C
15 pi PCR Product 
1.5pl Bel I 
3 pi Buffer C 
1.5 pi Spermidine 
9pi dH20
30pl total volume per digest
Expected fragm ent sizes: 84bp, 374bp
Prim ers:
P rim er Name Prim er Sequence
BRAF 15F TCATAATGCTTGCTCTGATAGGA
BRAF 15R GGCCAAAAATTTAATCAGTGG
B R A F Exon 15 i
V599E
Tsp R I 65°C
30pl PCR Product j 
3.5pl Tsp RI | 
5 pi Buffer 4 \ 
5pi BSA 
6.5pl dH20
50pl total volume per digest
Expected fragm ent sizes: 22bp, 202bp
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APPENDIX 4
HAPLOTYPE ANALYSIS OF M53I 
MUTATION NON-CARRIERS
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TABLE 1
Haplotype Analysis of M53I Mutation Non-Carriers from a Family 
from Toronto and a Family from Australia for 9p Markers
Haplotype for each Marker 
Family Identifier
Canadian Australian
FAM-1 41031
Markers T4 T5 B4 B5
D9S1749 13/14 11/12 15/16 14/15
D9S2136 6/8 7/8 4/9 4/9
D9S2060 2/2 2/2 2/3 2/2
RH103023 1/1 1/1 1/1 1/1
M53I G/G G/G G/G G/G
D9S974 6/9 8/8 6/7 6/7
D9S942 4/5 3/4 4/5 4/5
D9S1748 9/10 4/7 7/9 6/9
D9S1604 1/2 1/2 1/1 1/2
The position of the mutation relative to the markers is shown.
T4 and T5 denotes individuals not carrying the M53I mutation from a M53I 
mutation carrying Toronto family and B4 and B5 denotes individuals not 
carrying the M53I mutation from a M53I mutation carrying Brisbane family
Blue denotes most common allele for that marker as seen in the M53I carriers
Grey shaded area denotes individuals who do not carry the most common allele 
for that marker
Data collected from marker RH103023 was not informative as the families all 
shared the common population alleles.
Family members T4 and B4 both have melanoma but do not carry the M53I 
mutation that is carried in their family. They are therefore family members with 
sporadic melanoma in a familial setting. Family members T5 and B5 do not 
carry the M53I mutation and do not have melanoma.
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APPENDIX 5
STATISTICAL ANALYSIS
Statistical analysis was performed using the methods described in method 
3.17. For each Test of Independence a Two-tailed Fisher’s Exact Test was 
performed, unless stated otherwise. Odds ratios (OR) are indicated with 95% 
confidence interval (Cl) in all statistical analysis. Alleles were counted twice in 
homozygous individuals which increases the N value of subjects for certain 
variants.
TABLE 1
MC1R Variants Found in Familial and Sporadic Melanoma Patients
Compared with Control Subjects
No. of Cases No. of Controls
Any variant 83 53
No variant 5 14
P-value = 0.006 ** significant (not significant after Bonferroni correction)
OR = 4.385, Cl 1.492-12.883
L44I present 1 0
L44I absent 87 67
P-value = 1.000 (not significant)
V60L present 30 20
V60L absent 63 48
P-value = 0.733 (not significant)
OR = 1.143, Cl 0.580-2.254
D84E present 8 1
D84E absent 80 66
P-value = 0.079 (not significant)
OR = 6.600, Cl 0.805-54.128
V92M present 13 11
V92M absent 75 57
P-value = 0.826 (not significant)
OR = 0.898, Cl 0.375-2.152
T95M present 1 0
T95M absent 87 67
P-value = 1.000 (not significant)
R142H present 3 2
R142H absent 85 65
P-value = 1.000 (not significant)
O R = 1.147, Cl 0.186-7.066
R151C present 28 12
R151C absent 61 55
P-value = 0.065 (not significant)
OR = 2.104, Cl 0.976-4.536
I155T present 4 4
I155T absent 84 63
P-value = 0.727 (not significant)
OR = 0.750, Cl 0.181-3.115
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No. of Cases No. of Controls
R160W present 24 14
R160W absent 67 53
P-value = 0.457 (not significant)
OR = 1.356, Cl 0.640-2.874
R163Q present 12 7
R163Q absent 80 60
P-value = 0.805 (not significant)
O R= 1.286, Cl 0.478-3.462
A171G present 1 0
A171G absent 87 67
P-value = 1.000 (not significant)
D294H present 10 3
D294H absent 78 64
P-value = 0.152 (not significant)
OR = 2.735, Cl 0.722-10.361
Bonferroni adjusted significance level for multiple tests = 0.004 
TABLE 2
Correlation between MC1R Variants in Familial Melanoma Patients and
Control Subjects
No. of Cases No. of Controls
Any variant 58 53
No variant 2 14
P-value = 0.003 ** significant
OR = 7.660, Cl 1.663-35.296
V60L present 24 20
V60L absent 41 48
P-value = 0.461 (not significant)
O R = 1.405, Cl 0.680-2.901
D84E present 5 1
D84E absent 55 66
P-value = 0.100 (not significant)
OR = 6.000, Cl 0.680-52.902
V92M present 12 11
V92M absent 48 57
P-value = 0.648 (not significant)
O R = 1.295, Cl 0.525-3.198
T95M present 1 0
T95M absent 59 67
P-value = 0.472 (not significant)
R142H present 2 2
R142H absent 58 65
P-value = 1.000 (not significant)
O R = 1.121, Cl 0.153-8.213
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No. of Cases No. of Controls
R151C present 21 12
R151C absent 40 55
P-value = 0.043 * significant (not significant after Bonferroni correction) 
OR = 2.406, Cl 1.062-5.452
I155T present 3 4
I155T absent 57 63
P-value = 1.000 (not significant)
OR = 0.829, Cl 0.178-3.864
R160W present 13 14
R160W absent 49 53
P-value = 1.000 (not significant)
O R = 1.004, Cl 0.430-2.348
R163Q present 10 7
R163Q absent 53 60
P-value = 0.439 (not significant)
OR = 1.617, Cl 0.575-4.549
A171G present 1 0
A171G absent 59 67
P-value = 0.472 (not significant)
D294H present 6 3
D294H absent 54 64
P-value = 0.305 (not significant)
OR = 2.370, Cl 0.566-9.930
Bonferroni adjusted significance level for multiple tests = 0.004
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TABLE 3
Correlation between MC1R V ariants in Fam ilial M elanoma Patients with
and without a CDKN2A M utation
CDKN2A Mutation Positive CDKN2A Mutation Negative
Any variant 23 35
No variant 0 2
P-value = 0.519 (not significant)
V60L present 14 10
V60L absent 11 30
P-value = 0.017 * significant (not significant after Bonferroni correction)
OR = 3.818, Cl 1.315-11.084
D84E present 1 4
D84E absent 22 33
P-value = 0.640 (not significant)
OR = 0.375, Cl 0.039-3.582
V92M present 1 11
V92M absent 22 26
P-value = 0.021 * significant (not significant after Bonferroni correction)
OR = 0.107, Cl 0.013-0.899
[OR = 9.308, Cl 1.112-77.888]
T95M present 1 0
T95M absent 22 37
P-value = 0.383 (not significant)
R142H present 0 2
R142H absent 23 35
P-value = 0.519 (not significant)
R151C present 12 9
R151C absent 11 29
P-value = 0.029 * significant (not significant after Bonferroni correction)
O R = 3.515, Cl 1.160-10.650
I155T present 0 3
I155T absent 23 34
P-value = 0.279 (not significant)
R160W present 5 8
RI 60W absent 18 31
P-value = 1.000 (not significant)
O R = 1.076, Cl 0.306-3.792
R163Q present 1 9
R163Q absent 22 31
P-value = 0.078 (not significant)
OR = 0.157, Cl 0.018-1.327
A171G present 1 0
A171G absent 22 37
P-value = 0.383 (not significant)
D294H present 4 2
D294H absent 19 35
P-value = 0.191 (not significant)
OR =3.684, Cl 0.617-21.999
Bonferroni adjusted significance level for multiple tests = 0.004
317
TABLE 4
Correlation between MC1R Variants in Sporadic Melanoma Patients and 
Control Subjects
No. of Cases No. of Controls
Any variant 25 53
No variant 3 14
P-value = 0.379 (not significant)
OR = 0.454, Cl 0.120-1.726
L44I present 1 0
L44I absent 27 67
P-value = 0.295 (not significant)
V60L present 6 20
V60L absent 22 48
P-value = 0.463 (not significant)
OR = 0.655, Cl 0.231-1.857
D84E present 3 1
D84E absent 25 66
P-value = 0.075 (not significant)
OR = 7.920, Cl 0.787-79.753
V92M present 1 11
V92M absent 27 57
P-value = 0.105 (not significant)
OR = 0.192, Cl 0.024-1.564
R142H present 1 2
R142H absent 27 65
P-value = 1.000 (not significant)
OR = 1.204, Cl 0.105-13.839
R151C present 7 12
R151C absent 21 55
P-value = 0.574 (not significant)
O R = 1.528, Cl 0.530-4.406
I155T present 1 4
I155T absent 27 63
P-value = 1.000 (not significant)
OR = 0.583, Cl 0.062-5.464
R160W present 11 14
R160W absent 18 53
P-value = 0.127 (not significant)
OR = 2.313, Cl 0.891-6.004
R163Q present 2 7
R163Q absent 27 60
P-value = 0.719 (not significant)
OR = 0.635, Cl 0.124-3.259
D294H present 4 3
D294H absent 24 64
P-value = 0.190 (not significant)
OR = 3.556, Cl 0.741-17.069
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The following three tables are 2 x 4 tables on which Chi-Squared Tests 
were performed.
TABLE 5
Correlation between Hair Colour and MC1R Variants in Control Subjects
Red Blonde Light Brown Dark Brown/Black
Any variant 5 21 13 14
No variant 1 3 2 8
P-value = 0.188 (not significant)
V60L present 2 7 6 5
V60L absent 4 17 10 17
P-value = 0.796 (not significant)
V92M present 0 4 4 3
V92M absent 6 20 11 20
P-value = 0.553 (not significant)
RI 51C present 2 5 2 3
R151C absent 4 19 13 19
P-value = 0.660 (not significant)
R160W present 3 6 3 2
R160W absent 3 18 12 20
P-value = 0.159 (not significant)
TABLE 6
Correlation between Eye Colour and MC1R Variants in Control Subjects
Blue Green Brown Other
Any variant 33 3 12 5
No variant 5 3 5 1
P-value = 0.154 (not significant)
V60L present 12 3 3 2
V60L absent 26 4 14 4
P-value = 0.599 (not significant)
R151C present 6 1 4 1
R151C absent 32 5 13 5
P-value = 0.920 (not significant)
I155T present 2 0 2 0
I155T absent 36 6 15 6
P-value = 0.391 (not significant)
R160W presentt 10 1 1 2
R160W absent 28 5 16 4
P-value = 0.306 (not significant)
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TABLE 7
Correlation between Skin Type and MC1R variants in Control Subjects
Never Tans Burns Burns Never Burns
Always Easily Rarely Always
Burns Tans Rarely Tans Easily Tans
V60L present 5 6 9 0
V60L absent 7 23 16 2
P-value = 0.303 (not significant)
V92M present 1 7 3 0
V92M absent 10 23 22 2
P-value = 0.405 (not significant)
R151C present 3 6 3 0
R151C absent 8 23 22 2
P-value = 0.508 (not significant)
I155T present 0 2 2 0
I155T absent 11 27 23 2
P-value = 0.877 (not significant)
R160W 6 6 2 0
present
R160W absent 5 23 23 2
P-value = 0.007 ** significant
R163Q present 2 1 4 0
R163Q absent 9 28 21 2
P-value = 0.228 (not significant)
D294H present 0 1 2 0
D294H absent 11 28 23 2
P-value = 0.467 (not significant)
Bonferroni adjusted significance level for multiple tests = 0.0071
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TABLE 8
Correlation between H air Colour and M elanom a Patients (Familial and
Sporadic) and Control Subjects
No. of Cases No. of Controls
Red Hair 16 7
Other Hair Colour 72 61
P-value = 0.182 (not significant) 
OR = 1.937, Cl 0.748-5.014
Blonde Hair 24 24
Other Hair Colour 64 44
P-value = 0.299 (not significant)
OR =0.688, Cl 0.347-1.362
Light Brown Hair 32 15
Other Hair Colour 56 53
P-value = 0.056 (not significant)
OR = 2.019, Cl 0.984-4.145
Dark Brown/Black Hair 16 22
Other Hair Colour 72 46
P-value = 0.059 (not significant) 
OR = 0.465, Cl 0.221-0.976 
fOR = 2.152, Cl 1.024-4.5231
TABLE 9
Eye Colour in Melanoma Patients (Familial and Sporadic) Compared with
Control Subjects
No. of No. of
Cases Controls
Blue Eyes 63 38
Other Eye Colour 25 30
P-value = 0.045 * significant 
OR = 1.989, Cl 1.022-3.873
Green Eyes 7 6
Other Eye Colour 81 62
P-value = 1.000 (not significant) 
OR = 0.893, Cl 0.286-2.791
Brown Eyes 10 18
Other Eye Colour 78 50
P-value = 0.020 * significant 
OR = 0.356, Cl 0.152-0.832
[OR = 2.808, Cl 1.199-6.574]
Eye Colour other than Blue, Green or 8 6
Brown
Blue, Green or Brown Eyes 80 62
P-value = 1.000 (not significant) 
OR = 1.033, Cl 0.341-3.133
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TABLE 10
Correlation between Skin Type and M elanoma Patients (Familial and
Sporadic) and Control Subjects
No. of Cases No. of Controls
Never Tans, Always Burns 21 12
Other Skin Type 67 56
P-value = 0.430 (not significant) 
O R = 1.463, Cl 0.662-3.233
Burns Easily, Tans Rarely 60 29
Other Skin Type 28 39
P-value = 0.002 ** significant 
OR = 2.882, Cl 1.493-5.561
Burns Rarely, Tans Easily 7 25
Other Skin Type 81 43
P-value < 0.001 *** significant 
OR =0.149, Cl 0.059-0.372
[OR = 6.728, Cl 2.692-16.8161
Never Burns, Always Tans 0 2
Other Skin Type 88 66
P-value = 0.188 (not significant)
Bonferroni adjusted significance level for multiple tests = 0.013 
TABLE 11
Correlation between Lighter and Darker Hair Colour and Melanoma 
Patients (Familial and Sporadic) and Control Subjects
No. of Cases No. of Controls
Red or Blonde Hair 40 31
Brown or Black Hair 48 37
P-value = 1.000 (not significant)
OR = 0.995, Cl 0.527-1.875
TABLE 12
Correlation between Lighter and Darker Eye Colour and Melanoma 
Patients (Familial and Sporadic) and Control Subjects
No. of Cases No. of Controls
Blue or Green Eyes 70 44
Brown or Other Eye Colour 18 24
P-value = 0.046 * significant
OR = 2.212, Cl 1.034-4.350
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TABLE 13
Correlation between H air Colour and Fam ilial M elanoma Patients with and
without a CDKN2A Mutation
CDKN2A Mutation CDKN2A Mutation
Positive Negative
Red Hair 2 8
Other Hair Colour 18 34
P-value = 0.478 (not significant) 
OR = 0.472, Cl 0.091-2.463
Blonde Hair 7 8
Other Hair Colour 13 34
P-value = 0.211 (not significant) 
OR = 2.288, Cl 0.690-7.590
Light Brown Hair 7 14
Other Hair Colour 13 28
P-value = 1.000 (not significant) 
O R = 1.077, Cl 0.351-3.303
Dark Brown/Black 4 12
Hair
Other Hair Colour 16 30
P-value = 0.549 (not significant) 
OR = 0.625, Cl 0.173-2.257
TABLE 14
Correlation between Eye Colour and Familial Melanoma Patients with and
without a CDKN2A Mutation
CDKN2A Mutation CDKN2A Mutation
Positive Negative
Blue Eyes 15 28
Other Eye Colour 5 14
P-value = 0.569 (not significant) 
O R = 1.500, Cl 0.453-4.972
Green Eyes 1 3
Other Eye Colour 19 39
P-value = 1.000 (not significant) 
OR = 0.684, Cl 0.067-7.023
Brown Eyes 1 6
Other Eye Colour 19 36
P-value = 0.412 (not significant)
OR = 0.316, Cl 0.035-2.818
Eye Colour other than Blue, 3 5
Green or Brown
Blue, Green or Brown Eyes 17 37
P-value = 1.000 (not significant)
OR = 1.306, Cl 0.279-6.105
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TABLE 15
Correlation between Skin Type and Familial Melanoma Patients with and 
without a CDKN2A Mutation
CDKN2A Mutation CDKN2A Mutation
Positive Negative
Never Tans, Always 
Burns
5 10
Other Skin Type 15 32
P-value = 1.000 (not significant) 
OR = 1.067, Cl 0.310-3.673
Burns Easily, Tans 15 29
Rarely
Other Skin Type 5 13
P-value = 0.768 (not significant) 
OR = 1.345, Cl 0.403
Burns Rarely, Tans 0 3
Easily
Other Skin Type 20 39
P-value = 0.545 (not significant)
TABLE 16
Correlation between Lighter and Darker Hair Colour and Familial Melanoma
Patients with and without a CDKN2A Mutation
CDKN2A Mutation Positive CDKN2A Mutation Negative
Red or Blonde Hair 9 16
Brown or Black Hair 11 26
P-value = 0.782 (not significant) 
OR = 1.330, Cl 0.452-3.911
TABLE 17
Correlation between Lighter and Darker Eye Colour and Familial Melanoma
Patients with and without a CDKN2A Mutation
CDKN2A Mutation 
Positive
CDKN2A Mutation 
Negative
Blue or Green Eyes 16 31
Brown or Other Eye 
Colour
4 11
P-value = 0.755 (not significant) 
OR = 1.419, Cl 0.389-5.175
TABLE 18
Correlation between Skin Type 1 or 2 and Skin Type 3 or 4 and Familial
Melanoma Patients with and without a CDKN2A Mutation
CDKN2A Mutation Positive CDKN2A Mutation Negative
Skin Type lor 2 20 39
Skin Type 3 or 4 0 3
P-value = 0.545 (not significant)
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TABLE 19
Correlation between the Num ber of MC1R V ariants in Unaffected Familial
M elanoma and Control Subjects
< One MC1R 
Variant
> Two MC1R 
Variants
No. of Unaffected Familial 
Melanoma Individuals
15 10
No. of Controls 46 21
P-value = 0.465 (not significant) 
OR = 1.460, Cl 0.564-3.784
TABLE 20
Correlation between the Number of MC1R Variants in Familial Melanoma
Patients with and without a CDKN2A Mutation
< One MC1R 
Variant
> Two MC1R 
Variants
No. of CDKN2A Mutation Positive 
Cases
6 15
No. of CDKN2A Mutation 
Negative Cases
16 22
P-value = 0.402 (not significant) 
OR =1.818, Cl 0.579-5.714
TABLE 21
Correlation between Postulated Red Hair MC1R Variants in Melanoma 
Patients (Familial and Sporadic) and Control Subjects
Postulated Red Hair Variant 
Present
Postulated Red Hair Variant 
Absent
No. of Cases 10 4
No. of 5 5
Controls
P-value = 0.403 (not significant)
OR = 2.500, Cl 0.458-13.649
TABLE 22
Correlation between Postulated Red Hair MC1R Variants in All Red Haired 
Individuals (Affected and Unaffected Familial and Sporadic Melanoma and 
Control Subjects) and All Individuals without Red Hair (Affected and
Postulated Red Hair Postulated Red Hair
Variant Present Variant Absent
Red Hair 15 9
Other Hair 73 77
Colour
P-value = 0.272 (not significant) 
OR = 1.758, Cl 0.725-4.265
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TABLE 23
Correlation between Postulated Red H air MC1R V ariants in Control
Subjects with Red Hair and Control Subjects without Red Hair
Postulated Red Hair 
Variant Present
Postulated Red Hair 
Variant Absent
Red Hair 4 2
Other Hair 25 35
Colour
P-value = 0.392 (not significant)
OR = 2.800, Cl 0.475-16.493
TABLE 24
Correlation between MC1R R142H, R151C, R160W or D294H Variant in
Familial Melanoma Patients and Control Subjects
No. of Cases No. of Controls
R142H, R151C, R160W or D294H Present 33 29
R142H, R151C, R160W and D294H Absent 27 38
P-value = 0.216 (not significant)
OR = 1.602, Cl 0.794-3.230
TABLE 25
Correlation between MC1R R142H, R151C, R160W or D294H Variant in 
Familial Melanoma Patients without a CDKN2A Mutation and Control
Subjects
No. of Cases No. of Controls
R142H, R151C, R160W or D294H Present 19 29
R142H, R151C, R160W and D294H Absent 20 38
P-value = 0.687 (not significant)
OR= 1.245, Cl 0.564-2.749
TABLE 26
Correlation between MC1R R142H, R151C, R160W or D294H Variant in
Familial and Sporadic Melanoma Patients
No. of Familial 
Cases
No. of Sporadic 
Cases
R142H, R151C, R160W or D294H 33 18
Present
R142H, R151C, R160W and 27 10
D294H Absent
P-value = 0.490 (not significant)
OR = 0.679, Cl 0.269-1.713
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TABLE 27
Correlation between MC1R R142H, R151C, R160W or D294H Variant in 
Affected and Unaffected Familial Melanoma
No. of Familial No. of Unaffected Familial 
Melanoma Melanoma Individuals 
Individuals
R142H, R151C, 33 12
R160W or D294H
Present
R142H, R151C, 27 13
R160W and D294H
Absent
P-value = 0.636 (not significant)
OR = 1.324, Cl 0.520-3.373
TABLE 28
Correlation between MC1R R142H, R151C, R160W or D294H Variant in
Familial Melanoma Patients with and without a CDKN2A Mutation
CDKN2A CDKN2A
Mutation Mutation
Positive Negative
R142H, R151C, R160W or D294H 14 19
Present
R142H, R151C, R160W and D294H 7 20
Absent
P-value = 0.277 (not significant)
OR = 2.105, Cl 0.698-6.346
TABLE 29
Correlation between MC1R R142H, R151C, R160W or D294H Variant in
Unaffected Familial Melanoma and Control Subjects
No. of Unaffected Familial No. of
Melanoma Individuals Controls
R142H, R151C, R160W or 12 29
D294H Present
R142H, R151C, R160W 13 38
and D294H Absent
P-value = 0.814 (not significant)
O R = 1.210, Cl 0.481-3.040
TABLE 30
Correlation between MC1R R142H, R151C, R160W or D294H Variant in
Affected and Unaffected Familial Melanoma and Control Subjects
No. of Affected & No. of
Unaffected Familial Controls
Melanoma Individuals
R142H, R151C, R160W or 45 29
D294H Present
R142H, R151C, R160W and 40 38
D294H Absent
P-value = 0.256 (not significant)
OR = 1.474, Cl 0.774-2.807
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TABLE 31
Correlation between MC1R V ariants and Skin Type 1
Skin Type 1 O ther Skin Type
L44I present 1 0
L441 absent 33 140
P-value = 0.195 (not significant)
V60L present 11 42
V60L absent 23 98
P-value = 0.836 (not significant)
OR = 1.116, Cl 0.499-2.494
D84E present 3 5
D84E absent 31 135
P-value = 0.358 (not significant)
OR = 2.613, Cl 0.593-11.520
V92M present 2 25
V92M absent 32 115
P-value = 0.113 (not significant)
OR = 0.288, Cl 0.065-1.279
T95M present 1 0
T95M absent 33 140
P-value = 0.195 (not significant)
R142H present 3 2
R142H absent 31 138
P-value = 0.052 (not significant)
OR = 6.677, Cl 1.070-41.674
R151C present 9 31
R151C absent 25 109
P-value = 0.650 (not significant)
OR = 1.266, Cl 0.536-2.991
R160W present 18 24
R160W absent 16 116
P-value < 0.001 *** significant
OR = 5.438, Cl 2.433-12.152
R163Q present 2 15
R163Q absent 32 125
P-value = 0.531 (not significant)
OR = 0.521, Cl 0.113-2.395
A171G present 1 1
A171G absent 33 139
P-value = 0.354 (not significant)
OR = 4.212, Cl 0.257-69.109
Bonferroni adjusted significance level for multiple tests = 0.005
TABLE 32
Correlation between MC1R V ariants and Blue Eyes
Blue Eyes Other than Blue Eyes
L44I present 1 0
L44I absent 111 62
P-value = 1.000 (not significant)
V60L present 36 17
V60L absent 76 45
P-value = 0.607 (not significant)
OR = 1.254, Cl 0.632-2.486
D84E present 5 3
D84E absent 107 59
P-value = 1.000 (not significant)
OR = 0.919, Cl 0.212-3.982
V92M present 18 9
V92M absent 94 53
P-value = 0.831 (not significant)
OR = 1.128, Cl 0.473-2.687
T95M present 1 0
T95M absent 111 62
P-value = 1.000 (not significant)
M128K present 1 0
M128K absent 111 62
P-value = 1.000 (not significant)
R142H present 4 1
R142H absent 108 61
P-value = 0.656 (not significant)
OR = 2.259, Cl 0.247-20.671
R151C present 26 14
R151C absent 86 48
P-value = 1.000 (not significant)
OR = 1.037, Cl 0.495-2.171
I155T present 4 2
1155T absent 108 60
P-value = 1.000 (not significant)
OR= 1.111,Cl 0.198-6.245
R160W present 31 11
R160W absent 81 51
P-value = 0.195 (not significant)
OR = 1.774, Cl 0.820-3.840
R163Q present 12 5
R163Q absent 100 57
P-value = 0.610 (not significant)
OR= 1.368, Cl 0.459-4.080
A171G present 2 0
A171G absent 110 62
P-value = 0.539 (not significant)
D294H present 7 5
D294H absent 105 57
P-value = 0.757 (not significant)
OR = 0.760, Cl 0.231-2.503
329
TABLE 33
Correlation between MC1R Variants and Red Hair in all DNA Samples 
Available
Red Hair Other than Red Hair
L44I present 1 0
L44I absent 23 150
P-value = 0.138 (not significant)
V60L present 8 45
V60L absent 16 105
P-value = 0.812 (not significant)
OR =1.167, Cl 0.466-2.921
D84E present 2 6
D84E absent 22 144
P-value = 0.601 (not significant)
OR = 2.182, Cl 0.414-11.498
V92M present 2 25
V92M absent 22 125
P-value = 0.378 (not significant)
OR = 0.455, Cl 0.100-2.057
R142H present 3 2
R142H absent 21 148
P-value = 0.019 * significant (not significant after Bonferroni correction)
O R = 10.571, Cl 1.668-67.009
R151C present 7 33
R151C absent 17 117
P-value = 0.440 (not significant)
OR = 1.460, Cl 0.558-3.818
R160W present 11 31
R160W absent 13 119
P-value = 0.018 * significant (not significant after Bonferroni correction)
OR = 3.248, Cl 1.327-7.949
R163Q present 1 16
R163Q absent 23 134
P-value = 0.474 (not significant)
OR = 0.364, Cl 0.046-2.880 
Bonferroni adjusted significance level for multiple tests = 0.006
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